## University of California, Davis IACUC Business Administration System

### January 07, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M005, M102, M111, M090, M042, A095, M004, M092, A019, M119, M087, A109, M110, A013, M016, M024, M001, M112

#### Excused:

M093, M114

#### Guests:

M116, A017, A018

#### I. Minutes from Previous Meetings:

The IACUC reviewed	and appr	roved the November 12, 2020, meeting minutes as written.
	ote	
Approval	16	
Withhold Appr	oval 0	
Abstain	0	
Present	16	
The IACUC reviewed	and appr	roved the December 3, 2020, meeting minutes as written.
	ote	
Approval	16	
Withhold Appr	oval 0	
Abstain	0	
Present	16	
The IACUC reviewed	and appr	roved the December 17, 2020, meeting minutes as written
	ote	
Approval	16	
Withhold Appr	oval 0	
Abstain	0	
Present	16	

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

### IV. Reports of Concern, Events and Incidents:


The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

Action: Physical breach in isolators housing gnotobiotic mice; required euthanasia
Action: Genotyping policy not followed. PAM and amendment.
Action: Neck lesions; amendment forthcoming.

## V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

### VI. Designated Review Protocols:




a. None.			
6. #	DY		-
prior to the meet a. Pendin Additional discus	ing: g BUA amendn	the following points were addressed by the Princip nent. meeting included:	oal Investigator
7. #	D		01-04-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
a. None. 8. #	С		01-06-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
9. #	С		-
prior to the meet a. Clarific	ing: ation of and inc ssion during the	the following points were addressed by the Princip entive amount and procedures. e meeting included:	oal Investigator
10. #	D		-
prior to the meet a. Pendin Additional discus	ing: g CHEM.	the following points were addressed by the Princip meeting included:	oal Investigator
11. #	С		12-18-2020
prior to the meet a. Clarific	ing: ation on proced	the following points were addressed by the Princip lure and administration of drug meeting included:	oal Investigator
12. #	D		-
prior to the meet a. Clarific Additional discus	ing: ation on animal	the following points were addressed by the Princip numbers meeting included:	oal Investigator
13. #	C		01-04-2021

prior to the meeti a. None.	ng:	d the following points were addressed by the Princip ne meeting included:	oal Investigator
14.#	С		01-07-2021
prior to the meeti a. None. Additional discus a. None.	U U	ne meeting included:	
15. #	В		01-06-2021
prior to the meeti a. Adminis	ng: strative protoc	d the following points were addressed by the Princip col for ordering animals. ne meeting included:	pal Investigator

## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		01-07-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
2. #	D		-
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included:	incipal
3. #	DY		-
Investigator prio a. None. Additional discus	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
4. #	DY		-
Investigator prio a. Pendin contacting Additional discus	r to the meeting ig PI's response g waste manag	e to chemical safety officers statement regarding V	
5. #	D		01-07-2021
Investigator prio a. Clarific	r to the meeting ation of animal		incipal

6. #	E		01-06-2021
Investigator prior		and the following points were addressed by the Pr :	incipal
a. None. Additional discus a. None.	ssion during the	meeting included:	
7.#	СҮ		01-07-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
8. #	C		12-17-2020
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
9. #	С		01-07-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
10. #	D		01-04-2021
Investigator prior a. Clarific	r to the meeting ation on blood (		incipal
11. #	D		01-07-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
12. #	D		01-07-2021
Investigator prior a. Chemi	r to the meeting cal safety office	and the following points were addressed by the Pr : r confirmed no new VHSS was required for this stu meeting included:	
13. #	СҮ		12-17-2020
The amendment Investigator prio a. Clarific	was reviewed r to the meeting ation regarding	disposition provided by PI.	
Additional discus a. None.	ssion during the	meeting included:	
14. #	DY		12-18-2020
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal





### VIII. Administrative and Veterinary Verification Amendments:

Total of **153** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

#### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





## X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		01-07-2019	01-07-2021	01-07-2022
	D		01-19-2019	01-07-2021	01-19-2022

D		01-10-2019	01-07-2021	01-10-2022
D		01-17-2019	01-07-2021	01-17-2022
D		01-10-2019	01-07-2021	01-10-2022
C		01-09-2019	01-07-2021	01-09-2022
D		01-10-2019	01-07-2021	01-10-2022
С		01-10-2019	01-07-2021	01-10-2022
C		01-22-2019	01-07-2021	01-22-2022
C		01-22-2019	01-07-2021	01-22-2022
C		01-22-2019	01-07-2021	01-22-2022
D		01-10-2019	01-07-2021	01-10-2022
CY	·	01-10-2019	01-07-2021	01-10-2022
В		01-18-2019	01-07-2021	01-18-2022
D		01-23-2020	01-20-2022	04-27-2022
C		01-21-2020	01-06-2022	01-21-2023
DY	·	01-23-2020	01-20-2022	01-23-2023
D		01-23-2020	01-20-2022	01-23-2023
DY	·	01-16-2020	01-20-2022	01-16-2023
C		01-23-2020	01-20-2022	01-23-2023
D		01-23-2020	01-20-2022	01-23-2023
C		01-23-2020	01-07-2021	01-23-2022
C		01-13-2020	01-06-2022	01-13-2023
D		01-23-2020	01-20-2022	01-23-2023
D		01-23-2020	01-20-2022	01-23-2023
D		01-23-2020	01-07-2021	01-23-2022
D		01-23-2020	01-07-2021	01-12-2022
C		01-23-2020	01-20-2022	01-23-2023
			1	

Discussion: None.

Action Items:	None.		

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Prot	tocol	Categor	v Request		Date Approved
1.#		DY			01-07-2021
Investig Additio	gator pric a. None.	or to the me Ission during	ved and the following points were addre eting: g the meeting included:	essed by the P	rincipal
[	IAC	UC Vote			
	Approva	al	8		
		d Approval	ο		
	Abstain		0		
	Present		8		
2. #		DY			01-07-2021
			4a. 9 the meeting included:		
		ssion durin ved by vote	the meeting included:		
	a. Appro IAC	ved by vote CUC Vote	the meeting included:		
	a. Appro IAC Approva	ved by vote CUC Vote	the meeting included:		
	a. Appro IAC Approva Withhold	ved by vote CUC Vote	the meeting included:		
	a. Appro IAC Approva Withhold Abstain	ved by vote CUC Vote al d Approval	the meeting included:		
	a. Appro IAC Approva Withhold	ved by vote CUC Vote II d Approval	the meeting included:		
	a. Appro IAC Approva Withhold Abstain	ved by vote CUC Vote al d Approval	the meeting included:		02-03-2021
3. # The am Investig	a. Appro IAC Approva Withhold Abstain Present Present nendmen gator price a. None. nal discu a. Pendin	ved by vote CUC Vote al d Approval E t was review or to the me assion during ng PI respo	the meeting included:	ventive measu	rincipal res, and slow
3. # The am nvestic	a. Appro IAC Approva Withhold Abstain Present Present a. None. nal discu a. Pendin progress to DR.	ved by vote CUC Vote al d Approval E t was review or to the me assion during ng PI respo going forw	the meeting included: ved and the following points were addre tring: the meeting included: the meeting previous suggestion regarding previous suggestion	ventive measu	rincipal res, and slow
3. #	Approvation Approvation Withhold Abstain Present Present Abstain Present Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Abstain Present Abstain Abstain Present Abstain Absta	E t was review to the me ssion during poing forw CUC Vote	the meeting included: ved and the following points were addread the meeting included: the meeting included: the meeting included: the preclude a repeat of this incidence	ventive measu	rincipal res, and slow
3. #	a. Appro IAC Approva Withhold Abstain Present Present IAC a. None. nal discu a. Pendin progress to DR. IAC Approva	ved by vote CUC Vote al d Approval E t was review or to the me assion during ng PI respo going forw CUC Vote	the meeting included: the meeting included: red and the following points were address the meeting included: the meeting included: the review suggestion regarding prevair ard to preclude a repeat of this incidence 0	ventive measu	rincipal res, and slow
3. #	a. Appro IAC Approva Withhold Abstain Present Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Present Abstain Abstain Present Abstain Abstain Present Abstain	ved by vote CUC Vote al d Approval E t was review or to the me assion during ng PI respo going forw CUC Vote	the meeting included: the meeting included: red and the following points were address the meeting included: the meeting included: the review suggestion regarding prevent to preclude a repeat of this incidence	ventive measu	rincipal res, and slow
3. # The am Investig	a. Appro IAC Approva Withhold Abstain Present Present IAC a. None. nal discu a. Pendin progress to DR. IAC Approva	ved by vote CUC Vote al d Approval E t was review or to the me assion during p I respo going forw CUC Vote al d Approval	the meeting included: the meeting included: red and the following points were address the meeting included: the meeting included: the review suggestion regarding prevair ard to preclude a repeat of this incidence 0	ventive measu	rincipal res, and slow

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-02-2020		
		Obtained

2.07-27-2020	
3. 07-29-2020	
4.08-05-2020	
5.08-05-2020	
6.08-05-2020	
7.08-11-2020	
8.08-13-2020	
9. 08-19-2020	
10.09-24-2020	
11. 09-28-2020	
12. 11-04-2020	
13. 11-16-2020	
14. 11-17-2020	
15. 11-18-2020	
16. 11-18-2020	
17. 11-19-2020	
18. 11-19-2020	
19. 11-20-2020	
20. 11-24-2020	
21. 11-25-2020	
22. 11-25-2020	
23. 11-25-2020	
24. 11-30-2020	
25. 12-01-2020	
26. 12-03-2020	
27. 12-10-2020	
28. 12-16-2020	

Discussion	: None.	
Action	: None.	
	IACUC Vote	
App	roval	15
With	hold Approva	al O
Abs		0
Pres	sent	15

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 03-12-2020	LAB	
2.07-14-2020	LAB	
3. 07-20-2020	LAB	
4. 07-20-2020	LAB	
5. 07-20-2020	LAB	
6. 07-22-2020	LAB	
7.07-24-2020	LAB	
8. 07-27-2020	LAB	
9. 07-28-2020	LAB	
10. 07-28-2020	LAB	

Obtained by Rise for Animals. Uploaded to Animal Research Laboratory Overview (ARLO) on 02/06/2023

11.07-30-2020	LAB	
12.07-30-2020	LAB	
13. 07-30-2020	LAB	
14.08-03-2020	LAB	
15. 08-03-2020	LAB	
16.08-05-2020	LAB	,
17.08-10-2020	LAB	
18.08-10-2020	LAB	
19. 08-10-2020	LAB	
20. 08-11-2020	LAB	
21.08-20-2020	LAB	
22.08-26-2020	LAB	
23.09-16-2020	LAB	
24.09-17-2020	LAB	
25.09-23-2020	LAB	
26.09-24-2020	LAB	
27.09-25-2020	LAB	
28.09-29-2020	LAB	
29. 10-13-2020	LAB	
30. 10-23-2020	LAB	
31. 10-30-2020	LAB	
32. 11-05-2020	LAB	
33. 11-10-2020	LAB	
34. 11-13-2020	LAB	
35. 11-13-2020	LAB	
36. 11-16-2020	LAB	
37. 11-18-2020	LAB	
38. 11-18-2020	LAB	
39. 11-18-2020	LAB	
40. 11-20-2020	LAB	
41. 11-25-2020	LAB	
42. 11-25-2020	LAB	
43. 12-01-2020	LAB	
44. 12-02-2020	LAB	
45. 12-02-2020	LAB	
46. 12-07-2020	LAB	
47. 12-24-2020	LAB	
48. 12-28-2020	LAB	
49. 12-31-2020	LAB	
50. 12-22-2020	PAM	
	1	1

Discussion	None.	
Action	None.	
	IACUC Vote	
Арр	roval	14
With	hold Approval	0
Abs	tain	0
Pres	sent	14

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

#### XV. Other Discussion Items:

Торіс				
1. Facility an	d lab inspections moving forward under continued pandemic conditions			
Discussion:	Waiver still in effect. Will conduct in person where feasible, otherwise remote. Limit number of people to minimum needed. Ensure current COVID guidelines followed per county and campus.			
Action:	Limit number of people to minimum needed. Ensure current COVID guidelines followed per county and campus. Communicate plan and options with each facility manager.			
2. Time-mate	ed Breeding Colony Evaluations			
Discussion:	Summary presented by CNPRC veterinarian per USDA exemption requirement.			
Action:	None.			
3. UC ANR I	ACUC oversight			
Discussion:	FYI - ANR has requested UCD IACUC to serve as ANR IACUC. Under discussion with VCR. More information			
Action:	Obtain more information and suggest alternatives.			
4. Transparency Statement draft proposal				
Discussion:	Update website to increase campus and public awareness.			
Action:	Include additional statement on IACUC.			

## XVI. Program Updates:

# Торіс

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### January 21, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M005, M111, M042, A095, M092, A019, M119, M087, A109, M110, A013, M016, M024, M001, M114

#### Excused:

M102, M090, M004, M093, M112

#### **Guests:**

M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.


#### **IV. Reports of Concern, Events and Incidents:**

	CUC reviewed and discussed the following report(s) of concern, events, cidents:
mouse	pup
	Action: Unidentified mouse pup found in hood.
	Action: Discussed PAM and revisions to replacement protocol to correct deficiencies.
	Action: Deviation from toe clipping policy; PAM.
	&
	Action: Discussed PAM and added additional deficiencies recommended by the committee. Hazard deficiency moved to a significant.
	Action: Adverse effect from depilatory cream on mice. PI submitting amendment for depilatory cream and side effects.
Sheep	Facility incident
	Action: Add isolated and not common but potential adverse events in herd protocol.

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

Power outage Friday January 15th



## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved				
1. #	С		-				
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator				
2. <b>#</b>	E		-				
prior to the meet a. None.	Additional discussion during the meeting included:						
3. #	D		-				
prior to the meet a. Pendin	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BUA Additional discussion during the meeting included: a. None						
4. #	D		-				
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator				
5. #	D		01-18-2021				
prior to the meet a. Clarific	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of possible complications. Additional discussion during the meeting included: a None						
6. #	D		01-13-2021				
prior to the meet a. Clarific	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures, drug table, and adverse effects. Additional discussion during the meeting included: a None						
7. #	DY		-				

prior to the meet	ing:	the following points were addressed by the Princip	oal Investigator
Additional discus	g BUA amendr ssion during the ns in DMR.	nent. e meeting included:	
8. <b>#</b>	D		01-21-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip e meeting included:	bal Investigator
a. None. 9. <b>#</b>	С		01-08-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	oal Investigator
10. #	D		-
The protocol was prior to the meet a. Clarific	ing: ation of statisti	the following points were addressed by the Princip cal justification. e meeting included:	oal Investigator
11. #	D		-
prior to the meet a. Pendin Additional discus	ing: g CHEM	the following points were addressed by the Princip e meeting included:	oal Investigator
12. #	С		01-21-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	oal Investigator
13. #	С		-
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
14. #	С		01-20-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	bal Investigator
15. #	D		01-21-2021

Obtained by Rise for Animals. Uploaded to Animal Research Laboratory Overview (ARLO) on 02/06/2023

prior to the meet	ing:	the following points were addressed by the Princip with PI all grant sources are included.	oal Investigator		
Additional discus		meeting included:			
16. #	С		01-21-2021		
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator		
Additional discus a. None.	ssion during the	meeting included:			
17.#	DY		-		
prior to the meet a. Pendin Additional discus	ing: g BUA approva	the following points were addressed by the Princip I. meeting included:	oal Investigator		
18. #	D		01-08-2021		
prior to the meet a. Clarific	ing: ation on proced	the following points were addressed by the Princip lures and animal numbers. meeting included:	oal Investigator		
19. #	D		01-10-2021		
prior to the meet a. Typo c b. Clarific	iing: orrection. ation of numbe	the following points were addressed by the Princip rs justification. meeting included:	Jai Investigator		
20. #	С		-		
prior to the meet a. None.	ing:	the following points were addressed by the Princip	oal Investigator		
	ssion during the g MOU with AN	meeting included: IR.			
21. #	С		01-21-2021		
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator		
	ssion during the	meeting included:			
22. #	С		01-08-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
Additional discussion during the meeting included: a. None.					
23. #	В		01-08-2021		

The protocol was prior to the meeti a. None.		the following points were addressed by the Princip	oal Investigator
Additional discus a. None.	sion during the	e meeting included:	
24. #	С		01-21-2021
prior to the meeti a. Potentia	ng: ally useful refei	the following points were addressed by the Princip rences provided. e meeting included:	bal Investigator
25. #	D		01-21-2021
prior to the meeti a. None.	ng:	the following points were addressed by the Princip e meeting included:	
26. #	С		-
prior to the meeti a. None.	ng: sion during the	the following points were addressed by the Princip meeting included:	oal Investigator
27.#	D		01-21-2021
prior to the meeti a. Clarifica b. Additior	ng: ation of order o n of potential co	the following points were addressed by the Princip f events and timing of repetition. omplication. e meeting included:	bal Investigator

## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved				
1. #	D		-				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI.							
2. #			01-21-2021				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.							
3. #	DY		-				
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal				

Additional discus a. Pendin		e meeting included:	
4. #	DY		01-11-2021
Investigator prior a. Chemio	r to the meeting cal safety office	and the following points were addressed by the Pr g: r completed her review and provided an updated \ e meeting included:	
5. #	DY		01-11-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	incipal
6. #	D		01-20-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	incipal
7.#	D		01-21-2021
a. None. 8. #	D was reviewed	e meeting included: and the following points were addressed by the Pr	01-21-2021 incipal
Investigator prior a. None. Additional discus a. None.	-	: e meeting included:	
9. #	D		01-21-2021
Investigator prior a. VHSS	r to the meeting added to protoc		incipal
10. #	E		01-20-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
11. #	E		01-19-2021
Investigator prior a. Clarific	r to the meeting ation on proced	and the following points were addressed by the Pr g: dure and potential adverse effects e meeting included:	incipal

			01-20-2021
		and the following points were addressed by the Pri	ncipal
	ation on termin		
a. None.	SION during the	e meeting included.	
13.#	D		01-21-2021
Investigator prior a. Clarifica	to the meeting ation regarding	and the following points were addressed by the Pri g: negative outcomes and fur growth. e meeting included:	ncipal
14. #	D		01-21-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pri g: e meeting included:	ncipal
15.#	С		01-21-2021
Additional discus a. None.	ation of sampli sion during the	g: ng time points. e meeting included:	
16.#	С		01-14-2021
The amendment nvestigator prior	to the meeting		
The amendment Investigator prior a. Clarifica	to the meeting ation of dose a		
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b>	to the meeting ation of dose a sion during the C	g: nd adverse effects. e meeting included:	ncipal -
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None.	to the meeting ation of dose a sion during the C was reviewed to the meeting sion during the	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri	ncipal -
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None. Additional discus	to the meeting ation of dose a sion during the C was reviewed to the meeting sion during the	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri g:	ncipal -
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus	to the meeting ation of dose a soion during the C was reviewed to the meeting soion during the g Pl C was reviewed to the meeting	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri	ncipal - ncipal 01-20-2021
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None.	to the meeting ation of dose a soion during the C was reviewed to the meeting soion during the g Pl C was reviewed to the meeting	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri g:	ncipal - ncipal 01-20-2021
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. <b>19. #</b> The amendment Investigator prior a. None. <b>19. #</b>	to the meeting ation of dose a soion during the C was reviewed to the meeting soion during the g Pl C was reviewed to the meeting soion during the E was reviewed to the meeting	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri g: e meeting included:	ncipal - ncipal 01-20-2021 ncipal 01-21-2021
The amendment Investigator prior a. Clarifica Additional discus a. None. <b>17. #</b> The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>19. #</b> The amendment Investigator prior a. None.	to the meeting ation of dose a soion during the C was reviewed to the meeting soion during the g Pl C was reviewed to the meeting soion during the E was reviewed to the meeting	g: nd adverse effects. e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri g: e meeting included: and the following points were addressed by the Pri g:	ncipal - ncipal 01-20-2021 ncipal 01-21-2021

24 4	<b>_</b>		04 04 0004
21. #	D		01-21-2021
nvestigator prior		and the following points were addressed by the Pi	rincipal
a. None.	to the meeting	j.	
	sion during the	e meeting included:	
a. None.	J.	C C	
22. #	С		01-21-2021
The amendment	was reviewed	and the following points were addressed by the Pi	rincipal
nvestigator prior	to the meeting	j:	
a. None.			
Additional discus a. None.	sion during the	e meeting included:	
			01.00.0001
23. #	D		01-08-2021
		and the following points were addressed by the Pi	rincipal
nvestigator prior a. None.	to the meeting		
	sion durina the	e meeting included:	
a. None.			
24. #	D		01-21-2021
The amendment	was reviewed	and the following points were addressed by the Pi	rincipal
nvestigator prior	to the meeting	j:	
a. None.			
Additional discus	sion during the	e meeting included:	
	jj	Theeling moldaed.	
a. None.			01.01.0001
a. None.	E		01-21-2021
a. None. 25. #	E was reviewed	and the following points were addressed by the Pr	1
a. None. 25. # The amendment Investigator prior	E was reviewed	and the following points were addressed by the Pr	1
a. None. 25. # The amendment nvestigator prior a. None.	E was reviewed to the meeting	and the following points were addressed by the Pr g:	
a. None. 25. # The amendment nvestigator prior a. None.	E was reviewed to the meeting	and the following points were addressed by the Pr	1
a. None. 25. # The amendment investigator prior a. None. Additional discus	E was reviewed to the meeting	and the following points were addressed by the Pr g:	1
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. #	E was reviewed to the meeting sion during the D	and the following points were addressed by the Pr g: e meeting included:	rincipal 01-21-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment	E was reviewed to the meeting sion during the D was reviewed	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	rincipal 01-21-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting	and the following points were addressed by the Pro- g: e meeting included: and the following points were addressed by the Pro- g:	rincipal 01-21-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. Additional discus	E was reviewed to the meeting sion during the D was reviewed to the meeting	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	rincipal 01-21-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. Additional discus a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the	and the following points were addressed by the Pro- g: e meeting included: and the following points were addressed by the Pro- g:	rincipal 01-21-2021 rincipal
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. Additional discus a. None. Additional discus a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included:	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. Additional discus a. None. Additional discus a. None. 27. #	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: e meeting included: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro-	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. Additional discus a. None. 27. # The amendment nvestigator prior	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: e meeting included: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro-	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g:	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. Additional discus	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: e meeting included: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro-	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. Additional discus a. None. Additional discus a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. Additional discus	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting	and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g: and the following points were addressed by the Pro- g:	rincipal 01-21-2021 rincipal 01-12-2021
a. None. 25. # The amendment Investigator prior a. None. Additional discus a. None. 26. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 28. #	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the D Y	and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal 01-13-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 28. # The amendment	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the D Y was reviewed	and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal 01-13-2021
a. None. 25. # The amendment Investigator prior a. None. Additional discus a. None. 26. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 28. # The amendment Investigator prior a. None. 28. # The amendment Investigator prior a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the D Y was reviewed to the meeting ted veterinary	and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal 01-13-2021
a. None. 25. # The amendment nvestigator prior a. None. Additional discus a. None. 26. # The amendment nvestigator prior a. None. 27. # The amendment nvestigator prior a. None. 28. # The amendment nvestigator prior a. None. 28. # The amendment nvestigator prior a. None. 28. # The amendment nvestigator prior a. Sugges Additional discus	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the D Y was reviewed to the meeting ted veterinary	and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included: and the following points were addressed by the Program meeting included:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal 01-13-2021
a. None. 25. # The amendment Investigator prior a. None. Additional discus a. None. 26. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 27. # The amendment Investigator prior a. None. 28. # The amendment Investigator prior a. None. 28. # The amendment Investigator prior a. None.	E was reviewed to the meeting sion during the D was reviewed to the meeting sion during the D Y was reviewed to the meeting sion during the D Y was reviewed to the meeting ted veterinary	and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included: and the following points were addressed by the Program emeeting included:	rincipal 01-21-2021 rincipal 01-12-2021 rincipal 01-13-2021


Investigator prior a. None.	to the meeting		incipal
Additional discus a. None.	sion during the	meeting included:	
30. #	E		-
Investigator prior a. None. Additional discus	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
31. #	E		01-21-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal


#### VIII. Administrative and Veterinary Verification Amendments:


Total of **152** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.








11. #	СҮ			01-21-2021
prior to th a. Additiona	e meeting: None.		the following points were addressed by the Princip e meeting included:	oal Investigator
W	oproval lithhold Approval ostain resent	18 0 0 18		

# X. Annual Renewals:


Protocol Cat	tegory	Approvar	Last Reviewed	Expires
	D	D1-31-2019	01-21-2021	01-31-2022
	D	01-24-2019	01-21-2021	01-24-2022
	D	01-24-2019	01-21-2021	01-24-2022
	D	01-30-2019	01-21-2021	01-30-2022
	D	01-24-2019	01-21-2021	01-24-2022
	D	01-31-2019	01-21-2021	01-31-2022
[	DY	01-16-2019	01-21-2021	01-16-2022
	С	02-05-2019	01-21-2021	02-05-2022
	С	01-30-2019	01-21-2021	01-30-2022
	С	02-04-2019	01-21-2021	02-04-2022
	D	02-05-2019	01-21-2021	02-05-2022
(	СҮ	01-25-2019	01-21-2021	01-25-2022
	С	01-24-2019	01-21-2021	01-24-2022
	D	02-05-2019	01-21-2021	02-05-2022
[	DY	01-25-2019	01-21-2021	01-25-2022
	D	02-04-2019	01-21-2021	02-04-2022
	С	02-05-2019	01-21-2021	02-05-2022

С	02-04-2019	01-21-2021	02-04-2022
D	01-24-2019	01-21-2021	01-24-2022
С	01-24-2019	01-21-2021	01-24-2022
С	02-01-2019	01-21-2021	02-01-2022
С	02-05-2019	01-21-2021	02-05-2022
С	01-28-2020	01-20-2022	01-28-2023
DY	01-23-2020	01-20-2022	01-23-2023
С	02-06-2020	02-03-2022	02-06-2023
С	02-06-2020	02-03-2022	02-06-2023
D	02-05-2020	02-03-2022	02-05-2023
С	02-06-2020	01-21-2021	02-06-2022
D	02-06-2020	02-03-2022	02-06-2023
D	02-06-2020	02-03-2022	02-06-2023
D	01-24-2020	01-20-2022	01-24-2023
СҮ	02-06-2020	02-03-2022	02-06-2023
СҮ	01-27-2020	01-20-2022	01-27-2023
D	02-06-2020	02-03-2022	02-06-2023
С	02-06-2020	02-03-2022	02-06-2023
DY	02-06-2020	02-03-2022	02-06-2023
С	02-04-2020	01-20-2022	02-04-2023
С	02-06-2020	02-03-2022	02-06-2023
С	02-06-2020	02-03-2022	02-06-2023
С	02-04-2020	01-20-2022	02-04-2023
D	02-06-2020	02-03-2022	02-06-2023
DY	02-06-2020	02-03-2022	02-06-2023
D	02-06-2020	02-03-2022	02-06-2023
D	02-06-2020	02-03-2022	02-06-2023
		Obtaina	d by Rise for A




### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.



Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. 2nd reviewer approved verbally. IACUC Vote Approval 16 Withhold Approval 0 Abstain 1 Present 17 4. # D Y 01-21	
a. 2nd reviewer approved verbally. IACUC Vote Approval 16 Withhold Approval 0 Abstain 1 Present 17	
IACUC VoteApproval16Withhold Approval0Abstain1Present17	
Withhold Approval0Abstain1Present17	
Abstain 1 Present 17	
Present 17	
4. # DY 01-21	
	-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:	
a. Chem safety review and VHSS.	
Additional discussion during the meeting included:	
a. None.	
Approval 17 Withhold Approval 0	
Withhold Approval 0 Abstain 1	
Present 18	0004
5. # 01-21	-2021
Approval18Withhold Approval0Abstain0Present18	
6. # D 01-21	2024
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.	
Approval 18 Withhold Approval 0	
Withhold Approval 0 Abstain 0	
Abstain 0 Present 18	
	0004
7. # DY 01-21	-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.	



XII. Animal Housing/Facility Inspections:

Date
------

Discussion:	None.
Action:	None.

There are no Animal Housing Facility Inspections for this agenda.

#### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 01-13-2021	LAB	
2. 01-13-2021	LAB	
3. 01-19-2021	LAB	
4. 01-19-2021	LAB	

Discussion:	None.			
Action:	None.			
	IACUC Vote			
Appr	oval hold Approval	18		

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

# XV. Other Discussion Items:

Торіс			
1. Completion of AALAS Library Courses.			
	5 members have not completed all assigned classes to date. 2 members reported they were having IT issues.		
	IACUC staff to send out an additional reminder email to the 5 members who still have courses to complete.		

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

#### February 04, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

Present:

M009, M097, M005, M111, A095, M092, A019, M119, M087, A109, M110, M093, A013, M024, M001, M114

#### Excused:

M102, M090, M042, M004, M016, M112

#### Guests:

M116, A017, A018

#### I. Minutes from Previous Meetings:

The I/	CUC reviewed and	approved the January 21, 2021, meeting minutes as written.
	IACUC Vote	
	Approval	14
	Withhold Approval	0
	Abstain	0
	Present	14

### II. Protocols Tabled From Previous Meetings:

	T.				
1. #					Category:
					D
		nd the following poir	nts were addressed I	by the Principal Investigat	or prior to the
meetin					
			d local anesthesia fo	r genotyping.	
	nal discussion durin		d:		
	a. Approved by con	ittee vote.			
	IACUC Vote				
	Approval	5			
	Withhold Approval				
	Abstain				
	Present	5			
2. #					Category:
_					D
The pr	otocol was reviewed	nd the following poir	nts were addressed I	by the Principal Investigat	or prior to the
meetin		• •			
	a. PI clarified potent	adverse effects and	d local anesthesia fo	r genotyping. The protoco	I is still pending
	final chemical safet	eview.			
Additio	nal discussion durin		d:		
	a. Voted to send to	<u>/</u> R.			
	IACUC Vote				
	Approval				
	Withhold Approval				

Abstain	0	
Present	17	

## III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

-still reviewing protocol and procedures to determine if a protocol deviation occurred.

Action: Tabled to the next meeting.

### V. Veterinary Care Program Updates:


The Attending Veterinarian provided the following updates to the committee:

 1. Sustained release Buprenorphine

 DEA approval of new formulation available for ordering. Currently intended for rodents.

Action Items: Inform PIs of availability.

### VI. Designated Review Protocols:



The protocol was prior to the meet a. None.		the following points were addressed by the Princip	al Investigator
	sion during the	meeting included:	
5. #	DY		-
The protocol was	reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ing:	ty officer stated the BUA will be reviewed at the 2/2	-
Additional discus		meeting included:	g.
6. #	D		01-25-2021
The protocol was prior to the meet a. clarifica	ing: ation of statistica	the following points were addressed by the Princip al justification meeting included:	
7. <b>#</b>	D		02-02-2021
prior to the meet a. Clarific	ing: ation on proced	the following points were addressed by the Princip lures and postop care meeting included:	
8.#	D		02-04-2021
	ation of endpoir	nts. meeting included:	
9. #	С		02-03-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	al Investigator
10. #	D		01-21-2021
prior to the meet a. Protoco	ing: of updated to inc	the following points were addressed by the Princip clude all funding sources. meeting included:	al Investigator
11. #	DY		02-04-2021
prior to the meet a. Biosafe	ing: ty officer confin	the following points were addressed by the Princip med the BUA had been approved. meeting included:	al Investigator

12. #	D		01-25-2021
prior to the meet a. Clarific	ting: ation of drugs.	the following points were addressed by the Principa meeting included:	I Investigator
13. #	С		-
prior to the meet a. Clarific Additional discu	ting: ation of proced ssion during the	the following points were addressed by the Principa ures, drugs, adverse effects, and personnel. meeting included: rbiage recommendation.	I Investigator
14. #	В		01-25-2021
prior to the meet a. None. Additional discus a. None.	ting: ssion during the	the following points were addressed by the Principa meeting included:	I Investigator
15. #	С		-
prior to the meet a. None. Additional discu	ting: ssion during the	the following points were addressed by the Principa meeting included:	I Investigator
a. pendin			01 20 2021
16. #	D		01-29-2021
prior to the meet a. Clarific	ting: ation of source	the following points were addressed by the Principa of animals and locations. meeting included:	I Investigator
17. #	С		02-04-2021
prior to the meet a. Clarific	ting: ation of proced	the following points were addressed by the Principa ures and adverse effects. meeting included:	I Investigator
18. #	D		02-04-2021
The protocol wa prior to the meet a. None.		the following points were addressed by the Principa	I Investigator
	ssion during the	meeting included:	
19. #	DY		01-26-2021
	1		

The protocol was reviewed and the following points were addressed by the Principal Investigator					
prior to the meet					
	a. PI provided clarification regarding final disposition of any animals that sero-convert.				
	Additional discussion during the meeting included:				
	a. None.				
20. #	С		-		
		the following points were addressed by the Princip	oal Investigator		
prior to the meet					
	ation of proced				
		e meeting included:			
		ommendation of reviewer.			
21. #	DY		01-22-2021		
		the following points were addressed by the Princip	bal Investigator		
prior to the meet					
a. Clarify		and the first second state in the			
		mended for increased flexibility.	a data midina a a		
	e option to xylaz	zine vs dexmedetomidine; suggest including dexm	edetornidine as		
		e meeting included:			
a. None.	ssion during the	meeting molded.			
22. #	С				
22. 7	l C		_		
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator		
prior to the meet		the following points were addressed by the finite	a investigator		
		es and procedures.			
		e meeting included:			
a. Pendin					
23. #	B		02-04-2021		
	s reviewed and	the following points were addressed by the Princip			
prior to the meet		the following points were addressed by the Finite			
a. None.	g.				
Additional discus	ssion during the	e meeting included:			
a. None.	· ·				
24. #	С		02-04-2021		
The protocol wa	s reviewed and	the following points were addressed by the Princi	oal Investigator		
prior to the meet			•		
a. None.	-				
Additional discus	ssion during the	e meeting included:			
a. None.					
25. #	С		-		
		the following points were addressed by the Princip	oal Investigator		
prior to the meet					
	g PI response	and the standards			
	ssion during the	e meeting included:			
a. None.	<b></b>				
26. #	C		01-22-2021		
	The protocol was reviewed and the following points were addressed by the Principal Investigator				
prior to the meet	ting:				
a. None.					
Additional discussion during the meeting included: a. None.					
	BV		02.04.2024		
27.#	BY		02-04-2021		

The protocol was reviewed and the following points were addressed by the Principal Investigator						
prior to the meeting:						
a. None.	· ·					
Additional discus	Additional discussion during the meeting included:					
a. None.	_					
28. #	D		01-26-2021			
The protocol was	reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the meeti		51 5				
a. None.	5					
Additional discus	sion during the	e meeting included:				
a. None.	5	5				
29. #	С		_			
20. "	Ŭ					
The protocol was	roviowed and	the following points were addressed by the Princi	nal Investigator			
prior to the meeti		the following points were addressed by the Frinci	parinvestigator			
		n animal numbers and potential adverse effects.				
		e meeting included:				
	is in DMR.	meeting included.				
30. #	D		-			
		the following points were addressed by the Princi	pal Investigator			
prior to the meeti						
		procedure details.				
		e meeting included:				
a. Remain	ns in DMR.					
31. #	СҮ		02-04-2021			
The protocol was	s reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the meeti	ing:					
a. None.	-					
Additional discus	sion during the	e meeting included:				
a. None.						
32. #	С		02-04-2021			
The protocol was	reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the meeti			parinteetigator			
a. None.						
	sion during the	e meeting included:				
a. None.						
33. #	D		02-04-2021			
55. #	5		02-04-2021			
		the fellowing a sinte ways addressed by the Drivei				
		the following points were addressed by the Princi	pai investigator			
prior to the meeting: a. Clarification provided regarding animals numbers, anesthesia details, monitoring and						
			onitoring and			
	adverse effects					
	sion during the	e meeting included:				
a. None.	a. None.					

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	С		02-04-2021
The amendmen Investigator prio a. None.	or to the meeting	and the following points were addressed by the Pr g:	incipal
1			Obtained

Additional discussion during the meeting included: a. None.					
2. #	D		-		
The amendment		and the following points were addressed by the Pr	incipal		
Investigator prio a. None.			псра		
	scion during the	meeting included:			
a. Pendin					
3. #	DY		02-01-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	r.			
a. None.		we attend to shall all			
a. None.	ssion during the	e meeting included:			
4.#	D		02-01-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	r			
a. None.					
	ssion during the	meeting included:			
a. None.					
5.#	DY		-		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	Г.			
a. None.					
		meeting included:			
a. Pendin					
6. #	D		02-04-2021		
<b>T</b> I I I					
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. None.	r to the meeting				
	ssion during the	e meeting included:			
a. None.	selen dannig die				
7.#	DY		02-04-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio					
a. None.					
	ssion during the	meeting included:			
a. None.					
8.#	D		02-02-2021		
	The amendment was reviewed and the following points were addressed by the Principal				
Investigator prio					
	ation on justific	e meeting included:			
a. None.		meeting included.			
9.#	DY		01-25-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior to the meeting:					
a. None.	-				
	ssion during the	meeting included:			
a. None.					
10.#	DY		02-02-2021		

The amendment	t was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio			
	ation on advers		
	ssion during the	meeting included:	
a. None.	<b>- - - -</b>		
11. #	DY		01-29-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.			
	ssion during the	meeting included:	
a. None.			
12. #	D		02-04-2021
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	:	
a. None.			
	ssion during the	meeting included:	
a. None.			
13. #	DY		01-25-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	:	
a. None.			
	ssion during the	meeting included:	
a. None.			
14.#	DY		02-04-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	:	
a. None.			
	ssion during the	meeting included:	
a. None.			
15. #	DY		01-28-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	i -	
a. None.	a a i a ma a lu universe tila a	we atting in all rate of	
a. None.	ssion during the	meeting included:	
	<b></b>	n o sur of t	01.05.0001
16. #	D	nograft	01-25-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	:	
	scion during the	meeting included:	
a. None.	ssion during the		
17. #	DY		02-04-2021
17.#			02-04-2021
The amondment		and the following points were addressed by the Pr	incipal
Investigator prior			ncipai
a. None.	i to the meeting	•	
	ssion durina the	meeting included:	
a. None.			
18.#	DY		02-04-2021
		and the following points were addressed by the Pr	1
Investigator prior			
a. None.	. is the mooning		
	ssion during the	meeting included:	
a. None.		-	
19. #	D		02-04-2021

		and the following points were addressed by the Pr	incipal
Investigator prio a. None.	r to the meeting	Γ.	
	ssion during the	meeting included:	
20. #	D		02-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
a. None.	_		
21. #	с		01-27-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
22. #	С		02-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
23. #	С		02-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
24. #	D		02-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
25. #	DY		02-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
26. #	DY		01-23-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
27.#	D		02-01-2021
Investigator prio a. None. Additional discu	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
a. None.	DY		02-04-2021


The amendment Investigator prio		and the following points were addressed by g:	the Principal
a. None. Additional discus a. None.	ssion during the	e meeting included:	
29. #	С		01-29-2021
Investigator prio a. None.	r to the meeting		the Principal
Additional discus a. None.	ssion during the	e meeting included:	
30. #	D		01-29-2021
Investigator prio a. Clarific	r to the meeting ation on proce		the Principal
31. #	С		-
Investigator prio a. Pendin	r to the meeting g PI response		the Principal
32. #	E		-
a. None. Additional discus a. None. <b>33. #</b>	ssion during the	e meeting included:	
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by g: e meeting included:	the Principal
34. #	DY		02-03-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by g: e meeting included:	the Principal
35. <b>#</b>	E		02-03-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by g: e meeting included:	the Principal
36. #	D		02-04-2021
		and the following points were addressed by	

### VIII. Administrative and Veterinary Verification Amendments:

Total of **73** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.



4. #		D			02-04-2021
			and	I the following points were addressed by the Princi	pal Investigator
	the mee	ting: cation of LF		6	
1				e meeting included:	
	a. None.		gan		
	IAC	UC Vote			
	Approva	l	16		
	Withhold	Approval	0		
	Abstain		1		
	Present		17		
5. #		D			02-04-2021
	otocol wa	s reviewed	and	I the following points were addressed by the Princi	pal Investigator
prior to	the mee	ting:			, j
				II as BUA staff roster.	
Additio		ved by con		e meeting included: ee vote.	
		UC Vote			
	Approva		17		
		d Approval			
	Abstain		0		
	Present		17		
6. #	Tresent	D			02-16-2021
0.#		U			02-10-2021
The pr	otocol wa	s reviewed	and	I the following points were addressed by the Princi	pal Investigator
prior to	the mee	ting:			J J
				Reviewers request clarification on procedures.	
Additio		to send to		e meeting included:	
		UC Vote			
	Approva		0		
		Approval	-		
	Abstain	ar oppiorai	0		
	Present		17		
7 4	resent	P.V.			02.04.2024
7. #	otocol wa	B Y	land	the following points were addressed by the Princi	02-04-2021
	otocol wa		anc	a the following points were addressed by the Princi	parinvestigator
-	a. None.	-			
		ssion durin	ng the	e meeting included:	
	a. None.				
		UC Vote	10		
	Approva		16		
		d Approval	_		
	Abstain		0		
	Present		16		
8. #		E			02-04-2021
			1.00		al lauration t
	otocol wa the mee		and	the following points were addressed by the Princi	pai Investigator
	a. None.	ung.			
Additio	nal discu			e meeting included:	
	a. reques	st DMR so	PI ca	an add more about monitoring.	

IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	17

## X. Annual Renewals:

Protocol	Category	Title Original Approval	Last Reviewed	Expires
	С	02-11-2019	02-04-2021	02-11-2022
	D	02-07-2019	02-04-2021	02-07-2022
	D	02-07-2019	02-04-2021	02-07-2022
	С	02-13-2019	02-04-2021	02-13-2022
	DY	02-07-2019	02-04-2021	02-07-2022
	С	02-07-2019	02-04-2021	02-07-2022
	С	02-07-2019	02-04-2021	02-07-2022
	D	02-07-2019	02-04-2021	02-07-2022
	D	02-11-2019	02-04-2021	02-11-2022
	С	02-11-2019	02-04-2021	02-11-2022
	С	02-06-2019	02-04-2021	02-06-2022
	С	02-06-2019	02-04-2021	02-06-2022
	DY	02-14-2019	02-04-2021	02-14-2022
	DY	02-07-2019	02-04-2021	02-07-2022
	ΒY	02-11-2019	02-04-2021	02-11-2022
	С	02-19-2019	02-04-2021	02-19-2022
	D	02-20-2020	02-17-2022	02-20-2023
	E	02-12-2020	02-04-2021	02-12-2022
	С	02-13-2020	02-03-2022	02-13-2023
	С	02-11-2020	02-03-2022	02-11-2023

	00.44.0000		
E	02-11-2020	02-04-2021	02-11-2022
С	02-12-2020	02-03-2022	02-12-2023
С	02-12-2020	02-03-2022	02-12-2023
DY	02-13-2020	02-03-2022	02-13-2023
DY	02-20-2020	02-17-2022	02-20-2023
С	02-13-2020	02-03-2022	02-13-2023
EY	02-20-2020	02-17-2022	02-20-2023
С	02-20-2020	02-04-2021	02-20-2022
DY	02-07-2020	02-03-2022	02-07-2023
D	02-12-2020	02-03-2022	02-12-2023
D	02-18-2020	02-03-2022	02-18-2023
С	02-18-2020	02-03-2022	02-18-2023
С	02-18-2020	02-03-2022	02-18-2023
D	02-11-2020	02-03-2022	02-11-2023
С	02-19-2020	02-17-2022	02-19-2023
С	02-20-2020	02-17-2022	02-20-2023
С	02-19-2020	02-17-2022	02-19-2023
СҮ	02-20-2020	02-17-2022	02-20-2023

Discussion:	-PI listed in section 11. &permit listed on protocol has expired. PI's provided updated permit information. -Review of physical methods of euthanasia and 2020 AVMA Guidelines. PI provided updated wording for justification for RCC method. and One or more persons is in process of completing their OHSS renewal. They are pending the final step of completing an in person appointment.
Action Items:	- working on MOU. &

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

1. #       D       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting:       a. Clarification on procedure justification         a. Clarification on procedure justification       dditional discussion during the meeting included:       a. None.         IACUC Vote       Approval       16       Withhold Approval       0         Abstain       1       Present       17       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting:       a. None.       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting:       a. None.       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting:       a. None.       02-04-2021         Approval       16       Withhold Approval       0       Abstain       1         Present       17       0       02-04-2021       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting:       a. Discussed proposed plan to ameliorate adverse effect.         a. Discussed proposed plan to ameliorate adverse effect.       dditional discussion during the meeting included:       a. Approval       17      <	Protocol	Category	Request	Date Approved
a. Clarification on procedure justification (dditional discussion during the meeting included: <ul> <li>a. None.</li> <li>IACUC Vote Approval</li> <li>Abstain</li> <li>Present</li> <li>T</li> </ul> 02-04-2021             Abstain         1           Present         17           2. #         E         02-04-2021           he amendment was reviewed and the following points were addressed by the Principal twestigator prior to the meeting: <ul> <li>a. None.</li> <li>dditional discussion during the meeting included:             <ul> <li>a. None.</li> <li>IACUC Vote</li> <li>Approval</li> <li>16</li> <li>Withhold Approval</li> <li>Abstain</li> <li>T</li> <li>Tersent</li> <li>T</li> </ul> </li> <li>a. None.</li> <li>IACUC Vote</li> <li>Approval</li> <li>Abstain</li> <li>T</li> <li>Present</li> <li>T</li> </ul> <li>b. To compare the points were addressed by the Principal twestigator prior to the meeting:             <ul> <li>a. None.</li> <li>IACUC Vote</li> <li>Approval</li> <li>T</li> <li>D</li> <li>D</li> <li>O2-04-2021</li> </ul> </li> <li>he amendment was reviewed and the following points were addressed by the Principal twestigator prior to the meeting:                  <ul> <li>a. Discussed proposed plan to ameliorate adverse effect.</li> <li>dditional discussion during the meeting included:</li></ul></li>	1. #	D		02-04-2021
2. #       E       02-04-2021         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:       a. None.         a. None.       a. None.         dditional discussion during the meeting included:       a. None.         IACUC Vote       Approval         Abstain       1         Present       17         3. #       D         02-04-2021         the amendment was reviewed and the following points were addressed by the Principal numbers         a. biscussed proposed plan to ameliorate adverse effect.         a. Approved by committee vote.         IACUC Vote         Approval       17         Withhold Approval       0         Abstain       1         Present       17	nvestigator pri a. Clarif dditional discr a. None IA( Approv Withhol Abstain	or to the meetin ication on proce ussion during th CUC Vote al 16 d Approval 0 1	ig: edure justification	rincipal
he amendment was reviewed and the following points were addressed by the Principal vestigator prior to the meeting: a. None. dditional discussion during the meeting included: a. None. IACUC Vote Approval 16 Withhold Approval 0 Abstain 1 Present 17 3. # D 02-04-2021 the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following points were addressed by the Principal the amendment was reviewed and the following the meeting included: a. Approved by committee vote. IACUC Vote Approval 17 Withhold Approval 0 Abstain 0 Present 17				02-04-2021
Present       17         3. #       D         02-04-2021         The amendment was reviewed and the following points were addressed by the Principal hvestigator prior to the meeting:         a. Discussed proposed plan to ameliorate adverse effect.         additional discussion during the meeting included:         a. Approved by committee vote.         IACUC Vote         Approval       17         Withhold Approval       0         Abstain       0         Present       17	a. None IA( Approv Withhol	CUC Vote al 16 d Approval 0		
he amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting: a. Discussed proposed plan to ameliorate adverse effect. additional discussion during the meeting included: a. Approved by committee vote. IACUC Vote Approval 17 Withhold Approval 0 Abstain 0 Present 17				
a. Discussed proposed plan to ameliorate adverse effect. additional discussion during the meeting included: a. Approved by committee vote. IACUC Vote Approval 17 Withhold Approval 0 Abstain 0 Present 17	3. #	D		02-04-2021
	nvestigator pri a. Discu Additional discu a. Approv Approv Withhol Abstain	or to the meetin ssed proposed ussion during th oved by commit CUC Vote al 17 d Approval 0 0	g: plan to ameliorate adverse effect. le meeting included:	rincipal
	Present			02-04-2021

				and the following points were addressed by the	Principal
	gator pric a. None.	or to the me	eetir	g:	
			na th	e meeting included:	
	a. None.		.9	o mooting molace.	
	IAC	UC Vote			
	Approva	al	16		
	Withhold	d Approval	0		
	Abstain		1		
	Present		17		
5. #		С			02-04-2021
	a. Appro <b>IAC</b> Approva	<u>ved by con</u> E <b>UC Vote</b> Il d Approval	nmit 17	ie meeting included: tee vote.	
6. #		DY	••		02-04-2021
Investio Additio	gator pric a. None. nal discu a. None.	or to the me	eetir	and the following points were addressed by the g: he meeting included:	Principal
			10		
	Approva		16 0		
		d Approval			
	Abstain		1		
	Present		17		

# XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.01-19-2021		
2. 01-21-2021		
3. 01-26-2021		

Discussion:	None.	
Action:	None.	
	ACUC Vote	
Appro	oval	17
With	nold Approval	0
Absta		0
Prese	ent	17

### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
	LAB	
	PAM	

 Discussion:
 14. After the last IACUC meeting and discussion, the PAM was resent to the PI to update her protocol grants.

 16. The PAM was updated after the last meeting to include additional deficiencies and request for PI to hire a well trained lab manager.

 Action:
 14. PI updated new protocol to include all granting sources.

 16. PI has agreed to supervisor staff during procedures until a lab manager has been hired.

 IACUC Vote

 Approval
 17

 Withhold Approval
 0

 Abstain
 0

 Present
 17

#### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

#### XV. Other Discussion Items:

Торіс	Торіс				
1. 4th qrtr flu	1. 4th qrtr fluid report				
Discussion:	One husbandry staff fluid error previously reported; no animal welfare concerns.				
Action:					
2. VMTH Eq	uine anesthesia SOP				
Discussion:	Only minor typos and grammatical changes were suggested.				
Action:	Approved by committee vote.				
3. Wild gees	3. Wild geese				
Discussion:	None.				
Action:	None.				

# XVI. Program Updates:

Торіс

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### February 18, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M005, M111, M090, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M024, M001, M114

#### Excused:

M102, M016, M112

#### Guests:

M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### **IV. Reports of Concern, Events and Incidents:**

	CUC reviewed and discussed the following report(s) of concern, events, cidents:
CARU	fire
	Action: Under investigation. Storage area only, no animal housing.
	Action: Amendment submitted will be reviewed at the next meeting.
	Action: Miscommunication regarding housing return and monitoring. No animal welfare issues; noted as PAM.
	Action: Discrepancy in genotyping dates and procedures.
Holdin	g protocol -
	Action: Animals ordered via special order were not entered into the ATS as an import request. AV working with vendor to clarify health status before putting animals in the general population.


### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

#### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
2. #	E		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
3. #	D		02-18-2021
prior to the meet a. Clarific	ting: ation on termin	the following points were addressed by the Princip ology e meeting included:	oal Investigator
4. #	DY		-
prior to the meet a. Pendin Additional discus	ting: Ig BUA approva	the following points were addressed by the Princip al. e meeting included:	oal Investigator
5. #	С		02-16-2021
prior to the meet a. None. Additional discus	ling:	the following points were addressed by the Princip e meeting included:	oal Investigator
a. None. 6. #	С		02-18-2021
prior to the meet a. None.	ling:	the following points were addressed by the Princip	oal Investigator
a. None.	_	e meeting included:	
7. #	D		02-18-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator



a. Pendin	ig PI.		
15. #	D		02-04-2021
prior to the meet a. Clarific Additional discus	ting: ation of MTD st	the following points were addressed by the Princip tudy details and animal numbers justification provid meeting included:	C C
a. None. 16. #	С		02-09-2021
prior to the meet a. Clarific Additional discus	ting: ation on timepo	the following points were addressed by the Princip ints meeting included:	al Investigator
a. None. 17. #	С		02-18-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip	al Investigator
18. #	С		02-17-2021
orior to the meet a. Clarific	ting: ation provided r	the following points were addressed by the Princip regarding potential adverse effects. meeting included:	al Investigator
19. #	D		02-10-2021
prior to the meet a. Clarific	ting: ation provided r	the following points were addressed by the Princip numbers justification and demographics of study ar meeting included:	-
20. #	D		02-16-2021
prior to the meet a. Final re review.	ting: eview completed	the following points were addressed by the Princip d by the biosafety office and VHSS' updated based meeting included:	-
21. #	С		02-18-2021
The protocol was prior to the meet a. None.	s reviewed and ting:	the following points were addressed by the Princip meeting included:	
22. #	С		-
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	al Investigator

a. Pendin	g Review of res	sponses	
23. #	E		02-04-2021
prior to the meet a. Clarific b. clarific c. Clarific d. Clarific	ing: ation of anesthe ation of post pro ation of timeline ation of when C	the following points were addressed by the Princip esia and analgesia. bocedure monitoring. e. CVS will be contacted. e meeting included:	oal Investigator
24. #	СҮ		02-16-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	bal Investigator
25. #	С		02-17-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
26. #	CY		02-16-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	oal Investigator
27. #	С		02-17-2021
prior to the meet a. PI conf	ing: firmed campus l	the following points were addressed by the Princip breeding SOP would be followed. e meeting included:	bal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved		
1.#	D		-		
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	incipal		
2. #	DY		-		
2. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. None.       -         Additional discussion during the meeting included:       -         a. Pending reviewer.       -					

3. #	С		02-18-2021
The amendment	was reviewed	and the following points were addressed by the P	rincipal
Investigator prio			
a. None.	-		
Additional discus	ssion during the	e meeting included:	
a. None.			
4. #	DY		-
The amendment	was reviewed	and the following points were addressed by the P	rincipal
Investigator prio			
a. None.			
		e meeting included:	
a. Pendin	ig reviewer.		
5.#	D		02-18-2021
		and the following points were addressed by the P	rincipal
Investigator prio	r to the meeting	j:	
a. None.	ssion during the	e meeting included:	
a. None.	ssion during the		
6. #	D		02-18-2021
0. #			02-10-2021
The amendment	was reviewed	and the following points were addressed by the P	rincinal
Investigator prio			ппсіраі
a. None.	r to the meeting	j.	
	ssion during the	e meeting included:	
a. None.	•		
7.#	E		02-18-2021
The amendment	was reviewed	and the following points were addressed by the P	rincipal
Investigator prio			
a. None.			
	ssion during the	e meeting included:	
a. None.			
8. #	C		02-18-2021
		and the following points were addressed by the P	rincipal
Investigator prio	r to the meeting	j:	
a. None.		, una estimati in el cele els	
		e meeting included: If the amendment and the original objective of the	protocol
			-
9.#	DY		02-04-2021
		and the following points were addressed by the P	rincipal
Investigator prio a. None.		J.	
	ssion during the	e meeting included:	
a. None.		needing monded.	
10. #	D		02-18-2021
	<u> </u>	and the following points were addressed by the P	
Investigator prio			
a. None.		<del>,</del>	
	ssion during the	e meeting included:	
a. None.			
11. #	DY		02-09-2021
The amendment	t was reviewed	and the following points were addressed by the P	rincipal
Investigator prio			-
a. None.			
	ssion during the	e meeting included:	
a. None.			

12. #	С		02-17-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.	-		
	ssion during the	e meeting included:	
a. None.			
13. #	CY		02-16-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. Anesth	etic choice and	procedure clarifications.	
	ssion during the	e meeting included:	
a. None.			
14. #	B		02-09-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	r.	
a. None.			
	ssion during the	e meeting included:	
a. None.			
15. #	DY		02-17-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	Г.	
a. None.			
	ssion during the	e meeting included:	
a. None.	-		
16. #	C		02-18-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	i:	
a. None.		and the standards	
a. None.	ssion during the	e meeting included:	
	•		00.00.0004
17. #	C	· · · · · · · · · · · · · · · · · · ·	02-03-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	J.	
	ssion during the	e meeting included:	
a. None.	ssion during the		
18. #	D		
10. #			-
The amendment	was reviewed	and the following points were addressed by the Pr	incinal
Investigator prior			litipa
a. None.	i to the meeting		
	ssion durina the	e meeting included:	
	g verification of		
19. #	D		-
	_		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.	-		
		e meeting included:	
a. Pendin	g verification of	Lab SOP	
20. #	С		02-17-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. Clarific	ation on contan	ninated bedding disposal.	
	ssion during the	meeting included:	
a. None.			

21. #	DY		02-16-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
22. #	с		02-18-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
23. #	E		02-11-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	-
24. #	DY		02-10-2021
Investigator prior a. Clarific	to the meeting ation of adverse		incipal
25. #	D		02-08-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal


## VIII. Administrative and Veterinary Verification Amendments:

Total of **174** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protoco	I Catego	ory	Title	Date Approved
1. #	E			02-22-2021
		and	the following points were addressed by the Princi	pal Investigator
prior to the i	-			
a. No				
Additional d	iscussion durin	ng the	e meeting included:	
a. Pe	nding final edit	t by I	기	
	IACUC Vote			
App	roval	0		
With	hold Approval	0		
Abst	ain	0		
Pres	ent	21		



			the following points were addressed by the Princip	oal Investigator
	a. Clarify stu	idy groups.		
	a. None.	on during the	meeting included:	
	IACUC	Vote		
	Approval	21		
	Withhold Ap	oproval 0		
	Abstain	0		
	Present	21		
7. #		BY		02-22-2021
orior to	the meeting a. Pending F	j: Pl response	the following points were addressed by the Princip	oal Investigator
Additio	a. Assigned	to DMR	meeting included:	
	IACUC	Vote		
	Approval	0		
	Withhold Ap	oproval 0		
	Abstain	0		
	Present	19		
8. #		DY		02-18-2021
	IACUC			
	Approval	19		
	Withhold Ap	oproval 0		
	Abstain	0		
	Present	19		
9. #		СҮ		02-18-2021
prior to	the meeting a. None.	: on during the	the following points were addressed by the Princip meeting included:	bal Investigator
	Approval	20		
	Withhold Ap			
	Abstain	0		
	Present	20		
10. <i>‡</i>		DY		02-24-2021
he pr		eviewed and	the following points were addressed by the Princip	I
	a. Ongoing	discussion be	etween veterinarians regarding appropriate anesth meeting included:	etic plan
			meeting moldeed.	
	a. Assigned	to DMR	meeting moldeet.	
		to DMR		

	Withhold A	Approval 0		
	Abstain	0		
	Present	21		
11. #		DY		02-24-2021
orior to a Additio	the meeting a. Ongoing nal discuss a. Assigne	ng: g discussion b	I the following points were addressed by the Princip etween veterinarians regarding appropriate anesth e meeting included:	-
	Approval	0		
	Withhold A	Approval 0		
	Abstain	0		
	Present	21		

#### X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		02-21-2019	02-18-2021	02-21-2022
	С		02-19-2019	02-18-2021	02-19-2022
	DY	Q	02-21-2019	02-18-2021	02-21-2022
	D		03-01-2019	02-18-2021	03-01-2022
	С		02-21-2019	02-18-2021	02-21-2022
	DY		02-21-2019	02-18-2021	02-21-2022
	D		02-21-2019	02-18-2021	02-21-2022
			02-28-2019	02-18-2021	02-28-2022
	DY		02-22-2019	02-18-2021	02-22-2022
	D		02-21-2019	02-18-2021	02-21-2022
	С		02-21-2019	02-18-2021	02-21-2022
	С		02-20-2019	02-18-2021	02-20-2022
	D		02-21-2019	02-18-2021	02-21-2022
	CY		02-21-2019	02-18-2021	02-21-2022
	DY		02-21-2019	02-18-2021	02-21-2022
			02-20-2020	02-17-2022	02-20-2023
					1

D	02-25-2020	02-17-2022	02-25-2023
С	02-04-2020	02-18-2021	02-04-2022
СҮ	02-05-2020	02-17-2022	02-05-2023
D	02-25-2020	02-17-2022	02-25-2023
С	02-28-2020	02-17-2022	02-28-2023
С	03-05-2020	03-03-2022	03-05-2023
DY	03-04-2020	02-17-2022	03-04-2023
D	03-04-2020	02-17-2022	03-04-2023
С	03-05-2020	03-03-2022	03-05-2023
DY	03-04-2020	02-17-2022	03-04-2023
DY	02-21-2020	02-17-2022	02-21-2023
С	03-03-2020	02-17-2022	03-03-2023
D	03-05-2020	03-17-2022	03-05-2023
С	03-05-2020	03-17-2022	03-05-2023
СҮ	02-28-2020	02-18-2021	02-28-2022
D	03-02-2020	02-17-2022	03-02-2023
D	03-05-2020	03-03-2022	03-05-2023
С	02-24-2020	02-17-2022	02-24-2023
D	03-05-2020	02-18-2021	03-05-2022
С	03-04-2020	02-17-2022	03-04-2023
D	03-05-2020	03-03-2022	03-05-2023
С	03-05-2020	03-03-2022	03-05-2023
С	03-04-2020	02-17-2022	03-04-2023
С	03-04-2020	02-17-2022	03-04-2023
С	03-05-2020	03-03-2022	03-05-2023

Discussion:

And At least one staff member is in the process of renewing their occupational health status. All are in the last step either requiring an

	process. PI re to update the and	ports she needs to get information from her doctor in order form correctly. -permits on protocols are expired. Is not active be obtained prior to starting studies again.
Action Items:	s: Annual Renewals approved. and IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	
	ACUC Vote	
Appro	oval	17
Withh	old Approval	0
Absta	in	0
Prese	ent	17

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protoco	Category	Request	Date Approved
1. #	D		02-18-2021
Investigato a. E proc Additional o	r prior to the meetin dit regarding tubing edure.	d and the following points were addressed by the Pi ig: size and clarification regarding the number of anim he meeting included:	
	IACUC Vote		
App	roval 21		
Wit	nhold Approval 0		
Abs	tain 0		
Pre	sent 21		

### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 08-26-2020	
2. 01-21-2021	
3. 01-21-2021	
4. 01-21-2021	
5. 01-28-2021	
6. 01-28-2021	

Discussion: 2. PI maintained area approved for hand washing with QA testing verification. Re-testing was not performed on cage that failed QA testing.

Action: 2. PI acknowledges and will follow plan to implement QA testing in advance to ensure re-testing occurs prior to animals being housed on campus.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 11-10-2020	LAB	
2. 01-20-2021	LAB	
3. 11-27-2019	PAM	
4.06-30-2020	PAM	
5. 07-07-2020	PAM	
6. 10-15-2020	PAM	
7. 10-23-2020	PAM	
8. 11-10-2020	PAM	
9. 12-01-2020	PAM	
10. 12-01-2020	PAM	
11. 12-02-2020	PAM	
12. 12-23-2020	PAM	
13. 12-27-2020	PAM	
14. 01-15-2021	PAM	
15. 01-28-2021	PAM	
16. 02-05-2021	PAM	
17. 02-10-2021	PAM	

Discussion:	None.	
Action:	Approved.	
1	ACUC Vote	
Appr	oval	20
With	nold Approval	0
Absta	ain	0
Pres	ent	20

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс	
1) Policy Sul	pcommittee re-instatement- call for volunteers
	Role of subcommittee, anticipated meeting frequency, and current members. Request for additional volunteers.
	Volunteers asked to contact IACUC Chair or Director. If no volunteers, subcommittee appointments will be made by IACUC Chair per policy.
2) Ag Anima	l: Analgesia and Anesthesia subcommittee

Discussion:	Role of subcommittee, anticipated meeting frequency, and current members. Request for additional volunteers.
Action:	Volunteers asked to contact IACUC Chair or Director. If no volunteers, subcommittee appointments will be made by IACUC Chair per policy.
3) 47	mice to holding protocol
Discussion:	None.
Action:	None.
4) FYI - USE	DA incentive program ending
Discussion:	FYI.
Action:	None.
5) FYI - OHS	SS: COVID vaccination and TB testing delay
Discussion:	FYI. 4 week delay recommended. May delay completion of TB testing in timely manner for individuals receiving COVID-19 vaccination if there is overlap. Recognize individuals receiving vaccine may not always have ability to plan ahead or around this depending on short notice of vaccine
	distribution and availability.
Action:	
	distribution and availability.
6) New IACl	distribution and availability. Approved.

# XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### March 04, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M005, M222, M102, M111, M090, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M001, M112, M114

#### Excused:

M042

Guests:

M116, A018

#### I. Minutes from Previous Meetings:

The IACUC reviewed a	nd app	roved the January 7, 2021, meeting minutes as written.
IACUC Vot	te	
Approval	16	
Withhold Appro	val 0	
Abstain	0	
Present	16	
The IACUC reviewed a	nd app	roved the February 4, 2021, meeting minutes as written.
IACUC Vot	te	
Approval	16	
Withhold Appro	val 0	
Abstain	0	
Present	16	
The IACUC reviewed a	nd app	roved the February 18, 2021, meeting minutes as written
IACUC Vot	te	
Approval	16	
Withhold Appro	val 0	
Abstain	0	
Present	16	

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

	Action: PI submitted an amendment to change behavioral testing time point. Reviewed under FC amendments along with PAM.
SAEN	"news release" and USDA complaint
	Action: FYI only, "news release" not factual and non event. Old USDA complaint; previously addressed.
f.	
	Action: PI submitted an amendment to clarify incident. Approved procedure followed with euthanasia.
Expire	d <b>e se se</b>
	Action: ATS issue, not procedural issue.
CARL	break-in
	Action: FYI; under police investigation.

# V. Veterinary Care Program Updates:

٦	The Attending Veterinarian provided the following updates to the committee:
	None at this time.

# VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		-
prior to the meet a. None.	ling:	the following points were addressed by the Princip e meeting included:	oal Investigator
2. #	E		-
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
3. #	DY		02-23-2021
prior to the meet a. BUA a	ting: pproved by bios	the following points were addressed by the Princip safety. e meeting included:	oal Investigator
4. #	E		02-22-2021
prior to the meet a. None.	ling:	the following points were addressed by the Princip e meeting included:	bal Investigator

5. #	С		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator						
prior to the meeting: a. Pending PI's response to clarify procedures.						
	ns in DMR.	meeting included:				
6. #	DY		-			
The protocol was	s reviewed and	the following points were addressed by the Princip	bal Investigator			
prior to the meet a. None.			g			
	ssion during the	meeting included:				
a. None.	sion during the					
	<b>_</b>		00.40.0004			
7.#	D		02-18-2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	oal Investigator			
prior to the meet			-			
		r completed their review and provided VHSS for se	ection 19.			
		meeting included:				
a. None.	solori daning the	Theoding moladed.				
	-		00.04.0004			
8. #	D		02-24-2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	bal Investigator			
prior to the meet			rui inteetigutei			
	ation of number	re and druge				
	ssion during the	meeting included:				
a. None.						
9. #	DY		-			
The protocol was	s reviewed and	the following points were addressed by the Princip	oal Investigator			
prior to the meet			<b>..</b> <i>.</i> <b>..</b>			
a. None.	g.					
	scion during the	meeting included:				
a. None.	soon during the	meeting moluded.				
10. #	BY		02-22-2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	oal Investigator			
prior to the meet						
	ation on animal	numbers				
		meeting included:				
a. None.	set adding the					
			00.04.0004			
11.#	С		03-04-2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	pal Investigator			
prior to the meet						
	ation of drug do	se				
		meeting included:				
a. None.	contracting the					
	-					
12. #	С		-			
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator			
prior to the meet		and reacting points were addressed by the Filling	a intestigator			
a. Clarification of standard-of-care and adverse effects. Additional discussion during the meeting included:						
		meeung included.				
a. Pendin	g reviewer.					
13. #	С		03-04-2021			

prior to the meet	ting:	the following points were addressed by the Princip	oal Investigator
	ation of adverse ssion during the	e meeting included:	
14. #	С		-
prior to the meet a. Clarific Additional discus	ting: ation of abbrevi	the following points were addressed by the Princip iations and stem cell dose. e meeting included:	oal Investigator
15. #	D		03-04-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
16.#	С		-
prior to the meet a. Clarific Additional discus	ting: ation of blood c	the following points were addressed by the Princip collection. e meeting included:	oal Investigator
17.#	С		03-04-2021
Additional discus a. None. 18. #	ssion during the	e meeting included:	03-02-2021
	_		
prior to the meet a. Clarific	ting: ation on husbai	the following points were addressed by the Princip ndry care e meeting included:	oal Investigator
19. #	С		-
prior to the meet a. Clarific Additional discus	ting: ation of post-se	the following points were addressed by the Princip edation monitoring and adverse effects. e meeting included:	bal Investigator
20. #	С		-
prior to the meet a. Clarific	ting: ation of numbe	the following points were addressed by the Princip rs justification. e meeting included:	bal Investigator
21. #	С		03-01-2021

Additional discus a. None.	ssion during the	meeting included:	
22. #	DY		02-24-2021
prior to the mee a. Clarific	ting: ation on proced	the following points were addressed by the Princip lure, anesthesia and blood collection meeting included:	oal Investigator
23. #	СҮ		03-03-2021
prior to the meet a. Clarific	ting: ation on husbar	the following points were addressed by the Princip ndry care meeting included:	oal Investigator
24. #	С		02-25-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
25. #	С		-
prior to the mee a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		-
nvestigator prio a. Clarifi	or to the meetin cation of proce ission during th	and the following points were addressed by the P g: dures in pre and post-weaned mice. e meeting included:	rincipal
2. #	CY		-
nvestigator pric a. Dispo Additional discu	or to the meetin sition. Ission during th	I and the following points were addressed by the P g: e meeting included: additional time to review disposition.	rincipal
3. #	DY		-
Investigator pric a. None. Additional discu	or to the meetin	e meeting included:	rincipal

4. #	С		03-04-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator price		g:	
a. None.			
a. None.	-	e meeting included:	
5. #	DY		02-25-2021
5. #			02-25-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator price			in olpai
a. None.		-	
	-	e meeting included:	
a. None.			
6. #	DY		02-26-2021
		and the following points were addressed by the Pr	incipal
Investigator pric a. None.		j.	
		e meeting included:	
a. None.	-		
7. #	D		03-04-2021
		and the following points were addressed by the Pr	incipal
Investigator price		g:	
a. None.		monting included:	
a. None.		e meeting included:	
8. #	D		
	<u> </u>	and the following points were addressed by the Pr	incipal
Investigator price			nopa
a. None.			
		e meeting included:	
a. None.			
9. #	E		-
		and the following points were addressed by the Pr	incipal
Investigator pric a. None.		].	
		e meeting included:	
a. Pendir		0	
10. #	С		-
		and the following points were addressed by the Pr	incipal
Investigator price		<b>j</b> :	
a. None.		e meeting included:	
a. Pendir		included.	
11. #	D		03-04-2021
	_		
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator price		g:	
a. None.			
a. None.	-	e meeting included:	
12. #	CY		03-04-2021
		and the following points wore addressed by the Dr	
Investigator pric		and the following points were addressed by the Pr	ncipai
a. None.		J.	
		e meeting included:	
a. None.			

13. #	С		03-03-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior to the meeting:					
	ation of caging				
Additional discus a. None.	ssion during the	e meeting included:			
14. #	С		03-04-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio a. None.	r to the meeting	j:			
a. None.	ssion during the	e meeting included:			
15. #	D		-		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
a. None.					
a. pendin		e meeting included:			
16. #	D D		03-04-2021		
10. #	D		03-04-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
a. None.	ssion during the	e meeting included:			
a. None.	ssion during the	needing moldaed.			
17. #	С		03-04-2021		
	t was reviewed	and the following points were addressed by the Pr			
Investigator prio			nopu		
a. None.					
	ssion during the	e meeting included:			
a. None.	_				
18. #	D		03-04-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio a. None.	r to the meeting	].			
	ssion during the	e meeting included:			
a. None.					
19. #			-		
		and the following points were addressed by the Pr	incipal		
Investigator prio a. None.	r to the meeting	j:			
	ssion during the	e meeting included:			
	ng reviewer.				
20. #	С		03-04-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
	ation on husba				
	ssion during the	e meeting included:			
a. None.			02 40 2024		
21. #		and the following points were addressed by the Pr	02-19-2021		
u na amandmani	t was rowowd	and the following points were addressed by the Pr	Incinal		
			lincipal		
Investigator prio a. None.			псра		

a. None.			
22. #	D		03-01-2021
Investigator prio a. Clarific No other	r to the meeting ation provided changes reque	and the following points were addressed by the Pr g: about change in dose applying to all animals in hig sted and no new adverse effects are anticipated. e meeting included:	
23. #	D		-
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
24. #			03-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
25. #	DY		-
a. None.	-	e meeting included:	
26. #	D		-
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
27. #	E		03-02-2021
Investigator prio a. Clarific	r to the meeting ation regarding	and the following points were addressed by the Pr g: padding under equipment. e meeting included:	incipal
28. #	С		-
Investigator prio a. None.	r to the meeting		incipal
Additional discu a. None.	ssion during the	e meeting included:	
29. #	D		02-22-2021
Investigator prio a. Chemi	r to the meeting cal safety office	and the following points were addressed by the Pr g: er completed their review and provided a new VHS e meeting included:	
30. #	DY		03-04-2021

Investigator pri a. None	or to the meeting ussion during the	and the following points were : meeting included:	addressed by the Pr	incipal
31. #	С			03-04-2021
Investigator pri a. None	or to the meeting ussion during the	and the following points were : meeting included:	addressed by the Pr	incipal

## VIII. Administrative and Veterinary Verification Amendments:

Total of **146** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1.#	DY		03-08-2021
orior to the mee a. Clarify b. Clarify Additional discu a. Approv Approva	eting: y duration betwe y exclusion crite ussion during th oved for designa CUC Vote al 0 d Approval 0 0	e meeting included:	ncipal Investigator
2.#	CY		03-04-2021
orior to the mee a. None Additional discu	eting: ussion during th	d the following points were addressed by the Prine e meeting included:	
	CHSS clearanc	e step delay approved through Employee Health	
Approva	al 23		
	d Approval 0		
Abstain	-		
Present			
3. #	DY		03-04-2021
prior to the mee a. None	eting:	d the following points were addressed by the Prin e meeting included:	icipal Investigator

a.	None.			
	IACUC Vo	ote		
A	Approval 23			
V	Vithhold Appro	oval 0		
A	bstain	0		
F	Present	23		
4.#				03-04-202
		ewed and	d the following points were addressed by the Princ	ipal Investigato
	he meeting:		edure and adverse effects	
			e meeting included:	
	None.		0	
	IACUC Vo	ote		
A	Approval	24		
V	Vithhold Appro	oval 0		
A	bstain	0		
F	Present	24		
5. #		D		03-04-2021
The prot	ocol was revie	ewed and	d the following points were addressed by the Princ	ipal Investigato
•	he meeting:			
	. None.	during th	e meeting included:	
	. None.	uunng u	le meeting included.	
Ē	IACUC Vo	ote		
A	Approval	24		
	Withhold Approval 0			
	Abstain	0		
F	Present	24		
6. #		DY		03-04-2021
		ewed an	d the following points were addressed by the Princ	ipal Investigato
	he meeting:			
	. None. al discussion (	durina th	e meeting included:	
	None.	a an ing a		
	IACUC Vo	ote		
Δ	Approval	23		
v	Vithhold Appro	oval 0		
	Abstain	0		
F	Present	23		
7.#				03-04-2021
		ewed an	d the following points were addressed by the Princ	ipal Investigato
	he meeting:	م ما ما ب م		
			ed during the pre-review process. e meeting included:	
	. None.	aanny ti		
Γ	IACUC Vo	ote		
A	Approval	24		
	Vithhold Appro			
	manola Apple			

	Abstain		0			
	Present		24			
8. #		С				03-04-2021
orior to	the mee a. Clarifional discu	ting: cation on lit ssion durin	era	d the following points were ture search and disposition he meeting included:		pal Investigato
	a. None.	UC Vote				
	Approva		24			
	Withhold Approval 0		0			
	Abstain		0			
	Present		24			
9. #		D				03-17-2021
prior to	the mee a. Clarific nal discu a. None.	ting: cation on in ssion durin	ject	d the following points were ions ie meeting included:	addressed by the Princi	pal Investigato
	IAC	UC Vote				
	Approva		0			
		d Approval	0			
	Abstain		0			
	Present		24			

### X. Annual Renewals:


Protocol	Category		riginal pproval	Last Reviewed	Expires
	С	03-	-06-2019	03-04-2021	03-06-2022
	DY	03-	12-2019	03-04-2021	03-12-2022
	D	03-	-06-2019	03-04-2021	03-06-2022
	DY	03-	07-2019	03-04-2021	03-07-2022
	D	03-	12-2019	03-04-2021	03-12-2022
	E	03-	07-2019	03-04-2021	03-07-2022
	СҮ	03-	-07-2019	03-04-2021	03-07-2022
	С	03-	-07-2019	03-04-2021	03-07-2022
	С	03-	-18-2019	03-04-2021	03-18-2022
	С	03-	19-2019	03-04-2021	03-19-2022
	DY	03-	-09-2020	03-03-2022	03-09-2023


В		03-13-2020	03-03-2022	03-13-2023
D		03- <mark>1</mark> 9-2020	03-17-2022	03-19-2023
С		03-19-2020	03-17-2022	03-19-2023
D		03-19-2020	03-17-2022	03-19-2023
D		03-10-2020	03-03-2022	03-10-2023
DY		03-19-2020	03-17-2022	03-19-2023
D		03-06-2020	03-03-2022	03-06-2023
DY		03-19-2020	03-17-2022	03-19-2023
С		03-19-2020	03-17-2022	03-19-2023
D		03-19-2020	03-17-2022	03-19-2023
DY		03-19-2020	03-17-2022	03-19-2023
D		03-19-2020	03-17-2022	03-19-2023
D		03-19-2020	03-17-2022	03-19-2023
DY		03-19-2020	03-17-2022	03-19-2023
С		03-19-2020	03-17-2022	03-19-2023
D		03-18-2020	03-03-2022	03-18-2023
permit ir -F being do process appointr	Permit information on protocol is expired. PI pr formation. Permit information on protocol is expired. PI rep one and permit will be acquired prior to work st One staff member is in the process of renewing ; on the last step and needs to complete an in nent.	ports no work is tarting again. g their OHSS		
-C	Committee approved adding new permit inform Committee approved annual renewal. Committee approved the annual renewal.	ation to protocol.		
Approval Withhold Appr	23 oval 0			
Abstain				
Present	23			

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable

regulations, UC Davis policies, and IACUC policies and guidelines.





Additional discussion during the meeting included:

	a. Voted t	to send to	DM	R.	
	IAC	UC Vote			
	Approval		0		
	Withhold	Approval	0		
	Abstain		0		
	Present		23		
10. #		D			05-04-2021
The an	nendment	was revie	we	d and the following points were addressed by the P	rincipal
		r to the me	eetir	ng:	
	a. None.	ssion durin	na th	ne meeting included:	
Auditio				request DMR.	
		UC Vote			
	Approval		0		
	Withhold	Approval	0		
	Abstain		0		
	Present		23		
11. #		DY	20		03-04-2021
11.7	" <b></b>				03-04-2021
The an	nendment	was revie	we	d and the following points were addressed by the P	rincipal
	•	r to the me	eetir	ng:	
	a. None.	acion durin		a maating included:	
	a. None.	sion durin	ıg u	ne meeting included:	
		UC Vote			
	Approval		23		
	1	Approval			
	Abstain	Approva	0		
	Present		23		
42.4		DY	25		04.45.2024
12. #				d and the following points were addressed by the P	04-15-2021
		r to the me			ппсіраі
	a. PI clari	fied incide	ent.	-	
Additio				ne meeting included:	
			bath	ology results.	
		UC Vote	~		
	Approval		0		
		Approval	_		
	Abstain		0		
	Present		23		
13. #		DY			03-04-2021
				d and the following points were addressed by the P	rincipal
investi		r to the me stions add		ig. sed during pre-review.	
Additio				ne meeting included:	
	a. Commi	ittee voted	l to	approve.	
	IAC	UC Vote			
	Approval	Í	23		
	Withhold	Approval	0		
	Abstain		0		
	Present		23		

14. #	DY		03-04-2021
The amendm	ent was reviewe	d and the following points were addressed by the Pri	ncipal
nvestigator p	rior to the meeti	ng:	
a. Cla	rification provide	d regarding timing of acquisition and studying starting	g points.
		ne meeting included:	
<u>a. Cor</u>	nmittee approve	d the amendment.	
L	ACUC Vote		
Appro	oval 23		
Withh	old Approval 0		
Absta	in 0		
Prese	nt 23		

# XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 10-28-2020	
2.01-27-2021	
3. 01-28-2021	
4. 01-28-2021	
5. 01-29-2021	
6. 01-31-2021	
7.01-31-2021	
8. 02-04-2021	
9. 02-05-2021	
10. 02-11-2021	
11. 02-11-2021	
12. 02-24-2021	
13. 02-24-2021	
14. 02-25-2021	
15. 02-25-2021	
16. 02-25-2021	
17.02-26-2021	

Discussion	3. Room log wa	as missing entries on two dates.
Action	3. The PI clarifi	ied the animals were checked but the documentation was missed.
	·	
	ACUC Vote	
Appr	oval 2	0
With	nold Approval (	
Abst	ain C	
Pres	ent 2	0

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 02-08-2021	LAB	
2. 02-08-2021	LAB	
3. 02-10-2021	LAB	
4. 02-17-2021	LAB	
5. 02-18-2021	LAB	

6. 02-18-2021	LAB	
7. 02-22-2021	LAB	
8. 02-22-2021	LAB	
9. 02-23-2021	LAB	
10. 02-24-2021	LAB	
11. 02-25-2021	LAB	
12. 02-26-2021	LAB	
13. 12-01-2020	PAM	
14. 12-22-2020	PAM	
15. 02-18-2021	PAM	
16. 02-18-2021	PAM	
17.02-18-2021	PAM	

Discussion: 9. Room log was missing census and entries were not being initialed. One drug being used was non-pharmaceutical grade but not justified in protocol. 15. PI contacted CVS the following day. 16. Animals were purchased without CVS assessment. Animals were placed on holding protocol. 17. PI submitted an amendment to verify start time of behavior testing. Action: 9. Lab has corrected form entries to prevent missing information in the future. Lab has ordered pharmaceutical grade drug. 15. PI to ensure CVS is contacted right away for all future incidents. 16. CVS released animals from holding protocol and transferred them to PI's protocol. PI is informed that these special requests must be entered in the ATS as an import request. 17. PI ensures in the future amendments will be submitted and approved first prior to making adjustments to study details. IACUC Vote Approval 23 Withhold Approval 0 0 Abstain 23 Present

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс	
1. statu	S
Discussion:	PI requests permission for one lab staff to be able to work independently on breeding procedures. PI is still overeesing all lab procedures with staff while he works to hire a lab manager. In interim, the PI request permission for lab staff to be able to complete breeding procedures without his direct supervision. This lab member was observed by CVS performing the genotyping procedure and it was done appropriately.
Action:	IACUC approved one staff member to perform breeding procedures of pairing, separating, genotyping and weaning independently.
2. SAPR	
Discussion:	Reviewed 7/2020 - 12/2020 Animal Care Program events, activities and action plans. Discussed SAPR format plans moving forward with recommendation to adopt OLAW template pending IO's approval.

Action:	None.			
	3. IACUC member training opportunity - PRIM&R Conference April 14-16, 2021. https://www.eventscribe.com/2021/IACUC21/			
Discussion:	Discussion: Contact IACUC Director if interested.			
Action:	None.			

# XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

### University of California, Davis IACUC Business Administration System

### March 18, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M005, M111, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, A013, M016, M024, M223, M001, M112, M114

#### Excused:

M222, M102, M090, M093

#### **Guests:**

M116, A017, A018

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

. #			Category: D Y
he a	mendment was	reviewed	d and the following points were addressed by the Principal Investigator prior to
ne m	eeting:		
	a. Clarification	regardin	g monitoring of equipment and contact with animals.
dditi	onal discussion	durina th	ne meeting included:
	a. Committee		
	IACUC V	′ote	
	Approval	20	
	Withhold App	roval 0	
	Abstain	0	
	Present	20	
. #			Category: D Y
ne a	mendment was	reviewed	d and the following points were addressed by the Principal Investigator prior to
e m	eeting:		
	a. Pending pat	inology re	эроп.
dditi	onal discussion	during th	ne meeting included:
	a. Tabled.		
	IACUC V	ote	
	IACUC V Approval	<b>ote</b> 0	
	Approval	0	
		0	

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

A diama ta a diama	
Action: Location.	

### V. Veterinary Care Program Updates:

The Atter	nding Veterinarian provided the following updates to the committee:	
N	one at this time.	


### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		-
prior to the mee a. None. Additional discu	ting:	the following points were addressed by the Principle meeting included:	pal Investigator
2. #	E		-
prior to the mee a. None. Additional discu a. Pendir	ting: Ission during the ng Pl	the following points were addressed by the Principe meeting included:	
3. #	С		03-15-2021
prior to the mee a. Clarifi to COVII OHSS si	ting: cation regarding D vaccine and T tuations of this r ission during the	the following points were addressed by the Princip caging provided. Alternate contact's OHSS renew B testing scheduling conflict. IACUC approves monature. e meeting included:	/al is pending due
4. #	DY		03-08-2021
prior to the mee a. Pendi	eting: ng PI response. Ission during the	the following points were addressed by the Princi e meeting included:	pal Investigator
5. #	DY		-
The protocol wa prior to the mee a. None. Additional discu	as reviewed and ting:	the following points were addressed by the Princi e meeting included: rification	pal Investigator

6. #	С		-	
The protocol wa		the following points were addressed by the Princip	pal Investigator	
a. None.	0			
	ission during the ng ANR protocol	e meeting included: I discussion.		
7. #	DY		-	
The protocol wa prior to the mee a. None.	eting:	the following points were addressed by the Princip	pal Investigator	
	ission during the ng Location Clai	e meeting included: ification		
8. #	D		03-18-2021	
prior to the mee a. None.	eting:	the following points were addressed by the Princi	pal Investigator	
Additional discu a. pendir		e meeting included:		
9. #	D		03-18-2021	
prior to the mee a. None.	eting: Ission during the	the following points were addressed by the Principe meeting included:	pal Investigator	
10. #	С		03-17-2021	
prior to the mee a. Clarifi	eting: cation of standa ission during the	the following points were addressed by the Principrd-of-care and experimental procedures. e meeting included:	pal Investigator	
11. #	С		03-17-2021	
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of standard-of-care and experimental procedures. Additional discussion during the meeting included: a. None.				
12. #	С		-	
prior to the mee a. None. Additional discu	eting:	the following points were addressed by the Princip e meeting included:	pal Investigator	
13. #	C		03-18-2021	
The protocol wa prior to the mee a. None.	as reviewed and eting: ussion during the	the following points were addressed by the Princip e meeting included:	l	

14. #	С		03-10-2021
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
	ssion during the	e meeting included:	
15. #	С		-
prior to the mee	ting:	the following points were addressed by the Princip	oal Investigator
		e meeting included:	
16. #	С		03-09-2021
prior to the mee a. Clarific	ting: cation of group r ssion during the	the following points were addressed by the Princip numbers. e meeting included:	oal Investigator
17. #	С		03-17-2021
prior to the mee a. Clarific	ting: cation of advers	the following points were addressed by the Princip e effects. e meeting included:	oal Investigator
18. #	D		-
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
a. Pendir 19. #	ng SCRO		
prior to the mee a. None. Additional discu	ting:	the following points were addressed by the Princip e meeting included:	Dai Investigator
20. #	C		03-17-2021
prior to the mee a. Clarific	ting: cation of exclusi ssion during the	the following points were addressed by the Princip on criteria. e meeting included:	oal Investigator
21. #	С		03-17-2021
prior to the mee a. Clarific	ting: cation of exclusi ssion during the	the following points were addressed by the Princip on criteria. e meeting included:	oal Investigator

22. #	D		03-18-2021
The protocol wa prior to the mee a. None.	ting:	the following points were addressed by the Princi	oal Investigator
	ssion during the	e meeting included:	
23. #	D		-
The protocol wa prior to the mee a. None.		the following points were addressed by the Princip	pal Investigator
Additional discu	ssion during the ng Reviewer	e meeting included:	
24. #	CY		03-18-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princi	pal Investigator
a. None.	ssion during the	e meeting included:	
25. #	D		03-18-2021
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Principe meeting included:	oal Investigator
26. #	DY		-
prior to the mee a. None. Additional discu	ting:	the following points were addressed by the Princi e meeting included:	pal Investigator
27. #	D		03-18-2021
prior to the mee a. Clarific	ting: cation regarding ssion during the	the following points were addressed by the Princi monitoring of the animals provided. meeting included:	oal Investigator
28. #	D		03-17-2021
prior to the mee a. Clarific	ting: cation on anima	the following points were addressed by the Princi I numbers e meeting included:	pal Investigator
29. #	С		03-18-2021
The protocol wa prior to the mee a. None.		the following points were addressed by the Princi	pal Investigator
	-	e meeting included:	
30. #	СҮ		03-15-2021



### VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	С		03-04-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
2. #	D		-
Investigator prior a. Clarific	r to the meeting ation of proced ssion during the		incipal
3. #	CY		03-11-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Disposition. Additional discussion during the meeting included: a. None.			
4. #	DY		-
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal

Additional discus a. Pendin		meeting included:	
5. #	DY		03-16-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior		• • • •	
a. None.	-		
Additional discus a. None.	ssion during the	meeting included:	
6. #	DY		03-18-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.		<i></i>	
		meeting included:	
		wording/lay language terminology correction.	00.00.0004
7.#	D		03-09-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.	acion during the	monting included:	
a. None.	ssion during the	meeting included:	
8. #	E		03-10-2021
Investigator prior		and the following points were addressed by the Pr	incipal
	ation of DMSO		
		meeting included:	
a. None.	ssion during the	meeting metuded.	
9. #	С		03-18-2021
5. <del>n</del>			03-10-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incinal
Investigator prior			nopu
	ation of anesthe		
Additional discus	ssion during the	meeting included:	
a. None.	-	-	
10. #	D		03-17-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.	-		
	ssion during the	meeting included:	
a. None.			
11. #	D		-
The amendment	was reviewed	and the following points were addressed by the Pr	incinal
Investigator prior			incipal
a. None.		•	
Additional discus	ssion during the	meeting included:	
a. Pendin		-	
12. #	D		03-09-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None			
	ssion during the	meeting included:	
a. None.			
13. #	D		03-15-2021

The amendment was reviewed and the following points were addressed by the Principal				
Investigator prior				
	a. Removed personal information. Additional discussion during the meeting included:			
a. None.	ssion during the	e meeting included:		
14. #	D		03-15-2021	
14. #			03-13-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior			in olpai	
	ed personal inf			
Additional discus	ssion during the	e meeting included:		
a. None.				
15. #	DY		03-18-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting	Г.		
a. None.		and a time in a load a de		
		e meeting included: al approval at meeting.		
	_	a approvar at meeting.	03-16-2021	
16. #	D		03-10-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incinal	
Investigator prior			пора	
		, regarding humane endpoints, weight loss, and doo	umentation for	
	nimals.			
Additional discus	ssion during the	e meeting included:		
a. None.	-			
17.#	С		03-16-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting	l:		
a. None.				
	ssion during the	e meeting included:		
a. None.	•		00.40.0004	
18. #	С		03-18-2021	
The amondmont		and the following points were addressed by the Pr	inginal	
Investigator prior			incipal	
a. None.	to the meeting			
	ssion during the	e meeting included:		
a. None.	Ũ	C C		
19. #	E		03-18-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting	r.		
		ationale for acute and control doses.		
	ssion during the	e meeting included:		
a. None.	-			
20. #	С		03-18-2021	
The emergine of		and the following points were addressed by the Dr	inoinal	
Investigator prior		and the following points were addressed by the Pr	псра	
a. None.		j.		
	ssion durina the	e meeting included:		
a. None.		5		
21. #			03-15-2021	

The amendment was reviewed and the following points were addressed by the Principal				
a. None.	Investigator prior to the meeting: a. None.			
Additional discus a. None.	ssion during the	meeting included:		
22. #	CY		03-17-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pri : meeting included:	incipal	
23. #	Y		03-18-2021	
Investigator prior a. None.	r to the meeting		incipal	
a. None.	ssion during the	meeting included:		
24. #	С		03-18-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal	
25. #	С		03-18-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pri : e meeting included:	incipal	
26. #	D		03-17-2021	
Investigator prior a. clarifica	r to the meeting ation of when C	and the following points were addressed by the Pr : VS was notified. • meeting included:	incipal	
27. #	С		03-18-2021	
Investigator prior a. None.	r to the meeting		incipal	
Additional discus a. None.	ssion during the	e meeting included:		
28. #	Y		03-18-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pri : e meeting included:	incipal	
		verbal approval at meeting.		
29. #	D		03-09-2021	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.				
Additional discus a. None.	ssion during the	meeting included:		
30. #	D		03-17-2021	

The amendment was reviewed and the following points were addressed by the Principal					
Investigator prior					
		m the Chemical Hygiene Officer			
a. None.	Additional discussion during the meeting included:				
31. #	D		03-04-2021		
	_	and the following points were addressed by the Pr			
Investigator prior			incipal		
a. None.		•			
Additional discus	ssion during the	meeting included:			
a. None.	_				
32. #	DY		-		
		and the following points were addressed by the Pr	incipal		
Investigator prior	r to the meeting	:			
a. None.	ssion during the	meeting included:			
a. Pendin					
33. #	D		03-04-2021		
00. //			00-04-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior			inoipai		
		regarding monitoring of animals and incision sites	prior to		
behaviora					
	ssion during the	meeting included:			
a. None.					
34. #	Y		03-17-2021		
The encoderage		and the fellowing nainterways addressed by the D	in sin sl		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. None.	i to the meeting				
	ssion during the	meeting included:			
a. None.	· ·				
35. #	D		-		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior					
a. None.					
		meeting included:			
a. Pendin					
36. #	D		03-09-2021		
-					
		and the following points were addressed by the Pr	incipal		
Investigator prior a. None.	to the meeting				
	ssion durina the	meeting included:			
a. None.		·······			
37. #	DY		03-10-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior					
a. None.					
Additional discussion during the meeting included:					
	a. None.				
38. #	E		03-04-2021		

Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : • meeting included:	incipal
a. None.	•	-	
39. #	D		03-18-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
40. #	D		03-05-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
41.#	С		03-05-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
42. #	DY		03-15-2021
Investigator prior a. Wordin	r to the meeting g modifications	and the following points were addressed by the Pr : requested for clarity. meeting included:	incipal
43. #	СҮ		03-18-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal

### VIII. Administrative and Veterinary Verification Amendments:


Total of **156** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


#### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1. #	D		03-18-2021
prior to the mee a. Clarifi	eting: cation regardin	d the following points were addressed by the Princi g animals numbers. Chemical safety officer comple	
	l updated VHSS ussion during th	o. e meeting included:	

a. Committee voted to approve.





### X. Annual Renewals:

Protocol C	Category	Title O	Driginal pproval	Last Reviewed	Expires
	С	3-	-28-2019	03-18-2021	03-28-2022
	С	3-	-28-2019	03-18-2021	03-28-2022
	D	3-	-21-2019	03-18-2021	03-21-2022
	D	3-	-20-2019	03-18-2021	03-20-2022
	D	4-	-01-2019	03-18-2021	04-01-2022
	D	3-	-21-2019	03-18-2021	03-21-2022
	D	3-	-21-2019	03-18-2021	03-21-2022
	С	3-	-21-2019	03-18-2021	03-21-2022
	СҮ	3-	-21-2019	03-18-2021	03-21-2022
	С	3-	-21-2019	03-18-2021	03-21-2022
	С	3-	-21-2019	03-18-2021	03-21-2022
	С	3-	-20-2019	03-18-2021	03-20-2022
	С	3-	-21-2019	03-18-2021	03-21-2022
	D	3-	-26-2019	03-18-2021	03-26-2022
	СҮ	3-	-21-2019	03-18-2021	03-21-2022


CY	3-21	-2019	03-18-2021	03-21-202	2
CY	3-21	-2019	03-18-2021	03-21-202	2
С	3-27	7-2019	03-18-2021	03-27-202	2
	3-21	-2019	03-18-2021	03-21-202	2
С	3-28	8-2019	03-18-2021	03-28-202	2
С	3-28	3-2019	03-18-2021	03-28-202	2
С	4-02	2-2019	03-18-2021	04-02-202	2
С	3-25	5-2019	03-18-2021	03-25-202	2
D	4-02	2-2020	03-31-2022	04-02-202	3
D	4-01	-2020	03-17-2022	04-01-202	3
D	3-24	-2020	03-17-2022	03-24-202	3
С	3-19	9-2020	03-18-2021	03-19-202	2
DY	4-02	2-2020	03-31-2022	04-02-202	3
С	4-02	2-2020	03-31-2022	04-02-202	3
С	4-02	2-2020	03-31-2022	04-02-202	3
С	3-21	-2020	03-17-2022	03-21-202	3
D	3-24	-2020	03-17-2022	03-24-202	3
С	3-31	-2020	03-17-2022	03-31-202	3
D	4-01	-2020	03-17-2022	04-01-202	3
CY			03-31-2022		
E			03-17-2022		
D	4-02	2-2020	03-31-2022	04-02-202	3
С			03-17-2022		
C			03-31-2022		
C			03-17-2022		
С			03-17-2022		
DY	4-02	2-2020	03-31-2022		
			Obtaine	d by Rise fo	r Δi

Discussion:	person on the ro appointment.	oster is in the process of OHSS renewal and is awaiting an veterinarian listed in section 11.
Action Items:	approved the an -AV is loo	and The committee inual renewals. king into MOU status.
	ACUC Vote	
Appro	oval 19	
Withh	old Approval 0	
Absta	in O	
Prese	ent 19	

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	otocol	Category	Request	Date Approved
1. #		D		06-22-2021
Investigator prior to the meetin a. Amendment is pend Additional discussion during th a. Voted to send to DM IACUC Vote Approval 0			ng review of new Core facilities SOPs. e meeting included:	incipal
	Abstain	-		
2.#	Present	21 D Y		03-18-2021
Investi	igator pric a. Clarify	or to the meeting which animals/ ission during the	and the following points were addressed by the Pr g: /groups this applies to. e meeting included:	incipal
	IAC Approva	CUC Vote		
	1	d Approval 0		
	Abstain Present	0 21		
3. #		СҮ		03-18-2021
Investi	igator prio a. CHO onal discu a. None.	or to the meeting verification that ission during the	and the following points were addressed by the Pr g: VHSS is not needed. e meeting included:	incipal



### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	_
1.03-03-2021		
2. 03-11-2021		
3. 03-18-2021		

Discussion:	None.
Action:	None.

IACUC Vote		
Approval	21	
Withhold Appr	Withhold Approval 0	
Abstain	0	
Present	21	

### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 02-23-2021	LAB	
2. 02-25-2021	LAB	
3. 02-25-2021	PAM	
4. 02-25-2021	PAM	
5. 02-25-2021	PAM	
6. 02-25-2021	PAM	
7. 02-25-2021	PAM	
8. 03-09-2021	PAM	
9. 03-11-2021	PAM	

 Discussion:
 3-7= PI findings during a TRACS facility inspection that showed marked improvement in post-op documentation and Hazardous cage card labeling.

 8. PI working in non-approved lab space.

 Action:
 3-7=Positive PAMs sent to PIs.

 8. Amendments have been submitted and a lab inspection is being scheduled.

 IACUC Vote

 Approval
 21

 Withhold Approval
 0

 Present
 21

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс	
1. PI maintai	n form.
Discussion:	Clarification provided on SOP, room log and PI maintain form regarding staff training and husbandry care.
Action:	Committee voted to approve PI maintain request.
2. Semi-ann	ual program review update
Discussion:	Will transition to modified OAW template.
Action:	None.
3. ANR upda	ite - FYI
Discussion:	UC Merced will continue to cover through end of year. Recommendation for ANR to form own IACUC. AV and IACUC Director to further discuss with ANR.
Action:	FY - no IACUC action required at this time.

### XVI. Program Updates:

Торіс

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

April 01, 2021 Meeting Minutes

[regular view | VA view]

### Attendance:

### Present:

M009, M097, M005, M222, M102, M090, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M223, M001, M114

### Excused:

M111, M042, M016, M024, M112

### Guests:

M116, A017

### I. Minutes from Previous Meetings:

IACUC Vot	е
Approval	19
Withhold Approv	val 0
Abstain	0
Present	19
CUC reviewed a	nd app
IACUC Vot	е
Approval	19
Withhold Approv	val 0
Abstain	0
Present	19

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

#### **III. Amendments Tabled From Previous Meetings:**

1 ,		Category: D Y
The amendment was revie the meeting: a. Pending patholo		and the following points were addressed by the Principal Investigator prior to eport.
Additional discussion duri a. Tabled.	ng th	e meeting included:
a. Tabled.		
IACUC Vote		
Approval	0	
Withhold Approval	0	
Abstain	0	
/ ibotain		

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

CNPRC

Action: Escape from SC, recaptured without incident.

neep Barn
Action: Predation requiring treatment of one animal; USDA depredation contacted, and they investigated and found no sign of the predators returning.

# V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:	
None at this time.	

### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1.	С		-
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princi e meeting included:	pal Investigator
2.	E		-
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princi e meeting included:	pal Investigator
3.	DY		-
	-	e meeting included: nd AV.	
4.	DY		03-30-2021
prior to the mee a. None.	ting: ssion during th	the following points were addressed by the Princi e meeting included:	pal Investigator
5.	В		03-25-2021
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princi e meeting included:	pal Investigator
6.	С		03-23-2021
The protocol wa prior to the mee a. None.	s reviewed and ting:	the following points were addressed by the Princi e meeting included:	

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
a. None. Additional discussion during the meeting included: a. None.					
8.	С		03-29-2021		
prior to the mee a. Clarific b. Clarific	ting: cation of breedir cation of euthan		pal Investigator		
9.	D		03-23-2021		
prior to the mee a. None.	ting:	the following points were addressed by the Princi	pal Investigator		
10.	С		03-29-2021		
prior to the mee a. Clarific	ting: cation of standa	the following points were addressed by the Princi rd-of-care, and procedures. e meeting included:	pal Investigator		
11	D		03-30-2021		
prior to the mee a. None.	Additional discussion during the meeting included:				
12	С		-		
prior to the mee a. None. Additional discu	ting:	the following points were addressed by the Princi e meeting included:	pal Investigator		
13.	DY		-		
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princi e meeting included:	pal Investigator		
14.	С		-		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:					
a. Pendir 15.	ng PI. E		04-01-2021		

prior to the meet		the following points were addressed by the Princip	pal Investigator	
a. None. Additional discu	ssion during the	e meeting included:		
a. None.				
16	D		04-01-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princi	oal Investigator	
prior to the meet a. Added	ting: VHSS		g	
Additional discus a. None.	ssion during the	e meeting included:		
17.	D		04-01-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator	
prior to the mee			J J	
		nesia, drugs administration and VHSS		
	ssion during the	e meeting included:		
a. None.				
18.	C		04-01-2021	
The sum to a low		the falles in a sinte source address address the Drive i		
prior to the meet		the following points were addressed by the Princip	pai investigator	
		rd-of-care, procedures, and adverse effects.		
		e meeting included:		
a. None.	oolon daning the			
19.	D		04-01-2021	
	s reviewed and	the following points were addressed by the Princi		
prior to the meeting:				
		ocedure monitoring.		
Additional discu	ssion during the	e meeting included:		
a. None.				
20	D		03-18-2021	
		the following points were addressed by the Princip	pal Investigator	
prior to the meet	•			
		regarding potential adverse effects and updated V	HSS.	
a. None.	ssion during the	e meeting included:		
	С			
21.			-	
The protocol wa	s reviewed and	the following points were addressed by the Princi	al Investigator	
prior to the meet		The following points were addressed by the r find	oai investigator	
a. Pending BUA approved				
Additional discussion during the meeting included:				
a. None.	-	-		
22.	CY		03-31-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princi	bal Investigator	
prior to the meet		5,		
a. Clarific	ation on procee			
		e meeting included:		
a. None.				

23.	С		03-31-2021
prior to the mee a. Review confusior	ting: vers recommen n of past studies	the following points were addressed by the Princip ded brevity of section 12 for future submissions to s compared with studies in the proposed protocol. e meeting included:	-
24.	CY		04-01-2021
prior to the meet a. Clarific	ting: cation of animal	the following points were addressed by the Princip numbers. e meeting included:	pal Investigator
25	С		03-31-2021
prior to the meet a. Clarific	ting: cation on breedi	the following points were addressed by the Princing ng and terminology e meeting included:	pal Investigator
26.	С		04-01-2021
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	pal Investigator
27.	С		04-01-2021
prior to the mee a. None.	ting:	the following points were addressed by the Principle meeting included:	pal Investigator
28.	В		03-25-2021
The protocol wa prior to the mee a. None.	s reviewed and ting:	the following points were addressed by the Princip e meeting included:	
a. None.	_	-	
29.	C		03-30-2021
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	pal Investigator

### VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.	D		-

Investigator prio		and the following points were addressed by the P g:	rincipal
a. None. Additional discus a. Pendir		e meeting included:	
2	D		04-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
3.	DY		-
The amendment Investigator prio a. None. Additional discus	t was reviewed r to the meeting ssion during the	and the following points were addressed by the P g: e meeting included: ithdraw but remains in DMR.	rincipal
4.	D		04-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
5.	DY		04-01-2021
	cal safety comp	bleted review and verified no VHSS is required. e meeting included:	03-25-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
7.	D		04-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
8	С		03-30-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
9	DY		03-24-2021
The amendment Investigator prio a. None.	was reviewed r to the meeting	and the following points were addressed by the P g: e meeting included:	<u> </u>

a. None.					
10.	С		03-23-2021		
The amendment Investigator prio a. None.		and the following points were addressed by the Pr g:	incipal		
Additional discus a. None.	ssion during the	e meeting included:			
11.	D		-		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio					
		I providing imaging services.			
a. Remai	ssion during the ns in DMR.	e meeting included:			
12.	D		03-19-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
a. None.					
Additional discus a. None.	ssion during the	e meeting included:			
13.	С		04-01-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
		ns being used and procedures			
	ssion during the	e meeting included:			
a. None.					
14.	CY		04-01-2021		
Investigator prio a. None.	r to the meeting		incipal		
Additional discus a. None.	ssion during the	e meeting included:			
15.	С		04-01-2021		
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio					
		r completed review and provided new VHSS.			
a. None.	ssion during the	e meeting included:			
	C V		04.01.2021		
16.	CY		04-01-2021		
Investigator prio	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
a. None. Additional discus a. None.	ssion during the	e meeting included:			
17.	С		03-22-2021		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
	ssion during the	e meeting included:			
18.	С		03-22-2021		

The amendment Investigator prio a. None.		and the following points were addressed by the Pr j:	incipal
	ssion during the	e meeting included:	
19.	С		04-01-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None. Additional discus a. None.	-	e meeting included:	
	<u> </u>		02 02 0004
20.	С		03-23-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	incipal
21.	D		-
Investigator prio a. Chemi Additional discus	r to the meeting cal safety office	and the following points were addressed by the Pr g: r requests additional information (CAS) to complet e meeting included:	
22.	E		03- <mark>1</mark> 9-2021
Investigator prio a. Clarific procedure	r to the meeting ation on Food c es.	and the following points were addressed by the Pr g: or Water Regulation, number justification, and euth e meeting included:	
23.	D		03-25-2021
Investigator prio a. Clarific	r to the meeting ation regarding	and the following points were addressed by the Pr ; euthanasia method provided. meeting included:	incipal
24.	С		03- <mark>1</mark> 8-2021
Investigator prio a. Animal import ree	r to the meeting numbers clarifi quest for review	ied as well as entering animals in the animal tracki	
25.	DY		03-30-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal

26.	DY		-
Investigator prior a. None.	r to the meeting		incipal
Additional discus a. None.	ssion during the	meeting included:	
27.	DY		03-25-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
28.	D		-
The amendment Investigator prior a. None.	was reviewed r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included:	incipal
29.	CY		04-01-2021
Investigator prior a. None. Additional discus	r to the meeting	meeting included:	03-17-2021
		and the following points were addressed by the Pr	
Investigator prior a. Clarific	r to the meeting ation regarding		
31.	DY		03-31-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
32.	DY		03-26-2021
The amendment Investigator prior a. Typos b. Clarific	was reviewed r to the meeting identified and fin ation of pre-sur		
33.	DY		-
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus		e meeting included: n Biosafety for clarification. Remains in DMR.	
34.	D		03-23-2021
,			

Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
35.	СҮ		04-01-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
36.	СҮ		-
Investigator prior a. Clarify Additional discus	r to the meeting number of atter		incipal
37.	D		03-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
38.	D		03-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
39.	CY		-
Investigator prior a. None. Additional discus	r to the meeting	e meeting included:	incipal


## VIII. Administrative and Veterinary Verification Amendments:


Total of **153** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved			
1.	CY		04-01-2021			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of number of animals affected, age of animals and if age related. b. Sedation over time and experience with aged animals.						





The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

- a. Title change recommendation.
- b. Addition of biological sampling.
- c. Additional search recommendation.
- d. SOP reference requests.

Additional discussion during the meeting included:

# a. None.

IACUC Vote		
Approval	0	
Withhold Approval	0	
Abstain	0	
Present	19	

## X. Annual Renewals:

Protocol	Category	Title							Last Reviewed		oires
	DY							04-04-2019	04-01-2021	04-04	1-2022
	D							04-03-2019	04-01-2021	04-03	3-2022
	D							04-04-2019	04-01-2021	04-04	-2022
-	D							04-10-2019	04-01-2021	04-10	)-2022
	С							04-04-2019	04-01-2021	04-04	-2022
	D							04-03-2019	04-01-2021	04-03	3-2022
	D							04-04-2019	04-01-2021	04-04	-2022
	D							04-04-2019	04-01-2021	04-04	-2022
	С							04-03-2019	04-01-2021	04-03	3-2022
_	С							04-04-2019	04-01-2021	04-04	-2022
_	D							04-15-2019	04-01-2021	04-15	5-2022
_	D							04-03-2019	04-01-2021	04-03	3-2022
	СҮ							04-03-2019	04-01-2021	04-03	8-2022
	DY						 	04-04-2019	04-01-2021	04-04	-2022
	С							04-16-2019	04-01-2021	04-16	6-2022
	D							04-05-2019	04-01-2021	04-05	5-2022
	DY							04-04-2019	04-01-2021	04-04	-2022


С	0	4-16-2020	04-14-2022	04-16-2023
С	0	4-16-2020	04-28-2022	04-16-2023
E	0	4-16-2020	04-14-2022	04-16-2023
D	0	4-16-2020	04-14-2022	04-16-2023
E	0	4-16-2020	04-14-2022	04-16-2023
D	0	4-14-2020	04-14-2022	04-14-2023
D	0	4-07-2020	03-31-2022	04-07-2023
D	0	4-16-2020	04-14-2022	04-16-2023
DY	0	4-16-2020	04-14-2022	04-16-2023
С	. 0	4-16-2020	04-14-2022	04-16-2023
С	0	4-16-2020	04-14-2022	04-16-2023
D	0	4-16-2020	04-01-2021	04-16-2022
В	0	4-15-2020	03-31-2022	04-15-2023
С	0	4-16-2020	04-14-2022	04-16-2023
С	0	4-16-2020	04-14-2022	04-16-2023
CY	0	4-15-2020	04-01-2021	04-15-2022
D	0	4-16-2020	04-14-2022	04-16-2023
D		4-03-2020	03-31-2022	04-03-2023
С		4-16-2020	04-14-2022	04-16-2023
D	0	4-16-2020	04-14-2022	04-16-2023
С	0	4-16-2020	04-28-2022	04-16-2023
С	0	4-15-2020	03-31-2022	04-15-2023
DY	0	4-16-2020	04-14-2022	04-16-2023
DY		4-16-2020	04-14-2022	04-16-2023


Discussion: Protocols **Constants**, **Constants**, **Constants**, and **Constants**, at least one staff member is in progress of completing their OHSS renewal. Most are pending their in person appt. due to scheduling conflict based on COVID


		as another veterinarian listed in section 11. ation included in section 9 for fasting prior to glucose
Action Items:	renewals. AV to review Committee	v and determine if MOU is needed. agreed to keep the information in section 9 and review policy before making any changes.
	ACUC Vote	
Appro	val 18	
Withh	old Approval 0	
Absta	in O	
Prese	nt 18	


### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.









	Present	20		
17.		D		04-01-2021
Гhe a	mendment v	vas revieweo	I and the following points were addressed by the Pi	rincipal
nvest		to the meetin	g:	
\ d diti	a. None.	ion during th	e meeting included	
Additio	a. None.	aon during in	e meeting included:	
		C Vote		
	Approval	20		
	Withhold A	Approval 0		
	Abstain	0		
	Present	20		
18.		E		04-01-2021
		-		· · · ·
The a nvest	mendment v igator prior t a. None.	vas reviewed to the meetin	l and the following points were addressed by the Pi g: e meeting included:	rincipal
The a nvest	mendment v igator prior t a. None. onal discuss a. None.	vas reviewed to the meetin	g:	rincipal
Гhe a nvest	mendment v igator prior t a. None. onal discuss a. None.	vas reviewed to the meetin	g:	rincipal
The a nvest	mendment v igator prior t a. None. onal discuss a. None. IACU Approval	vas reviewed to the meetin ion during th <b>C Vote</b>	g:	rincipal
The a nvest	mendment v igator prior t a. None. onal discuss a. None. IACU Approval	vas reviewed to the meetin tion during th <b>C Vote</b> 20	g:	rincipal

## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1. 12-08-2020		
2. 03-10-2021		
3. 03-10-2021		
4. 03-11-2021		
5. 03-15-2021		
6. 03-17-2021		
7. 03-18-2021		
8. 03-30-2021		
9. 03-31-2021		

	#2 and #3- Discussed ensuring documentation for food mill dates and food barrel cleaning are clearly marked on the barrel and room log.					
Action:	Action: #2 and #3-Lab staff have updated their documentation procedures.					
l	ACUC Vote					
Appro	oval	19				
Withh	old Approval	0				
Absta	ain	0				
Prese	ent	19				

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol	
			Obtained by Rise for Animals.

1. 02-28-2021	LAB		
2. 03-18-2021	LAB		
3. 03-18-2021	LAB		
4. 03-19-2021	LAB		
5. 03-22-2021	LAB		
6. 03-25-2021	LAB		
7.03-25-2021	LAB		
8. 03-30-2021	LAB		
9. 01-28-2021	PAM		
10. 03-17-2021	PAM		

 Discussion:
 10. Positive PAM report sent to PI for thorough post-op records reviewed during the facility inspection.

 Action:
 10. None- FYI

 IACUC Vote

 Approval
 19

 Withhold Approval
 0

 Abstain
 0

 Present
 19

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс	
1. IACUC m	ember voting options - abstention reminders
Discussion:	FYI.
Action:	None.
	ember training opportunity - PRIM&R Conference April 14-16, 2021. eventscribe.com/2021/IACUC21/
Discussion:	FYI.
Action:	None.
3. FYI - Anin	nal Care Leadership Team Task Force member update
Discussion:	
Action:	None.
4. Sieving la	b
Discussion:	Completed lab inspection for 2 rooms requested by PI for ERG and OTC studies. Amendment to add these rooms will be on the next agenda. Deficiencies noted during the lab inspection were documented on a PAM and will be reviewed at the next committee meeting.
Action:	Inspection reports will be reviewed at the next meeting.

### XVI. Program Updates:

#### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### April 15, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M005, M102, M111, M090, M042, A095, M004, M092, A019, M087, A109, M110, A013, M016, M024, M223, M001, M112, M114

#### Excused:

M222, M119, M120, M093

#### **Guests:**

A017, A018

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

1. ,		Category: D Y
The amendment was	s reviewed a	and the following points were addressed by the Principal Investigator prior to
the meeting:		
a. Pathology	report indica	ates an underlying heart condition.
A dditional dia avaaiau	م ماد بیشت م	manatine in all relations
Additional discussion		
a. Committee	approved th	he amendment.
IACUC	Vote	
Approval	21	
Withhold App	oroval 0	
Abstain	0	

### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:		
Action: PAM report discussed self reported by PI.		
Action: IACUC director and chair to set up a Zoom meeting with the PI to		
review approved protocol.		

## V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this	time.
--------------	-------

## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
2. #	E		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
3. #	DY		04-14-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
4. #	DY		-
prior to the meet a. Additio	ting: nal information ssion during the	the following points were addressed by the Princip requested for number Justification. e meeting included:	oal Investigator
5. #	D		04-13-2021
prior to the meet a. Clarific	ting: ation of blood o	the following points were addressed by the Princip collection. e meeting included:	oal Investigator
6. #	DY		-
prior to the meet a. Potent b. Perfus f. Testing c. MRI loo	ting: ial adverse effe ion procedure u cage size and cation; MRI pro- ssion during the	the following points were addressed by the Princip ct clarification; ventilator use; timelines. update. chair clarification. cedures and intent. e meeting included:	bal Investigator
7. #	C		04-13-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
8. #	DY		-

The protocol was prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator
		e meeting included:	
9. #	DY		-
prior to the meet a. None.	ing:	the following points were addressed by the Princip	oal Investigator
a. Pendin	g PI.	e meeting included:	
10. #	С		04-13-2021
prior to the meet a. Clarific	ing: ation of blood c	the following points were addressed by the Princip collection. e meeting included:	oal Investigator
11. #	CY		04-15-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
12. #	D		-
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip e meeting included:	bal Investigator
13. #			04-15-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
14. #	D		04-01-2021
prior to the meet a. Clarific	ing: ation on dose a	the following points were addressed by the Princip administration, study time, anesthesia and monitori e meeting included:	-
15. #	С		04-15-2021
prior to the meet a. Clarific	ing: ation on animal	the following points were addressed by the Princip number justification and animal disposition. meeting included:	oal Investigator

16. #	С		-
prior to the meet		the following points were addressed by the Princip	oal Investigator
		e meeting included:	
a. Pendin 17. #	g PI. C		04-13-2021
	-	the following points were addressed by the Princip	
prior to the meet a. Clarific	ing: ation of objectiv	/es.	Jan Investigator
a. None.	ssion during the	meeting included:	
18. #	DY		04-05-2021
The protocol was	s reviewed and	the following points were addressed by the Princip	pal Investigator
prior to the meet	ing:		-
		regarding analgesia, monitoring and CVS assessn	nent.
a. None.	ssion during the	meeting included:	
19. #	С		04-15-2021
			04 10 2021
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet		the following points were addressed by the Princip	Jai Investigator
•	•	eter used to assess passive transfer.	
	ssion during the	meeting included:	
a. None.			
20. #	C		04-13-2021
		the following points were addressed by the Princip	pal Investigator
prior to the meet a. None.	ing:		
	ssion durina the	meeting included:	
a. None.			
21. #	DY		04-03-2021
		the following points were addressed by the Princip	pal Investigator
prior to the meet			
a. Title up		s and additions, sop references.	
	ire search reco	•	
Additional discus	ssion during the	meeting included:	
a. Title up	odate.		
22. #	D		04-15-2021
The protocol was	s reviewed and	the following points were addressed by the Princip	pal Investigator
prior to the meet	ing:		-
		procedure technique and method.	
Additional discus	ssion during the	meeting included:	
23. #	С		04-15-2021
		the following points were addressed by the Princip	
prior to the meet		the following points were addressed by the Princip	Jai investigator
•	•	nsure numbers were consistent through out protoc	ol.
Additional discus		meeting included:	
a. None.			

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	D		-
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pri : • meeting included:	incipal
2. #			-
Investigator prio a. BUA su B. Proced c. Numbe Additional discus a. Pendin	r to the meeting ubmission. dure clarificatior r justification. ssion during the g PI.		
3. #	CY		04-14-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
4.#	Y	•	04-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : • meeting included:	incipal
5.#	D		04-15-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
6. #	D		-
Investigator prio a. BUA a Additional discus	r to the meeting nd mouse strair		incipal
7. <b>#</b>	D		04-15-2021
The amendment Investigator prio a. None. Additional discus	t was reviewed r to the meeting	and the following points were addressed by the Pr : e meeting included:	
a. None.	<b>_</b>		
8.#	D		-
Investigator prio a. Pendin Additional discus	r to the meeting Ig lab manager	and the following points were addressed by the Pr of imaging facility creating SOPs to be managed a meeting included:	
9.#	D		04-15-2021

Investigator prio		and the following points were addressed by the Pr j:	incipal
	ssion during the	e meeting included:	
a. None.	D		
		and the following points were addressed by the Pr	- incinal
Investigator prio a. None.		and the following points were addressed by the Pr J:	псра
Additional discus a. Pendin		e meeting included:	
11. #	D		04-12-2021
Investigator prio a. None.	r to the meeting		incipal
a. None.	-	e meeting included:	
12. #	D		-
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included:	incipal
13. #	D		04-12-2021
The amendment Investigator prio a. None.	t was reviewed r to the meeting	and the following points were addressed by the Pr j: e meeting included:	
a. None.	5	5	
14. #	DY		04-13-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
15. #	D		04-12-2021
		and the following points were addressed by the Pr	incipal
	ation of how de	y: efecation will be monitored. e meeting included:	
16. #	D		04-15-2021
The amendment Investigator prio		and the following points were addressed by the Pr j:	incipal
a. Chemi	cal safety office	r completed review and provided and updated VH meeting included:	SS.
17. #	E	ure.	04-13-2021
Investigator prio a. None.	r to the meeting		incipal
Additional discus	ssion during the	e meeting included:	

a. None.			
18. #	CY		04-07-2021
The amendment Investigator prior a. None.		and the following points were addressed by the Pr j:	incipal
	ssion during the	e meeting included:	
19. #	DY		04-02-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None. Additional discus	-	: e meeting included:	
a. None.			
20. #	E		-
Investigator prior a. None. Additional discus	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
21. #	DY		04-15-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
22. #	D		04-15-2021
Investigator prior a. Clarific	r to the meeting ation on trackin	and the following points were addressed by the Pr g: ng neuronal activation e meeting included:	incipal
23. #	D		04-08-2021
Investigator prior a. Clarific	r to the meeting ation on blood	and the following points were addressed by the Pr g: volume injection and constant rate ICV injection e meeting included:	incipal
24. #	D		04-15-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
25. #	D		04-15-2021
Investigator prio a. None. Additional discus a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	incipal
26. #	D		-

Investigator prior		and the following points were addressed by the Pr :	incipal
a. None. Additional discus a. Pendin		e meeting included:	
27. #	C		04-15-2021
The amendment	was reviewed	and the following points were addressed by the Pr	
Investigator prior a. None.	r to the meeting	i:	
	ssion during the	e meeting included:	
a. None.			
28. #	DY		04-13-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	on policy consu		
		e meeting included:	
a. Adoptio		5	
29. #	D		04-14-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	i:	
	ssion during the	e meeting included:	
a. None.			
30. #	D		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	j:	
a. None.	a i a a du wina a Ala a		
a. Pendin	g reviewer	e meeting included:	
31. #	D		04-15-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	j:	
	ssion durina the	e meeting included:	
a. None.			
32. #	DY		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None	r to the meeting	Г.	
		e meeting included:	
		ormation from EH&S regarding recommendation.	
	ns in DMR.		04.00.0004
33. #	DY		04-09-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	r.	
a. None.	nion during the	mosting included:	
a. None.		e meeting included:	
	solon during the	-	
34. #			04-02-2021
The amendment	C Y was reviewed	and the following points were addressed by the Pr	
The amendment Investigator prior	C Y was reviewed r to the meeting	and the following points were addressed by the Pr	
The amendment Investigator prio a. Clarific	C Y was reviewed r to the meeting ation of proced	and the following points were addressed by the Pr	

35. #	С		04-15-2021
Investigator prior a. Discuss	to the meeting sion on site sel	and the following points were addressed by the P g: lection and variation e meeting included:	rincipal
36. #	DY		04-14-2021
	size determina	g: ation and rationale. e meeting included:	
37. #	CY		-
Investigator prior a. None.	to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal


## VIII. Administrative and Veterinary Verification Amendments:

Total of **141** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Proto	ocol	Category	Title	Date Approved
1. #		DY		05-05-2021
orior to t a. Additiona	he meet . Clarific al discus	ting: ation on anima	d the following points were addressed by the Princi al strain, numbers and signs of morbidity. e meeting included: send to DMR	pal Investigator
	IAC	UC Vote		
A	Approval	0		
V	Vithhold	Approval 0		
A	bstain	0		
F	Present	20		
2.#		D		04-28-2021
orior to ti a. to Additiona	he meet . Pendin oxicities. al discus . Voted t	ting: lg chemical sa	d the following points were addressed by the Princi fety review and PI's response to questions related t e meeting included: R.	-



Present	21
---------	----


## X. Annual Renewals:


Protocol Category	Title	Original Approval	1	Expires
D		04-30-2019	04-15-2021	04-06-2022
C		04-18-2019	04-15-2021	04-18-2022
D		04-18-2019	04-15-2021	04-18-2022
C		04-18-2019	04-15-2021	04-18-2022
D		04-18-2019	04-15-2021	04-18-2022
D		04-18-2019	04-15-2021	04-18-2022
D		04-22-2019	04-15-2021	04-22-2022
С		04-23-2019	04-15-2021	04-23-2022
D		04-29-2019	04-15-2021	04-29-2022
СҮ		04-18-2019	04-15-2021	04-18-2022
C		04-18-2019	04-15-2021	11-02-2021
C		04-17-2019	04-15-2021	04-17-2022
D		04-18-2019	04-15-2021	04-18-2022
DY		04-18-2019	04-15-2021	04-18-2022
С		04-29-2019	04-15-2021	04-29-2022
С		04-18-2019	04-15-2021	04-18-2022
С		04-18-2019	04-15-2021	04-18-2022
D		04-18-2019	04-15-2021	04-18-2022
C		04-29-2019	04-15-2021	04-29-2022
DY		04-30-2020	04-28-2022	04-30-2023
DY		04-30-2020	04-28-2022	04-30-2023
D		04-21-2020	04-15-2021	04-21-2022
C		04-28-2020	04-14-2022	04-28-2023
		04-21-2020	04-14-2022	04-21-2023

	C 04-24-2020 0	)4-14-2022	04-24-2023
	C 04-30-2020 0	)4-15-2021	04-30-2022
	C 04-21-2020 0	)4-14-2022	04-21-2023
	C 04-20-2020 0	)4-14-2022	04-20-2023
	C 04-21-2020 0	)4-14-2022	04-21-2023
	D 04-30-2020 0	)4-15-2021	04-30-2022
	E 04-17-2020 0	)4-14-2022	04-17-2023
	C 04-16-2020 0	)4-15-2021	04-16-2022
	D 04-17-2020 0	)4-14-2022	04-17-2023
	C 04-29-2020 0	)4-14-2022	04-29-2023
	D 04-30-2020 0	)4-28-2022	04-30-2023
	C Y 04-29-2020 0	)4-14-2022	04-29-2023
	O Y 04-30-2020 0	)4-28-2022	04-30-2023
	D 04-17-2020 0	)4-14-2022	04-17-2023
	D 04-30-2020 0	)4-28-2022	04-30-2023
	D 04-27-2020 0	)4-14-2022	04-27-2023
	D 04-30-2020 0	)4-28-2022	04-30-2023
Action Items:	completing their in person appointment to complete their OHSS renewal process. and the have expired permits. doing any work requiring a permit and it will be renewed before studies resume. The other two protocols provided the updated permit information to add to the protocol. -another veterinarian is listed in section 11. AV confirming if an MOU is needed. MOU is needed. and the protocol of the committee approved the annual renewal. and adding the updated permit information to the protocols. -the committee approved the annual renewals and adding the updated permit information to the protocols. -the committee approved the annual renewal. ACUC Vote		
Withh	old Approval 0		
		Obtaine	d by Rise for

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 02-25-2021	
2. 03-11-2021	
3. 03-15-2021	

Discussior	n: None.	
Actior	n: None.	
		ato .
	IACUC Vo	
	roval	20
With	hold Appro	oval 0
Abs	tain	0
Pres	sent	20

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 02-24-2021	LAB	
2. 03-11-2021	LAB	
3. 03-19-2021	LAB	
4. 04-07-2021	LAB	
5. 03-31-2021	PAM	
6. 04-08-2021	PAM	

Discussior	job communicati improving comm #5 - Housing occ non-compliance #6 - PI self repor	en on quarterly visits for over a year and has done a great ng with IACUC staff, implementing suggestions and unication with lab staff. curred without approval. Lab inspection revealed other issues. All have been resolved. ted staff member who performed technique not approved training has been completed and PI and alternate contact s animal work.
Actior	schedule. #5 - Lab is scheo compliance.	approved moving inspections back to semi-annual duled to be rechecked next month to ensure they remain in ctor to contact granting agency.
		-
	IACUC Vote	
Approval 19		
Withhold Approval 0		
Abs	stain 0	
Pre	sent 19	

## XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс	
Animals tran	sferred to holding protocol from
Discussion:	Animals placed on holding protocol due to expired protocol.
	Animals will be transferred to replacement protocol now that the renewal has been approved.
Animals tran	sferred to holding protocol from
Discussion:	None.
Action:	Animals placed on holding protocol due to expired protocol
SAPR Signa	ture pages (check information and degrees/certifications)
Discussion:	None.
Action:	None.

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### April 29, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M005, M222, M102, M042, A095, M004, M092, A019, M119, M087, A109, M110, M120, M093, A013, M024, M223, M001, M114

#### Excused:

M111, M090, M016, M112

#### Guests:

M116, A017, A018

### I. Minutes from Previous Meetings:

The IA	CUC reviewed a	nd app	roved the April 1, 2021, meeting minutes as written.
	IACUC Vot	е	
	Approval	17	
	Withhold Approv	val 0	
	Abstain	0	
	Present	17	

### II. Protocols Tabled From Previous Meetings:

1. #				Category: D
The proto meeting:	ocol was reviewed	and	d the following points were addressed by the Principal In	vestigator prior to the
a. cri	iteria		PI revised to be within humane endpoints and added add	litional monitoring
<u>a.</u>	Pending PI respo	nse	to location questions	
	IACUC Vote			
A	pproval	0		
v	/ithhold Approval	0		
А	bstain	0		
P	resent	20		

### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
PETA records request - Email follow-up
Action: FYI.

Action: Discussed facility and possible drain alternatives. CNPRC

Action: 1)Caging, 2)Field pen foreign object.

# V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:	
None at this time.	

## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		04-26-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
2. #	E		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
3. #	DY		-
prior to the meet a. Pendin Additional discus	ting: Ig BUA	the following points were addressed by the Princip e meeting included:	oal Investigator
4. #	DY		-
prior to the meet a. MRI lo b. Pairing Additional discus	ting: cation criteria a ) criteria.	e meeting included:	oal Investigator
5. #	D		04-26-2021
prior to the meet a. Clarific	ting: ation of dose, s	the following points were addressed by the Princip standard of care, and adverse effects. e meeting included:	oal Investigator
6. #	С		04-29-2021
prior to the meet		the following points were addressed by the Princip source.	oal Investigator

Additional discus a. None.	ssion during the	meeting included:	
7. #	С		-
prior to the meet a. Clarific	ing: ation of procedu ssion during the	the following points were addressed by the Princip ures. meeting included:	oal Investigator
8. #	CY		04-29-2021
prior to the meet a. Clarific	ing: ation of number	the following points were addressed by the Princip rs justification. meeting included:	oal Investigator
9. #	D		-
prior to the meet a. Specia b. Proced c. Proced c. Chem s Additional discus	ing: I procedure just lural clarificatior ural clarificatior safety review up	n, sample collections.	oal Investigator
10. #	D		04-28-2021
prior to the meet a. Chemic	ing: cal safety office	the following points were addressed by the Princip r completed their review and provided updated VH meeting included:	-
11. #	С		04-29-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
12. #	С		04-29-2021
prior to the meet a. Clarific	ing: ation of blood v	the following points were addressed by the Princip olume. meeting included:	oal Investigator
13. #	С		-
prior to the meet a. None. Additional discus	ing: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
a. Pendin 14. #	g Pl. C		04-27-2021

prior to the meet a. None.	ing:	the following points were addressed by the Princip	oal Investigator
Additional discus a. None.	ssion during the	meeting included:	
15. #	С		04-29-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
16. #	С		-
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included: sponses	oal Investigator
17. #	В		-
prior to the meet a. Pendin Additional discus	ing: g Reviewer	the following points were addressed by the Princip meeting included:	oal Investigator

## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved			
1.#	D	)	04-28-2021			
Investigator prio a. None.	Additional discussion during the meeting included:					
2. #	С		04-29-2021			
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal			
3. #			-			
Investigator prio a. Pendin Additional discus	r to the meeting Ig BUA	and the following points were addressed by the Pr : e meeting included:	incipal			
4. #	С		04-28-2021			
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal			

5. #	С		-
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus	ssion during the Ig reviewer	meeting included:	
6. #	DY		04-27-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
a. None.			
7.#	D		-
Investigator prior a. None. Additional discus	r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included:	incipal
a. Pendin 8. #	ng reviewer D		04-26-2021
The amendment Investigator prio a. None.	t was reviewed r to the meeting	and the following points were addressed by the Pr : e meeting included:	
a. None.			
9. #	D		04-29-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
10. #	D		04-19-2021
The amendment Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
11. #	CY		04-29-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
a. None.	CY		04-29-2021
The amendment Investigator prior a. None. Additional discus	t was reviewed r to the meeting	and the following points were addressed by the Pr : e meeting included:	
a. None. 13. #	DY		04-28-2021

		and the following points were addressed by the Pr	incipal		
Investigator prior to the meeting: a. None.					
	ssion during the	e meeting included:			
14. #	D		-		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior					
	g SOPs for	facility.			
	ssion during the ns in DMR.	e meeting included:			
15. #	D		-		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior a. None.	-				
		e meeting included:			
a. Pendin 16. #	g reviewer D		04-29-2021		
		and the following points were addressed by the Dr			
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	пора		
a. None.					
17. #	DY		-		
		and the following points were addressed by the Pr	incipal		
Investigator prio		): e to clarify use and duration.			
Additional discus		e meeting included:			
18.#	С		04-27-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prior	r to the meeting	r.			
a. None.	anian duwina tha	we atime included			
a. None.	ssion during the	e meeting included:			
19. #	D		04-27-2021		
10. //			04 21 2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio					
	ation of analge				
a. None.	ssion during the	e meeting included:			
20. #	С		04-29-2021		
	· ·	and the following points were addressed by the Pr			
Investigator prior			nopa		
		nistration frequency.			
Additional discus		meeting included:			
a. None.					
21. #	С		04-27-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prior a. None.	r to the meeting	Г.			
Additional discus a. None.	ssion during the	e meeting included:			

22. #	D		04-29-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.	-		
Additional discus	sion during the	e meeting included:	
a. None.			
23. #	D		04-27-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incinal
nvestigator prior			linoipai
a. None.	to the meeting	j.	
	sion during the	e meeting included:	
a. None.	ionon dannig die		
24. #	E		
		and the faller in a sinte ways addressed by the Dr	-
		and the following points were addressed by the Pr	incipal
nvestigator prior	to the meeting	j.	
a. None.	aion during the	maating included:	
	g reviewer	e meeting included:	
	-		04 45 0004
25. #	CY		04-15-2021
		and the following points were addressed by the Pr	incipal
nvestigator prior			
	status date cla		
a. None.	sion during the	e meeting included:	
			04-27-2021
26. #	D		
	D		
26. #			
26. #	was reviewed	and the following points were addressed by the Pr	
26. #	was reviewed		
26. #	was reviewed to the meeting	j:	
26. #	was reviewed to the meeting		
26. # The amendment nvestigator prior a. None. Additional discus a. None.	was reviewed to the meeting sion during the	j:	
26. #	was reviewed to the meeting	j:	
26. # The amendment Investigator prior a. None. Additional discus a. None. 27. #	was reviewed to the meeting ssion during the D was reviewed	g: e meeting included: and the following points were addressed by the Pr	incipal
26. # The amendment Investigator prior a. None. Additional discus a. None. 27. #	was reviewed to the meeting ssion during the D was reviewed	g: e meeting included: and the following points were addressed by the Pr	incipal
26. # The amendment Investigator prior a. None. Additional discus a. None. 27. # The amendment Investigator prior a. None.	was reviewed to the meeting ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g:	incipal
26. #	was reviewed to the meeting sion during the D was reviewed to the meeting sion during the	g: e meeting included: and the following points were addressed by the Pr	incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g:	incipal
26. #	was reviewed to the meeting sion during the D was reviewed to the meeting sion during the	g: e meeting included: and the following points were addressed by the Pr g:	incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C	g: e meeting included: and the following points were addressed by the Pr g: e meeting included:	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed	and the following points were addressed by the Pr meeting included: meeting included: and the following points were addressed by the Pr	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting	and the following points were addressed by the Pr meeting included: meeting included: and the following points were addressed by the Pr	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting sion during the D was reviewed to the meeting g Reviewer. C was reviewed to the meeting ation on animal	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting sion during the D was reviewed to the meeting g Reviewer. C was reviewed to the meeting ation on animal	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting sion during the D was reviewed to the meeting g Reviewer. C was reviewed to the meeting ation on animal	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia	incipal - incipal 04-29-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia	incipal - incipal 04-29-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included:	incipal - incipal 04-29-2021 incipal 04-27-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included:	incipal - incipal 04-29-2021 incipal 04-27-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included:	incipal - incipal 04-29-2021 incipal 04-27-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: l source and anesthesia e meeting included: and the following points were addressed by the Pr g:	incipal - incipal 04-29-2021 incipal 04-27-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included:	incipal - incipal 04-29-2021 incipal 04-27-2021
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ation during the	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: l source and anesthesia e meeting included: and the following points were addressed by the Pr g:	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ssion during the D	and the following points were addressed by the Pr and the following points were addressed by the Pr	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting to the meeting to the meeting to the meeting	g: e meeting included: and the following points were addressed by the Pr g: and the following points were addressed by the Pr g: source and anesthesia e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included:	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal
26. #	was reviewed to the meeting ssion during the D was reviewed to the meeting ssion during the g Reviewer. C was reviewed to the meeting ation on animal ssion during the D was reviewed to the meeting ssion during the D was reviewed to the meeting to the meeting to the meeting to the meeting	g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: I source and anesthesia e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	incipal - incipal 04-29-2021 incipal 04-27-2021 incipal

31. #	DY		04-19-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior to the meeting:					
a. None. Additional discussion during the meeting included:					
Additional discus	ssion during the	e meeting included:			
	<b></b>		04.07.0004		
32. #	D		04-27-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
a. None.		and the second			
a. None.	ssion during the	e meeting included:			
33. #	E		04-29-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio			litelpai		
	ation on anima				
	ssion during the	e meeting included:			
a. None.					
34. #	C		04-29-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio	r to the meeting	j:			
a. None.					
Additional discus	ssion during the	e meeting included:			
	D.V.				
35. #	DY		-		
		and the following points were addressed by the Pr	incipal		
Investigator prio		a. on of procedure.			
		e meeting included:			
	ns in DMR.	5			
36. #	DY		04-29-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior					
a. None.					
	ssion during the	e meeting included:			
a. None.					
37. #	DY		-		
			· · · ·		
		and the following points were addressed by the Pr	incipal		
Investigator prior a. None.	r to the meeting				
	ssion durina the	e meeting included:			
a. None.					
38. #	С		04-27-2021		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior					
a. None.	-				
	ssion during the	e meeting included:			
a. None.					
39. #	C		04-27-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prior	r to the meeting	j:			
a. None.	cion during the	meeting included:			
a. None.	sour auring me	e meeting included:			
a. 110110.					

40. #	С		04-29-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pri : meeting included:	incipal
a. None.			
41. #	CY		-
Investigator prior a. None. Additional discus	to the meeting	and the following points were addressed by the Pri : meeting included:	in cipai
42. #	DY		04-29-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
43. #	DY		04-15-2021
Investigator prior a. None.	to the meeting		incipal
a. None.	sion during the	meeting included:	


## VIII. Administrative and Veterinary Verification Amendments:


Total of **192** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	otocol	Category	Title	Date Approved
1. #		DY		07-08-2021
prior to	the meet	ing:	the following points were addressed by the Princi ultation on anesthesia recovery plan.	ipal Investigator
Additio	nal discus		e meeting included:	
	IAC	UC Vote		
	Approval	0		
	Withhold	Approval 0		
	Abstain	0		
	Present	20		
2. #		DY		04-29-2021





	#	С	05-03-202
			d the following points were addressed by the Principal Investigato
prior t	o the meeti a Pending	ng: g Reviewer	
Additio	onal discus	sion during th	ne meeting included:
			send to DMR
	IACL	JC Vote	
	Approval	0	
	Withhold	Approval 0	
	Abstain	0	
	Present	21	
11.	#	D	05-02-202
The n	rotocol was	reviewed an	d the following points were addressed by the Principal Investigato
	o the meeti		a the following points were addressed by the rinnopar investigate
		•	ed regarding rooms used for procedures.
Additio			ne meeting included:
		o send to DM	R.
		JC Vote	
	Approval		
		Approval 0	
	Abstain	0	
	Present	21	
12.	#	D	04-29-202
The p	# <b>I</b> rotocol was	D reviewed an	d the following points were addressed by the Principal Investigate
The p	# <b>I</b> rotocol was o the meeti	D reviewed an ng:	d the following points were addressed by the Principal Investigato
The p prior t	# rotocol was o the meeti a. Clarifica	D reviewed and ng: ation provided	d the following points were addressed by the Principal Investigato
The p prior t	# rotocol was o the meeti a. Clarifica onal discus	D reviewed and ng: ation provided	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve	D reviewed an ng: ation provided sion during th	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve	D reviewed an ation provided sion during th ed by commit JC Vote	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval	D reviewed an ation provided sion during th ed by commit JC Vote	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval	D reviewed an ng: ation provided sion during th ed by commit JC Vote 21	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACU Approval Withhold	D a reviewed and ng: ation provided sion during th ed by commit JC Vote 21 Approval 0	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The p prior t	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval Withhold Abstain Present	D s reviewed an ng: ation provided sion during th ed by commit JC Vote 21 Approval 0 0	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included:
The prortor to Addition 13.	# Totocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval Withhold Abstain Present	D s reviewed an ng: ation provided sion during th ed by commit JC Vote 21 Approval 0 0 21 D	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202
The proprior to Addition 13.	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval Withhold Abstain Present # rotocol was	D s reviewed an ng: ation provided sion during th ed by commit JC Vote 21 Approval 0 0 21 D	d the following points were addressed by the Principal Investigato d regarding housing and procedures. ne meeting included: tee vote.
The proprior to Addition 13.	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval Withhold Abstain Present # rotocol was o the meeti	D s reviewed and ng: ation provided sion during the ed by commit JC Vote 21 Approval 0 0 21 D s reviewed and ng:	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202
The proprior to Addition 13. The proprior to	# rotocol was o the meeti a. Clarifica onal discus a. Approve IACL Approval Withhold Abstain Present # rotocol was o the meeti a. Pending onal discus	D reviewed an ation provided sion during the ed by commit JC Vote 21 Approval 0 0 21 D reviewed an ng: g RAD sion during th	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato he meeting included:
The proprior to Addition 13. The proprior to	# Clarification of the meeting on al discuss a. Commit	D s reviewed an ng: ation provided sion during th ed by commit JC Vote 21 Approval 0 0 21 D s reviewed an ng: g RAD sion during th tee voted to s	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato
The proprior to Addition 13. The proprior to	# Clarification of the meeting a. Clarification of the meeting a. Clarification of the meeting a. Approved <b>IACL</b> Approved <b>IACL</b> Approval Withhold Abstain Present # Control of the meeting on the meeting on al discuss a. Commit	D reviewed an ation provided sion during the ed by commit JC Vote 21 Approval 0 0 21 D reviewed an ng: g RAD sion during th	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato he meeting included:
The proprior to Addition 13. The proprior to	# Clarification of the meeting a. Clarification of the meeting a. Clarification of the meeting a. Approved <b>IACL</b> Approved <b>IACL</b> Approval Withhold Abstain Present # Control of the meeting on the meeting on al discuss a. Commit	D s reviewed an ng: ation provided sion during th ed by commit JC Vote 21 Approval 0 0 21 D s reviewed an ng: g RAD sion during th tee voted to s	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato he meeting included:
The proprior to Addition 13. The proprior to	# Clarification of the meeting a. Clarification of the meeting a. Clarification of the meeting a. Approved <b>IACL</b> Approval Withhold Abstain Present # Concol was on the meeting a. Pending on al discuss a. Commite <b>IACL</b> Approval discuss a. Commite <b>IACL</b>	D s reviewed and ng: ation provided sion during the ed by commit JC Vote 21 Approval 0 0 21 D s reviewed and ng: g RAD sion during the tee voted to s JC Vote	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato he meeting included:
The proprior to Addition 13. The proprior to	# Clarification of the meeting a. Clarification of the meeting a. Clarification of the meeting a. Approved <b>IACL</b> Approval Withhold Abstain Present # Concol was on the meeting a. Pending on al discuss a. Commite <b>IACL</b> Approval discuss a. Commite <b>IACL</b>	D s reviewed an ation provided sion during th ed by commit JC Vote 21 Approval 0 0 21 D s reviewed an ng: g RAD sion during th tee voted to s JC Vote 0	d the following points were addressed by the Principal Investigato d regarding housing and procedures. he meeting included: tee vote. 04-30-202 d the following points were addressed by the Principal Investigato he meeting included:

Protocol Category     Title     Original Last Approval Reviewed     Expires
---

DY	05-02-2019	04-29-2021	05-02-2022
D	05-09-2019	04-29-2021	05-09-2022
D	05-01-2019	04-29-2021	05-01-2022
D	05-06-2019	04-29-2021	05-06-2022
D	05-02-2019	04-29-2021	05-02-2022
D	04-18-2019	04-29-2021	04-18-2022
В	04-18-2019	04-29-2021	04-18-2022
D	05-03-2019	04-29-2021	05-03-2022
D	05-02-2019	04-29-2021	05-02-2022
DY	05-07-2019	04-29-2021	05-07-2022
D	05-02-2019	04-29-2021	05-02-2022
С	05-01-2019	04-29-2021	05-01-2022
С	05-14-2019	04-29-2021	05-14-2022
С	05-14-2020	05-12-2022	05-14-2023
CY	05-12-2020	04-29-2021	05-12-2022
С	05-14-2020	05-12-2022	05-14-2023
CY	04-16-2020	04-14-2022	04-16-2023
DY	05-14-2020	05-12-2022	05-14-2023
D	05-14-2020	05-12-2022	05-14-2023
С	04-30-2020	04-28-2022	04-30-2023
DY	05-14-2020	05-12-2022	05-14-2023
E	05-01-2020	04-28-2022	05-01-2023
С	05-01-2020	05-12-2022	05-01-2023
DY	05-04-2020	04-28-2022	05-04-2023
E	05-14-2020	05-26-2022	05-14-2023
E	05-14-2020	05-26-2022	05-14-2023
		Obto !	all have the second second

С	04-20-2020	04-14-2022	04-20-2023
D	05-07-2020	04-28-2022	05-07-2023
С	05-14-2020	05-12-2022	05-14-2023
С	05-11-2020	04-28-2022	05-11-2023
С	05-04-2020	04-28-2022	05-04-2023
DY	05-14-2020	05-12-2022	05-14-2023
DY	05-01-2020	04-28-2022	05-01-2023
E	05-04-2020	04-28-2022	05-04-2023
- Y		05-12-2022	
DY		05-12-2022	
DY		05-12-2022	
С	05-12-2020	05-12-2022	05-12-2023
D	05-14-2020	05-12-2022	05-14-2023


Discussion:	completing the C person appt. -approved -section 1	one staff member is in the process of DHSS renewal process. Pending completion due to in amendment to add minor surgery changes category. 1 other vet listed. AV reviewing all MOUs. on requested regarding husbandry procedures.		
Action Items:	-committe protocol format a -committe -committe	-committee approved renewal and for IACUC staff to update ocol format and update category. -committee approved renewal. -committee approved renewal. -committee approved renewal. mittee approved renewal and IAUC staff working with PI to update ion 7.		
	ACUC Vote			
Appro				
Withh	old Approval 0			
Absta	in O			
Prese	ent 16			

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
----------	----------	---------	------------------

1. #	E		06-11-2021
he amen	ndment was revi	ewed and the following points were addressed by the I	Principal
	tor prior to the m		
	Clarification of fi		
		ing the meeting included: DR to get Committee member's new question addres	bae
a.	IACUC Vote	JER to get committee members new question addres	3eu.
		0	
	pproval	0	
	ithhold Approval		
Ab	bstain	0	
Pr	resent	21	
2. #	D		04-29-2021
		ewed and the following points were addressed by the I	Principal
	tor prior to the m		
		ndment request was following campus policy. ing the meeting included:	
	Committee appr		
	IACUC Vote		
Δr	pproval	21	
	•		
	ithhold Approval		
	bstain	0	
Pr	resent	21	
2 4	D		04-29-2021
<b>3. #</b> The amen	ndment was revi	ewed and the following points were addressed by the I	Principal
The amen			Principal
The amen nvestigat	ndment was revie tor prior to the m Clarified maximu	leeting:	Principal
The amen nvestigate a. ( Additional	tor prior to the m Clarified maximu I discussion duri	neeting: um encounters. ing the meeting included:	Principal
The amen nvestigate a. ( Additional	tor prior to the m Clarified maximu I discussion duri Committee appr	neeting: um encounters. ing the meeting included:	Principal
The amen nvestigati a. ( Additional a. (	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote	neeting: um encounters. ing the meeting included: roved by vote.	Principal
The amen nvestigati a. ( Additional a. (	tor prior to the m Clarified maximu I discussion durin <u>Committee appr</u> IACUC Vote pproval	aeeting: um encounters. ing the meeting included: roved by vote. 21	Principal
The amen nvestigati a. ( Additional a. (	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote	aeeting: um encounters. ing the meeting included: roved by vote. 21	Principal
The amen nvestigati a. ( Additional a. ( A Ap	tor prior to the m Clarified maximu I discussion durin <u>Committee appr</u> IACUC Vote pproval	aeeting: um encounters. ing the meeting included: roved by vote. 21	Principal
The amen nvestigati a. ( a. dditional a. ( Ap M At	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval	eeting: um encounters. ing the meeting included: roved by vote. 21 I 0	Principal
The amen nvestigati a. ( Additional a. ( Ap M At	tor prior to the m Clarified maximu I discussion durin <u>Committee appr</u> IACUC Vote pproval /ithhold Approval bstain	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0	Principal 04-29-2021
The amen nvestigati a. ( Additional a. ( A Additional a. ( A A A Pr <b>4. #</b>	tor prior to the m Clarified maximu I discussion durin Committee appr IACUC Vote pproval /ithhold Approval bstain resent	eeeting: um encounters. ing the meeting included: roved by vote. 21 I 0 0 21	04-29-2021
The amen nvestigati a. ( Additional a. ( Additional a. ( Ap W At Pr <b>4. #</b>	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent C ndment was revie tor prior to the m	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the R eeeting:	04-29-2021
The amen nvestigati a. ( Additional a. ( A A M At Pr <b>4. #</b> The amen nvestigati a. (	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent C ndment was revie tor prior to the m Confirmed room	eeeting: um encounters. ing the meeting included: 21 21 ewed and the following points were addressed by the following: is already approved for dark adaptation.	04-29-2021
The amen nvestigati a. ( Additional a. ( Additional W At Pr <b>4. #</b> The amen nvestigati a. ( Additional	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent Confirmed room I discussion duri	eved and the following points were addressed by the Reeting: eved and the following points were addressed by the Reeting: is already approved for dark adaptation. ing the meeting included:	04-29-2021
The amen nvestigati a. ( Additional a. ( A Additional The amen nvestigati a. ( Additional	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent C ndment was revie tor prior to the m Confirmed room I discussion duri Committee appr	eved and the following points were addressed by the Reeting: eved and the following points were addressed by the Reeting: is already approved for dark adaptation. ing the meeting included:	04-29-2021
The amen nvestigati a. ( Additional a. ( Additional Pr <b>4. #</b> The amen nvestigati a. ( Additional a. (	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent C mdment was revie tor prior to the m Confirmed room I discussion duri Committee appr IACUC Vote	eved and the following points were addressed by the F every and the following points were addressed by the F every and the following points were addressed by the F every and the following points were addressed by the F every and the following points were addressed by the F every and the following points were addressed by the F every and the following points were addressed by the F every addres	04-29-2021
The amen nvestigati a. ( Additional a. ( At Pr 4. # The amen nvestigati a. ( Additional a. ( Ap	tor prior to the m Clarified maximu I discussion durin Committee appr IACUC Vote pproval Vithhold Approval bistain resent Confirmed room I discussion durin Committee appr IACUC Vote pproval	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21	04-29-2021
The amen nvestigati a. ( Additional a. ( Additional M The amen nvestigati a. ( Additional a. ( Additional a. ( Apple of the amen nvestigati a. ( Apple of the amen a. ( Additional a. ( Apple of the amen a. ( Ap	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent C ndment was revie tor prior to the m Confirmed room I discussion duri Committee appr IACUC Vote pproval /ithhold Approval	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21	04-29-2021
The amen nvestigati a. ( Additional a. ( A M A M A The amen nvestigati a. ( Additional a. ( A Additional a. ( A A M M	tor prior to the m Clarified maximu I discussion durin Committee appr IACUC Vote pproval Vithhold Approval bistain resent Confirmed room I discussion durin Committee appr IACUC Vote pproval	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21	04-29-2021
The amen nvestigati a. ( Additional a. ( A A A A A A A A A A A A A A A A A A A	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent C ndment was revie tor prior to the m Confirmed room I discussion duri Committee appr IACUC Vote pproval /ithhold Approval	eveting: um encounters. ing the meeting included: 21 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1	04-29-2021
The amen nvestigat a. ( Additional a. ( At Pr 4. # The amen nvestigat a. ( Additional a. ( Additional a. ( At Mathematical a. ( At Mathematical a. ( At At At At At At At At At At At At At	tor prior to the m Clarified maximu I discussion durin Committee appr IACUC Vote pproval Vithhold Approval bistain resent Confirmed room I discussion durin Committee appr IACUC Vote pproval Vithhold Approval Vithhold Approval bistain	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21 1 0 0 0	04-29-2021
The amen nvestigat a. ( Additional a. ( Additional Additional a. ( Additional a. ( Additional a. ( Additional a. ( At Pr S. #	tor prior to the m Clarified maximu I discussion duri Committee appre- IACUC Vote pproval //ithhold Approval bstain resent Confirmed room I discussion duri Committee appre- IACUC Vote pproval //ithhold Approval bstain resent D	eeeting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following: is already approved for dark adaptation. ing the meeting included: roved by vote. 21 1 0 0 0	04-29-2021 Principal
The amen nvestigat a. ( Additional a. ( Additional At Pr 4. # The amen nvestigat a. ( Additional a. ( Additional a. ( At Pr 5. # The amen nvestigat	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent Confirmed room I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent D mdment was revie tor prior to the m	eveting: um encounters. ing the meeting included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following included: roved by vote. 21 1 0 0 21 ewed and the following points were addressed by the following he meeting included: 1 0 0 21 ewed and the following points were addressed by the following points were addressed	04-29-2021 Principal 04-29-2021 Principal
The amen nvestigat a. ( Additional a. ( Ar W At Pr Additional a. ( Additional a. ( Additional a. ( Additional a. ( Additional a. ( At Pr 5. # The amen nvestigat a. ( At At Pr At At At At At At At At At At	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent Confirmed room I discussion duri Committee appr IACUC Vote pproval //ithhold Approval bstain resent D Mement was revie tor prior to the m Committee conc	eved and the following points were addressed by the Reeting: a already approved for dark adaptation. a already approved for dark adaptation. ing the meeting included: oved by vote. 21 eved and the following points were addressed by the Reeting: a already approved for dark adaptation. ing the meeting included: oved by vote. 21 eved and the following points were addressed by the Reeting: a construction of the section of the sec	04-29-2021 Principal 04-29-2021 Principal
The amen nvestigat a. ( Additional a. ( Additional a. ( At Pr Additional a. ( Additional a. ( Additional a. ( Additional a. ( At Pr 5. # The amen nvestigat a. ( Sur	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent Confirmed room I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent D Mement was revie tor prior to the m Committee conc re if animals had	eved and the following points were addressed by the Field by vote.	04-29-2021 Principal 04-29-2021 Principal
The amen nvestigat: a. ( Additional a. ( Additional At Pr <b>4. #</b> The amen nvestigat: a. ( Additional a. ( Additional <b>5. #</b> The amen nvestigat: a. ( At Pr <b>5. #</b>	tor prior to the m Clarified maximu I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent Confirmed room I discussion duri Committee appr IACUC Vote pproval /ithhold Approval bstain resent Dommittee conc re if animals had I discussion duri	eved and the following points were addressed by the Reeting: a already approved for dark adaptation. a already approved for dark adaptation. ing the meeting included: oved by vote. 21 eved and the following points were addressed by the Reeting: a already approved for dark adaptation. ing the meeting included: oved by vote. 21 eved and the following points were addressed by the Reeting: a construction of the section of the sec	04-29-2021 Principal 04-29-2021 Principal



Approv	al (	5				
Withho	d Approval (	וכ				
Abstair	(	כ				
Presen	t 2	:1				
10. #	D					04-29-202
dditional disc a. Com IA	nittee approv	the meetined by vote	ng included:	euc procedu	ure.	
Approv		20				
	d Approval (					
Abstair		כ				
Presen	t 2	0				

# XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.03-17-2021		
2. 03-29-2021		
3. 03-31-2021		
4. 04-02-2021		
5. 04-19-2021		
6. 04-19-2021		
7.04-21-2021		
8. 04-21-2021		

Discussion	Discussion: 5. Despite the minor deficiency resulting in using an expired drug, the IACUC was very impressed with the overall management of the clinic. The organization, thoroughness of records and attention to detail is commended.				
Action	Action: 5. Deficiencies have been corrected.				
	IACUC Vote				
App	roval	15			
With	hold Approval	0			
Abst	ain	0			
Pres	ent	15			

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 10-27-2020	LAB	
2. 04-15-2021	LAB	
3. 04-21-2021	LAB	
4. 04-21-2021	LAB	
5. 04-15-2021	PAM	
6. 04-20-2021	PAM	
7. 04-21-2021	PAM	

Discussion:	<ol> <li>This room is not used for animal work. Discussed combining the inspection in the room that is shared and alternating every 3 months between the two PI's.</li> <li>PI was breeding animals without IACUC approval.</li> </ol>					
Action:	inspection will be 5. Meeting betwe clarify to the PI w	m will be removed from the IACUC protocol and this PI's lab tion will be scheduled at her collaborators lab on a rotating basis. eting between PI, IACUC Director and Committee Chair helped to the PI what needs to be included in his protocol and when an liment is needed. Procedure has now been approved via an liment.				
	IACUC Vote	]				
Appr	oval 20					
With	hold Approval 0					
Abst	ain 0					
Pres	ent 20					

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс					
Animals tran	Animals transferred to holding protocol from				
Discussion:	None.				
Action:	None.				
PI Maintaine	d Form				
Discussion:	None.				
Action:	Approved.				

# XVI. Program Updates:

Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### May 13, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M005, M222, M102, M111, M042, A095, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M114

### Excused:

M090, M004, M112

#### Guests:

M116, A017

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

1. #		Category: D Y
The protocol was reviewed meeting: a. None.	l an	d the following points were addressed by the Principal Investigator prior to the
Additional discussion durin a. Pending PI const		
IACUC Vote		
Approval	0	
Withhold Approval	0	
Abstain	0	
Present	21	

#### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
AMP news alert: SAEN complaint to USDA
Action: FYI
Action: Surgical prep retraining; self -reported no animal welfare impact.
Action: Fracture pending pathology results and inquire to vendor, no experimental procedures.

#### V. Veterinary Care Program Updates:


The Attending Veterinarian provided the following updates to the committee:

#### Sentinel Program

corynebacterium bovis

## Action Items: Pull all current sentinal cages; cull; PCR. PI notification. Evaluate other program options.

## VI. Designated Review Protocols:



a. Pendin 7. #	D		05-06-2021
prior to the meet a. Clarific Additional discus	ing: ation of timing f ssion during the	the following points were addressed by the Princip for suspension test. meeting included: vailable; Substitute reviewer.	oal Investigator
8. #	D		05-11-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	al Investigator
9.#	D		-
prior to the meet a. Pendin Additional discus	ing: g Reviewer and	the following points were addressed by the Princip BUA meeting included:	al Investigator
10. #	D		-
Additional discus	g Reviewer ssion during the ns in DMR <b>C</b>	meeting included:	-
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip	oal Investigator
12. #	E		-
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
13. #	C		05-03-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
14. #	С		05-12-2021
		the following points were addressed by the Princip	al Investigator
prior to the meet a. Clarific	ing: ation of animal	disposition.	

Additional discu a. None.	ssion during the	e meeting included:	
15. #	D		05-02-2021
prior to the mee a. PI was procedur	ting: agreeable to ι e room and onl	I the following points were addressed by the Princip updating the protocol to include survival surgeries in y terminal surgeries in the lab. e meeting included:	_
16. #	С		05- <mark>1</mark> 1-2021
orior to the mee a. None. Additional discu	ting:	I the following points were addressed by the Princip e meeting included:	oal Investigator
a. None. 17. #	СҮ		05-13-2021
orior to the mee a. Clarific expected	ting: cation provided I to be infected	I the following points were addressed by the Princip regarding adoption procedures, numbers justificati with WT. e meeting included:	-
18. #	СҮ		05-13-2021
Additional discu a. None.	cation on refine ssion during the	ment. e meeting included:	
19.#	С		-
orior to the mee a. Clarific	ting: cation of proced	I the following points were addressed by the Princip lures. e meeting included:	oal Investigator
20. #	В		04-30-2021
prior to the mee a. None.	ting:	I the following points were addressed by the Princip e meeting included:	oal Investigator
21. # <b>11</b>	СҮ		05-13-2021
The protocol wa		the following points were addressed by the Princip	oal Investigator
a. None.	ssion during the	e meeting included:	

prior to the mee	ting:	the following points were addressed by the Princip	
a. Clarific transport		lures, post-operative, potential side effects and an	imal
	-	meeting included:	
a. None.			
23. #	C		-
prior to the mee a. Pendir	ting: ng Reviewer	the following points were addressed by the Princip meeting included:	pal Investigator
a. Remai	ins in DMR		
24. #	С		05-12-2021
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	pal Investigator
25. #	D		05-13-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip meeting included:	pal Investigator
26. #	B		05-11-2021
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	pal Investigator
27. #	В		05-11-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip meeting included:	pal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	DY		05-13-2021
Investigator pric a. None.	or to the meetin Ission during th	and the following points were addressed by the Pr g: e meeting included:	incipal
2.#			05-07-2021
Investigator pric a. Clarifi	or to the meetin cation on proce	and the following points were addressed by the Pr g: dures and animal numbers. e meeting included:	incipal

a. None.			
3. #	СҮ		05-13-2021
Investigator prio a. None.	or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	incipal
4. #	С		05-11-2021
Investigator prio a. None.	or to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
5. <b>#</b>	D		05-13-2021
Investigator prio a. None.	or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	incipal
6. #	D		05-12-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
7.#	DY		05-11-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
8. #	DY		05-11-2021
Investigator prio a. None.	or to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
9. #	D		05-13-2021
The amendmen Investigator prio a. None.	r to the meeting		incipal
Additional discu a. None.	ssion during the	e meeting included:	
10. #	D		05-13-2021
Investigator prio a. None.	or to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
a. None.	-		
11. #	C		-

The amendmen Investigator price		and the following points were addressed by the Pr	incipal
	ng reviewer	j.	
Additional discu		e meeting included:	
12. #	D		05-13-2021
	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.	or to the meeting	j:	
a. Pendir	ssion during the ng Reviewer	e meeting included:	
13. #	D	•	-
		and the following points were addressed by the Pr	incipal
Investigator prio			
	ng facility SOPs	e meeting included:	
	ins in DMR.	meeting included.	
14. #	D		05-11-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.	r to the meeting	j:	
Additional discu a. None.	•	e meeting included:	
15. #	С		05-13-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incinal
Investigator prio a. None. Additional discu	or to the meeting ssion during the		
a. None.			
16. #	DY		05-10-2021
		and the following points were addressed by the Pr	incipal
Investigator price	or to the meeting	j:	
a. None.	coion during the	mosting included:	
a. None.		e meeting included:	
17. #			-
		and the following points were addressed by the Pr	incipal
Investigator price	-	j:	
a. None.		meeting included:	
		e meeting included: to chem question.	
18. #	DY		
		and the following points were addressed by the Pr	incipal
Investigator prio			nopu
		n of procedures.	
Additional discu	ssion during the	e meeting included:	
a. Remai	ins in DMR.		
19. #	DY		05-10-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	or to the meeting		
		e meeting included:	

20. #	E		05-11-2021			
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal			
Investigator prio	Investigator prior to the meeting:					
a. None.						
Additional discussion during the meeting included:						
a. None.	_					
21. #	E		05-12-2021			
		and the following points were addressed by the Pr	incipal			
Investigator prio	r to the meeting	j:				
a. None.	ccion during the	maating included:				
a None	ssion during the	e meeting included:				
22. #	D		05-13-2021			
22. 11			00-10-2021			
The amendmen	t was reviewed	and the following points were addressed by the Pr	incinal			
Investigator prio			incipal			
		ied no new VHSS was required.				
		e meeting included:				
a. None.		-				
23. #	DY		-			
		and the following points were addressed by the Pr	incipal			
Investigator prio						
		d regarding animal numbers and how animals will l	be generated to			
		not be required to be updated. e meeting included:				
a. None.	ssion during the					
24. #	D		05-04-2021			
		and the following points were addressed by the Pr				
Investigator prio			linopul			
a. None.						
Additional discu	ssion during the	e meeting included:				
a. None.						
25. #	В		04-29-2021			
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal			
Investigator prio						
		regarding animal numbers.				
Additional discu a. None.	ssion during the	e meeting included:				
	-					
26. #	E	· · · · · · · · · · · · · · · · · · ·	-			
		and the following points were addressed by the Pr	incipal			
Investigator prio a. None.	r to the meeting					
	ssion during the	e meeting included:				
	ng chem and re					
27. #	Č C		05-13-2021			
	-					
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal			
Investigator prio						
a. None.	-					
	Additional discussion during the meeting included:					
a. None.	-					
28. #	D		05-13-2021			

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
a. None.		<b>.</b>		
Additional discu a. None.	-	e meeting included:		
29. #	D		05-11-2021	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio a. None.	or to the meeting			
Additional discur a. None.	ssion during the	e meeting included:		
30. #	D		-	
Investigator prio a. None. Additional discu	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal	
31. #	DY		05-13-2021	
		and the following points were addressed by the D	I	
Investigator prio a. More o	or to the meeting details provided	and the following points were addressed by the Pr g: on how the procedure will be performed. e meeting included:	incipal	
32. #	DY		05-02-2021	
		and the following points were addressed by the Pr	l	
Investigator prio			nopa	
		the dose given to each animal.		
		e meeting included:		
Additional discu			-	
Additional discu a. None. 33. #	ssion during the	e meeting included:	-	
Additional discu a. None. 33. #	D Y t was reviewed	e meeting included: and the following points were addressed by the Pr	- incipal	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu	D Y D Y t was reviewed or to the meeting	and the following points were addressed by the Pr g: e meeting included:	- incipal	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu	D Y D Y t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	- incipal 05-13-2021	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. Additional discu	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g: with EH&S. and the following points were addressed by the Pr	05-13-2021	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. Additional discu a. None.	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included: with EH&S. and the following points were addressed by the Pr g:	05-13-2021 incipal	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. Additional discu	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included: with EH&S. and the following points were addressed by the Pr g:	05-13-2021	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. Additional discu a. None. 35. #	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the C Y	and the following points were addressed by the Pr g: e meeting included: v with EH&S. and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	05-13-2021 incipal 05-11-2021	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. 35. # The amendmen Investigator prio a. None. 35. #	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the C Y t was reviewed or to the meeting	and the following points were addressed by the Pr g: e meeting included: v with EH&S. and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	05-13-2021 incipal 05-11-2021	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. 35. # The amendmen Investigator prio a. None. Additional discu a. None. Additional discu a. None.	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the c Y t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included: with EH&S. and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	05-13-2021 incipal 05-11-2021 incipal	
Additional discu a. None. 33. # The amendmen Investigator prio a. None. Additional discu a. Pendir 34. # The amendmen Investigator prio a. None. Additional discu a. None. 35. # The amendmen Investigator prio a. None. Additional discu	ssion during the D Y t was reviewed or to the meeting ssion during the ng further reviewed C t was reviewed or to the meeting ssion during the C Y t was reviewed or to the meeting	and the following points were addressed by the Pr g: e meeting included: with EH&S. and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	05-13-2021 incipal 05-11-2021	


Investigator prio a. None.	or to the meetin	and the following points were addressed b g: e meeting included:	y the Pr	rincipal
37.#	D			05-10-2021
Investigator prio a. None.	or to the meetin	and the following points were addressed b g: e meeting included:	y the Pr	incipal


## VIII. Administrative and Veterinary Verification Amendments:

Total of **148** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





Approval	0
Withhold Approval	0
Abstain	0
Present	21

### X. Annual Renewals:


Protocol	Category	Title Original Approval	Last Reviewed	Expires
	С	05-20-2019	05-13-2021	05-20-2022
	E	05-16-2019	05-13-2021	05-16-2022
	DY	05-16-2019	05-13-2021	05-16-2022
	D	05-16-2019	05-13-2021	05-16-2022
	D	05-17-2019	05-13-2021	05-17-2022
	D	05-24-2019	05-13-2021	05-24-2022
	С	05-16-2019	05-13-2021	05-16-2022
	С	05-16-2019	05-13-2021	05-16-2022
	D	05-16-2019	05-13-2021	05-16-2022
	D	05-16-2019	05-13-2021	05-16-2022
	CY	05-15-2019	05-13-2021	05-15-2022
	D	05-15-2019	05-13-2021	05-15-2022
	D	05-15-2019	05-13-2021	05-15-2022
	D	05-16-2019	05-13-2021	01-11-2022
	DY	05-15-2019	05-13-2021	05-15-2022
	С	05-16-2019	05-13-2021	05-16-2022
	С	05-27-2019	05-13-2021	05-27-2022
	DY	05-16-2019	05-13-2021	05-16-2022
	DY	05-28-2020	05-26-2022	05-28-2023
	D	05-28-2020	05-26-2022	05-28-2023
	С	05-15-2020	05-12-2022	05-15-2023
	E	05-28-2020	05-26-2022	05-28-2023

	_				
	С	5-1	5-2020	05-12-2022	05-15-2023
	С	5-2	8-2020	05-26-2022	05-28-2023
	CY	5-2	8-2020	05-26-2022	05-28-2023
	С	5-1	3-2020	04-28-2022	05-13-2023
	D	5-2	8-2020	05-26-2022	05-28-2023
		5-2	8-2020	05-26-2022	05-28-2023
	DY	5-2	8-2020	05-26-2022	05-28-2023
	D	5-2	8-2020	05-26-2022	05-28-2023
	D	5-2	8-2020	05-26-2022	05-28-2023
	С	5-2	8-2020	05-26-2022	05-28-2023
	С	5-2	8-2020	05-26-2022	05-28-2023
	С	5-1	9-2020	05-12-2022	05-19-2023
	С	5-1	9-2020	05-12-2022	05-19-2023
	D	5-2	8-2020	05-26-2022	05-28-2023
	С	5-2	8-2020	05-13-2021	10-18-2021
	DY	5-2	8-2020	05-26-2022	05-28-2023
Discus Action It	protoco pendin ems:	is on the last step of the OHSS renewal process. They a their in person appointment at occupational health.	re		1
				_	
	Approval	18			
	Nithhold App Abatain				
	Abstain	0			
ŀ	Present	18			

#### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Catagory	Request	Date
FIOLOCOI	Category	Request	Approved



 The amendment was reviewed and the following points were addressed by the Principal

 Investigator prior to the meeting:

 a. Committee requests a literature search and a change in pain category to D. Additional

 information requested to understand cause of lameness and more thorough plan for

 prevention.

 Additional discussion during the meeting included:

 a. Voted to send to DMR.

 IACUC Vote

 Approval
 0

 Withhold Approval
 0

 Present
 22

### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 04-14-2021	
2. 04-26-2021	
3. 04-28-2021	
4. 05-04-2021	

Discussion:1. Facility shared by two PI's. On quarterly rotation to ensure both PI's are seen every 6 months.Action:1. None at this time. PI is just starting project and everything looked good thus far with their set up.

IACUC Vote	
Approval	20
Withhold Approval	0
Abstain	0
Present	20

### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 04-12-2021	LAB	
2. 04-29-2021	LAB	
3. 04-08-2021	PAM	
4. 04-15-2021	PAM	
5. 05-05-2021	PAM	

Discussion:	None.	
Action:	None.	
ļ	IACUC Vote	
Appr	oval	22
With	hold Approval	0
Absta	ain	0
Pres	ent	22

#### **XIV. Regulatory Inspections:**

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс				
1. PI Maintai	n Form			
	Previous location for housing was shared between PI and TRACS. New location which is already set up for aquatic housing cannot be accommodated by TRACS staff at this time.			
	Committee approved request for PI maintain housing. Protocol, SOP and room log will be reviewed at the next meeting.			
2. House kee	eping reminder - protocol/amendment review availability			
Discussion:	n: None.			
Action:	None.			

# XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

#### May 27, 2021 Meeting Minutes

#### [regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M005, M222, M102, M111, M090, A095, M092, A019, M119, A109, M110, M120, A013, M016, M024, M223, M001, M114

#### Excused:

M042, M004, M087, M093, M112

#### **Guests:**

M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

#			Category: E
ne amendment was e meeting: a. None.	reviewed and t	ne following points were addressed	by the Principal Investigator prior to
dditional discussion a. Send to DR		ting included: ndment with plan proposed at Facili	ty Inspection.
	/ote		
Approval	0		
Withhold App	oroval 0		
Abstain	0		
Present	20		
#			Category: D
	s reviewed and t	he following points were addressed	by the Principal Investigator prior to
e meeting:	numbers justifi	cation and total number of animals.	
a DI modified	numbers justing		
a. PI modified			
ditional discussion			
dditional discussior	n during the mee voted to approv		
ditional discussion	voted to approv		
lditional discussion a. Committee	voted to approv		
ditional discussion a. Committee	voted to approv /ote 20		
dditional discussion a. Committee IACUC V Approval	voted to approv /ote 20		

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events,
and incidents:

- AV consulted with vendor. No other reports of concern.
Action: Tabled - pending pathology results.
heep Barn coyote activity
Action: Fencing; sheep euthanized at VMTH, engaged APHIS.
NPRC roundup
Action: Myocardiomyopathy; genetic condition; human disease model.
edia contact
Action: FYI.

# V. Veterinary Care Program Updates:


The Attending Veterinarian provided the following updates to the committee:

None at this time.

## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved		
1. #	E		-		
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip meeting included: Response	oal Investigator		
2. #	DY		-		
prior to the meet a. None. Additional discus a. Pendin	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.				
3. #	с		05-27-2021		
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator		
4. #	D		05-18-2021		
prior to the meet a. Clarific	ting: ation on wire m	the following points were addressed by the Princip lesh flooring. e meeting included:	oal Investigator		
5. #	С		05-27-2021		
prior to the meet		the following points were addressed by the Princip e effects.	oal Investigator		

Additional discussion during the meeting included:



13. #	D		05-27-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
		meeting included:			
14.#	С		-		
The protocol was prior to the meet		the following points were addressed by the Princip	al Investigator		
a. Clarific Additional discus	ation of doses, ssion during the	maximum volume, and overnight housing. meeting included: earance and review of PI response by reviewer.			
15. #	C		05-14-2021		
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator		
prior to the meet a. Clarific	ting: ation of proced		g		
16. #	С		-		
	d of Urine Samp ssion during the	bling to be clarified meeting included:			
17.#	DY		05-24-2021		
prior to the meet a. Clarific	ting: ation on implan	the following points were addressed by the Princip t apparatus fractures. meeting included:	al Investigator		
18. #	С		05-13-2021		
The protocol wa prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	al Investigator		
19. #	D		-		
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	al Investigator		
		meeting included:			
20. #	D		05-17-2021		
prior to the meet a. Clarific b. Clarific	ting: ation of pain ca ation of timing f	the following points were addressed by the Princip tegory for increased monitoring meeting included:	al Investigator		

21. #	С		-			
prior to the meet a. None.	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
Additional discus a. Pendin		meeting included:				
22. #	С		05-27-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Prince	sipal Investigator			
a. None.	-					
23. #	С		05-27-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Prince meeting included:	cipal Investigator			
24. #	D		05-13-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Prince	cipal Investigator			
25. #	D		05-25-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Prince meeting included:	cipal Investigator			
26. #	С		-			
prior to the meet a. Clarific Additional discus	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of maximum volume and overnight housing. Additional discussion during the meeting included: a. Pending Biosafety and Occ Health clearance.					
27.#			-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:						
	-	ernate reviewer volunteered.				
28. #	С		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of numbers and procedures. Additional discussion during the meeting included: a. Pending Occ Health clearance.						
29. #	C		05-21-2021			

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Approved via DR for tracking purposes only. Additional discussion during the meeting included: a. None.					
30. #	D			-	
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending BIO and CHEM Additional discussion during the meeting included: a. Remains in Designated Reviewer					

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	D		05-27-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
2. #	D		05-25-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
3.#	DY		05-24-2021
Investigator prio a. None.			
Additional discus a. None.	ssion during the	e meeting included:	
a. None. 4. #	DY		05-24-2021
a. None. 4. # The amendment Investigator prio a. None.	D Y t was reviewed r to the meeting	and the following points were addressed by the Pr	
a. None. 4. # The amendment Investigator prio a. None. Additional discus	D Y t was reviewed r to the meeting	and the following points were addressed by the Pr g:	00 21 2021
a. None. 4. # The amendment Investigator prio a. None. Additional discus a. None. 5. # The amendment Investigator prio a. Clarific	D Y t was reviewed r to the meeting ssion during the t was reviewed r to the meeting ation on statist	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr	05-27-2021
a. None. 4. # The amendment Investigator prio a. None. Additional discus a. None. 5. # The amendment Investigator prio a. Clarific Additional discus	D Y t was reviewed r to the meeting ssion during the t was reviewed r to the meeting ation on statist	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: ical rationale and animal number justification.	05-27-2021
a. None. 4. # The amendment Investigator prio a. None. Additional discus a. None. 5. # The amendment Investigator prio a. Clarific Additional discus a. None. 6. # The amendment Investigator prio a. Pendir	DY t was reviewed r to the meeting ssion during the t was reviewed r to the meeting sation on statistic ssion during the C t was reviewed r to the meeting ng Reviewer	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: ical rationale and animal number justification. e meeting included: and the following points were addressed by the Pr g:	05-27-2021 incipal
a. None. 4. # The amendment Investigator prio a. None. Additional discus a. None. 5. # The amendment Investigator prio a. Clarific Additional discus a. None. 6. # The amendment Investigator prio a. Pendir Additional discus	DY t was reviewed r to the meeting ssion during the t was reviewed r to the meeting sation on statistic ssion during the C t was reviewed r to the meeting ng Reviewer	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: ical rationale and animal number justification. e meeting included: and the following points were addressed by the Pr g: e meeting included:	05-27-2021 incipal

The amendment was reviewed and the following points were addressed by the Principal				
Investigator prio a. None.	r to the meeting	j:		
Additional discussion during the meeting included:				
a. None.				
8.#	С		05-18-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio	r to the meeting	j:		
	•	larvae at the experimental endpoint.		
	ssion during the	e meeting included:		
a. None.				
9.#	DY		05-26-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prio a. None.	r to the meeting	].		
	ssion during the	e meeting included:		
a. None.	ssion during the	meeting moduled.		
10. #	D		05-13-2021	
	was reviewed	and the following points were addressed by the Pr		
Investigator prio			inoipui	
a. None.				
		e meeting included:		
a. Numbe	ers clarified by I	기		
11. #	D		-	
		and the following points were addressed by the Pr	incipal	
Investigator prio	r to the meeting ig facility SOPs			
		e meeting included:		
	ns in DMR.			
12. #			-	
	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio				
a. None.	-			
		e meeting included:		
	g PI response	to Chem.		
13. #			-	
		and the following points were addressed by the Pr	incipal	
Investigator prio				
	ig PI's response	e. e meeting included:		
	ns in DMR.			
14.#	D		05-21-2021	
	_			
The amendment was reviewed and the following points were addressed by the Principal				
Investigator prior to the meeting:				
a. None.				
Additional discussion during the meeting included: a. Post procedural question addressed by PI				
15. #			05-26-2021	
13. 1			05-20-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio				
a. None.				
Additional discussion during the meeting included:				
a. None.				

16. #	DY		-	
		and the following points were addressed by the Pr	incipal	
Investigator prio		i: I from biosafety.		
		e meeting included:		
	ns in DMR.			
17.#	CY		05-21-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting arificiation.	i:		
		meeting included:		
a. None.				
18. #	E		05-27-2021	
Investigator prior a. None. Additional discus	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal	
a. None.	DY		05-24-2021	
19. #		and the following points were addressed by the Pr		
Investigator prior a. None.	r to the meeting		пара	
20. #	D		05-27-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal	
21. #	DY		05-25-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal	
22. #	DY		-	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending further discussion with EH&S.				
23. #	С		05-27-2021	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:				
a. None.				
24. #	С		05-27-2021	

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of bleeding technique. Additional discussion during the meeting included: a. None.					
25. #	DY		05-25-2021		
Investigator prior a. Clarifie	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified saline will be used instead of ultrasound gel. Additional discussion during the meeting included: a. None				
26. #	С		05-18-2021		
The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.					

### VIII. Administrative and Veterinary Verification Amendments:


Total of **86** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

#### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	tocol	Category	Title	Date Approved
1. #		D		05-27-2021
prior to Additio	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on BUA, animal numbers, procedures and adverse effects. Additional discussion during the meeting included: a. Discussion on compliance issue and PAM requested for follow up.			
	IAC	UC Vote		
	Approval	20		
	Withhold	Approval 0		
	Abstain	0		
	Present	20		
2. #		DY		05-27-2021

The pr	The protocol was reviewed and the following points were addressed by the Principal Investigator					
prior to the meeting:						
a. EH&S comments.						
	Additional discussion during the meeting included:					
	a. None.		_			
		UC Vote				
	Approval		19			
		Approval	0			
	Abstain		0			
	Present		19			
3. #		D			05-27-2021	
-		•				
	the meet		and	I the following points were addressed by the Princip	bal Investigator	
			ectio	n volume and contents.		
Additio	nal discus			e meeting included:		
	a. None.					
		UC Vote				
	Approval		20			
		Approval	0			
	Abstain		0			
	Present		20			
4. #		DY			05-27-2021	
-						
			and	I the following points were addressed by the Princip	bal Investigator	
•	the meet a. None.	ing:				
		ssion durin	a the	e meeting included:		
	a. None.		<u> </u>	5		
	IAC	UC Vote				
	Approval		19			
	Withhold	Approval	0			
	Abstain		0			
	Present		19			
5. #		CY			05-27-2021	
	otocol was	s reviewed	and	the following points were addressed by the Princip	al Investigator	
prior to	the meet					
	a. None.					
	nal discus a. None.	ssion durin	ig the	e meeting included:		
		UC Vote				
	Approval		19			
		Approval				
	Abstain	, approva	0			
	Present		19			
<u>ц</u>	Tresent	0	15		07.07.2024	
6. #		С			07-07-2021	
The pr	otocol wa	s reviewed	and	the following points were addressed by the Princip	al Investigator	
	the meet					
a. Pending final biosafety approval.						
	Additional discussion during the meeting included: a. Voted to send to DMR.					
	a. Voted to send to DIVIR.					



	Abstain	0		
1	Present	20		
11. #		СҮ		05-27-2021
prior to t a Addition	the meeti a. Fosterir	ng: 1g contigenc	nd the following points were addressed by the Principa cy plan. the meeting included:	I Investigator
		JC Vote	7	
	Approval	19		
		Approval 0		
	Abstain	0		
I	Present	19	9	
12. #		С		05-27-2021
prior to f a Addition	the meeti a. Biosafe al discus a. Commit	ng: ty officer and	nd the following points were addressed by the Principa d chemical safety officer provided updated VHSS for at the meeting included: approve.	-
	Approval	20		
,	Withhold	Approval 0		
	Abstain	0		

# X. Annual Renewals:

Protocol Category	Title	Original Approval	Last Reviewed	Expires
С		6-04-2019	05-27-2021	06-04-2022
С		5-30-2019	05-27-2021	05-30-2022
DY		5-30-2019	05-27-2021	05-30-2022
		6-05-2019	05-27-2021	06-05-2022
DY		5-30-2019	05-27-2021	05-30-2022
С		5-30-2019	05-27-2021	05-30-2022
D		5-30-2019	05-27-2021	05-30-2022
D		5-30-2019	05-27-2021	05-30-2022
D		6-03-2019	05-27-2021	06-03-2022
D		6-03-2019	05-27-2021	06-03-2022
			Obtaine	ed by Rise for A


С		15_30_2010	05-27-2021	05-30-2022
٦U		05-30-2019	05-27-2021	05-30-2022
D		06-01-2019	05-27-2021	06-01-2022
С		06-03-2019	05-27-2021	06-03-2022
Y		05-30-2019	05-27-2021	05-30-2022
D		05-30-2019	05-27-2021	05-30-2022
D		)5-30-2019	05-27-2021	05-30-2022
C		)5-30-2019	05-27-2021	05-30-2022
DY	·	05-30-2019	05-27-2021	05-30-2022
D		)5-29-2020	05-26-2022	05-29-2023
D		06-03-2020	05-26-2022	06-03-2023
CY		06-03-2020	05-26-2022	06-03-2023
DY		06-01-2020	05-26-2022	06-01-2023
D		06-01-2020	05-26-2022	06-01-2023
DN		06-11-2020	06-09-2022	06-11-2023
D		)5-29-2020	05-26-2022	05-29-2023
D		06-11-2020	06-09-2022	06-11-2023
DY		)6-04-2020	06-09-2022	06-04-2023
D		06-08-2020	05-26-2022	06-08-2023
C		06-03-2020	05-27-2021	06-03-2022
D		06-11-2020	06-09-2022	06-11-2023
C		06-11-2020	06-09-2022	06-11-2023
DY		06-11-2020	06-09-2022	06-11-2023
С		06-11-2020	06-09-2022	06-11-2023
С		06-11-2020	06-09-2022	06-11-2023
			<u> </u>	
Discussion: Ol	and <b>Control</b> -One staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>Second</b> staff member is in the process of updates and <b>S</b>	ating their		

tion Items:	-Committee approved annual renewals.	
IACUC Vo	ie	
Approval	17	
Withhold Appro	val 0	
Abstain	0	
Present	17	


### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1.#	D		06-07-2021
nvestigator prio a. Pendir dditional discu	r to the meeting g Reviewer ssion during the	and the following points were addressed by the Pr g: e meeting included: signated Reviewer.	incipal
	UC Vote		
Approva			
	Approval 0		
Abstain	0		
Present	20		
2. #	C		05-27-2021
	-		
	ssion during the	e meeting included:	
a. None.	ssion during the	e meeting included:	
a. None.	UC Vote	e meeting included:	
a. None. IAC Approva	UC Vote	e meeting included:	
a. None. IAC Approva	UC Vote	e meeting included:	
a. None. IAC Approva Withhold	UC Vote 20 Approval 0	e meeting included:	
a. None. IAC Approva Withhold Abstain Present 3. #	UC Vote Approval 0 0 20 D		
a. None. IAC Approva Withhold Abstain Present 3. # The amendment nvestigator prio a. Pendir Additional discus a. Voted IAC Approva Withhold	UC Vote Approval 0 0 20 D t was reviewed r to the meeting g BUA ssion during the to move to Des UC Vote 0 Approval 0	and the following points were addressed by the Pr	
a. None. IAC Approva Withhold Abstain Present <b>3. #</b> The amendment nvestigator prio a. Pendir Additional discus a. Voted IAC Approva Withhold Abstain	UC Vote Approval 0 0 20 D t was reviewed r to the meeting g BUA ssion during the to move to Des UC Vote 0 Approval 0 0 0	and the following points were addressed by the Pr g: e meeting included:	<b>05-28-2021</b> incipal
a. None. IAC Approva Withhold Abstain Present 3. # Neamendment nvestigator prio a. Pendir Additional discus a. Voted IAC Approva Withhold	UC Vote Approval 0 0 20 D t was reviewed r to the meeting g BUA ssion during the to move to Des UC Vote 0 Approval 0	and the following points were addressed by the Pr g: e meeting included:	



Additional discussion during the meeting included:



### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.04-02-2021		
2. 04-19-2021		
3. 04-21-2021		
4. 04-22-2021		
		Obtained

Discu		iite powder beled.	substance in a clear container was being housed in the room however it was
A	Action: 2. Reviewed labeling criteria with lab staff. Lab staff has since removed the substance and properly disposed it.		
	IACUC	Vote	
	Approval	19	
	Withhold Ap	oproval 0	
	Abstain	0	
	Present	19	

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1.04-22-2021	LAB	
2. 05-13-2021	LAB	
3. 05-13-2021	LAB	
4. 05-13-2021	LAB	
5. 05-18-2021	LAB	
6. 05-20-2021	LAB	
7. 05-20-2021	LAB	
8. 05-24-2021	PAM	

Discussion:	None.	
Action:	None.	

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

# XV. Other Discussion Items:

Торіс	
2021-2022 I	ACUC Membership
Discussion:	Please notify IACUC Director if any plans to step down.
Action:	None.
Animals tran	sferred to holding protocol from
Discussion:	None.
Action:	None.
Future meet	ing format
Discussion:	Please notify IACUC Director if strong preference to resume in-person or continue Zoom format in Fall.
Action:	TBD.
PI Maintaine	d Form
Discussion:	None.
Action:	Approved.

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### June 10, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M005, M222, M111, M042, A095, M004, M092, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M114

#### Excused:

M102, M090, M112

#### Guests:

M116

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

1. #		Category: D Y
the meeting:		and the following points were addressed by the Principal Investigator prior to
	leeue	led regarding in vivo trials and dose/prep.
Additional discussion durin a. Tabled. Will invite	•	•
IACUC Vote		
Approval	0	
Withhold Approval	0	
Abstain	0	
Present	22	

### **IV. Reports of Concern, Events and Incidents:**

The IACU and incid	JC reviewed and discussed the following report(s) of concern, events, ents:
Ac	ction: Pending pathology results.
Ĩ	
	ction: Long term anesthesia evaluation for source and project moving rward.
Ac	ction: Veterinary consult for fish.
M	S22 and water drainage.
WCW en	nails targeting VA

Action: FYI

## V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee: None at this time.

### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1.#	E		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
2.#	DY		-
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip meeting included: mains in DMR.	oal Investigator
3. #	C		06-10-2021
prior to the meet a. Clarifyi	ting: ing drug table	the following points were addressed by the Princip meeting included:	oal Investigator
4. #	С		-
prior to the meet a. None. Additional discus	ting: ssion during the	the following points were addressed by the Princip meeting included: d Member Review	oal Investigator
5. #	C		05-28-2021
prior to the meet a. Clarific b. Clarific c. Clarific d. Remov e. Clarific	ting: ation of what pa ation of treatme ation of formula /al of reference ation of age and	to estimate energy.	-
6. #	С		-
prior to the meet a. None. Additional discus	ting: ssion during the	the following points were addressed by the Princip meeting included: Remains in DMR.	oal Investigator

7.#	D		-
The protocol was	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:		
a. None.			
		meeting included:	
		ig account approval.	
8.#	С		06-08-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			
	•	lume and overnight housing.	
a. None.	ssion during the	meeting included:	
	С		06.02.2021
9.#	<u> </u>	the following paints were added as a discussion of the star	06-02-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip	al Investigator
Additional discus a. None.	ssion during the	meeting included:	
10. #	С		-
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			al inteological
a. Pendin			
	ssion during the ns in DMR.	meeting included:	
11. #	D		06-09-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet		51 5 1	J J
		ch, adverse effects, and staff roster.	
	ssion during the	meeting included:	
a. None.			
12. #	D		-
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:		
a. None.		and a first include de	
a. Pendin		meeting included:	
			06.00.2021
13. #	С		06-09-2021
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet		the following points were addressed by the finning	armesugator
		UA approval and provided updated VHSS. All occu	pational health
status we	ere updated.		
	ssion during the	meeting included:	
a. None.	-	r	
14. #	С		06-08-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			
a. Clarific	ation of cystoce	ntesis and adverse effects.	
	ssion during the	meeting included:	
a. None.			

15. #	С		06-09-2021
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator
Additional discus		e meeting included: et additive to protocol.	
16. #	С		06-08-2021
prior to the meet a. Clarific	ing: ation of drug vo	the following points were addressed by the Princip plume and overnight housing. e meeting included:	oal Investigator
17. #	D		06- <mark>1</mark> 0-2021
prior to the meet a. Pendin Additional discus	ing: g PI ssion during the	the following points were addressed by the Princip e meeting included: d Member Review	oal Investigator
18. #			05-28-2021
prior to the meet a. clarifica	ing: ation of endpoin	the following points were addressed by the Princip Its from disposition added to section 14. meeting included:	oal Investigator
19. #	С		06-01-2021
prior to the meet a. Chemi	ing: cal safety office	the following points were addressed by the Princip r completed review and provided an updated VHS meeting included:	-
20. #	С		05-28-2021
prior to the meet a. Clarific	ing: ation of standa	the following points were addressed by the Princip rd-of-care procedures and numbers. e meeting included:	oal Investigator
21. #	С		06-03-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included:	al Investigator
a. None.	С		06-10-2021
			00 10 2021
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator
	ssion during the	e meeting included:	

23. #	С		06-09-2021
orior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip e meeting included:	oal Investigator
a. None. 24. #	D		06-10-2021
The protocol was prior to the meet a. None.	s reviewed and ing:	the following points were addressed by the Principe meeting included:	
25. #	С		06-07-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip e meeting included: liculated.	bal Investigator
26. #	С		06-09-2021
		the following points were addressed by the Princip	al Investigator
prior to the meet a. Clarific Additional discus a. None. 27. #	ing: ation on proced sion during the D	dure and terminology. e meeting included:	06-10-2021
Additional discus a. None. 27. # The protocol was prior to the meet a. Chemic	ing: ation on procee sion during the <b>D</b> s reviewed and ing: cal safety office	dure and terminology.	06-10-2021
Additional discus a. None. <b>27.</b> # The protocol was prior to the meet a. Chemic Additional discus	ing: ation on procee sion during the <b>D</b> s reviewed and ing: cal safety office	dure and terminology. e meeting included: the following points were addressed by the Principer completed review and provided updated VHSS.	06-10-2021
prior to the meet a. Clarific Additional discus a. None. <b>27.</b> # The protocol was prior to the meet a. Chemic Additional discus a. None. <b>28.</b> # The protocol was prior to the meet a. None. Additional discus	ing: ation on proceed sision during the D s reviewed and ing: cal safety office sision during the C s reviewed and ing:	dure and terminology. e meeting included: the following points were addressed by the Principer completed review and provided updated VHSS.	06-10-2021 pal Investigator 06-10-2021
prior to the meet a. Clarific Additional discus a. None. <b>27. #</b> The protocol was prior to the meet a. Chemic Additional discus a. None. <b>28. #</b> The protocol was prior to the meet a. None.	ing: ation on proceed sision during the D s reviewed and ing: cal safety office sision during the C s reviewed and ing:	dure and terminology. e meeting included: I the following points were addressed by the Principer completed review and provided updated VHSS. e meeting included:	06-10-2021 pal Investigator 06-10-2021
prior to the meet a. Clarific Additional discus a. None. <b>27.</b> # The protocol was prior to the meet a. Chemic Additional discus a. None. <b>28.</b> # The protocol was prior to the meet a. None. <b>29.</b> # The protocol was prior to the meet a. None. <b>29.</b> #	ing: ation on proceed sion during the D s reviewed and ing: cal safety office sion during the C s reviewed and ing: sion during the C s reviewed and ing: ation of method	dure and terminology. e meeting included: I the following points were addressed by the Principer completed review and provided updated VHSS. e meeting included:	06-10-2021 pal Investigator 06-10-2021 pal Investigator 06-09-2021
prior to the meet a. Clarific Additional discus a. None. <b>27.</b> # The protocol was prior to the meet a. Chemic Additional discus a. None. <b>28.</b> # The protocol was prior to the meet a. None. <b>29.</b> # The protocol was prior to the meet a. Clarific	ing: ation on proceed sion during the D s reviewed and ing: cal safety office sion during the C s reviewed and ing: sion during the C s reviewed and ing: ation of method	dure and terminology. e meeting included: the following points were addressed by the Principle er completed review and provided updated VHSS. e meeting included: the following points were addressed by the Principle e meeting included: the following points were addressed by the Principle the following points were addressed by the Principle for determining death vs deep anesthesia.	06-10-2021 pal Investigator 06-10-2021 pal Investigator 06-09-2021

a. Remains in Designated Membe	Reviewer
--------------------------------	----------

a. 1 (on	and in Boolghate		
31. #	D		-
The protocol prior to the me		the following points were addressed by the Princip	pal Investigator

a. Pending chemical safety review and final BUA approval.

Additional discussion during the meeting included: a. Remains in DMR.

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	D		06-07-2021
nvestigator prior a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
2. #	С		06-10-2021
nvestigator prio a. None.	r to the meeting	and the following points were addressed by the P g: e meeting included:	rincipal
3. #	D		-
nvestigator prio a. Pendin Additional discus	r to the meeting g BIO ssion during the	and the following points were addressed by the P g: e meeting included: ed Member Review	ппара
4. #	D		06-07-2021
a. None			
a. None.	_	e meeting included:	05 00 0004
Additional discus	ssion during the	e meeting included:	05-28-2021
Additional discus a. None. 5. # The amendment nvestigator prior a. None.	C was reviewed to the meeting	and the following points were addressed by the P	
Additional discus a. None. 5. # The amendment nvestigator prior a. None. Additional discus	C was reviewed to the meeting	and the following points were addressed by the P g:	
Additional discus a. None. 5. # The amendment nvestigator prior a. None. Additional discus a. None. 6. # The amendment nvestigator prior a. Pendin Additional discus	C was reviewed to the meeting ssion during the D was reviewed to the meeting g approval of S	and the following points were addressed by the P g: e meeting included: and the following points were addressed by the P g:	rincipal
Additional discus a. None. 5. # The amendment nvestigator prior a. None. Additional discus a. None. 6. # The amendment nvestigator prior a. Pendin Additional discus	C was reviewed to the meeting ssion during the D was reviewed to the meeting g approval of S ssion during the	and the following points were addressed by the P g: e meeting included: and the following points were addressed by the P g: SOPs.	rincipal
Additional discus a. None. 5. # The amendment nvestigator prior a. None. Additional discus a. None. 6. # The amendment nvestigator prior a. Remain 7. # The amendment nvestigator prior a. Pendin Additional discus	C was reviewed to the meeting asion during the basion during the g approval of S ssion during the ns in DMR. D was reviewed to the meeting g CHEM asion during the ssion during the	and the following points were addressed by the P g: e meeting included: and the following points were addressed by the P g: SOPs. e meeting included: and the following points were addressed by the P g: e meeting included:	rincipal
Additional discus a. None. 5. # The amendment nvestigator prior a. None. Additional discus a. None. 6. # The amendment nvestigator prior a. Remain 7. # The amendment nvestigator prior a. Pendin Additional discus	C was reviewed to the meeting asion during the basion during the g approval of S ssion during the ns in DMR. D was reviewed to the meeting g CHEM asion during the ssion during the	and the following points were addressed by the P g: and the following points were addressed by the P g: GOPs. e meeting included: and the following points were addressed by the P g:	rincipal

		and the following points were addressed by the Pr	incipal	
Investigator prior to the meeting:				
a. Clarification on procedure Additional discussion during the meeting included:				
Additional discus a. None.	ssion during the	meeting included:		
9. #			-	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior a. None.				
	ssion during the	meeting included:		
a. Pendin				
10. #	DY		06-09-2021	
	was reviewed	and the following points were addressed by the Pr		
Investigator prior			nopa	
a. None.				
Additional discus	ssion during the	meeting included:		
a. None.	-	-		
11. #	DY		-	
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior		:		
		meeting included:		
	ns in DMR.			
12. #	С		-	
	· · ·	and the following points were addressed by the Pr	incinal	
Investigator prior			nopa	
	veterinarian or s			
		meeting included:		
	ig PI, Remains i			
13. #	E		06-05-2021	
The amendment	was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting	:		
a. None.				
	ssion during the	meeting included:		
a. None.	-			
14. #	C		06-09-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prior	r to the meeting	:		
a. None.				
Additional discus	naion during the	meeting included:		
	ssion during the	meeting included:		
a. None.	_	meeting included:		
	ssion during the	meeting included:	-	
a. None.	_	meeting included:	-	
a. None. 15. <b>#</b>	DY		-	
a. None. 15. #	D Y	and the following points were addressed by the Pr	- incipal	
a. None. 15. #	D Y t was reviewed a r to the meeting	and the following points were addressed by the Pr	- incipal	
a. None. 15. # The amendment Investigator prior a. Pendin	D Y t was reviewed a r to the meeting ng BUA approva	and the following points were addressed by the Pr	- incipal	
a. None. <b>15. #</b> The amendment Investigator prior a. Pendin Additional discus	D Y t was reviewed a r to the meeting ng BUA approva	and the following points were addressed by the Pr : I.	- incipal	
a. None. <b>15. #</b> The amendment Investigator prior a. Pendin Additional discus	DY t was reviewed a r to the meeting by BUA approva	and the following points were addressed by the Pr : I.	- incipal	
a. None. <b>15. #</b> The amendment Investigator prior a. Pendin Additional discus a. Remain <b>16. #</b>	DY t was reviewed a r to the meeting by BUA approva ssion during the ns in DMR. DY	and the following points were addressed by the Pr : I. meeting included:	· 	
a. None. <b>15. #</b> The amendment Investigator prior a. Pendin Additional discus a. Remain <b>16. #</b>	DY t was reviewed a r to the meeting og BUA approva ssion during the ns in DMR. DY t was reviewed a	and the following points were addressed by the Pr : I. meeting included: and the following points were addressed by the Pr	· 	
a. None. <b>15.</b> # The amendment Investigator prior a. Pendin Additional discus a. Remain <b>16.</b> # The amendment Investigator prior a. None.	DY t was reviewed a r to the meeting g BUA approva ssion during the ns in DMR. DY t was reviewed a r to the meeting	and the following points were addressed by the Pr : I. meeting included: and the following points were addressed by the Pr	· 	
a. None. <b>15.</b> # The amendment Investigator prior a. Pendin Additional discus a. Remain <b>16.</b> # The amendment Investigator prior a. None. Additional discus	DY t was reviewed a r to the meeting g BUA approva ssion during the ns in DMR. DY t was reviewed a r to the meeting ssion during the	and the following points were addressed by the Pr : I. meeting included: and the following points were addressed by the Pr	· 	
a. None. 15. # The amendment Investigator prior a. Pendin Additional discus a. Remain 16. # The amendment Investigator prior a. None. Additional discus a. Pendin	DY t was reviewed a r to the meeting ng BUA approva ssion during the ns in DMR. DY t was reviewed a r to the meeting ssion during the ng path results.	and the following points were addressed by the Pr : I. meeting included: and the following points were addressed by the Pr	· 	
a. None. <b>15.</b> # The amendment Investigator prior a. Pendin Additional discus a. Remain <b>16.</b> # The amendment Investigator prior a. None. Additional discus	DY t was reviewed a r to the meeting g BUA approva ssion during the ns in DMR. DY t was reviewed a r to the meeting ssion during the	and the following points were addressed by the Pr : I. meeting included: and the following points were addressed by the Pr	· 	


Investigator prior		and the following points were addressed by the Pri :	incipal
		meeting included:	
	g path results.		
18. #	DY		-
The amendment	was reviewed	and the following points were addressed by the Pri	incipal
Investigator prior			
	g follow-up with		
	ns in DMR	meeting included:	
19. #	D		06-02-2021
		and the following points were addressed by the Pr	incipal
Investigator prior			
		sm and pilot experiment.	
a. None.		meeting included:	
20. #	DY		06-10-2021
		and the following points were addressed by the Dr	
Investigator prior		and the following points were addressed by the Pri	incipal
a. None.	to the meeting		
	ssion during the	meeting included:	
a. None.	ionen dannig die		
21. #	DY		06-10-2021
	was reviewed	and the following points were addressed by the Pri	
Investigator prior			inopul
a. None.		-	
Additional discus	sion during the	meeting included:	
a. Duplica	ate entry.		
22. #	D		06-10-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.			
	ssion during the	meeting included:	
a. None.	•		00.07.0004
23. #	C		06-07-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	to the meeting		
	sion during the	meeting included:	
a. None.	ionen dannig die		
24. #	С		06-07-2021
	•		
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.			
	ssion during the	meeting included:	
a. None.			
25. #	СҮ		06-01-2021
The envertees f		and the falles in a naiste scene addressed by the D	in ain al
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	to the meeting		
	sion during the	meeting included:	
a. None.		<b>_</b>	


## VIII. Administrative and Veterinary Verification Amendments:

Total of **203** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





IACUC Vote	
Approval	0
Withhold Approval	0
Abstain	0
Present	22

## X. Annual Renewals:

Protocol Category	Title	Original Approval	Last Reviewed	Expires
D		6-17-2019	06-10-2021	06-17-2022
D		6-13-2019	06-10-2021	06-13-2022
		0.44.0040	00.40.0004	00.44.0000
D			06-10-2021	
C		6-12-2019	06-10-2021	06-12-2022
D		6-19-2019	06-10-2021	06-19-2022
С		6-12-2019	06-10-2021	06-12-2022
D		6-13-2019	06-10-2021	06-13-2022
D		6-13-2019	06-10-2021	06-13-2022
С		6-13-2019	06-10-2021	06-13-2022
D		6-14-2019	06-10-2021	06-14-2022
DY		6-13-2019	06-10-2021	06-13-2022
D		6-13-2019	06-10-2021	06-13-2022
D		6-13-2019	06-10-2021	06-13-2022
C		6-13-2019	06-10-2021	06-13-2022
С		6-19-2019	06-10-2021	06-19-2022
D		6-13-2019	06-10-2021	06-13-2022
CY		6-13-2019	06-10-2021	06-13-2022
		6-14-2019	06-10-2021	06-14-2022
D		6-13-2019	06-10-2021	06-13-2022
D		6-13-2019	06-10-2021	06-13-2022
D		6-12-2019	06-10-2021	06-12-2022
DY		6-13-2019	06-10-2021	06-13-2022

Y 06-	-25-2019	06-10-2021	06-25-2022
06-	-17-2020	06-09-2022	06-17-2023
06-	-25-2020	06-23-2022	06-25-2023
Y 06-	-22-2020	06-09-2022	06-22-2023
06-	-22-2020	06-09-2022	06-22-2023
Y 06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
06-	-18-2020	06-09-2022	06-18-2023
06-	-22-2020	06-09-2022	06-22-2023
06-	-24-2020	06-09-2022	06-24-2023
Y 00-	-25-2020	00-23-2022	00-20-2023
E 06-	-25-2020	06-23-2022	06-25-2023
Y 06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
06-	-25-2020	06-23-2022	06-25-2023
Y 06-	-25-2020	06-23-2022	06-25-2023
enewal process and just needs to complete the in person appoint the permit on the protocol is expired. -the committee approved the annual renewals -the committee approved the annual renew	intment.		I]
	O       06         Y       06         Y       06         Y       06         Y       06         O       06         Y       06         O       06         Y       06         O       06         Y       06         O       06         O       06         Y       06         O       06         O	0       06-17-2020         0       06-25-2020         Y       06-22-2020         Y       06-25-2020         Y       06-25-2020         Y       06-25-2020         O       06-25-2020         Y       06-25-2020 <th>0       06-17-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-22-2020       06-09-2022         0       06-22-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022</th>	0       06-17-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-22-2020       06-09-2022         0       06-22-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-09-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022         0       06-25-2020       06-23-2022

IACUC Vote	
Approval	19
Withhold Approval	0
Abstain	0
Present	19

XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1.#	E		06-11-2021
nvestigator pri a. Clarifi dditional discu a. Discu	or to the meetir cation of plan. ussion during th ssed facility op	d and the following points were addressed by the ng: ne meeting included: tions with CABA Director. Voted to send to DR to	·
	CUC Vote		
Approva			
	d Approval 0		
Abstain	_		
Present	22		
2.#	DY	d and the following points were addressed by the	
	CUC Vote	pproved for DMR.	
Withhol			
	d Approval 0		
Abstain	d Approval 0 0		
Abstain Present 3. #	d Approval 0 0 21 D Y nt was reviewed	d and the following points were addressed by the	06-24-2021 Principal
Abstain Present Abstain Present Abstain Abstain Abstain	d Approval 0 0 21 D Y nt was reviewed or to the meetin nittee requests ussion during th nittee voted to CUC Vote al 0 d Approval 0 0	ng: clarification as to how many animals are being at ne meeting included:	Principal
Abstain Present Abstain Present Additional discu a. Comm Additional discu a. Comm IAC Approva Withhol Abstain Present	d Approval 0 0 21 D Y nt was reviewed or to the meetin nittee requests ussion during th nittee voted to CUC Vote al 0 d Approval 0 0 22	ng: clarification as to how many animals are being at ne meeting included:	Principal ffected.
Abstain Present Abstain Present Additional discu a. Comr Additional discu a. Comr Approva Withhol Abstain Present 4. # The amendmen nvestigator priva a Discu adverse protocol additional discu	d Approval 0 0 21 D Y nt was reviewed or to the meetin nittee requests ussion during th nittee voted to CUC Vote al 0 d Approval 0 0 22 D nt was reviewed or to the meetin ssed PAM asso events to CVS	d and the following points were addressed by the	Principal ffected. 06-10-2021 Principal . PI to report
Abstain Present Abstain Present Additional discu a. Comm Additional discu a. Comm Approva Withhol Abstain Present 4. # The amendmen nvestigator priva adverse protocol additional discu a. Comm Approva	d Approval 0 0 21 D Y nt was reviewed or to the meetin nittee requests ussion during th nittee voted to CUC Vote al 0 d Approval 0 0 22 D nt was reviewed or to the meetin ssed PAM asse events to CVS ussion during th nittee voted to CUC Vote	ng: clarification as to how many animals are being at the meeting included: send to DMR. d and the following points were addressed by the ng: ociated with amendment under inspection section of first and seek assessment for issues not covered the meeting included:	Principal ffected. 06-10-2021 Principal . PI to report

	Present		22		
5. #		С			06-10-2021
Investi Additio	gator prior to a. Pending onal discussi	o the m Pl on durir	eetin ng th	e meeting included:	incipal
	a. Voted to		ated	Member Review	
		• vote	0		
	Approval	nnroval	-		
	Withhold A Abstain	pprovai	0		
	Present		22		
6. #	Fresent	С	22		06-10-2021
0. 1		Ŭ			00-10-2021
Additio	a. Committe	ee voteo		e meeting included: approve amendment.	
	IACUC	C Vote			
	Approval		22		
	Withhold A	pproval	0		
	Abstain		0		
	Present		22		
7.#		D			06-10-2021
nvesti Additio	gator prior to a. Clarificati	o the me ion on a	eetin Inima	d and the following points were addressed by the Pi ig: al numbers and second surgery ie meeting included:	
	IACUC	C Vote			
	Approval		21		
	Withhold A	pproval	0		
	Abstain		1		
	Present		22		
<mark>8.</mark> #		СҮ			06-10-2021
nvesti Additio	gator prior to a. None. mal discussi	o the m on durin ee voted	eetin ng th	and the following points were addressed by the Pr ng: ne meeting included: approve amendment.	incipal
		- vote	22		
	Approval	pprovel	22		
	Withhold A	pproval	U		
	Abotein		0		
	Abstain Present		0 22		

XII. Animal Housing/Facility Inspections:

Date
------

1. 04-28-2021				
2. 05-06-2021				
Discussion:	lana			
Discussion.		 	 	
Action:				

IACUC Vote	
Approval	22
Withhold Approval	0
Abstain	0
Present	22

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 05-24-2021	LAB	
2. 05-27-2021	LAB	
3. 05-27-2021	LAB	
4. 05-27-2021	LAB	
5. 06-01-2021	PAM	

Discus		are not cover	ed ir	e they must contact CVS for all actions requiring care that in the protocol and submit an amendment for approval to ures in the future.
A	ction:	5. Committee	app	proved the proposed plan.
	L	ACUC Vote		
	Appro	oval	22	
	Withh	old Approval	0	
	Absta	in	0	
	Prese	ent	22	

## XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

# XV. Other Discussion Items:

Торіс	
1.	protocol
Discussion:	Replacement protocol was approved during the meeting.
Action:	Animals will be transferred to the replacement protocol after the meeting.
2. Guest - C	VS resident
Discussion:	None.
Action:	None.
3. IACUC Of	fice staffing update
Discussion:	Assistant Director appointment.
Action:	None.
4. Guest -	
Discussion:	Discuss potential options for CABA tanks.
Action:	None.

# XVI. Program Updates:

Торіс

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### June 24, 2021 Meeting Minutes

### [regular view | VA view]

#### Attendance:

## Present:

M097, M005, M222, M102, M111, M042, A095, M092, A019, M119, M087, A109, M110, M093, A013, M024, M001, M112, M114

#### Excused:

M009, M090, M004, M120, M016, M223

#### Guests:

M116, A017, A018

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

## III. Amendments Tabled From Previous Meetings:

1. #		Category: D Y
The amendment was reviewe the meeting:	ed and the following points were addressed by the Principal In	vestigator prior to
a. PI attended meetin cohort of 4 animals at	g to provide clarification of changes proposed and concerns al a time.	bout not doing a
of concept or add an a proceed with cohort o	the meeting included: ed PI's responses and proposed to suggest PI either complete additional animal to the protocol for the proof of concept and if f n=4. Voted to send the DMR. Chair or Director to contact PI t to amendment for approval.	no adverse occur,
IACUC Vote	7	
Approval 0		
Withhold Approval 0		
Abstain 0		
Present 20		

### IV. Reports of Concern, Events and Incidents:

ACUC reviewed and discussed the following report(s) of concern, events, ncidents:
Action: Pathology results inconclusive for cause of fractures.
Action: No deficiencies by PI. CVS made an error in volume of one of the two analgesics. PAM report at the end of the agenda discussed.

Action: Protocol includes peritonitis as an adverse effect however the incident has exceeded 10 %. The PI will be submitting a Care Update report and plans to decrease incidents.
Action: PI/vet staff timely communication. Blood from food source mistaken as injury.
Action: Discussed lower dose of analgesic being given and poor documentation.
Action: Discussion of event and amendment to follow.

# V. Veterinary Care Program Updates:


The Attending Veterinarian provided the following updates to the committee: None at this time.

# VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	E		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	oal Investigator
2. #	DY		-
prior to the meet a. None. Additional discus a. Pendin	ting: ssion during the ig reviewer. Rer	the following points were addressed by the Princip e meeting included: mains in DMR,	oal Investigator
3. #	С		-
prior to the meet a. Recom Additional discus	ting: Imendation to w	the following points were addressed by the Princip vithdraw protocol. Waiting for PI to respond. e meeting included:	oal Investigator
4. #	С		06-23-2021
prior to the meet a. Proced	ting: lural clarificatio	the following points were addressed by the Princip ns. e meeting included:	oal Investigator
5. #	D		06-22-2021
prior to the meet a. Contro	ting:	the following points were addressed by the Princip val still pending. Removed controlled drug and left	-

Additional discus a. None.	ssion during the	e meeting included:	
6. #	DY		06-24-2021
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip e meeting included: nains in DMR.	oal Investigator
7.#	С		-
prior to the meet a. Pendin Additional discus	ting: Ig BUA approva	the following points were addressed by the Princip II. e meeting included:	bal Investigator
8. #			06-23-2021
prior to the meet a. Clarific	ting: ation of animal	the following points were addressed by the Princip sources. e meeting included:	oal Investigator
9. #	D		06-14-2021
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
10. #	D		06- <mark>1</mark> 0-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
11. #	С		-
prior to the meet a. Pendin Additional discus	ting: Ig PI's response	the following points were addressed by the Princip to clarifying questions. meeting included:	oal Investigator
12. #	D		06-23-2021
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
a. None. 13. #	D		06-10-2021

		the following points were addressed by the Princip	oal Investigator
prior to the meet		in a fat, we in the annulated	
		iosafety reviews completed. • meeting included:	
a. None.			
14. #	D		06-14-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet		<b>3</b> 1 <b>7</b> 1	J
a. None.			
		e meeting included: ers questions addressed by PI	
15. #	D Y		06-24-2021
15. #			00-24-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:		
a. None.		we after the body de	
a None	ssion during the	meeting included:	
16. #	D		06-10-2021
10. #			00-10-2021
		the following points were addressed by the Princip	al Investigator
prior to the meet			_
	e on drug table.	we after the body de	
Additional discus	ssion during the	meeting included:	
17. #	D		06-24-2021
17.#			00-24-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			-
	ation on VHSS.		
a. None.	ssion during the	meeting included:	
18. #	D		06-22-2021
10. #			00-22-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:		J. J
	ation on VHSS.		
	ssion during the	meeting included:	
a. None.	<b></b>		06 02 2021
19. #	D	the following a sinte ways addressed by the Drinei	06-23-2021
prior to the meet		the following points were addressed by the Princip	bal investigator
		ews completed.	
		meeting included:	
a. None.	_		
20. #	D		06-24-2021
		the following points were addressed by the Princip	al Investigator
prior to the meet	•	a ta shaadaal a fat - ff	
		es to chemical safety officer.	
	ssion during the ned in DMR.	meeting included:	
21. #	C		06-24-2021
	<u> </u>	the following points were addressed by the Princip	
prior to the meet		are renewing pointe were addressed by the Fillion	a intestigator
a. None.	-		
1			



## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	E		06-11-2021
Investigator prio a. Revisio	r to the meeting on of plan base	and the following points were addressed by the Pr g: d on IACUC discussion. e meeting included:	incipal
2. #	С		06-24-2021
Investigator prio a. None. Additional discus	r to the meeting	e meeting included:	псра
3. #	DY		06-14-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
4. #	DY		06-14-2021

The amendmen Investigator prio a. None.		and the following points were addressed by the Pr j:	incipal
	ssion during the	e meeting included:	
5. #	D		06-17-2021
	_	and the following points were addressed by the Pr	
Investigator prio			
	-	e meeting included:	
a. None.			06.01.0001
6. #		and the following points were addressed by the Pr	06-21-2021
Investigator prio a. None.	r to the meeting	j:	пара
a. None.	ssion during the	e meeting included:	
7.#	С		06-17-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
8.#	D		06-23-2021
Investigator prio a. None. Additional discu	r to the meeting	e meeting included:	incipal
9.#	D		06-24-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.	r to the meeting	i:	
Additional discu a. None.	ssion during the	e meeting included:	
10. #	СҮ		06-21-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
11. #	DY		-
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	incipal
	ng further discus		
12. #	DY		06-22-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.	r to the meeting		
a. None.	-		00.04.0004
13. #	C		06-24-2021

The amendment Investigator prior		and the following points were addressed by the Pr g:	incipal
a. None.	-	e meeting included:	
14. #	DY		06-22-2021
Investigator prio a. None.	r to the meeting		incipal
Additional discus a. None.	ssion during the	e meeting included:	
15. #	С		06-24-2021
nvestigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
a. None. 16. #	D		06-23-2021
Additional discus a. None. 17. #	ssion during the	e meeting included:	06-22-2021
are appro	oved.	tudies and will submit another amendment in the f e meeting included:	
18. #	D		06-11-2021
nvestigator prio a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	incipal
19. #			06-17-2021
nvestigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
20. #	С		06-24-2021
Investigator prio a. None. Additional discus	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
a. None. 21. #	D		06-23-2021
21.#			00-23-2021
The amendment Investigator prio	was reviewed	and the following points were addressed by the Pr	incipal

Additional discus a. None.	ssion during the	meeting included:	
22. #	D		06-24-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
23. #	DY		06-24-2021
		and the following points were addressed by the Pr	
Investigator prior a. Incider	r to the meeting it of adverse eff	:	
24. #	DY		06-24-2021
Investigator prio a. Incider Additional discus a. None.	r to the meeting it of adverse eff		
25. #	DY		06-21-2021
Investigator prior a. Monito	r to the meeting ring procedures		incipal
26. #	С		06-23-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : • meeting included:	incipal
27. #	E		06-24-2021
Investigator prior a. None. Additional discus	r to the meeting ssion during the	and the following points were addressed by the Pr : meeting included: Iment applies to	incipal
28. #	С		06-24-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
29. #	С		06-24-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
30. #	DY		06-22-2021

The amendment Investigator prior		and the following points were addressed by the Pr	incipal
a. None.	r to the meeting		
Additional discus a. None.	ssion during the	meeting included:	
31. #	DY		06-21-2021
		and the following points were addressed by the Pr	
Investigator prio			
a. None.	-		
	ssion during the	meeting included:	
a. None.			
32. #	DY		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.	naina duwina Aha		
a. None.	ssion during the	meeting included:	
33. #	D		06-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.			
	ssion during the	meeting included:	
a. None.	D V		
34. #	DY		-
The amendment	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
	g BUA approva		
		meeting included:	
	ns in DMR.		00.00.0004
35. #	CY		06-22-2021
		and the following points were addressed by the Pr	incipal
Investigator prior			
a. Clarific neutraliza		pinant antibody, species origin and potential for all	ergic reaction or
		meeting included:	
a. None.		meeting moldeed.	
36. #	С		06-24-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.		maating included:	
a. None.	ssion during the	meeting included:	
37. #	D		-
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	:	
a. None.	cion during the	meeting included:	
a. Pendin		meeting included:	
38. #	D		06-23-2021

The amendment Investigator prio		and the following points were addressed by the Pr	incipal
a. None.	i to the meeting		
Additional discus a. None.	ssion during the	meeting included:	
39. #	D		06-23-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
a. None.	-		
40. #	с		06-11-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
41. #	С		06-24-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
42. #	E		06-23-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
43. #	С		06-23-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
44.#	D		06-24-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
45. #	C		06-10-2021
Investigator prio a. Clarific	r to the meeting aiton on therma	and the following points were addressed by the Pr al perch temperatures and potential adverse effect meeting included:	
46. #	C		06-24-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
47. #	С		06-21-2021

a. None.	to the meeting		
Additional discus a. None.	sion during the	e meeting included:	
48.#	DY		-
The amendment Investigator prior a. None.		and the following points were addressed by the Pri :	ncipal
	sion during the g path results.	e meeting included:	
49. #	DY		-
a. Pending	g path results.	meeting included:	
50. #	DY		-
50. n			
The amendment Investigator prior a. None. Additional discus	to the meeting sion during the	meeting included:	ncipal
The amendment Investigator prior a. None. Additional discus	to the meeting sion during the	Г.	ncipal 06-23-2021
The amendment Investigator prior a. None. Additional discus a. Pending 51. # The amendment Investigator prior a. None.	to the meeting sion during the g further discus C was reviewed to the meeting	remeeting included: assion with EH&S.	06-23-2021

## VIII. Administrative and Veterinary Verification Amendments:


Total of **143** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1.#	D		08-05-2021
The protocol wa prior to the mee		d the following points were addressed by the Princi	pal Investigator
a. Pendir	ssion during th ng PI and revie	ne meeting included: ewer. Voted to send to DR.	
Additional discu a. Pendir	ssion during th		
Additional discu a. Pendir	ssion during th ng PI and revie C <b>UC Vote</b>		
Additional discu a. Pendir IAC Approva	ssion during th ng PI and revie C <b>UC Vote</b>		

	Present	2	20		
2. #		С	_		07-01-2021
prior to Additio	the meet a. Clarific nal discus	ting: ations reque	este the	d the following points were addressed by the Princip ed for final approval. e meeting included:	al Investigator
		UC Vote	T		
	Approva		D		
	Withhold	Approval (	D		
	Abstain	(	D		
	Present	2	0		
3. #		D			07-01-2021
prior to Additio	the meet a. Pendin nal discus	ting: Ig final chem	nica the	d the following points were addressed by the Princip al safety review. e meeting included: 3.	al Investigator
		UC Vote	T		
	Approva	ı (	D		
	Withhold	Approval (	D		
	Abstain	C	D		
	Present	2	20		
4. #		CY			06-28-2021
prior to Additio	the meet a. None. nal discus	ting: ssion during	the	the following points were addressed by the Princip e meeting included: proved for DMR.	al Investigator
		UC Vote	1		
	Approva	I (	D		
	Withhold	Approval (	וס		
	Abstain	-	וס		
	Present		20		
5. #		CY			06-24-2021
prior to	the meet	ting:		the following points were addressed by the Princip nd maintenance of colony.	al Investigator
Additio	nal discus	ssion during	the	e meeting included: approve with PI status confirmed.	
	IAC	UC Vote			
	Approva		20		
		Approval (	ם ו		
	Abstain	-	D		
	Present		0		
6. #		D			06-24-2021
				•	



The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:

a. Pending PI response. Additional discussion during the meeting included:

a. Voted to DMR.	 

IACUC Vote				
Approval	0			
Withhold Approval	0			
Abstain	0			
Present	20			

# X. Annual Renewals:

Protocol Category	Title	Original Approval	Last Reviewed	Expires
D		06-27-2019	06-24-2021	06-27-2022
D		06-26-2019	06-24-2021	06-26-2022
D		07-02-2019	06-24-2021	07-02-2022
D		06-27-2019	06-24-2021	06-27-2022
С		07-09-2019	06-24-2021	07-09-2022
		07-05-2019	06-24-2021	07-05-2022
С		07-01-2019	06-24-2021	07-01-2022
С		06-26-2019	06-24-2021	06-26-2022
D		06-27-2019	06-24-2021	06-27-2022
D		06-27-2019	06-24-2021	06-27-2022
DY		06-27-2019	06-24-2021	06-27-2022
С		07-02-2019	06-24-2021	07-02-2022
D		07-02-2019	06-24-2021	07-02-2022
В		07-03-2019	06-24-2021	07-03-2022
D		06-27-2019	06-24-2021	06-27-2022
D		06-27-2019	06-24-2021	06-27-2022
D		07-01-2019	06-24-2021	07-01-2022
С		06-27-2019	06-24-2021	06-27-2022
DY		06-27-2019	06-24-2021	06-27-2022

	С	06-27-2019	06-24-2021	06-27-2022
	С	06-26-2019	06-24-2021	06-26-2022
	С	07-05-2019	06-24-2021	07-05-2022
	С	06-27-2019	06-24-2021	06-27-2022
	УY	06-27-2019	06-24-2021	06-27-2022
C	CY	06-27-2019	06-24-2021	06-27-2022
	D	07-08-2020	06-23-2022	07-08-2023
	С	06-23-2020	06-09-2022	06-23-2023
	ΥC	06-29-2020	06-23-2022	06-29-2023
	D	06-25-2020	06-23-2022	06-25-2023
	С	07-07-2020	06-24-2021	04-06-2022
	С	)7-09-2020	07-07-2022	07-09-2023
		07-09-2020	07-07-2022	07-09-2023
	С	07-09-2020	07-07-2022	07-09-2023
C	CY	07-09-2020	07-07-2022	07-09-2023
C	CY	07-09-2020	07-07-2022	07-09-2023
	С	07-05-2020	06-24-2021	07-05-2022
	С	07-06-2020	06-23-2022	07-06-2023
	D	07-09-2020	07-07-2022	07-09-2023
	D	07-09-2020	07-07-2022	07-09-2023
C	CY	07-09-2020	07-07-2022	07-09-2023
	С	07-09-2020	07-07-2022	07-09-2023
	С	07-09-2020	07-07-2022	07-09-2023

Discussion: None. Action Items: None.

IACUC Vote	
Approval 1	16
Withhold Approval	0
Abstain	0
Present	16

# XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

	Category	Request	Date Approved
1.#	СҮ		06-24-2021
nvestigator prio a. Criteri	or to the meetin ia for evaluating ussion during th	and the following points were addressed by the P g: g and assessing effect of night time separation. he meeting included:	rincipal
	CUC Vote		
Approva			
	d Approval 0		
Abstain			
Present	t 20		
2. #	СҮ		06-24-2021
	CUC Vote		
Approva	al 19		
Approva	al 19 d Approval 0		
Approva Withhol	al 19 d Approval 0 1		
Approva Withhole Abstain	al 19 d Approval 0 1		06-24-2021
Approva Withhold Abstain Present <b>3. #</b> The amendmer nvestigator pric a. Clarifi Additional discu a. Comn IAC Approva Withhold Abstain	al 19 d Approval 0 1 t 20 D Y nt was reviewed or to the meetin cation regardin ussion during th nittee voted to a CUC Vote al 20 d Approval 0 0	g maximum volume. e meeting included:	
Approva Withhold Abstain Present 3. # The amendmer nvestigator prio a. Clarifi Additional discu a. Comn IAC Approva Withhold	al 19 d Approval 0 1 t 20 D Y nt was reviewed or to the meetin cation regardin ussion during th nittee voted to a CUC Vote al 20 d Approval 0 0	g: g maximum volume. e meeting included:	

nvestigator prior	o tha maatin		rincipal
		ig: ects clarified. Chemical safety officer provided upda	ated VHSS
		e meeting included:	
a. Committ	ee voted to a	approve.	
IACU	C Vote		
Approval	20		
Withhold A	Approval 0		
Abstain	0		
Present	20		
5. #	С		06-24-2021
I ne amendment v Investigator prior		and the following points were addressed by the P	rincipal
a. None.		·9·	
	ion during th	e meeting included:	
a. None.			
	C Vote		
Approval	19		
	Approval 0		
Abstain	1		
Present	20		
6. #	CY		06-24-2021
Approval	C Vote 19 Approval 0		
Abstain	1		
Present	20		
7.#	С		06-24-2021
The amendment v nvestigator prior a. None.		and the following points were addressed by the P 	rincipal
a. None.	ion during th	e meeting included:	
a. None. IACU	ion during th C Vote	e meeting included:	
a. None. IACU Approval	ion during th <b>C Vote</b> 19	e meeting included:	
a. None. IACU Approval Withhold A	ion during th C Vote	e meeting included:	
a. None. IACU Approval	ion during th <b>C Vote</b> 19 Approval 0 1	e meeting included:	
a. None. IACU Approval Withhold A	tion during th <b>C Vote</b> 19 Approval 0	e meeting included:	
a. None. IACU Approval Withhold A Abstain	ion during th <b>C Vote</b> 19 Approval 0 1	e meeting included:	06-30-2021

Approval	0
Withhold A	pproval 0
Abstain	0
Present	19

## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	_
1. 06-14-2021		

Discussion	No deficiency of the PI's staff. CVS provides the post-op care and miscalculated one of the analgesia doses. The animal had no signs of pain and was being covered by two analgesics.					
Action	Response to	deficiency approved.				
	IACUC Vote					
Appr	oval	19				
With	hold Approval	0				
Abst	ain	0				
Pres	ent	19				

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 01-20-2021	LAB	
2. 01-26-2021	LAB	
3. 06-10-2021	LAB	
4. 03-22-2021	PAM	
5. 03-22-2021	PAM	
6. 04-22-2021	PAM	
7. 04-26-2021	PAM	
8. 05-04-2021	PAM	
9. 05-18-2021	PAM	
10. 06-01-2021	PAM	
11. 06-01-2021	PAM	
12.06-01-2021	PAM	
13. 06-01-2021	PAM	
14. 06-13-2021	PAM	

Discussion:	None.	
Action:	None.	
<b></b>		
	IACUC Vote	
Appr	oval	20
With	hold Approval	0
Abst	ain	0
Pres	ent	20

# XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:

Inspection Date	Agency	Location	Summary	Discussion
1. 06-23-2021	USDA	site 2; focused	None.	None.

#### XV. Other Discussion Items:

Торіс				
1) P	I Maintained form			
Discussion:	All CABA PI areas are now being required to have a PI maintain form on file.			
Action:	Committee approved the PI maintain request form.			
2) Imaging S	SOP for			
Discussion:	None.			
Action:	None.			
3) Retiring C	committee Member(s).			
Discussion:	Dedicated career service .			
Action:	None.			
Guest-				
Discussion:	See notes at top of agenda under tabled amendments.			
Action:	See notes at top of agenda under tabled amendments.			

# XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

#### July 08, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

# Present:

M009, M097, M102, M111, A095, M092, A019, M119, M087, M110, M120, M093, A013, M016, M024, M223, M001, M114

#### Excused:

M222, M090, M042, M004, M100, M112

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

The IACUC reviewed and	approved the April 15, 2021, meeting minutes as writte
IACUC Vote	
Approval	14
Withhold Approval	
Abstain	0
Present	14
The IACUC reviewed and	approved the April 29, 2021, meeting minutes as writte
IACUC Vote	
Approval	13
Withhold Approval	0
Abstain	0
Present	1
The IACUC reviewed and	approved the May 13, 2021, meeting minutes as writte
IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14
The IACUC reviewed and	approved the May 27, 2021, meeting minutes as writte
IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

The Physicians Committee for Responsible Medicine, pursuant to the California Public Records Act, requests copies of the following: Period: October 10, 2020 to present Scope: 1. The current version of all Institutional Animal Care and Use Committee (IACUC) protocols and protocol reviews related to the training of the University of California Davis' general surgery residents. 2. IACUC annual reports, reviews, meeting minutes, and other IACUC documentation related to the use of animals for training general surgery residents. 3. Documents that include training schedules that involve animal use for training general surgery residents. 4. Documents related to the purchase or acquisition of animals for use in training general surgery residents. 5. All photographs and video footage related to the items above.

Action: None.

Action: Sturgeon found out of outdoor tank; presumed spooked by fireworks activity. Sturgeon euthanized. Tank shade cover repaired and realigned.

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee: None at this time.

#### VI. Designated Review Protocols:


Protocol	Category	Title	Date Approved	
1. #	E		-	
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending PI				
2. #	DY		07-08-2021	
prior to the mee a. Anima b. Transp	ting: I numbers. portation. ssion during the	the following points were addressed by the Princip e meeting included:	pal Investigator	
3. #	DY		06-24-2021	
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator	

4. #	С		07-07-2021
The protocol wa		the following points were addressed by the Princip	oal Investigator
	eview and appro	oval of BUA. IACUC director working with PI on CE	DFW
Additional discu a. None.		e meeting included:	
5. #	С		-
prior to the mee	ting:	the following points were addressed by the Princip	oal Investigator
Additional discu		to chemical safety officer. e meeting included:	
6. #	D		-
		the following points were addressed by the Princip	oal Investigator
	cation of Consei ission during the	nt Form, drug volume and drug route, group, and a e meeting included:	dverse effects.
7.#	С		07-01-2021
prior to the mee a. PI clar	ting: ified drugs dosa ission during the	the following points were addressed by the Princip ages and maximum volume of samples. e meeting included:	oal Investigator
8. #	С		07-08-2021
prior to the mee a. correc b.upload	eting: tion of ANS stud ed SOP. Ission during the	the following points were addressed by the Princip dent numbers e meeting included:	oal Investigator
9.#	С		-
prior to the mee a. None.	ting: Ission during the	the following points were addressed by the Princip e meeting included:	oal Investigator
10. #	D		07-01-2021
prior to the mee a. Final r Recomm	eting: review complete nended statemer rssion during the	the following points were addressed by the Princip d by chemical safety officer. Verified no VHSS are nt put in section 7. e meeting included:	Ū.
11. #	D		06-24-2021
The protocol wa prior to the mee a. PI pro	as reviewed and ting: vided clarifications ssion during the	the following points were addressed by the Princip on about protentional adverse effects. e meeting included:	

12. #	С		07-08-2021
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator
prior to the mee	ting:		-
		to PI about MOU vs. TAF process and requiremen	
		as not required for this study but the PI requested	the review for
publicatio		e meeting included:	
a. None.		Theeting included.	
13. #	СҮ		06-28-2021
		the following points were addressed by the Princi	I
prior to the mee		the following points were addressed by the Finite	parinvestigator
a. None.	-		
	-	e meeting included:	
a. None.			
14. #	C		-
		the following points were addressed by the Princi	pal Investigator
prior to the mee	•		
a. None.		mosting included:	
a. Pendir		e meeting included:	
15. #	DY		07-05-2021
13. 7			07-03-2021
a. None. Additional discu a. None.	ssion during the	e meeting included:	
16. #	С		07-07-2021
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator
prior to the mee	•		
a. None.		a manating included	
a. None.	-	e meeting included:	
17. #	D		
17.#			-
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator
prior to the mee		;;;;;;	<b>........</b>
		transportation and drug administration.	
		meeting included:	
	ng BUA. Remaii	ns in DMR	
18. #	CY		07-08-2021
		the following points were addressed by the Princi	pal Investigator
prior to the mee	-		
a. None. Additional discu		e meeting included:	
a. None.			
19. #	D		_
		the following points were addressed by the Princi	nal Investigator
protocol wa		are renowing points were addressed by the Phild	parinivesligator
		ent options for pain and itch as well as breeding.	
		e meeting included:	
	ng CHEM. Rem		
20. #	D		07-02-2021

prior to the mee a. None.	ting:	the following points were addressed by the Princip	pal Investigator
Additional discu a. None.	ssion during the	e meeting included:	
21. #	DY		06-25-2021
prior to the mee a. Clarific	ting: cation on proced	the following points were addressed by the Princip dure e meeting included:	pal Investigator
22. #	С		07-08-2021
prior to the mee a. Clarific	ting: cation on persor ssion during the	the following points were addressed by the Princip nnel training. e meeting included:	pal Investigator
23. #	D		06-27-2021
prior to the mee a. Clarific	ting: cation on dispos	the following points were addressed by the Princip ition. e meeting included:	pal Investigator
24. #	C		07-08-2021
prior to the mee a. Clarific b.Calrific c. Clarific d. Clarific e. Correc	ting: ed breed ation of husban cation of study ti cation of advers ction of dairy pa	e effects	

# VII. Designated Review Amendments:



The amendmen Investigator price		and the following points were addressed by the Pr	incipal
a. None.	r to the meeting	j.	
	ssion during the	e meeting included:	
4. #	С		-
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio		j:	
	ng reviewer.	meeting included:	
a. Remai	ns in DMR.	e meeting included:	
5.#	B		07-01-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
6. #			06-29-2021
	t was reviewed	and the following points were addressed by the Pr	
Investigator prio			
a. None.	-		
Additional discu a. None.	ssion during the	e meeting included:	
7.#	D		07-08-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	j:	
a. None.	coion during the	maating included:	
a. None.	ssion during the	e meeting included:	
8.#	С		06-29-2021
Investigator prio a. None.	r to the meeting		incipal
a. None.	ssion during the	e meeting included:	
9. #	D		07-08-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
a. None.	-	meeting moluded.	
10. #	D		07-08-2021
	_	and the following points were addressed by the Pr	
Investigator prio a. None.			
	ssion during the	e meeting included:	
11. #	D		-
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting ation on habitu		
		e meeting included:	
		emains in DMR.	

12. #	D		07-08-2021		
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prior to the meeting:					
a. None.					
		e meeting included:			
a. None.					
13. #	D		07-08-2021		
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator price	or to the meeting	j:			
	cation on drugs				
	-	e meeting included:			
a. None.					
14. #	D		-		
		wth			
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator prio					
	cation of endpoi				
	cation of drug fo				
		e meeting included:			
	ng reviewer.				
15. #	Y		07-08-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio	or to the meeting	g:			
a. None.					
	ssion during the	e meeting included:			
a. None.					
16. #	DY		07-08-2021		
		and the following points were addressed by the Pr	incipal		
Investigator prio		<b>j</b> :			
a. None.		- monting included			
		e meeting included:			
	-	nor GABA require a VHSS.			
17.#	DY		-		
		and the following points were addressed by the Pr	incipal		
Investigator prio					
	ng final approva	e meeting included:			
	ins in DMR.	Theeding included.			
18. #			07-06-2021		
		and the following points were addressed by 0			
		and the following points were addressed by the Pr	incipal		
Investigator prio a. None.		j.			
		e meeting included:			
a. None.	-	Theoding molducu.			
19. #	D				
		and the following prints were a literative of the	-		
		and the following points were addressed by the Pr	incipal		
Investigator prio		j.			
a. None.		meeting included:			
a. Pendir		e meeting included:			
	-		07 02 2024		
20. #	DY		07-02-2021		

Investigator pris		I and the following points were addressed by the Pr	incipal		
	or to the meetin				
a. PI modified amendment to meet committee recommendations. PI to start with an n of 1					
		I work with CVS regarding outcomes before procee	ding with next		
	cohort of 4. Additional discussion during the meeting included:				
a. None.	-	e meeting included:			
			07.00.0004		
21. #	D		07-08-2021		
		I and the following points were addressed by the Pr	incipal		
Investigator price		g:			
a. None.		- waa stie e in slude de			
a. None.		e meeting included:			
22. #	DY		-		
The ensemdinger		and the following points ways addressed by the Dr	incinal		
Investigator pric		l and the following points were addressed by the Pr	incipal		
a. None.		y.			
		e meeting included:			
		period for AAV.			
b. Rema	ins in DMR.				
23. #	DY		-		
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal		
Investigator price					
a. None.		-			
Additional discu	ssion during th	e meeting included:			
a. Keep i	in DMR until ne	cropsy results are available (second pending amer	ndment).		
24. #	DY		-		
The amondmon		and the following points were addressed by the Pr	in air al		
The amenumen	it was reviewed	and the following points were addressed by the Pr	incipal		
Investigator price	or to the meetin	g:			
Investigator pric a. Neuro	or to the meetin logical findings				
Investigator pric a. Neuro device co	or to the meeting logical findings compatibility.	g: are consistent with inflammation; possible foreign b			
Investigator prio a. Neuro device co b. Future	or to the meetin logical findings ompatibility. e mitigation met	g: are consistent with inflammation; possible foreign b			
Investigator pric a. Neuro device co b. Future c. Antibio	or to the meetin logical findings ompatibility. e mitigation met otic use.	g: are consistent with inflammation; possible foreign b hods.			
Investigator pric a. Neuro device co b. Future c. Antibio d. Mitigat	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures t	g: are consistent with inflammation; possible foreign b hods. to prevent potential infection.			
Investigator pric a. Neuro device co b. Future c. Antibio d. Mitigat e. Device	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures t e sterilization te	g: are consistent with inflammation; possible foreign b hods. to prevent potential infection. echniques.			
Investigator pric a. Neuro device cc b. Future c. Antibio d. Mitiga e. Device Additional discu	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures t e sterilization te ission during th	g: are consistent with inflammation; possible foreign b hods. to prevent potential infection.			
Investigator pric a. Neuro device co b. Future c. Antibio d. Mitiga e. Device Additional discu a. Rema	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures t e sterilization te ission during th ins in DMR.	g: are consistent with inflammation; possible foreign b hods. to prevent potential infection. echniques.	body reaction and		
Investigator pric a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Remai	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ssion during th ins in DMR. D Y	g: are consistent with inflammation; possible foreign b hods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Remai	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te assion during the ins in DMR. D Y t was reviewed	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigar e. Device Additional discu a. Rema 25. # The amendmen Investigator price	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures f e sterilization te ssion during th ins in DMR. D Y t was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigar e. Device Additional discu a. Remai 25. # The amendmen Investigator price a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ission during th ins in DMR. D Y t was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigar e. Device Additional discu a. Remai 25. # The amendmen Investigator price a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ission during th ins in DMR. D Y It was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator prid a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema 25. # The amendmen Investigator prid a. None. Additional discu a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te assion during th ins in DMR. D Y t was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	06-29-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitiga e. Device Additional discu a. Rema 25. # The amendmen Investigator price a. None. Additional discu	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ission during th ins in DMR. D Y It was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included:	body reaction and		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema <b>25.</b> # The amendmen Investigator price a. None. Additional discu a. None. <b>26.</b> #	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures f e sterilization te ussion during th ins in DMR. D Y It was reviewed or to the meetin ussion during th	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema <b>25.</b> # The amendmen Investigator price a. None. Additional discu a. None. <b>26.</b> #	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures f e sterilization te ission during th ins in DMR. D Y t was reviewed or to the meetin ission during th ussion during th ussion during th	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigar e. Device Additional discu a. Remai 25. # The amendmen Investigator price a. None. Additional discu a. None. 26. #	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ission during th ins in DMR. <b>D Y</b> it was reviewed or to the meetin ussion during th <b>D</b>	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal		
Investigator prid a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema 25. # The amendmen Investigator prid a. None. 26. # The amendmen Investigator prid a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te assion during th ins in DMR. D Y tt was reviewed or to the meetin the was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema 25. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. Additional discu a. None. Additional discu a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te assion during th ins in DMR. <b>D</b> Y it was reviewed or to the meetin assion during th us vas reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigar e. Device Additional discu a. Rema 25. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. 26. #	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures f e sterilization te ission during th ins in DMR. D Y it was reviewed or to the meetin ission during th c Y	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal 07-08-2021 incipal		
Investigator price a. Neuro device cc b. Future c. Antibio d. Mitiga e. Device Additional discu a. Remai 25. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. Additional discu a. None. Additional discu a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures f e sterilization te ission during th ins in DMR. <b>D Y</b> it was reviewed or to the meetin ission during th <b>D</b> it was reviewed or to the meetin ission during th <b>C Y</b> it was reviewed	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal 07-08-2021 incipal		
Investigator price a. Neuro device cc b. Future c. Antibio d. Mitiga e. Device Additional discu a. Remai 25. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. Additional discu a. None. 27. #	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te ission during th ins in DMR. <b>D Y</b> it was reviewed or to the meetin ission during th <b>D</b> it was reviewed or to the meetin ission during th <b>C Y</b> it was reviewed or to the meetin	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal 07-08-2021 incipal		
Investigator prid a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema 25. # The amendmen Investigator prid a. None. 26. # The amendmen Investigator prid a. None. 26. # The amendmen Investigator prid a. None. Additional discu a. None. Additional discu a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures to e sterilization te assion during the ins in DMR. D Y to the section assion during the c to the meeting assion during the c Y to the meeting assion during the c Y to the meeting assion during the c Y	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal 07-08-2021 incipal		
Investigator price a. Neuro device co b. Future c. Antibio d. Mitigat e. Device Additional discu a. Rema 25. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. 26. # The amendmen Investigator price a. None. Additional discu a. None. Additional discu a. None.	or to the meetin logical findings ompatibility. e mitigation met otic use. tion measures file e sterilization te assion during th ins in DMR. D Y t was reviewed or to the meetin assion during th C Y t was reviewed or to the meetin assion during th c y	g: are consistent with inflammation; possible foreign b thods. to prevent potential infection. echniques. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: e meeting included:	06-29-2021 incipal 07-08-2021 incipal		

28. #	D			06-30-2021
Investigator pric a. None.	r to the meeting	and the following points were ad g: e meeting included:	dressed by the Pr	incipal
29. #	DY			07-08-2021
Investigator pric a. Potent Additional discu	r to the meeting ial risk of aspira	ation and management. e meeting included:	aressea by the Pr	incipai
30. #	CY			07-08-2021
Investigator pric a. None.	r to the meeting	and the following points were ad g: e meeting included:	dressed by the Pr	incipal

### VIII. Administrative and Veterinary Verification Amendments:

Total of **164** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


# IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Categor	у	Title	Date Approved
1. #	DY			07-08-2021
prior to the r a. Ad b. Cla c. Cla frequ d. Fre e. Pe f. MR g. Dru h. Tes i. Ado Additional di a. IAO agen now a	neeting: ditional inform rification on fa rification on se ency of assess quency of we sonnel OHSS location conf g and proced ting cage clar itional consult soussion durin CUC staff note las or minutes <u>I summarized</u> ACUC Vote oval nold Approval ain	ation asting urgic smer ight i irme ure c ificat atior og the d IT s acro d abc	monitoring. ewals. d. clarification. tion. n with vets recommended for anesthesia recovery e meeting included: error in protocol review tracking history. Did not tra oss meetings. IT recovery was required. Previousl	t, clarification and plan.
2. #	D			07-14-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.						
Additio	nal discu			e meeting included: d for DMR		
	IACUC Vote					
	Approval 0					
	Withhold Approval 0					
	Abstain		0			
	Present	t	17			
3. #		D			08-18-2021	
The pr	otocol w	as reviewed	and	d the following points were addressed by the Princi	pal Investigator	
	the mee				parimeetigator	
	a. None					
				e meeting included: /oted to send to DR.		
		CUC Vote	3. 1			
	Approv		0			
		d Approval	-			
	Abstain		0			
	Present		17			
4. #		C			07-12-2021	
<b></b> <i>n</i>		l v			07-12-2021	
prior to Additio	a. Clarifi a. discu a. Voted	eting: cation requ ussion durir to send to CUC Vote	este ig th	d the following points were addressed by the Princi ed maintenance and training procedures. e meeting included: २.		
	Withhol	d Approval	0			
	Abstain		0			
	Present	t	17			
5. #		D			08-09-2021	
prior to	the means the means the means the means the two sets the	eting:		d the following points were addressed by the Princi	pal Investigator	
				e meeting included: wer. Request DR.		
	IAC	CUC Vote				
	Approva	al	0			
	Withhol	d Approval	0			
	Abstain		0			
	Present	t	17			
6. #		D			07-08-2021	
			and	d the following points were addressed by the Princi	pal Investigator	
		fety and ch		al safety officers completed their reviews and prov		
				ges removed from section 9 and included in sectio	n 7.	
AdaltiO	nai discl	ussion durir	ig th	e meeting included:		

a. Committee voted to approve.



# X. Annual Renewals:


Protocol C	Category		Last Reviewed	Expires
	DY	7-11-2019	07-08-2021	07-11-2022
	С	7-12-2019	07-08-2021	07-12-2022
	С	7-11-2019	07-08-2021	07-11-2022
	С	7-10-2019	07-08-2021	07-10-2022
	D	7-11-2019	07-08-2021	07-11-2022
	С	7-11-2019	07-08-2021	07-11-2022
	С	7-11-2019	07-08-2021	07-11-2022
	D	7-11-2019	07-08-2021	07-11-2022
	E	7-15-2019	07-08-2021	07-15-2022
	СҮ	7-22-2019	07-08-2021	07-22-2022
	С	7-11-2019	07-08-2021	07-11-2022
	С	7-11-2019	07-08-2021	07-11-2022
	СҮ	7-10-2019	07-08-2021	07-10-2022
	D	7-10-2019	07-08-2021	07-10-2022
	D	7-18-2019	07-08-2021	07-18-2022


DY	07-20-2020	07-07-2022	07-20-2023
DY	07-17-2020	07-07-2022	07-17-2023
С	07-23-2020	07-08-2021	07-23-2022
С	07-13-2020	07-07-2022	07-13-2023
D	07-23-2020	07-08-2021	07-23-2022
С	07-17-2020	07-07-2022	07-17-2023
D	07-23-2020	07-08-2021	07-23-2022
С	07-23-2020	07-08-2021	07-23-2022
С	07-23-2020	07-08-2021	07-23-2022
D	07-23-2020	07-08-2021	07-23-2022
С	07-08-2020	06-23-2022	07-08-2023
E	07-23-2020	07-08-2021	07-23-2022
D	07-23-2020	07-08-2021	07-23-2023
D	07-23-2020	07-08-2021	07-23-2022
D	07-23-2020	07-08-2021	07-23-2022
	and -one staf		]

Discus						ar		e staπ
		member is in pro	ogress to up	date their	OHSS	status. All	are either p	ending
		their in person a	ppointment	of awaitin	ng lab re	sults.		
		-Categoriz	zed as D ho	ed as D however PI provided video demonstrating the				
		procedure does	not cause n	nore than	momen	tary pain o	or distress.	
			of the protocol was missed during the original final					
		approval proces						
		Section 15 clarif						
						-	nimals, end	points
		and analgesic re		arogaran	ing mon	lioning of o	initiale, ena	
A ation It			ginte.					
Action It						ar	ia	
		committee voted						
			e voted to					
			e voted to r	emove w	oraing ir	n section s	and update	a
		category to D.						
					staff to	work with	PI to update	e
		protocol via an a	mendment.					
	I/	ACUC Vote						
Approval 17								
Withhold Approval 0								
/	Abstain 0							
	Prese	nt 17						

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium		-
1. 02-25-2021			
2. 03-02-2021			
3. 03-02-2021			
4. 03-11-2021			
5. 03-15-2021			
6. 03-18-2021			
7. 03-25-2021			
8. 04-09-2021			

9. 04-13-2021	
10. 04-27-2021	
11. 04-28-2021	
12. 05-07-2021	
13. 05-12-2021	
14. 05-17-2021	
15. 05-21-2021	
16. 05-21-2021	
17. 05-24-2021	
18. 06-02-2021	
19. 07-01-2021	

Discussion: 17. Animals were housed at the facility however the location was not approved on the PI's protocol.

Action: 17. Facility will perform a better review process to ensure animals are not transferred to their facility if the location has not been approved by IACUC.

IACUC Vote	
Approval	14
Withhold Approval	0
Abstain	0
Present	14

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 12-30-2020	LAB	
2. 01-26-2021	LAB	
3. 02-01-2021	LAB	
4. 02-02-2021	LAB	
5. 02-04-2021	LAB	
6. 03-11-2021	LAB	
7. 03-18-2021	LAB	
8. 03-19-2021	LAB	
9. 03-19-2021	LAB	
10. 03-22-2021	LAB	
11. 04-01-2021	LAB	
12. 04-02-2021	LAB	
13. 04-02-2021	LAB	
14. 04-16-2021	LAB	
15. 04-19-2021	LAB	
16. 04-19-2021	LAB	
17.04-19-2021	LAB	
18. 04-26-2021	LAB	
19. 04-28-2021	LAB	
20. 04-28-2021	LAB	
21. 04-28-2021	LAB	
22. 04-28-2021	LAB	
23. 04-28-2021	LAB	
24. 04-28-2021	LAB	

25. 05-03-2021	LAB	
26. 05-05-2021	LAB	
27.05-07-2021	LAB	
28. 05-07-2021	LAB	
29. 05-20-2021	LAB	
30. 05-25-2021	LAB	
31. 05-25-2021	LAB	
32. 05-28-2021	LAB	
33. 06-29-2021	LAB	
34.06-30-2021	LAB	
35. 06-30-2021	LAB	
36.06-30-2021	LAB	
37.06-01-2021	PAM	
38.06-18-2021	PAM	

Discussion: None	э.
Action: None	э.
IACU	C Vote
Approval	16
Withhold /	Approval 0
Abstain	0
Present	16

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

# XV. Other Discussion Items:

Торіс	
1) Introduce	IACUC Office Specialist
Discussion:	None.
Action:	None.

# XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

#### July 22, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M222, M102, M111, M042, A095, M100, M092, A019, M119, M087, A109, M110, M120, A013, M024, M223, M001, M114

#### Excused:

M090, M004, M093, M016, M112

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

The IACUC reviewe	ed and app	roved the June 10, 2021, meeting minutes as written.
IACUC	Vote	
Approval	19	
Withhold Ap	proval 0	
Abstain	0	
Present	19	
The IACUC reviewe	ed and app	roved the June 24, 2021, meeting minutes as written.
IACUC	Vote	
Approval	19	
Withhold Ap	proval 0	
Abstain	0	
Present	19	

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

the protocol was written regarding analgesia doses and frequency as well as when CVS will be contacted.


Action: Reviewed PAM responses and post-op record documentation. Committee agreed the PI's staff assessment was in line with the study model. All deficiencies noted were minor. PI is working on submitting an amendment to clarify the protocol.

Action: Committee heard concerns expressed by two VMTH clinicians regarding anesthesia project study design, potential adverse effects, length of anesthesia, and drugs being studies. PI presented summary of project to date, potential future mitigation measures, number of animals required, and value of this model. IACUC members discussed risk/benefit. IACUC appointed subcommittee for further review.
Action: Tabled to next meeting.

### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

#### VI. Designated Review Protocols:



a. Pendir	ng PI.		
6. #	D		-
prior to the mee a. None.	ting:	the following points were addressed by the Princip	pal Investigator
	ssion during the ng reviewer.	e meeting included:	
7. #	С		07-12-2021
prior to the mee	ting:	the following points were addressed by the Princip housing and maintenance procedures provided by	-
		working with PI to amend CDFW permit. meeting included:	
8. #	C		07-21-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator
9. #	D		-
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator
		terinary questions.	
10. #	С		07-22-2021
prior to the mee a. Clarific	ting: ation of husbar	the following points were addressed by the Princip ndry. e meeting included:	oal Investigator
11. #	С		07-14-2021
prior to the mee a. IACUC	ting: Cmember sugge	the following points were addressed by the Princip ested wording change. e meeting included:	pal Investigator
12. #	С		07-22-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator
a. None.		-	
13. #	С		07-22-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator
14. #	D		-

The protocol wa prior to the meet		the following points were addressed by the Princi	pal Investigator			
		ons for housing and procedures. Clarification on po	tential adverse			
	om neuroblasto					
		e meeting included:				
a. Pendir	•	C C				
15. #	D		07-14-2021			
		the following points were addressed by the Princi	pal Investigator			
prior to the mee	•					
		dures regarding itch and animal numbers.				
a. None.	ssion during the	e meeting included:				
	DV		07 14 2021			
16. #	DY		07-14-2021			
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the meet						
		w and addition of VHSS's.				
	ssion during the	e meeting included:				
a. None.	• •					
17. #	СҮ		07-16-2021			
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the mee			p			
a. None.	C					
	ssion during the	e meeting included:				
a. None.						
18. #	С		-			
		the following points were addressed by the Princi	pal Investigator			
prior to the meet		allastion and advance offects				
		ollection and adverse effects. e meeting included:				
	ng reviewer.					
19. #	DY		_			
	I	the following points were addressed by the Princi	nal Investigator			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:						
a. None.	ung.					
Additional discussion during the meeting included:						
a. Pending reviewer.						
20. #	C		-			
	s reviewed and	the following points were addressed by the Princi	pal Investigator			
prior to the meet						
		egarding collaboration and BUA amendment appro	oval.			
	Additional discussion during the meeting included:					
a. Remains in DMR.						

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	С		-
Investigator pric a. None. Additional discu	or to the meetin	I and the following points were addressed by the Pr g: e meeting included:	incipal
2. #	С		-

The amendment Investigator prior		and the following points were addressed by the Pr g:	incipal
		e meeting included:	
	g reviewer.		
3. #	С		07-13-2021
The amendment Investigator prior		and the following points were addressed by the Pr	incipal
		sample collection.	
		e meeting included:	
4. #			-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
		y chemical safety.	
		e meeting included:	
	ns in DMR.		
5. #	C		07-22-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	_		
Additional discus a. None.	ssion during the	e meeting included:	
6. #	D		07-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None.			
	ssion during the	e meeting included:	
a. None.			
7.#	С		07-21-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	j:	
a. None.	scion during the	e meeting included:	
a. None.			
8. #	DY		07-16-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	j:	
a. None.			
Additional discus a. None.	ssion during the	e meeting included:	
9. #	C		07-22-2021
		and the following points were addressed by the Pr	incipal
Investigator prio			
	ation of study of		
Additional discus	ssion during the	e meeting included:	
10. #	С		07-21-2021
Investigator prior		and the following points were addressed by the Pr j:	incipal
a. None.	ssion during the	e meeting included:	
	soon during the		

a. None.			
11. #	D		07-09-2021
Investigator prio a. Sugge	r to the meeting stion to increase	and the following points were addressed by the Pr j: e habituation in behavioral room. e meeting included:	incipal
12. #	D		07-21-2021
The amendment Investigator prio a. Room	t was reviewed a r to the meeting will be set up as	and the following points were addressed by the Pr s a lab inspection. e meeting included:	1
13. #	D		07-22-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	rincipal
14. #	D		07-13-2021
Investigator prio a. None. Additional discu	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
a. None.			
15. #	D		-
Investigator prio a. Clarific	r to the meeting ation of euthan ssion during the		incipal
16. #	С		-
Investigator prio a. None. Additional discu	r to the meeting	and the following points were addressed by the Pr : e meeting included:	rincipal
17. #	DY		07-10-2021
Investigator prio a. Optima	r to the meeting al treatment inte	and the following points were addressed by the Pr p: erval and potential pilot study. e meeting included:	incipal
18. #	E		07-22-2021
The amendment Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr j: e meeting included:	1
19. #	D		07-22-2021

The amendment Investigator prio		and the following points were addressed by the Pr	incipal
a. None.		•	
Additional discus a. None.	ssion during the	e meeting included:	
20. #	D		07-20-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.			
	ssion durina the	e meeting included:	
a. None.	J		
21. #	D		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. correct	ion of mouse st	train name typo.	
	ssion during the	meeting included:	
a. None.			
22. #	DY		07-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
		med approval of BUA amendment.	
	ssion during the	e meeting included:	
a. None.			
23. #	E		07-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
Additional discus	ssion during the	e meeting included:	
a. None.			
24. #	E		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.	-		
Additional discus	ssion during the	e meeting included:	
a. Pendin	g CHEM.		
25. #	D		07-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
	ssion during the	e meeting included:	
a. None.			
26. #	С		07-22-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.	-		
Additional discus	ssion during the	e meeting included:	
a. None.			
27. #	D		07-21-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			•
	ation on anima		
	ssion during the	e meeting included:	
a. None.		-	
28. #	D		07-16-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Chem safety review and recommendations for Vancomycin use.         Additional discussion during the meeting included:       a. None.         29. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Seven day shedding period for AAV.         b. Recommend further discussion with Biosafety officer and IBC.       Additional discussion during the meeting included:         a. Remains in DMR.       30. #       -         30. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Keep in DMR until necropsy results are available (second pending amendment).         31. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Neore.         Additional discussion during the meeting included:       a. Neerological findings are consistent with inflammation; possible foreign body reaction at device compatibility.       b. Future mitigation methods.         c. Antificational path result consultation required.       32. #       D       07-21-2021         The amendment was reviewed and the follow				
Additional discussion during the meeting included:          a. None.       D Y       -         29. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Seven day shedding period for AAV.</li> <li>b. Recommend further discussion with Biosafety officer and IBC.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Remains in DMR.</li> </ul> 30. # <ul> <li>D Y</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:                  <ul> <li>a. None.</li></ul></li></ul>				incipal
a. None.       DY         29. #       DY         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Seven day shedding period for AAV.</li> <li>b. Recommend further discussion with Biosafety officer and IBC.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Remains in DMR.</li> </ul> 30. #         DY       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Keep in DMR until necropsy results are available (second pending amendment).</li> </ul> 31. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility.</li> <li>b. Future mitigation mesures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> <li>Additional discussion during the meeting included:</li> <li>a. Additional apath result consultation required.</li> <li>32. #</li> <li>D</li> <li>O1-08-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:</li> <l< td=""><td>a. Chem</td><td>safety review a</td><td>nd recommendations for Vancomycin use.</td><td></td></l<></ul>	a. Chem	safety review a	nd recommendations for Vancomycin use.	
29. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Seven day shedding period for AAV.</li> <li>b. Recommend further discussion with Biosafety officer and IBC.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Remains in DMR.</li> <li>J. #</li> <li>D Y</li> <li>-</li> </ul> 30. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Activity and discussion during the meeting included:</li> <li>a. Keep in DMR until necropsy results are available (second pending amendment).</li> <li>31. #</li> <li>D Y</li> <li>-</li> </ul> The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility.</li> <li>b. Future mitigation methods.</li> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Additional path result consultation required.</li> <li>a. Additional discussion during the meeting included:                 <ul> <li>a. None.</li> </ul></li></ul>		ssion during the	e meeting included:	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Seven day shedding period for AAV.</li> <li>b. Recommend further discussion with Biosafety officer and IBC.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Remains in DMR.</li> </ul> 30. #         D Y             Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:             <ul> <li>a. Keep in DMR until necropsy results are available (second pending amendment).</li> </ul>            31. #         D Y        </li></ul>		D.V.		
Investigator prior to the meeting: a. Seven day shedding period for AAV. b. Recommend further discussion with Biosafety officer and IBC. Additional discussion during the meeting included: a. Remains in DMR. 30. # D Y	29. #	DY		-
				incipal
b. Recommend further discussion with Biosafety officer and IBC.         Additional discussion during the meeting included:         a. Remains in DMR.         30. #       DY         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. None.       -         Additional discussion during the meeting included:       -         a. Keep in DMR until necropsy results are available (second pending amendment).       -         31. #       DY       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. Nece       -       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. Nutrue mitigation methods.       c. Antibiotic use.       -         d. Mitigation measures to prevent potential infection.       -       -         e. Device sterilization techniques.       -       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. Additional discussion during the meeting included:       -       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeti				
Additional discussion during the meeting included:          a. Remains in DMR.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li> <li>a. Keep in DMR until necropsy results are available (second pending amendment).</li> </ul> 31. #         D Y         -           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
a. Remains in DMR.         30. #       D Y         31. #       D Y         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Keep in DMR until necropsy results are available (second pending amendment).</li> </ul> 31. #       D Y         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction at device compatibility.</li> <li>b. Future mitigation methods.</li> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> <li>Additional discussion during the meeting included:</li></ul>				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li></ul>				
Investigator prior to the meeting:  a. None.  Additional discussion during the meeting included:  a. Keep in DMR until necropsy results are available (second pending amendment).  31. # DY  The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:  a. Neurological findings are consistent with inflammation; possible foreign body reaction an device compatibility. b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques.  Additional discussion during the meeting included: a. Additional path result consultation required.  32. # D  07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification.  Additional discussion during the meeting included: a. None.  33. # D Y  The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management.  Additional discussion during the meeting included: a. None.  Additional discussion during the meeting included: a. None.  34. # D  07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management.  Additional discussion during the meeting included: a. None.	30. #	DY		-
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Keep in DMR until necropsy results are available (second pending amendment). 31. # DY The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Neurological findings are consistent with inflammation; possible foreign body reaction an device compatibility. b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques. Additional discussion during the meeting included: a. Additional path result consultation required. 32. # D 0 07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # D 0 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 33. # D 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 35. # C 0 17-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. Additional di	The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Additional discussion during the meeting included:          a. Keep in DMR until necropsy results are available (second pending amendment).       -         31. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction at device compatibility.</li> <li>b. Future mitigation methods.</li> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> </ul> <li>Additional discussion during the meeting included:         <ul> <li>a. Additional path result consultation required.</li> <li>32. #</li> <li>D</li> <li>O</li> <li>O7-21-2021</li> </ul> </li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:             <ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included:                 <ul> <li>a. None.</li></ul></li></ul></li>				
a. Keep in DMR until necropsy results are available (second pending amendment).         31. #       D Y         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
31. #       D Y       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility.</li> <li>b. Future mitigation methods.</li> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> </ul> <li>Additional discussion during the meeting included:         <ul> <li>a. Additional path result consultation required.</li> <li>32. #</li> <li>D</li> <li>O</li> <li>O7-21-2021</li> </ul> </li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:             <ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included:             <ul> <li>a. None.</li> <li>33. #</li> <li>D</li> <li>O</li> </ul> </li> <li>Or-08-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:             <ul> <li>a. Aspiration risk and management.</li> <li>Additional discussion during the meeting included:             <ul> <li>a. None.</li> <li>34. #</li> <li>D</li> <li>O</li> <li>O</li> </ul> </li> <li>A spiration risk and the following points were addressed by the Principal Investigator prior to the meeting:             <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:                 <ul></ul></li></ul></li></ul></li></ul></li>				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:  a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility. b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques. Additional discussion during the meeting included: a. Additional path result consultation required. 32. # D 0 07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # D Y 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 4dditional discussion during the meeting included: a. None. 4dditinal discussion during th	<u> </u>		cropsy results are available (second pending amen	idment).
Investigator prior to the meeting:  a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility. b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques. Additional discussion during the meeting included: a. Additional path result consultation required. 32. # 0 07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # 0 Y 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 35. # 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 35. # 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 4dditional discussion during the meeting included: a. Pending reviewer.				-
<ul> <li>a. Neurological findings are consistent with inflammation; possible foreign body reaction and device compatibility.</li> <li>b. Future mitigation methods.</li> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> <li>Additional discussion during the meeting included: <ul> <li>a. Additional path result consultation required.</li> </ul> </li> <li>32. # D 07-21-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>33. # D 0 07-08-2021</li> </ul> </li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Aspiration risk and management.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 0 07-22-2021</li> </ul> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> </li> <li>35. # C 0 07-22-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting includ</li>				incipal
device compatibility.       b. Future mitigation methods.         c. Antibiotic use.       d. Mitigation measures to prevent potential infection.         e. Device sterilization techniques.       Additional discussion during the meeting included:         a. Additional path result consultation required.       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       -         a. None.       35. #       C       -         Additional discu				a du un a ation and
b. Future mitigation methods. c. Antibiotic use. d. Mitigation measures to prevent potential infection. e. Device sterilization techniques. Additional discussion during the meeting included: a. Additional path result consultation required. 32. # D 07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # D Y 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: a. None. 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. Additional discussion during the meeting included: a. Pending reviewer.			are consistent with inflammation; possible foreign t	body reaction and
<ul> <li>c. Antibiotic use.</li> <li>d. Mitigation measures to prevent potential infection.</li> <li>e. Device sterilization techniques.</li> <li>Additional discussion during the meeting included:</li> <li>a. Additional path result consultation required.</li> <li>32. # D 07-21-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included:</li> <li>a. None.</li> </ul> </li> <li>33. # D Y 07-08-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included:</li> <li>a. None.</li> </ul> </li> <li>33. # D Y 07-08-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Aspiration risk and management.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 07-22-2021</li> </ul> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 07-22-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Addition</li>			bods	
d. Mitigation measures to prevent potential infection.       e. Device sterilization techniques.         Additional discussion during the meeting included:       a. Additional path result consultation required.         32. #       D       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified source and numbers justification.         Additional discussion during the meeting included:       a. None.         33. #       D       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.       -         Additional discussion during the meeting included:       a. None.       -         Additional discussion during the meeting included:       a. None.       -         35. #		-	1005.	
e. Device sterilization techniques. Additional discussion during the meeting included: a. Additional path result consultation required. 32. # D 07-21-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # D Y 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.			o prevent potential infection.	
a. Additional path result consultation required.       07-21-2021         32. #       D       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
32. #       D       07-21-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified source and numbers justification.         Additional discussion during the meeting included:       a. None.         33. #       D Y       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.         34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         A. None.       -				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified source and numbers justification. Additional discussion during the meeting included: a. None. 33. # D Y 07-08-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 0 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 4dditional discussion during the meeting included: a. None. Additional discussion during the meeting included: a. None. Additional discussion during the meeting included: a. None. Additional discussion during the meeting included: a. None.	a. Additio	nal path result	consultation required.	
Investigator prior to the meeting: <ul> <li>a. Clarified source and numbers justification.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> <li>33. # D Y 07-08-2021</li> The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Aspiration risk and management.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> <li>34. # D 0 07-22-2021</li> The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. None.</li> </ul> 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li>	32. #	D		07-21-2021
<ul> <li>a. Clarified source and numbers justification.</li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>33. # D Y 07-08-2021</li> </ul> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Aspiration risk and management.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 07-22-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 07-22-2021</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>35. # C</li>				incipal
Additional discussion during the meeting included:       a. None.         33. #       D Y       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.         34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. None.       -       -         Additional discussion during the meeting included:       -         a. None.       -         Additional discussion during the meeting included:       -         a. None.       -         Additional discussion during the meeting included:       -         a. None.       -         Additional discussion during the meeting included:       -				
a. None.       D Y       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Aspiration risk and management.</li> <li>Additional discussion during the meeting included:</li></ul>				
33. #       D Y       07-08-2021         The amendment was reviewed and the following points were addressed by the Principal       Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal       Investigator prior to the meeting:         a. None.       34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal       Investigator prior to the meeting:       a. None.         35. #       C       -       -         The amendment was reviewed and the following points were addressed by the Principal       -         Investigator prior to the meeting:       a. None.       -         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal       -         Investigator prior to the meeting:       a. None.       -         Additional discussion during the meeting included:       a. None.       -         Additional discussion during the meeting included:       a. Pending reviewer.       -		sion during the	e meeting included:	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Aspiration risk and management.         Additional discussion during the meeting included:       a. None.         34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. Pending reviewer.				07.09.2021
Investigator prior to the meeting: a. Aspiration risk and management. Additional discussion during the meeting included: a. None. 34. # D 07-22-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.			and the following points were addressed by the Dr	
<ul> <li>a. Aspiration risk and management.</li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>34. # D 07-22-2021</li> </ul> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>35. # C -</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li> <li>Additional discussion during the meeting included: <ul> <li>a. None.</li> </ul> </li>				incipal
Additional discussion during the meeting included:       a. None.         34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. Pending reviewer.				
34. #       D       07-22-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       07-22-2021         Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         35. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending reviewer.				
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. 35. # C - The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.	a. None.	-	-	
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. 35. # C	34. #	D		07-22-2021
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. 35. # C	The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Additional discussion during the meeting included:       a. None.         35. #       C         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. None.       Additional discussion during the meeting included:       -         Additional discussion during the meeting included:       a. Pending reviewer.	Investigator prior			
a. None.  35. # C		sion during the	e meeting included:	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.				
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending reviewer.	35. #	С		-
Additional discussion during the meeting included: a. Pending reviewer.	Investigator prior			incipal
a. Pending reviewer.			- meeting included:	
			e meeung includea:	
		-		07 22 2024
	JU. #			01-22-2021

Investigator prior a. None.	to the meeting	and the following points were addressed by the Pri : meeting included:	incipal
37. #	D		-
Investigator prior a. None. Additional discus	to the meeting	and the following points were addressed by the Pri : meeting included:	пара
38. #	С		-
Investigator prior a. None. Additional discus	to the meeting	and the following points were addressed by the Pri meeting included:	incipal


## VIII. Administrative and Veterinary Verification Amendments:

Total of **346** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

#### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Prot	tocol	Category	Title	Date Approved
1.#		D		07-22-2021
prior to Additio	the mee a. None.	ting: Ission during th	d the following points were addressed by the Princi e meeting included:	pal Investigator
	IAC	UC Vote		
	Approva	al 20		
	Withhold	d Approval 0		
	Abstain	0		
	Present	20		
2. #		E		07-22-2021



### X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	С		07-25-2019	07-22-2021	07-25-2022
	D		07-29-2019	07-22-2021	07-29-2022
	С		07-09-2019	07-22-2021	07-09-2022
	С		07-09-2019	07-22-2021	07-09-2022
			07-24-2019	07-22-2021	07-24-2022
	D		07-25-2019	07-22-2021	07-25-2022
	С		07-25-2019	07-22-2021	07-25-2022
	С		07-31-2019	07-22-2021	07-31-2022
	С		07-24-2019	07-22-2021	07-24-2022
	DY		07-25-2019	07-22-2021	07-25-2022
	D		07-24-2019	07-22-2021	07-24-2022
			07-24-2019	07-22-2021	07-24-2022

_			
D	07-30-2019	07-22-2021	07-30-2022
С	07-25-2019	07-22-2021	07-25-2022
С	07-25-2019	07-22-2021	07-25-2022
D	08-05-2019	07-22-2021	08-05-2022
С	07-10-2019	07-22-2021	07-10-2022
CY	08-05-2019	07-22-2021	08-05-2022
DY	07-25-2019	07-22-2021	07-25-2022
 С	07-26-2019	07-22-2021	07-26-2022
 С	07-24-2019	07-22-2021	07-24-2022
 D	08-02-2019	07-22-2021	08-02-2022
 С	08-05-2019	07-22-2021	08-05-2022
С	08-02-2019	07-22-2021	08-02-2022
С	08-05-2019	07-22-2021	08-05-2022
E	08-06-2020	07-22-2021	08-06-2022
С	07-20-2020	07-22-2021	07-22-2022
D	08-06-2020	07-22-2021	08-06-2022
D	07-31-2020	07-22-2021	07-31-2022
С	07-28-2020	07-22-2021	07-28-2022
С	07-28-2020	07-22-2021	07-28-2022
D	07-23-2020	07-22-2021	07-23-2022
DY	08-06-2020	07-22-2021	08-06-2022
D	08-06-2020	07-22-2021	08-06-2022
D	08-06-2020	07-22-2021	08-06-2022
С	07-21-2020	07-07-2022	07-21-2023
С	08-04-2020	07-22-2021	08-04-2022
CY	08-06-2020	07-22-2021	08-06-2022
С	08-06-2020	07-22-2021	08-06-2022


40.	С	08-05-2020	07-22-2021	08-05-2022
#				

	-IACUC st alternate contac -PI submit	ast step of OHSS renewal process. taff is working with PI to amend protocol to update the t. tted an amendment clarifying monitoring procedures and and will be reviewed under the FC amendments.
Action Items:	-Committe	ee approved the annual renewal. ee approved the annual renewal. ee approved the annual renewal.
I.	ACUC Vote	
Appro	val 18	
Withh	old Approval 0	
Absta	in O	
Prese	nt 18	

# XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Categor	y Request	Date Approved
1.#	D		07-26-2021
nvestigator p a. Clar Additional dise	rior to the me fication on pr	ocedure. g the meeting included:	ressed by the Principal
IA	CUC Vote		
Appro	val	0	
Withh	old Approval	0	
Abstai	n	0	
Prese	nt	20	
2. #	CY		07-22-2021
a. Non Additional dis a. Non	cussion durin	g the meeting included:	
14	CUC Vote		
Appro	val	19	
Withho	old Approval	0	
Abstai	n	0	
Prese	nt	19	
3. #	D		07-22-2021
Investigator p a. Revi	rior to the me	I the additional wording clarify the sco	



XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1.03-23-2021	
2.03-24-2021	
3. 03-30-2021	
4.04-06-2021	
5. 04-20-2021	
6. 04-22-2021	
7.04-30-2021	
8.05-06-2021	
9. 05-07-2021	
10. 05-20-2021	
11.05-26-2021	
12.07-16-2021	
Discussion: Non	е.
Action: Non	е.

	IACUC Vote	
A	pproval	19
V	Vithhold Approval	0
A	bstain	0
Р	resent	19

### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 04-23-2021	LAB	
2. 04-23-2021	LAB	
3. 06-29-2021	LAB	
4. 06-29-2021	LAB	
5. 06-30-2021	LAB	
6. 06-30-2021	LAB	
7.06-30-2021	LAB	
8. 06-18-2021	PAM	
9. 07-12-2021	PAM	

Discussion: 9. Review of post-op records and protocol revealed confusion and inconsistencies.

Action: 9. PI to modify surgery records and submit an amendment to the pro	otocol
to clarify monitoring and analgesia.	

# IACUC Vote

Approval	19	
Withhold Approval	0	
Abstain	0	
Present	19	

#### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

# XV. Other Discussion Items:

Торіс	
1. Guests to	discuss protocol
Discussion:	See above section 4.
Action:	IACUC appointed subcommittee for further review.
2. IACUC Cł	nair and Vice-Chair appointments
Discussion:	Appointment letter sent from VCR.
Action:	None.
3. 2021-202	2 IACUC appointment letter and meeting dates
Discussion:	Appointment letters sent from VCR.
Action:	None.

# XVI. Program Updates:

#### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

#### August 05, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M102, M111, M090, M042, A095, M100, M092, A019, M119, M087, A109, M110, M120, M093, A013, M016, M024, M223, M001, M112, M114

#### Excused:

M222, M004

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC and inciden	reviewed and discussed the following report(s) of concern, events, its:
Actio	on: 2.9% fish mortality; aging infrastructure
	on: IACUC updated on subcommittee approach to engage external ect matter reviewers.

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:	
None at this time.	_

## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	С		-
prior to the mee a. Pendir	ting: ng Pl's respons	d the following points were addressed by the Princi es. e meeting included:	pal Investigator
			Obtair

2. #	D		08-05-2021
rior to the mee a. None.	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
a. None.		incering included.	
3. #	D		-
orior to the mee a. Furthe Additional discu	ting: r clarification of ssion during the	the following points were addressed by the Princip experimental procedures versus standard of care. meeting included:	-
a. Pendir	ng. D		
4. #			-
	cation of experir	mental procedures versus standard of care.	
	-	-	
a. Pendir 5. <b>#</b> The protocol wa prior to the mee a. None.	ng. D Is reviewed and ting:	the following points were addressed by the Princip	- oal Investigator
a. Pendir 5. # The protocol wa prior to the mee a. None. Additional discu a. Pendir	ng. D Is reviewed and ting: ssion during the ng PI response	the following points were addressed by the Princip e meeting included:	
a. Pendir 5. # The protocol wa prior to the mee a. None. Additional discu	ng. D Is reviewed and ting: ssion during the		- pal Investigator 07-28-2021
a. Pendir 5. # The protocol wa prior to the mee a. None. Additional discu a. Pendir 6. # The protocol wa prior to the mee a. None.	ng. D Is reviewed and ting: ssion during the p PI response C Is reviewed and ting: ssion during the		07-28-2021
a. Pendir 5. # The protocol was prior to the mee a. None. Additional discu a. Pendir 6. # The protocol was prior to the mee a. None. Additional discu	ng. D Is reviewed and ting: ssion during the p PI response C Is reviewed and ting: ssion during the	e meeting included: the following points were addressed by the Princip	07-28-2021
a. Pendir 5. # The protocol was prior to the mee a. None. Additional discu a. Pendir 6. # The protocol was prior to the mee a. None. 7. # The protocol was prior to the mee a. Clarific	ng. D Is reviewed and ting: ssion during the ng PI response C Is reviewed and ting: ssion during the D Is reviewed and ting: cation on location	e meeting included: the following points were addressed by the Princip e meeting included: the following points were addressed by the Princip on for BUA.	07-28-2021 Dal Investigator 08-05-2021
a. Pendir 5. # The protocol was prior to the mee a. None. Additional discu a. Pendir 6. # The protocol was prior to the mee a. None. 7. # The protocol was prior to the mee a. Clarific	ng. D Is reviewed and ting: ssion during the ng PI response C Is reviewed and ting: ssion during the D Is reviewed and ting: cation on location	e meeting included: the following points were addressed by the Princip e meeting included: the following points were addressed by the Princip	07-28-2021 Dal Investigator 08-05-2021
a. Pendir 5. # The protocol was prior to the mee a. None. Additional discu a. Pendir 6. # The protocol was prior to the mee a. None. 7. # The protocol was prior to the mee a. Clarific Additional discu	ng. D Is reviewed and ting: ssion during the ng PI response C Is reviewed and ting: ssion during the D Is reviewed and ting: cation on location	e meeting included: the following points were addressed by the Princip e meeting included: the following points were addressed by the Princip on for BUA.	07-28-2021 Dal Investigator 08-05-2021
a. Pendir 5. # The protocol was prior to the mee a. None. Additional discu a. Pendir 6. # The protocol was prior to the mee a. None. 7. # The protocol was prior to the mee a. Clarific Additional discu a. None. 8. # The protocol was prior to the mee a. Clarific Additional discu a. None. 8. #	ng.  D Is reviewed and ting: ssion during the ng PI response  C Is reviewed and ting: ssion during the Is reviewed and ting: cation on locatio ssion during the D Is reviewed and ting: cation on locatio ssion during the ssice du	e meeting included: the following points were addressed by the Princip e meeting included: the following points were addressed by the Princip on for BUA.	07-28-2021 Dal Investigator 08-05-2021 Dal Investigator

The protocol wa prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator
	ssion during the	e meeting included:	
10. #	D		08-05-2021
The protocol wa prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator
		e meeting included: lousing and controls.	
11. #			-
prior to the meet a. Reque Additional discu	ting: st update on Ol	the following points were addressed by the Princip HSS. e meeting included:	oal Investigator
12. #	С		-
prior to the meet a. None. Additional discu	ting:	the following points were addressed by the Princip e meeting included:	oal Investigator
13. #	DY		08-03-2021
	-	e meeting included:	-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip e meeting included:	pal Investigator
15. #	С		08-02-2021
prior to the meet a. None. Additional discu	ting:	the following points were addressed by the Princip e meeting included: ers.	oal Investigator
16. #	С		-
prior to the meet a. Pendir Additional discu	ting: Ig approval of B	the following points were addressed by the Princip UA amendment. e meeting included:	oal Investigator
17. #	С		-
The protocol wa prior to the meet a. None.		the following points were addressed by the Princip	oal Investigator

	ssion during the g Reviewer	meeting included:	
18. #	C		-
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	bal Investigator
Additional discus	ssion during the g Reviewer	meeting included:	
19. #	С		-
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
20. #	С		07-29-2021
prior to the meet a. Sugge	ting: stions on wordir	the following points were addressed by the Princip ng in the protocol. meeting included:	oal Investigator
21. #	B		07-27-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
22. #	В		07-27-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
23. #	D		08-05-2021
prior to the meet a. Chemi	ting: cal safety office	the following points were addressed by the Princip r completed review and provided updated VHSS. meeting included:	oal Investigator
24. #	С		08-05-2021
prior to the meet a. Clarific	ting: ation on proced	the following points were addressed by the Princip lure. meeting included:	bal Investigator
25. #	С		08-05-2021
The protocol was prior to the meet a. None.	s reviewed and ting:	the following points were addressed by the Princip meeting included:	I
26. #	С		08-02-2021

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:

a. None.

## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	С		07-26-2021
nvestigator prior a. None.	r to the meeting		rincipal
Additional discus a. None.	ssion during the	e meeting included:	
2. #	СҮ		07-27-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pi g: e meeting included:	rincipal
3. #	СҮ		08-03-2021
Investigator prior a. None. Additional discus a. None.	r to the meeting	and the following points were addressed by the Pi g: e meeting included:	
4. #	D		-
a. Remair <b>5. #</b> The amendment	ns in DMR. C was reviewed	e meeting included: and the following points were addressed by the Pl	08-03-2021 rincipal
Investigator prior a. None. Additional discus a. None.		g: e meeting included:	
6. #	С		-
Investigator prior a. None. Additional discus	r to the meeting	and the following points were addressed by the Pi g: e meeting included:	rincipal
7. #	C		08-05-2021
The amendment Investigator prior a. Clarific	r to the meeting ation of statisti		1
8. #	D		08-02-2021
The amendment Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pi g: e meeting included:	rincipal

9.#	D		08-05-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pri : e meeting included:	incipal
a. None.	_		
10. #	DY		07-29-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
11. #			08-04-2021
The amendment Investigator prio		and the following points were addressed by the Pr	incipal
a. Chemi	cal safety office	r completed final review and provided updated VH meeting included:	SS.
12. #	С		08-05-2021
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included:	incipal
13. #	D		08-02-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
14. #	D		08-03-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
15. #	С		08-04-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
16. #	D		07-26-2021
The amendment Investigator prio a. Clarific	t was reviewed r to the meeting ation on procee		
17.#	С		08-04-2021

The amendment Investigator prior		and the following points were addressed by the Pr	incipal
a. None.	i to the meeting	j.	
	ssion during the	e meeting included:	
18. #	D		08-05-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	j:	
a. Chemi	cal safety office	r completed final review and provided updated VH	SS.
Additional discus a. None.	ssion during the	e meeting included:	
19. #	D		08-05-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
	ation of drug pr		
	ssion during the	e meeting included:	
a. None.	_		
20. #	D		08-03-2021
Investigator prior a. None.	r to the meeting		incipal
	ssion during the	e meeting included:	
a. None.	•		
21. #	C		08-04-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	j:	
a. None.	cion during the	maating included:	
a. None.	sion during the	e meeting included:	
22. #	D		08-02-2021
	was reviewed	and the following points were addressed by the Pr	
Investigator prior a. None.			in cipai
	ssion during the	e meeting included:	
a. None.	-	-	
23. #	D		08-02-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	j:	
	int clarification.		
		nistration and diet prep clarification.	
	ssion during the	e meeting included:	
a. None.	-		
24. #	С		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None.			
		e meeting included:	
25. #	C C		08-05-2021
		and the following points were addressed by the Pr	
Investigator prior a. None.			incipai
	sion during the	e meeting included:	
a. None.			

26. #	D		08-03-2021
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
	strain clarificat		
a. None.	ssion during the	e meeting included:	
27. #	E		08-05-2021
		and the following points were addressed by the Pr	1
Investigator prio			inopai
a. None.			
Additional discus a. None.	ssion during the	e meeting included:	
28. #	D		08-03-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
	ssion during the	e meeting included:	
a. None. 29. #	СҮ		08-02-2021
		and the following points were addressed by the Pr	
Investigator prio			incipal
a. None.	i to the meeting	g.	
Additional discu	ssion during the	e meeting included:	
a. None.			
30. #	С		08-03-2021
<b>—</b> •••••	<u> </u>		
		and the following points were addressed by the Pr	incipal
Investigator prio a. None.	r to the meeting	J.	
	ssion during the	e meeting included:	
a. None.	_	-	
31. #	C		07-21-2021
		and the following points were addressed by the Pr	incipal
Investigator prio		j:	
a. None. Additional discu		e meeting included:	
a. None.	solon during the		
32. #	DY		-
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
	ssion during the ns in DMR.	e meeting included:	
33. #			
33.#			-
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.			molpul
	ssion during the	e meeting included:	
a. Remai	ns in DMR.		
34. #	DY		-
	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
Additional discu	ssion during the	e meeting included:	

a. Remai	ns in DMR		
35. #	E		08-03-2021
Investigator prior		and the following points were addressed by the Pr :	incipal
a. None. Additional discus a. None.	ssion during the	meeting included:	
36. #	DY		07-30-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None. Additional discus	-	r meeting included:	
a. None.	selen dannig die		
37. #	D		08-03-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. Refere b. Value o c. Add blo	r to the meeting nce request for of Serum chemi ood glucose and	i: dosing.	·
38. #	D		08-05-2021
		and the following points were addressed by the Pr	
Investigator prior a. None.	r to the meeting		inoipai
39. #	D		07-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	nopa
40. #	D		08-05-2021
Investigator prio a. Maxim	r to the meeting um imaging and	and the following points were addressed by the Pr : d anesthesia episodes. e meeting included:	incipal
41. #	CY		07-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
42. #	С		08-03-2021
The amendment Investigator prior a. None.	was reviewed r to the meeting	and the following points were addressed by the Pr : • meeting included:	
43. #	D		08-03-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal

a. None.			
44. #	С		08-05-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
45.#	CY		08-05-2021
Investigator prior a. None. Additional discus a. None.	-	meeting included:	
46. #	D		08-03-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
47.#	D		08-04-2021
Investigator prior a. Clarific	to the meeting ation requested		incipal


#### VIII. Administrative and Veterinary Verification Amendments:


Total of **253** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1.#	DY		08-19-2021
prior to the mee a. Pendii b. Updat c. Dosing d. Frequ g. Poteti h. Pairing additional discu	ting: ng Chem safet ed literature se g and duration ency of AST/Al al ART reaction g.	arch requested. clarifications. _T assessment.f. Animal number justification. n/mitigation. e meeting included:	ncipal Investigator
IAC	CUC Vote		
Approva	al O		
Withhold	d Approval 0		
Abstain	0		
Present	23		








## X. Annual Renewals:


Protocol Cate	gory	Title	Original Approval	Last Reviewed	Expires
C			08-08-2019	08-05-2021	08-08-2022
D	Y		08-08-2019	08-05-2021	08-08-2022
C	C		08-08-2019	08-05-2021	08-08-2022
E	C		08-09-2019	08-05-2021	08-09-2022
C	D		08-08-2019	08-05-2021	08-08-2022
C	2		08-14-2019	08-05-2021	08-14-2022
C	D		08-08-2019	08-05-2021	08-08-2022
C	2		08-20-2019	08-05-2021	08-20-2022
C	C		08-08-2019	08-05-2021	08-08-2022
	C		08-08-2019	08-05-2021	08-08-2022
C	C		08-08-2019	08-05-2021	08-08-2022
C	C		08-19-2019	08-05-2021	08-19-2022
С	Y		08-08-2019	08-05-2021	08-08-2022

DY		08-08-2019	08-05-2021	08-08-2022
С		08-17-2020	08-05-2021	08-17-2022
D		08-20-2020	08-05-2021	08-20-2022
D		08-19-2020	08-05-2021	08-19-2022
С		08-13-2020	08-05-2021	08-13-2022
С		08-20-2020	08-05-2021	08-20-2022
С		08-20-2020	08-05-2021	08-20-2022
С		08-20-2020	08-05-2021	08-20-2022
D		08-20-2020	08-05-2021	08-20-2022
D		08-18-2020	08-05-2021	08-18-2022
DY		08-20-2020	08-05-2021	08-20-2022
D		08-10-2020	08-05-2021	08-10-2022
C		08-17-2020	08-05-2021	08-17-2022
D		08-20-2020	08-05-2021	08-20-2022
D		08-20-2020	08-05-2021	08-20-2022
С		08-20-2020	08-05-2021	08-20-2022
DY		08-20-2020	08-05-2021	08-20-2022
renew updat PI pro Action Items: annua updat	ed permit information. -Section 9 was not clear as to how lo vided wording that was presented to and renewals.	oired. Both PI's provided the ong animals are singly housed. the committee. Committee approved e permit information being annual renewals.		
IACUC				
Approval	20			
Withhold Ap				
Abstain	0			
Present	20			

#### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





	nendment gator prior			and the following points were addressed by the Pr	incipal
	a. Amend would usu	ment was ually not re	put equir	on agenda because it was time sensitive to study s re full committee review.	tart date and
Additio				e meeting included:	
	a. Commi	ttee voted	1 to a	approve.	
			~		
	Approval	Approval	23		
	Abstain	Appiovai	0		
	Present		23		
40.4			23		00.05.0004
10. ‡		DY			08-05-2021
Investi Additic	gator prior a. None. nal discus a. None.	r to the me	eetin	and the following points were addressed by the Pr g: ne meeting included:	
		UC Vote			
	Approval		23		
		Approval			
	Abstain		0		
	Present		23		
11. #		D			08-05-2021
Investi	gator prior a. Study i dispositio	r to the me s finished n if PI is a ssion durir	eetin and ble t ng th	colony is being culled. Committee approved other to find alternatives. The meeting included:	
	IAC	UC Vote			
	Approval		23		
	Withhold	Approval	0		
	Abstain		0		
	Present		23		

## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.05-20-2021		
2. 07-22-2021		
3. 07-28-2021		
4. 07-28-2021		

Discussion: None.	
Action: None.	
IACUC Vote	
Approval	22
Approval Withhold Approv	al O
Abstain	0
Abstain	

Present 22

#### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 07-23-2021	LAB	
2. 01-20-2021	PAM	
3. 03-22-2021	PAM	

Discussion:	None.	
Action:	None.	
L	ACUC Vote	
Appro	oval	22
Withh	oval iold Approval	0
Absta		0
Prese	ent	22

#### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс	
1. New SIC a	and Chair for Animal Science.
Discussion:	None.
Action:	Approved.
2. Guest:	
Discussion:	Attendance of 1st committee meeting.
Action:	None.

#### XVI. Program Updates:

## Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

August 19, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M102, M111, M090, M004, M100, M092, A019, M087, A109, M110, M120, M093, A013, M024, M223, M001, M114

#### Excused:

M222, M042, A095, M119, M016, M112

Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

1. #			Category: E
The protoc	ol was reviewed	and	the following points were addressed by the Principal Investigator prior to the
meeting:			
a. D	iscussion on PA	M ar	nd Post Operative monitoring.
Additional of	discussion during	g the	e meeting included:
a. V	oted to sent to D	MR.	
	IACUC Vote		
Арр	oroval	0	
Wit	hhold Approval	0	
Abs	stain	0	
Pre	sent	18	

#### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
PETA records request
Action: Notification.
SAEN records request
Action: Notification.
PCRM lawsuit
Action: Notification.
Action: PAM; mice unattended, procedural retraining.
Update
Action: Recommended modifications successful.

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

#### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	DY		08-19-2021
prior to the meet a. PI addi	ing: ressed all previ	the following points were addressed by the Princip ously identified questions. e meeting included:	oal Investigator
2. #	С		-
prior to the meet a. None.	ing:	the following points were addressed by the Princip	bal Investigator
dditional discus a. None.	ssion during the	e meeting included:	
3. #	D		08-18-2021
rior to the meet a. Further	ing: r clarification of	the following points were addressed by the Princip standard of care versus experimental procedures. meeting included:	-
4. #	D		08-18-2021
he protocol was	s reviewed and	the following points were addressed by the Princip	
he protocol was rior to the meet a. Further	s reviewed and ing: r clarification of	the following points were addressed by the Princip standard of care versus experimental procedures. e meeting included:	oal Investigator
The protocol was prior to the meet a. Further additional discus a. None. 5. #	s reviewed and ing: r clarification of ssion during the D	standard of care versus experimental procedures. meeting included:	08-09-2021
The protocol was orior to the meet a. Further additional discus a. None. 5. <b>#</b> The protocol was orior to the meet a. Pendin	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev	standard of care versus experimental procedures.	08-09-2021 08I Investigator
The protocol was prior to the meet a. Further Additional discus a. None. 5. # The protocol was prior to the meet a. Pendin Additional discus	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev	standard of care versus experimental procedures. e meeting included: the following points were addressed by the Princip view questions were answered regarding sterilizati	08-09-2021 08I Investigator
The protocol was rior to the meet a. Further additional discus a. None. <b>5.</b> The protocol was rior to the meet a. Pendin additional discus a. None. <b>6.</b> The protocol was rior to the meet a. Further effects.	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev ssion during the D s reviewed and ing: r clarification of	standard of care versus experimental procedures. e meeting included: the following points were addressed by the Princip view questions were answered regarding sterilizati	08-09-2021 08-09-2021 oal Investigator on. 08-18-2021 oal Investigator
The protocol was rior to the meet a. Further additional discus a. None. <b>5.</b> # The protocol was rior to the meet a. Pendin additional discus a. None. <b>6.</b> # The protocol was rior to the meet a. Further effects.	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev ssion during the D s reviewed and ing: r clarification of	standard of care versus experimental procedures. e meeting included: the following points were addressed by the Princip view questions were answered regarding sterilizati e meeting included: the following points were addressed by the Princip standard of care versus experimental procedures	08-09-2021 08-09-2021 oal Investigator on. 08-18-2021 oal Investigator
The protocol was brior to the meet a. Further Additional discus a. None. <b>5.</b> # The protocol was brior to the meet a. Pendin Additional discus a. None. <b>6.</b> # The protocol was brior to the meet a. Further effects. Additional discus a. None. <b>7.</b> # The protocol was brior to the meet a. None. <b>7.</b> #	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev ssion during the D s reviewed and ing: r clarification of ssion during the D s reviewed and ing:	standard of care versus experimental procedures. e meeting included: the following points were addressed by the Princip view questions were answered regarding sterilizati e meeting included: the following points were addressed by the Princip standard of care versus experimental procedures	08-09-2021 08-09-2021 0al Investigator on. 08-18-2021 0al Investigator and adverse 08-05-2021
The protocol was prior to the meet a. Furthen Additional discus a. None. <b>5.</b> # The protocol was prior to the meet a. Pendin Additional discus a. None. <b>6.</b> # The protocol was prior to the meet a. Furthen effects. Additional discus a. None. <b>7.</b> # The protocol was prior to the meet a. None. <b>7.</b> #	s reviewed and ing: r clarification of ssion during the D s reviewed and ing: g veterinary rev ssion during the D s reviewed and ing: r clarification of ssion during the D s reviewed and ing: s reviewed and ing: s reviewed and	standard of care versus experimental procedures. the following points were addressed by the Princip view questions were answered regarding sterilization meeting included: the following points were addressed by the Princip standard of care versus experimental procedures e meeting included: the following points were addressed by the Princip	08-09-2021 0al Investigator oal Investigator on. 08-18-2021 0al Investigator and adverse 08-05-2021 0al Investigator

Additional discussion during the meeting included:

a. Remair	ns in DMR.	5	
9. #	С		08-17-2021
prior to the meet	ing:	the following points were addressed by the Princip standard of care versus experimental procedures.	-
Additional discus a. None.	sion during the	e meeting included:	
10. #	CY		-
prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip meeting included:	pal Investigator
11. #	C		_
The protocol was prior to the meet a. None.	ing: ssion during the	the following points were addressed by the Princip meeting included:	pal Investigator
12. #	С		08-06-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	pal Investigator
13. #	с		08-06-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	pal Investigator
a. None.		moduly modulou.	
14. #	D		08-12-2021
prior to the meet	ing: ided updated ir	the following points were addressed by the Princip nformation regarding training of TAs and students p	-
Additional discus a. None.		meeting included:	
15. #	D		-
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	pal Investigator
	sion during the	e meeting included:	
16. #	D		-
prior to the meet a. None.	ing:	the following points were addressed by the Princip	pal Investigator
a. None.		e meeting included:	

17. #	D		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.						
Additional discus	ssion during the g bio and chem	e meeting included: n review.				
18. #	C		08-10-2021			
prior to the meet a. Further	ting: r clarification of	the following points were addressed by the Princip standard of care versus experimental procedures. meeting included:	· ·			
19. #	DY		08-06-2021			
prior to the meet a. None.	Additional discussion during the meeting included:					
20. #	С		08-19-2021			
prior to the meet a. Clarific	ting: ation on termine	the following points were addressed by the Princip ology and euthanasia method. e meeting included:	pal Investigator			
21. #	D		08-19-2021			
prior to the meet a. Clarific	ting: ation on animal	the following points were addressed by the Princip source and euthanasia method. meeting included:	oal Investigator			
22. #	CY		08-11-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	pal Investigator			
23. #	С		08-19-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator			
24. #	С		08-13-2021			
prior to the meet a. None.	ting:	the following points were addressed by the Princip e meeting included:	bal Investigator			

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved			
1.#	D		08-19-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.						
2. #	D		08-19-2021			
Investigator prio a. Rat we	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Rat weight discussed. Additional discussion during the meeting included: a. None					
3. #	DY		-			
Investigator prio a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr : meeting included:	incipal			
4. #	D		08-19-2021			
Investigator prio a. Clarific	r to the meeting ation of justifica		incipal			
5.#	С		08-19-2021			
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal			
6. #	С		08-19-2021			
Investigator prio a. None.	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:					
7.#			08-17-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.						
8. #	D		08-19-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.						
9. #	D		08-19-2021			
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal			

a. None.					
10. #	DY		08-10-2021		
The amendment Investigator prio a. None.		and the following points were addressed by the Pr :	incipal		
	ssion during the	e meeting included:			
11. #	D		08-19-2021		
The amendment Investigator prio a. None.		and the following points were addressed by the Pr :	incipal		
a. None.	ssion during the	e meeting included:			
12. #	D		08-18-2021		
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal		
13. #	D		08-19-2021		
	was reviewed	and the following points were addressed by the Pr			
Investigator prio a. None.	r to the meeting		·		
14. #	D		08-19-2021		
Investigator prio a. None.	r to the meeting		incipal		
a. None.		e meeting included:			
15. #	С		08-09-2021		
The amendment Investigator prio a. None.		and the following points were addressed by the Pr :	incipal		
Additional discus a. None.	ssion during the	e meeting included:			
16. #	DY		-		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
Additional discussion during the meeting included: a. Pending recommended rewording for clarity. Remains in DMR.					
17.#	DY		-		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response.					
	ssion during the ns in DMR.	e meeting included:			
18. #	С		-		

		and the following points were addressed by the Pr	incipal			
Investigator prio	r to the meeting 1g PI response.	j:				
Additional discus		e meeting included:				
19. #	E		08-19-2021			
Investigator prio a. None.	r to the meeting		incipal			
a. None.	_	e meeting included:				
20. #	D		08-19-2021			
Investigator prio a. None.	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:					
a. None.	-					
21. #	DY		-			
Investigator prio a. None. Additional discus	r to the meeting	e meeting included:	incipai			
22. #	DY		-			
Investigator prio a. Reque Additional discus	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Request time reevaluation by Bio. Additional discussion during the meeting included:					
23. #	St time reevalua	ation by Bio; including references. Remains in DMI	<b>۲.</b>			
23. #			-			
Investigator prio a. None. Additional discus	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal			
24. #	D		08-19-2021			
Investigator prio a. None.	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:					
25. #	С		08-18-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of standard of care versus experimental procedures. Additional discussion during the meeting included: a. None.						
26. #	D		-			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Requested specification of breeding lines and total offspring. Additional discussion during the meeting included: a. None.						
27.#	C		-			

Investigator prior	r to the meeting	and the following points were addressed by the P i:	rincipal			
	a. Pending Reviewer. Additional discussion during the meeting included:					
	ssion during the ns in DMR.	e meeting included:				
28. #	С		08-19-2021			
The amendment	was reviewed	and the following points were addressed by the P	rincipal			
Investigator prior	r to the meeting	μ.				
a. None.						
	ssion during the	e meeting included:				
a. None.						
29. #	CY		08-12-2021			
Investigator prior a. None.	r to the meeting	and the following points were addressed by the P : e meeting included:	rincipal			
a. None.		0				
30. #	D		08-19-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Grammar correction. Additional discussion during the meeting included: a. None.						
31. #	D		_			
	_	and the following points were addressed by the P	rinoinal			
			nncipai			
Investigator prior to the meeting: a. None.						
	ssion during the	e meeting included:				
a. Pendin						


### VIII. Administrative and Veterinary Verification Amendments:


Total of **196** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Catego	y Title	Date Approved			
1.#	D		12-17-2021			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on hazardous material and procedure. Additional discussion during the meeting included: a. Voted to send to DMR.						
IAC	UC Vote					
Approva	d .	0				
Withhold	d Approval	0				







## X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	CY		08-22-2019	08-19-2021	08-22-2022
	С		08-14-2019	08-19-2021	08-14-2022
	D		08-22-2019	08-19-2021	08-22-2022
	D		08-27-2019	08-19-2021	08-27-2022
	С		08-22-2019	08-19-2021	08-22-2022
	С		08-09-2019	08-19-2021	08-09-2022
-	D		08-29-2019	08-19-2021	08-29-2022
	D		08-22-2019	08-19-2021	08-22-2022
	D		08-22-2019	08-19-2021	08-22-2022


	С	08-22-2019	08-19-2021	08-22-2022
	С	08-22-2019	08-19-2021	08-22-2022
	СҮ	08-26-2019	08-10-2021	08-26-2022
	DY	08-22-2019	08-19-2021	08-22-2022
	D	08-22-2019	08-19-2021	08-22-2022
	С	08-22-2019	08-19-2021	08-22-2022
	D	08-22-2019	08-19-2021	08-22-2022
	С	08-23-2019	08-19-2021	08-23-2022
	С	08-28-2019	08-19-2021	08-28-2022
	D	08-30-2019	08-19-2021	08-30-2022
	D	09-03-2020	08-19-2021	09-03-2022
_	D	09-02-2020	08-19-2021	09-02-2022
	С	09-03-2020	08-19-2021	09-03-2022
	D	08-26-2020	08-19-2021	08-26-2022
	DY	09-03-2020	08-19-2021	09-03-2022
	D	09-03-2020	08-19-2021	09-03-2022
	С	09-02-2020	08-19-2021	09-02-2022
	DY	09-03-2020	08-19-2021	09-03-2022
	С	09-03-2020	08-19-2021	09-03-2022
	С	09-03-2020	08-19-2021	09-03-2022
	DY	09-03-2020	08-19-2021	09-03-2022
	СҮ	09-03-2020	08-19-2021	09-03-2022
	С	09-02-2020	08-19-2021	09-02-2022
	С	09-03-2020	08-19-2021	09-03-2022
	DY	09-03-2020	08-19-2021	09-03-2022
	CY	08-28-2020	08-19-2021	08-28-2022
				·

	С					09-02-2020	08-19-2021	09-02-2022
	С					09-03-2020	08-19-2021	09-03-2022
	С					09-03-2020	08-19-2021	09-03-2022
Discu	ission: Lit se	arch ameno	dment ne	eded for				
Action	Items: Move	d protocol t	to next ag	jenda.	 			
	IACUC	: Vote						
	Approval	17						
	Withhold Ap	oproval 0						
	Abstain	0						
	Present	17						

#### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Proto	ocol	Category	Request	Date Approved		
1.#		DY		08-19-2021		
Investiga a. Additiona	The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.					
	IAC	UC Vote				
A	Approva	I 18				
V	Vithhold	Approval 0				
A	bstain	0				
F	Present	18				
2. #		DY		08-19-2021		
Investiga a. Additiona	ator prio . None.	r to the meeti	d and the following points were addressed by the Pi ng: he meeting included:	incipai		
		UC Vote				
	Approva					
		Approval 0				
	Abstain	0				
	Present	18		00 40 2024		
3. # D Y       08-19-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.						



	Present		18			
8. #		D			08-19-2021	
Investi Additic	gator pric a. None.	or to the me	etin	d and the following points were addressed by the P ng: ne meeting included:	rincipal	
	IAC	UC Vote				
	Approva	d ·	18			
	Withhold	d Approval	0			
	Abstain		0			
	Present		18			
9. #		С			08-19-2021	
Investi Additic	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.					
	IAC	UC Vote				
	Approva	d ·	18			
	Withhold	d Approval	0			
	Abstain		0			
	Present		18			

## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-14-2021		
2. 07-19-2021		
3. 07-26-2021		
4. 08-09-2021		
5. 08-09-2021		

Discussion: None.	
Action: None.	
	4-4-
IACUC	
Approval	17
Approval Withhold App	oroval 0
Abstain	0
Present	17

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1.07-14-2021	LAB	
2.07-14-2021	LAB	
3. 07-14-2021	LAB	
4. 07-14-2021	LAB	

5. 07-14-2021	LAB	
6.07-26-2021	LAB	
7.08-03-2021	LAB	
8. 08-11-2021	LAB	
9. 08-12-2021	LAB	
10. 08-18-2021	LAB	
11. 08-18-2021	LAB	
12. 08-09-2021	PAM	
13. 08-16-2021	PAM	

Discussion: None. Action: None.

IACUC Vote	
Approval	18
Withhold Approval	0
Abstain	0
Present	18

## XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

#### XV. Other Discussion Items:

Торіс			
2nd quarter	fluid report		
Discussion:	All compliant.		
Action:	None.		
Animals mov	ved from # to holding protocol.		
Discussion:	None.		
Action:	None.		
Guest			
Discussion:	2nd meeting attended. Can now serve as an alternate member.		
Action:	on: None.		
UC Exemption form and training policy			
Discussion:	on: Recommended modification to broaden to non-UC Davis.; Require UCD ACU101.		
Action:	Action: Changes approved.		

#### XVI. Program Updates:

#### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

#### September 02, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M222, M102, M111, M090, M042, M004, M100, M092, A019, M119, M087, A109, M110, M120, M093, A013, M001, M114

#### Excused:

A095, M016, M024, M223, M112

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
PETA records request to USDA
Action: FYI - Courtesy notification.
Action: PAM, amendment

#### V. Veterinary Care Program Updates:

There are no Attending Veterinarian updates for this agenda.

#### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	D		-
prior to the mee a. Pendir Additional discu	ting: ng Pl.	d the following points were addressed by the Princi e meeting included:	pal Investigator
2. #	С		-

The protocol was prior to the meet		the following points were addressed by the Princip	oal Investigator
a. None.	ing.		
	ssion durina the	meeting included:	
a. Pendin			
3. #			08-25-2021
The protocol was	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			j
		expired OHSS or ACU 101	
		meeting included:	
a. None.			
4. #	CY		-
		the following points were addressed by the Princip	bal Investigator
prior to the meet	ing:		
a. None.		and a first short of the	
Additional discus a. Pendin		meeting included:	
5. #	C		09-01-2021
5. #	5		03-01-2021
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet		are following points were addressed by the rinning	our investigator
a. None.	5		
Additional discus	ssion during the	meeting included:	
a. None.			
6. #	DY		-
		the following points were addressed by the Princip	oal Investigator
prior to the meet			
		anged from CAT imaging to CT scans.	
	safety clearance	e.	
	e change.	meeting included:	
		ection following renovation. Remains in DMR.	
7. #	C		08-26-2021
	-	the fellowing a cinter ways and descend by the Driver	
		the following points were addressed by the Princip	bal Investigator
prior to the meet a. None.	ing:		
	sion during the	meeting included:	
a. None.	solution during the	meeting metudeu.	
8. #	DY		
0. 7			-
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			
a. None.	J		
		meeting included:	
a. Pendin			
9. #	С		09-02-2021
		the following points were addressed by the Princip	oal Investigator
prior to the meet			
	ation of number		
	ssion during the	meeting included:	
a. None.			00.04.0004
10. #	D		08-31-2021

prior to the meet		the following points were addressed by the Princip	al Investigator
a. None. Additional discus a. None.	ssion during the	meeting included:	
11. #	D		08-31-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip	oal Investigator
Additional discus a. None.	ssion during the	meeting included:	
12. #	D		-
prior to the meet a. Update b> Additional discus	ting: ed title. onal Eh&S revie	the following points were addressed by the Princip w. meeting included:	oal Investigator
13. #	С		09-01-2021
prior to the meet a. Clarific	ting: ation of procedu	the following points were addressed by the Princip ures. meeting included:	oal Investigator
14. #	E	the following points were addressed by the Princip	08-23-2021
	sed analgesia a	and animal housing. meeting included:	
15.#	D		09-02-2021
prior to the meet a. Dosag B. Wordir c. Animal	ting: e clarification. ng edits. movement/bios	the following points were addressed by the Princip security meeting included:	oal Investigator
16. #	D		09-02-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
17. #	D		-
prior to the meet a. None.	ting:	the following points were addressed by the Princip	oal Investigator
Additional discus a. None.	ssion during the	meeting included:	
18.#	D		-

The protocol was prior to the meet		the following points were addressed by the Princip	oal Investigator
	ssion during the	meeting included:	
a. None.	6		00.04.0004
19. #	С		09-01-2021
prior to the meet a. Clarific	ing: ation of proced	the following points were addressed by the Princip ures. meeting included:	oal Investigator
20. #	D		09-02-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
21. #	С		-
prior to the meet a. Pendin	ing: g Pl.	the following points were addressed by the Princip meeting included:	oal Investigator
22. #	С		-
prior to the meet a. Clarific Additional discus	ing: ation of number	the following points were addressed by the Princip rs and adverse effects. meeting included: response.	oal Investigator
23. #	С		-
prior to the meet a. Clarific Additional discus	ing: ation of adverse	meeting included:	oal Investigator
24. #	С		09-01-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
a. None.	<b>^</b>		
25. #	С		-
prior to the meet a. Pendin Additional discus	ing: g PI response.	the following points were addressed by the Princip meeting included:	oal Investigator

## VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	DY		-
nvestigator pric a. Pendir Additional discu	or to the meeting		incipal
2. #			08-31-2021
nvestigator pric a. None.	or to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
3. #	DY		08-30-2021
nvestigator pric a. None.	or to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
4. #	С		09-02-2021
nvestigator pric a. None. Additional discu	ssion during the	e meeting included:	
5. #	ng review of res		09-01-2021
5. # The amendmen nvestigator pric a. None.	C t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr	
5. # The amendmen Investigator pric a. None. Additional discu	C t was reviewed or to the meeting ssion during the	and the following points were addressed by the Pr g:	
5. # The amendmen nvestigator pric a. None. Additional discu a. None. 6. # The amendmen nvestigator pric a. Pendir Additional discu	C t was reviewed or to the meeting ssion during the E t was reviewed or to the meeting ng PI response.	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	incipal -
5. # The amendmen nvestigator pric a. None. Additional discu a. None. 6. # The amendmen nvestigator pric a. Pendir Additional discu	C t was reviewed or to the meeting ssion during the E t was reviewed or to the meeting ng PI response. ssion during the	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	incipal - incipal
5. # The amendmen nvestigator pric a. None. Additional discu a. None. 6. # The amendmen nvestigator pric a. Remai 7. # The amendmen nvestigator pric a. Remai 7. # The amendmen nvestigator pric a. None. Additional discu	C t was reviewed or to the meeting assion during the E t was reviewed or to the meeting PI response. Ission during the ins in DMR. D Y t was reviewed or to the meeting t was reviewed or to the meeting	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included:	incipal - incipal 08-30-2021
5. # The amendmen nvestigator pric a. None. Additional discu a. None. 6. # The amendmen nvestigator pric a. Remai 7. # The amendmen nvestigator pric a. Remai 7. # The amendmen nvestigator pric a. None. Additional discu	C t was reviewed or to the meeting assion during the E t was reviewed or to the meeting PI response. Ission during the ins in DMR. D Y t was reviewed or to the meeting t was reviewed or to the meeting	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g:	incipal - incipal 08-30-2021
5. # The amendmen nvestigator pric a. None. Additional discu a. None. 6. # The amendmen nvestigator pric a. Pendir Additional discu a. Remai 7. # The amendmen nvestigator pric a. None. Additional discu a. Amend 8. # The amendmen nvestigator pric a. Pendir Additional discu a. Pendir Additional discu	C t was reviewed or to the meeting assion during the E t was reviewed or to the meeting ng PI response. Ission during the ins in DMR. D Y t was reviewed or to the meeting ssion during the dment wording D Y t was reviewed or to the meeting assion during the dment wording D Y	and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: and the following points were addressed by the Pr g: e meeting included: updated per AV. and the following points were addressed by the Pr	incipal - incipal 08-30-2021 incipal -


Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
10. #	С		-
Investigator prior a. Pendin Additional discus a. Remain	r to the meeting g PI response. ssion during the ns in DMR.	and the following points were addressed by the Pr : e meeting included:	incipal
11. #	DY		09-02-2021
Investigator prior a. Freque b. Method	r to the meeting ency of weighing ds to control spi	g.	incipai
12. #	D		09-01-2021
Investigator prior a. Discus Additional discus a. None.	r to the meeting sed dose-findin ssion during the	and the following points were addressed by the Pr g and biosafety. e meeting included:	
13. #	D		08-26-2021
Investigator prior a. Specifi	r to the meeting ed breeding line	and the following points were addressed by the Pr es and disposition. e meeting included:	incipal
14. #	C		09-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
15. #	D		09-02-2021
Investigator prior a. Clarify b. Include c. PLX33 Additional discus	r to the meeting who will be han VHSS. 97 dosing.	and the following points were addressed by the Pr p ndling the PLX3397 chow. e meeting included:	incipal
16.#	D		09-02-2021
Investigator prior a. Clarify b. Include c. PLX33 Additional discus	r to the meeting who will be han VHSS. 97 dosing.	and the following points were addressed by the Pr i adling the PLX3397 chow. e meeting included:	incipal


## VIII. Administrative and Veterinary Verification Amendments:

Total of **178** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





## X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		9-04-2019	09-02-2021	09-04-2022
	D		9-17-2019	09-02-2021	09-17-2022
	С		9-12-2019	09-02-2021	09-12-2022

С	9-05-2019	09-02-2021	09-05-2022
С	9-05-2019	09-02-2021	09-05-2022
С	9-06-2019	09-02-2021	09-06-2022
Y	9-05-2019	09-02-2021	09-05-2022
С	9-05-2019	09-02-2021	09-05-2022
С	9-05-2019	09-02-2021	09-05-2022
D	9-04-2019	09-02-2021	09-04-2022
С	9-16-2019	09-02-2021	09-16-2022
С	9-17-2019	09-02-2021	09-17-2022
СҮ	9-04-2019	09-02-2021	09-04-2022
D	9-05-2019	09-02-2021	09-05-2022
С	9-17-2019	09-02-2021	01-18-2022
С	9-12-2019	09-02-2021	09-12-2022
CY	9-17-2020	09-02-2021	09-17-2022
Y	9-04-2020	09-02-2021	09-04-2022
DY	9-03-2020	09-02-2021	09-03-2022
С	9-17-2020	09-02-2021	09-17-2022
D		09-02-2021	
DY		09-02-2021	
С		09-02-2021	
CY		09-02-2021	
С	9-16-2020	09-02-2021	09-16-2022
С	9-16-2020	09-02-2021	09-16-2022
С	9-17-2020	09-02-2021	09-17-2022
С	9-15-2020	09-02-2021	09-15-2022


E	09-17-2020	09-02-2021	09-17-2022
D	09-17-2020	09-02-2021	09-17-2022
D	09-11-2020	09-02-2021	09-11-2022
DY	09-17-2020	09-02-2021	09-17-2022
D	09-17-2020	09-02-2021	09-17-2022
С	09-17-2020	09-02-2021	09-17-2022

Discu	ssion: None.	
Action	Items: None.	
		/ote
	Approval	20
	Withhold App	roval 0
	Abstain	0
	Present	20

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	tocol	Category	Request	Date Approved
1. #		DY		09-02-2021
Investi Additio	gator pric a. None. onal discu a. None. IAC Approva	or to the meetin ssion during th : <b>UC Vote</b>	and the following points were addressed by the Pi g: e meeting included:	rincipal
	Present	20		
2. #		D		09-03-2021
Investi Additio	gator pric a. None.	or to the meetin	and the following points were addressed by the Pi g: ne meeting included:	rincipal
	IAC	UC Vote		
	Approva	ıl 20		
	Withhold	d Approval 0		
	Abstain	0		
	Present	20		



The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. PI and veterinary staff interpret path results differently. Recommend phone consultation with AV. b. Approved for DMR. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 19

#### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1. 04-22-2021		
2. 08-20-2021		
3. 08-23-2021		
4. 08-25-2021		

Discussion: General update on inspection logistics and options with consideration of current COVID restrictions and precautions.

Action: None.

IACUC Vote	
Approval	17
Withhold Approval	0
Abstain	0
Present	17

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 07-30-2021	LAB	
2.07-30-2021	LAB	
3. 08-23-2021	LAB	
4. 08-25-2021	LAB	
5. 08-25-2021	LAB	
6. 08-25-2021	LAB	
7. 08-26-2021	LAB	
8. 08-26-2021	LAB	
9. 08-26-2021	LAB	
10. 09-01-2021	LAB	
11. 07-23-2021	PAM	
12. 08-23-2021	PAM	

Discussion:	None.
Action:	None.

IACUC Vote	
Approval 1	19
Withhold Approval	0
Abstain	0
Present 1	19

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

There are no other discussion topics for this agenda.

## XVI. Program Updates:

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### September 16, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M097, M102, M111, M090, M042, A095, M004, M100, M092, A019, M119, M087, A109, M110, M093, A013, M016, M024, M001, M112, M114

#### Excused:

M009, M222, M223

#### **Guests:**

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

1.#			Category: E
he p	protocol was revie	ewed and	d the following points were addressed by the Principal Investigator prior to the
neeti	•		
	•		review of PI response.
dditi	a. Voted to DM	•	ne meeting included:
	IACUC Vo	ote	
	Approval	20	
	Withhold Appr	oval 0	
	Abstain	0	
	Present	20	
. #			Category: E
	vrotocol was revi	ewed an	d the following points were addressed by the Principal Investigator prior to the
ieeti			a the following points were addressed by the rinneipar investigator phorite the
	a. Pending PI r	response	e to questions.
	•	•	ne meeting included:
dditi		d and dia	cussed pain management and procedures in more detail. Voted to DMR.
dditi	a. PI presentec	and dis	bussed pair management and procedures in more detail. Voted to Dimit.
dditi	a. PI presented		
dditi			
dditi	IACUC Vo	ote 21	
dditi	IACUC Vo Approval	ote 21	

## **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

<b>(Y)</b>	
	Action: Net capture and section 15 recommendation.
Í	
	Action: Potential actions going forward; provide consult feedback; suspend additional work under current proposal

## V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:
None at this time.

## VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	DY		-
prior to the meet a. IACUC Additional discus	ing: staff will work ssion during the	the following points were addressed by the Princip with PI on modifications and editing. e meeting included: with PI on modifications and editing.	pal Investigator
2. #	D		-
prior to the meet a. Pendin Additional discus	ing: g PI response.	the following points were addressed by the Princip e meeting included:	pal Investigator
3. #	С		-
prior to the meet a. Pendin Additional discus	ing: g PI responses	the following points were addressed by the Princips. e meeting included:	pai investigator
4. #	С		09-09-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip e meeting included: me	pal Investigator
5. #	CY		09-09-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip e meeting included:	pal Investigator
6. <b>#</b>	DY		-

		the following points were addressed by the Princip	oal Investigator
prior to the meet a. None.	ing:		
	ssion during the	meeting included:	
	ig location renov ns in DMR.	vation.	
7. #	DY		-
The protocol was	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:		J. J
	g PI's response		
	ssion during the ns in DMR.	e meeting included:	
8. #	D		09-14-2021
The protocol was	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet	ting:	31	J
	ion to title.		
Additional discus	ssion during the	e meeting included:	
9. #	D		09-07-2021
J			00-07-2021
		the following points were addressed by the Princip	oal Investigator
prior to the meet		med BUA has been approved.	
		meeting included:	
a. None.		mooning molaced.	
10. #	D		09-07-2021
<b>T</b> he survey of the second	 	the fellowing and the the Driver	al lassa di natan
prior to the meet		the following points were addressed by the Princip	bal Investigator
		med BUA has been approved.	
		meeting included:	
a. None.			
11.#	D		09-16-2021
The protocol was prior to the meet		the following points were addressed by the Princip	oal Investigator
a. None.			
Additional discus a. None.	ssion during the	meeting included:	
12. #	С		09-13-2021
The protocol was	s reviewed and	the following points were addressed by the Princip	pal Investigator
prior to the meet			gan an a
	ation of proced		
Additional discus a. None.	ssion during the	e meeting included:	
13.#	D		09-09-2021
The protocol was			al Investigator
prior to the meet	s reviewed and	the following points were addressed by the Princi	
	ting:	the following points were addressed by the Princip	Jai Investigator
	ting: ation on proced	lures.	
Additional discus	ting: ation on proced		
Additional discus a. None.	ting: ation on proced ssion during the	lures.	
Additional discus	ting: ation on proced	lures.	09-07-2021
Additional discus a. None.	ting: ation on proced ssion during the	lures.	

Obtained by Rise for Animals. Uploaded to Animal Research Laboratory Overview (ARLO) on 02/06/2023

The protocol was prior to the meet		the following points were addressed by the Princip	oal Investigator
a. None.	ung.		
	ssion during the	meeting included:	
a. None.	-	-	
15. #	С		09-07-2021
The protocol wa		the following points were addressed by the Drineir	
prior to the meet		the following points were addressed by the Princip	bal investigator
a. None.	ung.		
	ssion during the	meeting included:	
a. None.	selen dannig die		
16.#	D		09-09-2021
	_		
The protocol was	s reviewed and	the following points were addressed by the Princip	bal Investigator
prior to the meet			
a. clarifica	ation of retinogr	aphy timing.	
		ocedure housing	
	ation of training		
	ssion during the	meeting included:	
a. None.			
17.#	С		-
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet			
a. Pendin			
		meeting included:	
	ns in DMR.	-	
18. #	С		-
The protocol way	s reviewed and	the following points were addressed by the Princip	pal Investigator
prior to the meet			an investigator
a. None.	:	was atime in all all all	
		e meeting included:	
	ig reviewer.		00.07.0004
19. #	CY		09-07-2021
The unstand	 	the falles in a sinte scare addressed by the Drinei	
		the following points were addressed by the Princip	bal investigator
prior to the meet a. None.	ung.		
	ssion during the	meeting included:	
a. None.	colori dalling die		
20. #	DY		-
20. //			
The protocol wa	c reviewed and	the following points were addressed by the Princip	
prior to the meet		the following points were addressed by the Frincip	ai investigator
a. None.	ung.		
	ssion durina the	meeting included:	
	methods and d		
21. #	С		09-16-2021
	· · ·	the following points were addressed by the Princip	
prior to the meet		and renowing points were addressed by the Fillibly	annosugator
	ed collection tim	es.	
		meeting included:	
a. None.	-	-	

22. #	С		-
prior to the meet a. Clarifie	ting: ed housing and f	the following points were addressed by the Princip feed. meeting included:	oal Investigator
23. #	С		09-16-2021
prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
24. #	С		-
prior to the meet a. Review	ting: ved facility SOP	the following points were addressed by the Princip s. meeting included:	oal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	DY		09-07-2021
nvestigator prio a. PI pro\	r to the meetin vided clarification	and the following points were addressed by the Pr g: on regarding monitoring of animals and feeding. e meeting included:	rincipal
2. #	DY		09-13-2021
nvestigator prio a. None. Additional discus a. None.		g: e meeting included:	
3. #	С		09-02-2021
nvestigator prio a. None. Additional discu	r to the meetin ssion during th	and the following points were addressed by the Pr g: e meeting included: d add other supportive methods	
4. #	D		09-16-2021
nvestigator prio a. None.	r to the meetin	and the following points were addressed by the Pr g: e meeting included:	incipal
5. #	D		09-13-2021
nvestigator prio a. None.	r to the meetin	and the following points were addressed by the Pr g: e meeting included:	incipal
			Obta

6.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         7.#       DY       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending BIO.         Additional discussion during the meeting included:       a. Remains in DMR.         8.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         9.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         9.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       -         a. None.       -       -         10.#       C       -         Additional discussion during the meeting included:       -         a. None.       -       -         11.#       E       09-16-2021	a. None.				
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None. Additional discussion during the meeting included: a. None. 7. # D Y 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Remains in DMR. 8. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 9. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 9. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified injection volume. Additional discussion during the meeting included: a. None. 10. # C 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified injection volume. Additional discussion during the meeting included: a. None. 11. # C 009-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. 12. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer. 11. # C 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI. Additional discussion during the meeting included: a. Remains in DMR. 12. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes and procedures. Additional discussion during the meeting included: a. None. 13. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes and procedures. Additional discussion	6. #	D		09-16-2021	
a. None.       0.9-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Pending BIO.</li> <li>Additional discussion during the meeting included:</li> <li>a. Remains in DMR.</li> </ul> 09-16-2021           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul></ul>	Investigator prio	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Rending BIO.         Additional discussion during the meeting included:       a. Remains in DMR.         8.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.         9.#       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         10. #       C       -         10. #       C       -         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending Reviewer.         11. #       D       09-16-202		ssion during the	e meeting included:		
Investigator prior to the meeting:  a. Pending BIO. Additional discussion during the meeting included: a. Remains in DMR.  8. # 0 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.  9. # 0 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified injection volume. Additional discussion during the meeting included: a. None.  10. # C The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified injection volume. Additional discussion during the meeting included: a. None.  10. # C The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.  11. # E 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.  11. # E 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending Reviewer.  11. # E 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PL. Additional discussion during the meeting included: a. Remains in DMR.  12. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes and procedures. Additional discussion during the meeting included: a. None.  13. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes and procedures. Additional discussion during the meeting included: a. None.  13. # D 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes. Additi	7.#	DY		09-16-2021	
a. Pending BIO.         Additional discussion during the meeting included:       a. Remains in DMR.         8. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         9. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified injection volume.         Additional discussion during the meeting included:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         11. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.				incipal	
Additional discussion during the meeting included:       a. Remains in DMR.         8. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         9. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified injection volume.         Additional discussion during the meeting included:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         4dditional discussion during the meeting included:       a. Pending Reviewer.       -         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.         a. Remains in DMR.       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <t< td=""><td></td><td></td><td>i.</td><td></td></t<>			i.		
a. Remains in DMR.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:			meeting included:		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         9. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified injection volume.         Additional discussion during the meeting included:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.       -         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         <	a. Remai				
Investigator prior to the meeting:          a. None.       Additional discussion during the meeting included:         a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarified injection volume.</li> <li>Additional discussion during the meeting included:</li> <li>a. None.</li> </ul> 09-16-2021           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>10.#</li> <li>C</li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:             <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li> <li>a. Pending Reviewer.</li> <li>11.#</li> <li>E</li> <li>09-16-2021</li> </ul> </li> </ul> <li>Additional discussion during the meeting included:         <ul> <li>a. Pending PI.</li> </ul> </li> <li>Additional discussion during the meeting included:</li>		· -			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified injection volume.         Additional discussion during the meeting included:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending Pl.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clar	Investigator prio a. None. Additional discus	r to the meeting	Г	incipal	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarified injection volume.         Additional discussion during the meeting included:       a. None.         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending Pl.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clar	9. #	D		09-16-2021	
Investigator prior to the meeting:		t was reviewed a	and the following points were addressed by the Pr	I	
Additional discussion during the meeting included:       a. None.         10. #       C         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. Clarific	Investigator prio	r to the meeting	r		
a. None.       C       -         10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li></ul>					
10. #       C       -         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. Clarification on changes.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additiona		ssion during the	meeting included:		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending Pl.         Additional discussion during the meeting included:       a. Pending Pl.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.		<b>C</b>			
Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Pending Reviewer.         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.			and the following points were addressed by the Pr	- incipal	
a. None.         Additional discussion during the meeting included:         a. Pending Reviewer.         11. #       E         11. #       D         11. #       D         12. #       D         12. #       D         13. #       D         13. #       D         13. #       D         14. *       O         15. *       D         16. *       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal         Investigator prior to the meeting:       09-16-2021         The amendment was reviewed and the following points were addressed by t				incipai	
a. Pending Reviewer.       09-16-2021         11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Pending PI.</li> <li>Additional discussion during the meeting included:</li></ul>		5			
11. #       E       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting:       a. Clarification on changes.       Additional discussion during the meeting included:         a. None.       E       E       E       E         B. Additional discussion during the meeting included:       a. None.       E			meeting included:		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       a. None.         Additional discussion during the meeting included:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.         a. None.       a. None.				00.40.0004	
Investigator prior to the meeting:       a. Pending PI.         Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.         Additional discussion during the meeting included:       a. None.					
a. Pending PI.         Additional discussion during the meeting included:         a. Remains in DMR.         12. #       D         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-16-2021         Additional discussion during the meeting included:       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-16-2021         Additional discussion during the meeting included:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.				incipal	
Additional discussion during the meeting included:       a. Remains in DMR.         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.			i.		
a. Remains in DMR.       09-16-2021         12. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarification on changes and procedures.</li> <li>Additional discussion during the meeting included:</li></ul>			meeting included:		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes and procedures.         Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.					
Investigator prior to the meeting: a. Clarification on changes and procedures. Additional discussion during the meeting included: a. None. <b>13. # D</b> 09-16-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes. Additional discussion during the meeting included: a. None.	12. #	D		09- <mark>1</mark> 6-2021	
a. Clarification on changes and procedures.         Additional discussion during the meeting included:         a. None.         13. #       D         O9-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. Clarification on changes.         Additional discussion during the meeting included:         a. None.	The amendment	t was reviewed	and the following points were addressed by the Pr	incipal	
Additional discussion during the meeting included:       a. None.         13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. Clarification on changes.         Additional discussion during the meeting included:       a. None.					
a. None.       09-16-2021         13. #       D         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. Clarification on changes.</li> <li>Additional discussion during the meeting included:                  <ul></ul></li></ul>			•		
13. #       D       09-16-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-16-2021         a. Clarification on changes.       Additional discussion during the meeting included:       09-16-2021		ssion during the	meeting included.		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on changes. Additional discussion during the meeting included: a. None.		D		09-16-2021	
Investigator prior to the meeting: a. Clarification on changes. Additional discussion during the meeting included: a. None.		-			
Investigator prior to the meeting: a. Clarification on changes. Additional discussion during the meeting included: a. None.	The amendment	t was reviewed	and the following points were addressed by the Pr	incipal	
Additional discussion during the meeting included: a. None.	Investigator prio	r to the meeting	r	-	
a. None.					
		ssion during the	meeting included:		
	14. #	DY		-	

		and the following points were addressed by the Pr	incipal
Investigator prior a. Pendin		j:	
Additional discus		e meeting included:	
15. #	D		09-13-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	μ	-
a. None.		<i></i>	
	ssion during the	e meeting included:	
a. None.	DY		00.40.0004
16. #	DY	and the fellowine mainternance addressed by the D	09-16-2021
Investigator prior		and the following points were addressed by the Pr	incipal
		nt and monitoring.	
		e meeting included:	
a. None.			
17. #	D		09-03-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
	al of TRDRP n		
	ssion during the	e meeting included:	
a. None.	-		
18. #	С		09-08-2021
The emendment		and the following points were addressed by the Pr	inginal
Investigator prior			incipal
		, ent and procedure.	
		meeting included:	
a. None.	C C	C C	
19. #	E		09-13-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	μ.	-
a. None.			
	ssion during the	e meeting included:	
a. None.			00.40.0004
20.#	D		09-16-2021
The emendment	was reviewed	and the following points were addressed by the Pr	incinal
Investigator prior			incipal
a. None.	r to the meeting		
	ssion during the	e meeting included:	
a. None.	Ŭ	5	
21. #	D		09-08-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
a. None.			
	ssion during the	e meeting included:	
a. None.			
22. #	DY		-
The amendment	was reviewed	and the following points were addressed by the Pr	incinal
Investigator prior			nopa
		, owing AV consultation.	
Additional discus	ssion during the	e meeting included:	
	g revisions follo	owing AV consultation.	
23. #	DY		-

		and the following points were addressed by the Pri	incipal
Investigator prio			Vatariaarian
		nt to PI following phone consultation with Attending e meeting included:	y veterinarian.
		owing AV consultation.	
24. #	C		09-13-2021
			00 10 2021
		and the following points were addressed by the Pri	incipal
Investigator prior a. None.	r to the meeting	li -	
	ssion during the	e meeting included:	
a. None.			
25. #	С		-
		and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	l:	
a. None.			
		e meeting included:	
		to Biosafety reviewer's question.	00.44.0004
26. #	С		09-14-2021
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal
Investigator prio			in to pai
a. None.			
Additional discus	ssion during the	e meeting included:	
a. None.			
27. #	D		09-03-2021
		and the following points were addressed by the Pri	incipal
Investigator prio			
		nalysis of animal numbers.	
	ssion during the	e meeting included:	
a. None.	•		00.40.0004
28. #	СҮ		09-16-2021
The amendment	was reviewed	and the following points were addressed by the Pri	incipal
Investigator prior			
a. None.	_		
	ssion during the	e meeting included:	
a. None.			
29. #	E		09-14-2021
		and the following points were addressed by the Pri	incipal
Investigator prior	r to the meeting	i:	
a. None.	noion during the	macting included:	
a. None.	ssion during the	e meeting included:	
a. None.			


## VIII. Administrative and Veterinary Verification Amendments:

Total of **128** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved	



5. #		D			09-20-2021
prior to	otocol wa the mee a. None.	ting:	lano	d the following points were addressed by the Princi	pal Investigator
Additio	nal discu	ission durin		e meeting included: clearance, voted for DMR	
		CUC Vote			
	Approva	al	0		
	Withhold	d Approval	0		
	Abstain		0		
	Present		21		
6. #		D			09-16-2021
			and	d the following points were addressed by the Princi	pal Investigator
	the mee a. None.				
			ig th	e meeting included:	
	a. None.				
		CUC Vote			
	Approva		21		
		d Approval			
	Abstain		0		
	Present		21		
7.#		D			09-30-2021
			and	d the following points were addressed by the Princi	pal Investigator
	the mee		stion	ns regarding euthanasia, housing, and pain evalua	tion
				e meeting included:	
		ng PI respo	nse		
		CUC Vote			
	Approva		0		
		d Approval	0		
	Abstain		0		
	Present		22		

## X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		9-18-2019	09-16-2021	09-18-2022
	С		9-19-2019	09-16-2021	09-23-2021
	D		9-20-2019	09-16-2021	09-20-2022
	СҮ		9-19-2019	09-16-2021	09-19-2022
	DY		9-05-2019	09-16-2021	09-05-2022
	D		9-19-2019	09-16-2021	09-19-2022

. =			
D	09-23-2019	09-16-2021	09-23-2022
D	09-20-2019	09-16-2021	09-20-2022
D	09-19-2019	09-16-2021	09-19-2022
D	09-05-2019	09-16-2021	09-05-2022
DY	09-19-2019	09-16-2021	09-19-2022
DY	09-19-2019	09-16-2021	09-19-2022
	00.00.0010	00.40.0004	00.00.0000
D		09-16-2021	
С	09-11-2019	09-16-2021	09-11-2022
E	09-19-2019	09-16-2021	09-19-2022
DY	09-20-2019	09-16-2021	09-20-2022
D	09-19-2019	09-16-2021	09-19-2022
С	09-19-2019	09-16-2021	09-19-2022
	09-18-2019	09-16-2021	09-18-2022
С	09-19-2019	09-16-2021	09-19-2022
D	10-01-2020	09-16-2021	10-01-2022
D		09-16-2021	
D	10-01-2020	09-16-2021	10-01-2022
С	09-30-2020	09-16-2021	09-30-2022
С	10-01-2020	09-16-2021	10-01-2022
E	09-17-2020	09-16-2021	09-17-2022
DY	09-17-2020	09-16-2021	09-17-2022
С	09-30-2020	09-16-2021	09-30-2022
С	09-25-2020	09-16-2021	09-25-2022
D	09-29-2020	09-16-2021	09-29-2022
D	10-01-2020	09-16-2021	10-01-2022
С	09-29-2020	09-16-2021	09-29-2022
С	10-01-2020	09-16-2021	10-01-2022
		Obtaina	d by Rise for A

C C	09-17-202	0 09-16-2021	09-17-2022
С			
	10-01-202	0 09-16-2021	10-01-2022
С	09-29-202	0 09-16-2021	09-29-2022
С	10-01-202	0 09-16-2021	10-01-2022
С	09-24-202	0 09-16-2021	09-24-2022
D	09-17-202	0 09-16-2021	09-17-2022
С	09-30-202	0 09-16-2021	09-30-2022
D	09-28-202	0 09-16-2021	09-28-2022
С	09-25-202	0 09-16-2021	09-25-2022
С	09-24-202	0 09-16-2021	09-24-2022
С	09-24-202	0 09-16-2021	09-24-2022
С	10-01-202	0 09-16-2021	10-01-2022
С	10-01-202	0 09-16-2021	10-01-2022
D	10-01-202	0 09-16-2021	10-01-2022

Discussion:	the OHSS renewal process.
	PI provided IACUC staff with updated literature search in
	reference to recently approved amendment. IACUC staff working with PI to clarify terminal procedure and/or
	euthanasia technique.
Action Items:	with annual renewals.
	-Committee approved staff adding the updated literature search to
	the original protocol. Committee approved IACUC staff to update the original protocol.
L	ACUC Vote
Appro	oval 19
Withh	old Approval 0
Absta	in 0
	ent 19

## XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date	
FICIOCOI	Category	Request	Approved	

1. #	D		10-13-2021
		d and the following points were addresse	ed by the Principal
vestigator prio			
	nce of previous		
		a for removal form study.euthanasia. ne meeting included:	
		that PI follow up with CVS on clarificatio	n of criteria for removal from
study/eut			
IAC	UC Vote		
Approva	0		
	Approval 0		
Abstain	0		
Present	21		
2. #	D		09-16-2021
		d and the following points were addresse	ed by the Principal
vestigator prio			mandations from IAOLIC to
		omitted in response to a PAM and recom clear and consistent.	mendations from IACUC to
		ne meeting included:	
	itted voted to		
IAC	UC Vote		
Approva	I 21		
	Approval 0		
Abstain	0		
Abstain	0		
Dresent	04		
Present	21		
Present	21 D		09-16-2021
3. #	D	d and the following points were addresse	
3. #	D t was reviewed r to the meetir	ng:	
3. # ne amendment vestigator prio a. incider	<b>D</b> t was reviewed r to the meetin the of previous	ng: s occurrence.	
3. # ne amendmen vestigator prio a. incider b. clarific	D t was reviewed r to the meetin nce of previous ation of criteria	ng: s occurrence. a for removal form study.euthanasia.	
3. # ne amendmen vestigator prio a. incider b. clarific dditional discus	D t was reviewed r to the meetin nce of previous ation of criteria ssion during th	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # ne amendmen vestigator prio a. incider b. clarific dditional discus	D t was reviewed r to the meetin nce of previous ation of criteria ssion during th ver requested	ng: s occurrence. a for removal form study.euthanasia.	ed by the Principal
3. # ne amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut	D t was reviewed r to the meetin nce of previous ation of criteria ssion during th ver requested	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # ne amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC	D t was reviewed r to the meetin nce of previous ation of criteria ssion during th ver requested hanasia. UC Vote	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # he amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # ne amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withhold	D t was reviewed r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote I 21 Approval 0	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote I 21 Approval 0 0	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # ne amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withhold	D t was reviewed r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote I 21 Approval 0	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # he amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote I 21 Approval 0 0	ng: s occurrence. a for removal form study.euthanasia. ne meeting included:	ed by the Principal
3. # ne amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. #	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote I 21 Approval 0 0 21 D t was reviewer	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio	ed by the Principal n of criteria for removal from 09-16-2021
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # the amendment vestigator prio	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # a amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # ne amendment vestigator prio a. Ameno	D t was reviewed r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewed r to the meetin ment was sub	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addresseng: pomitted in response to a PAM and recom	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # a amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # ne amendment vestigator prio a. Ameno ensure prio	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent.	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # a amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withhold Abstain Present 4. # vestigator prio a. Amend ensure prioditional discus	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present te amendment vestigator prio a. Ameno ensure prio a. Comm	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # the amendment vestigator prio a. Ameno ensure prioditional discus a. Comm	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to UC Vote	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withhold Abstain Present 4. # the amendment vestigator prio a. Amend ensure prioditional discus a. Comm IAC	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to UC Vote 1 21	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # The amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # The amendment vestigator prio a. Ameno ensure prioditional discus a. Comm IAC Approva	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to UC Vote 1 21 Approval 0	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # the amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withhold Abstain Present 4. # the amendment vestigator prio a. Amend ensure prio a. Comm IAC Approva	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to UC Vote 1 21 Approval 0 0 21	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal
3. # The amendment vestigator prio a. incider b. clarific dditional discus a. Review study/eut IAC Approva Withholo Abstain Present 4. # The amendment vestigator prio a. Ameno ensure prioditional discus a. Comm IAC Approva	D t was reviewer r to the meetin ace of previous ation of criteria ssion during th ver requested hanasia. UC Vote 1 21 Approval 0 0 21 D t was reviewer r to the meetin ment was sub rotocols were ssion during th ittee voted to UC Vote 1 21 Approval 0	ng: s occurrence. a for removal form study.euthanasia. he meeting included: that PI follow up with CVS on clarificatio d and the following points were addressen ng: pomitted in response to a PAM and recom clear and consistent. he meeting included:	ed by the Principal n of criteria for removal from 09-16-2021 ed by the Principal

a. Reviewer requested that PI foliow up with CVS on clarification of criteria for removal from study/euthanasia.           IACUC Vote           Approval         0           Withhold Approval         0           Abstain         0           Present         21           6. #         C         10-13-2021           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. incidence of previous occurrence.           b. clarification of criteria for removal from study/euthanasia.         Additional discussion during the meeting included:           a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.         IACUC Vote           Approval         0         Withhold Approval         0           Withhold Approval         0         Withhold Approval         0           Vithhold Approval         0         Withhold Approval         0           Present         21         21         0         09-23-2021           7. #         D         09-23-2021         0           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. None.
b. clarification of criteria for removal form study.euthanasia. Additional discussion during the meeting included: a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 6. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. incidence of previous occurrence. b. clarification of criteria for removal from study/euthanasia. Additional discussion during the meeting included: a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. IACUC Vote Approval 0 Withhold Approval 0 Withhold Approval 0 Present 21 7. # D 09-23-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Withold Approval 0 Withhold Approval 0 Wit
a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.          IACUC Vote       Approval       0         Withhold Approval       0       Abstain       0         Present       21       10-13-2021         6. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.       Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.       Investigator prior to the meeting:         a. Netweer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.       Investigator prior to the meeting included:         a. Reviewer and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Withhold Approval       0         Withhold Approval       0         Abstain       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the foll
study/euthanasia.       IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         6.#       C         10-13-2021         The amendment was reviewed and the following points were addressed by the Principal         Investigator prior to the meeting:         a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.         Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.         IACUC Vote         Approval       0         Withhold Approval       0         Present       21         7.#       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Abstain       0       0 </td
IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         6. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.       Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.       IACUC Vote         Approval       0       Withhold Approval       0         Withhold Approval       0       O9-23-2021       09-23-2021         7. #       D       09-23-2021       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.       IACUC Vote         Approval       0       Withhold Approval       0         Additional discussion during the meeting included:       a. Request edit to remove personal names.       IACUC Vote         Approval       0       O       O       Investigaton       Investigaton      <
Approval       0         Withhold Approval       0         Abstain       0         Present       21         6.#       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.       Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.       IACUC Vote         Approval       0         Withhold Approval       0         Withhold Approval       0         Present       21         7.#       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Approval       0       Vithhold Approval       0         Abstain       0       0      <
Withhold Approval 0         Abstain       0         Present       21         6.#       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. incidence of previous occurrence.</li> <li>b. clarification of criteria for removal from study/euthanasia.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</li> </ul> IACUC Vote         Approval         0           Abstain         0         Present         21           7.#         D         09-23-2021         09-23-2021           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote</li> <li>Approval</li> <li>Quitable to remove personal names.&lt;</li></ul>
Abstain       0         Present       21         6.#       C         10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. incidence of previous occurrence.</li> <li>b. clarification of criteria for removal from study/euthanasia.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</li> </ul> IACUC Vote Approval       0         Withhold Approval       0         Abstain       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote Approval</li> <li>Q</li> <li>Withhold Approval</li> <li>Q</li> <li>Abstain</li> <li>Q</li> <li>Present</li> <li>21</li> </ul> 8.#       C       10-13-2021<
Present       21         6.#       C         10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.         Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.         IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.       09-23-2021         Additional discussion during the meeting included:       a. Request edit to remove personal names.       IACUC Vote         Approval       0       0       Withhold Approval       0         Withhold Approval       0       Abstain       0       0         Present       21       21       10-13-2021         8. #       C
6. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. incidence of previous occurrence.</li> <li>b. clarification of criteria for removal from study/euthanasia.</li> </ul> Additional discussion during the meeting included: <ul> <li>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</li> </ul> IACUC Vote         Approval           Approval         0           Withhold Approval         0           Present         21           7. #         D         09-23-2021           The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:</li> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote</li> <li>Approval</li> <li>Q</li> <li>Withhold Approval</li> <li>Q</li> <li>Withhold Approval</li> <li>Q</li> <li>Withhold Approval</li> <li>Q</li> <li>Withhold Approval</li> <li>Q</li> </ul> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote</li> <li>Approval</li> <li>Q</li> <li>Present</li> <li>21</li> <li>8. # C</li> <li>C</li> <li>IO-13-2021</li> <li>The amendment was reviewed and</li>
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. incidence of previous occurrence.         b. clarification of criteria for removal from study/euthanasia.       Additional discussion during the meeting included:         a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.       IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.       Investigator prior to the meeting:         a. None.       Additional discussion during the meeting included:       a. Request edit to remove personal names.       Investigator prior to the meeting included:         a. Request edit to remove personal names.       IACUC Vote       Approval       0         Abstain       0       Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
Investigator prior to the meeting: <ul> <li>a. incidence of previous occurrence.</li> <li>b. clarification of criteria for removal from study/euthanasia.</li> </ul> <li>Additional discussion during the meeting included: <ul> <li>a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.</li> </ul> </li> <li>IACUC Vote <ul> <li>Approval</li> <li>Withhold Approval</li> <li>Present</li> <li>21</li> </ul> </li> <li>The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting included: <ul> <li>a. Request edit to remove personal names.</li> </ul> </li> <li>IACUC Vote <ul> <li>Approval</li> <li>Withhold Approval</li> <li>Present</li> <li>21</li> </ul> </li> <li>The amendment was reviewed and mathematication of criteria for removal from study/euthanasia.</li> <li>IACUC Vote <ul> <li>Additional discussion during the meeting included:</li> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote <ul> <li>Approval</li> <li>Withhold Approval</li> <li>Withhold Approval</li> <li>Withhold Approval</li> <li>Approval</li> <li>Withhold Approval</li> <li>Withhold Approval</li> <li>Withhold Approval</li> <li>Abstain</li> <li>Present</li> <li>21</li> </ul> </li> <li>8. # C</li> <li>Investigator prior was reviewed and the following points were addressed by the Principal</li> </ul></li>
b. clarification of criteria for removal from study/euthanasia. Additional discussion during the meeting included: a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 7. # D 09-23-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal The amendment was reviewed and the following points were addressed by the Principal B. # C 10-13-2021
Additional discussion during the meeting included: a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 7. # D 09-23-2021 The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal 10-13-2021
a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from study/euthanasia.          IACUC Vote         Approval       0         Withhold Approval       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval         Approval       0         Withhold Approval       0         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Withhold Approval       0         Withhold Approval       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
study/euthanasia.         IACUC Vote         Approval       0         Withhold Approval       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       0         a. None.       Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Withhold Approval       0       Withhold Approval         Abstain       0       Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal       10-13-2021
Approval       0         Withhold Approval       0         Abstain       0         Present       21         7. #       D         Image: Description of the meeting:       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       09-23-2021         Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval       0         Withhold Approval       0         Withhold Approval       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
Withhold Approval 0         Abstain       0         Present       21         7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:             <ul></ul></li></ul>
Abstain       0         Present       21         7. #       D         D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: <ul> <li>a. None.</li> <li>Additional discussion during the meeting included:                 <ul> <li>a. Request edit to remove personal names.</li> <li>IACUC Vote</li> <li>Approval</li> <li>0</li> <li>Present</li> <li>21</li> </ul> </li> <li>8. #</li> <li>C</li> <li>10-13-2021</li> </ul>
Present       21         7. #       D         09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. None.         Additional discussion during the meeting included:         a. Request edit to remove personal names.         IACUC Vote         Approval       0         Withhold Approval       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
7. #       D       09-23-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:       a. None.         Additional discussion during the meeting included:       a. Request edit to remove personal names.         IACUC Vote       Approval         Approval       0         Withhold Approval       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. None.         Additional discussion during the meeting included:         a. Request edit to remove personal names.         IACUC Vote         Approval       0         Withhold Approval       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal
Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal
a. None. Additional discussion during the meeting included: a. Request edit to remove personal names. IACUC Vote Approval 0 Withhold Approval 0 Abstain 0 Present 21 8. # C 10-13-2021 The amendment was reviewed and the following points were addressed by the Principal
Additional discussion during the meeting included:         a. Request edit to remove personal names.         IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         8. #       C         Inclusion       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
IACUC Vote         Approval       0         Withhold Approval       0         Abstain       0         Present       21         8. #       C         The amendment was reviewed and the following points were addressed by the Principal
Approval       0         Withhold Approval       0         Abstain       0         Present       21         8. #       C         The amendment was reviewed and the following points were addressed by the Principal
Withhold Approval 0         Abstain       0         Present       21         8. #       C         Image: Comparison of the transformed structure
Abstain       0         Present       21         8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
Present     21       8. #     C     10-13-2021       The amendment was reviewed and the following points were addressed by the Principal
8. #       C       10-13-2021         The amendment was reviewed and the following points were addressed by the Principal
The amendment was reviewed and the following points were addressed by the Principal
Investigator prior to the meeting:
<ul> <li>a. incidence of previous occurrence.</li> <li>b. clarification of criteria for removal form study.euthanasia.</li> </ul>
Additional discussion during the meeting included:
a. Reviewer requested that PI follow up with CVS on clarification of criteria for removal from
study/euthanasia.
IACUC Vote
Approval 0
Withhold Approval 0
Abstain 0
Present 21

9. #	D		11-03-2021
I he amendment Investigator prio		ed and the following points were addressed by the Pr ng:	incipal
		sent Form, and number of kittens affected, and total t	hat received the
transplan		he meeting included:	
		he meeting included: ollaboration with CTRB, altering source of animals, a	nd experimental
design. T		,	
IAC	UC Vote		
Approva	0		
Withhold	Approval 0		
Abstain	0		
Present	21		
10. #	D		09-16-2021
		d and the following points were addressed by the Pr	incipal
Investigator prio			
		bmitted in response to a PAM and recommendations clear and consistent.	s from IACUC to
		he meeting included:	
	ittee voted to		
IAC	UC Vote		
Approva	21		
Withhold	Approval 0		
Abstain	0		
Present	21		
11. #	D		09-16-2021
		d and the following points were addressed by the Pr	incipal
Investigator prio			
		bmitted in response to a PAM and recommendations clear and consistent.	
		he meeting included:	
	ttee voted to	approve.	
IAC	UC Vote		
Approva	21		
	21		
Withhold	21 Approval 0		
Withhold Abstain	21 Approval 0 0		09-16-2021
Withhold Abstain Present	21 Approval 0 0 21 <b>C</b>		
Withhold Abstain Present 12. #	Approval 0 0 21 C	ed and the following points were addressed by the Pr	
Withhold Abstain Present 12. # The amendment Investigator prio	Approval 0 0 21 C was reviewer to the meet	ed and the following points were addressed by the Pring:	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific	Approval 0 0 21 C was reviewer to the meet ation on loca	ed and the following points were addressed by the Pr	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific Additional discus a. None.	21 Approval 0 0 21 C was reviewer to the meet ation on loca ssion during	ed and the following points were addressed by the Pring: tion, chambers and objective.	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific Additional discus a. None.	Approval 0 0 21 C was reviewer to the meet ation on loca	ed and the following points were addressed by the Pring: tion, chambers and objective.	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific Additional discus a. None.	Approval 0 0 21 C was reviewer to the meet ation on loca ssion during UC Vote	ed and the following points were addressed by the Pring: tion, chambers and objective. the meeting included:	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific Additional discus a. None. IAC Approva	Approval 0 0 21 C was reviewer to the meet ation on loca ssion during UC Vote	ed and the following points were addressed by the Pring: tion, chambers and objective. the meeting included:	
Withhold Abstain Present 12. # The amendment Investigator prio a. Clarific Additional discus a. None. IAC Approva	Approval 0 0 21 C was reviewer to the meet ation on loca ssion during UC Vote 20	ed and the following points were addressed by the Pring: tion, chambers and objective. the meeting included:	

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.01-08-2021		
2. 08-04-2021		
3. 08-30-2021		
4. 09-09-2021		
5. 09-09-2021		
6. 09-14-2021		
7. 09-15-2021		

Discussion:	Discussion: 2. Facility is working with FM to have fire damage/debris removed from the outside of the facility. IACUC director to discuss in next leadership meeting to help assist PI. The front door lock has been repaired and the inside of the facility is very clean.			
Action:	2. Committee	approved inspection updates and PI moving forward with ordering animals.		
	·			
	ACUC Vote			
Appro	oval <sup>,</sup>	19		
With	nold Approval	0		
Absta	ain	0		
Prese	ent <sup>,</sup>	19		

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 08-11-2021	LAB	
2.08-25-2021	LAB	
3. 08-30-2021	LAB	
4.08-30-2021	LAB	
5.08-30-2021	LAB	
6. 08-31-2021	LAB	
7.09-01-2021	LAB	
8.09-02-2021	LAB	
9. 09-13-2021	LAB	
10. 09-14-2021	LAB	
11. 06-01-2021	PAM	
12.06-14-2021	PAM	
13. 07-27-2021	PAM	
14. 08-09-2021	PAM	
15. 09-08-2021	PAM	

	<ol> <li>PI has hired a new lab manager who used to work for another lab. One out of four protocols was missed updating the animal numbers this past quarter. Otherwise, records looked good.</li> <li>During facility inspection, noted post-op records in the animal room. Documentation was not clear leading to confusion of whether there were protocol deficiencies. After further review with the lab it was identified as a record deficiency and not a protocol deficiency. Re-training provided for clear record documentation.</li> </ol>
Action:	<ol> <li>No further action at this time other than to remain on quarterly inspection until new manager is fully trained.</li> <li>Committee approved the lab's plan to prevent the deficiency in the future.</li> </ol>

	IACUC Vote	
Approval	18	
Withhold App	oroval 0	
Abstain	0	
Present	18	

### XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:				
Inspection Date	Agency	Location	Summary	Discussion
1. 09-08-2021	USDA	Site 1	Inspection dates for Site 1 (routine) and Site 2 (focused): 9/8/21, 9/9/21, 910/21 No non-compliant items.	items documented. b. Pending final report.

## XV. Other Discussion Items:

Торіс	
1. Guest: PI	
Discussion:	Reviewed protocol objectives and pain management plan.
Action:	None.
2.	PI maintain request form.
Discussion:	Discussed preliminary inspection attended by AV, Aquatics IACUC member and IACUC staff. Facility is appropriate for study. PI will be working with other aquatic users on campus to ensure proper set up and consistent SOPs. Once the facility is completely set up, another inspection will be completed prior to approval of the IACUC protocols.
Action:	Committee approved PI to maintain the facility.
3. Semi Ann	ual Program Review
Discussion:	None.
Action:	Deferred to next meeting.
4.	
Discussion:	None.
Action:	See section 4.
5. FYI -	- Animals moved to holding protocol
Discussion:	None.
Action:	None.
6. FYI -	- Animals moved to holding protocol.
Discussion:	None.
Action:	None.

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

#### September 30, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M102, M111, M090, M042, A095, M004, M100, M092, A019, M119, A109, M110, M093, A013, M024, M223, M001, M114

#### Excused:

M222, M087, M016, M112

#### Guests:

M224, A017

#### I. Minutes from Previous Meetings:

The IACUC reviewed a	and app	roved the July 8, 2021, meeting minutes as written.
	ote	
Approval	18	
Withhold Appro	oval 0	
Abstain	0	
Present	18	
The IACUC reviewed a	and app	roved the July 22, 2021, meeting minutes as written.
	ote	
Approval	18	
Withhold Appro	oval 0	
Abstain	0	
Present	18	

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### III. Amendments Tabled From Previous Meetings:

1. #			Category: D
The amendment was revie the meeting: a. None.	wed and the following po	ints were addressed by the Principal In	vestigator prior to
Additional discussion durin a. CTRB ad-hoc me		Will prepare a report to IACUC. Amend	ment tabled.
Approval	0		
Withhold Approval	0		
Abstain	0		
1			Obtained by Rise for

# IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
Action: None.
Action: PAM.
Records request: PRCM follow-up requests for Neuralink
Action: Notification of additional information requested.
Action: Root cause analysis to be performed

## V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:	
None at this time.	

# VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	DY		-
prior to the meet a. IACUC Additional discus	ting: Office working ssion during the	the following points were addressed by the Princip with PI on protocol modifications. meeting included: with PI on protocol modifications.	oal Investigator
2. #	D		-
prior to the meet a. Pendin Additional discus	ting: Ig PI response.	the following points were addressed by the Princip e meeting included:	oal Investigator
3. #	С		-
prior to the meet a. Pendin Additional discus	ting: Ig completion of	the following points were addressed by the Princip f OHSS. e meeting included:	oal Investigator
4. #	DY		09-17-2021
prior to the meet a. None.	ling:	the following points were addressed by the Princip meeting included:	bal Investigator
5. #	DY		-

The protocol was reviewed and the following points were addressed by the Principal Investigator						
prior to the meeting: a. numbers justification.						
b. analgesia criteria.						
c. clarification of number of procedures.						
	d. clarification of clinical vs teaching procedures					
Additional discus	sion during the	meeting included:				
a. Pendin	g PI.					
6. #	E		-			
		the following points were addressed by the Princip	oal Investigator			
prior to the meet						
		view of responses. meeting included:				
	ns in DMR.	meeting metudeu.				
7. #	DY		_			
The protocol was	s reviewed and	the following points were addressed by the Princip	bal Investigator			
prior to the meet			g			
a. None.	-					
		meeting included:				
		location renovation is complete and inspected.				
8. #	DY		-			
		the following points were addressed by the Princip	oal Investigator			
prior to the meet						
		es regarding procedures.				
	ns in DMR.	meeting included:				
9. #	E					
		the following points were addressed by the Drinei	-			
prior to the meet		the following points were addressed by the Princip	bai investigator			
	g PI response.					
		meeting included:				
a. Remair	ns in DMR.	•				
10. #	D		09-21-2021			
		the following points were addressed by the Princip	oal Investigator			
prior to the meet						
		numbers and procedure.				
a. None.	sion during the	meeting included:				
11. #	D					
11. #	<b>D</b>		-			
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator			
prior to the meet		the following points were addressed by the Finite	oal investigator			
a. Pending room approval.						
Additional discussion during the meeting included:						
a. None.						
12. #	DY		09-17-2021			
The protocol was reviewed and the following points were addressed by the Principal Investigator						
prior to the meeting:						
a. None.						
	sion during the	meeting included:				
a. None.						
13. #	CY		09-30-2021			

The protocol was prior to the meet		the following points were addressed by the Princip	oal Investigator
	sion during the	meeting included:	
a. None.	с		
14. #	C		-
prior to the meet a. Pendin	ing: g BIO.	the following points were addressed by the Princip meeting included:	oal Investigator
a. Remair	ns in DMR.	meeting included.	
15. #	D		09-30-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
a. None.	j		
16. #	С		09-21-2021
prior to the meet a. Clarific	ing: ation of adverse	the following points were addressed by the Princip e effects. e meeting included:	
17. #	D		09-20-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oai investigator
18. #	D		09-30-2021
prior to the meet a. Clarific b. clarifica c. Clarifica	ing: ation of endpoir ation of housing ation of pain.		oal Investigator
19. #	DY		09-21-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included:	bal Investigator
a. None.	D		_
20. 1	L.		_
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	bal Investigator

a. Pendin	g PI response t	o reviewers questions.	
21. #	C		09-28-2021
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	al Investigator
Additional discus a. None.	ssion during the	meeting included:	
22. #	C		09-24-2021
prior to the meet a. Clarifie	ing: d timeline and s	the following points were addressed by the Princip significance of study. meeting included:	al Investigator
23. #	С		09-24-2021
	-	the following points were addressed by the Princip	
	d adverse effec	ets and staff roster. meeting included:	
24. #	С		09-23-2021
	ed referenced	SOPs. meeting included:	
25. #	С		-
prior to the meet a. Clarific b. clarifica Additional discus	iing: ation of animal ation of drug do		al Investigator
26. #	C		09-30-2021
prior to the meet a. Clarific	ing: ation of proced	the following points were addressed by the Princip ures and adverse effects. meeting included:	al Investigator
27.#	D		09-30-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip	al Investigator
a. None. 28. #	С		09-30-2021
The protocol was prior to the meet a. None.		the following points were addressed by the Princip	al Investigator

Additional discussion during the meeting included:

a. None.	j		
29. #	С		09-30-2021
prior to the meet a. Clarifie	ting: ed animal feed a	the following points were addressed by the Princip and housing. e meeting included:	oal Investigator
30. #	В		09-30-2021
prior to the mee a. None.	ting:	the following points were addressed by the Princip meeting included:	oal Investigator

VII. Designated Review Amendments:

Investigator prior to a. clarificatio b. clarificatio euthanized. Additional discussi a. Request humanely e <b>2. #</b> The amendment w Investigator prior to a. None.	o the meeting on of previous on of when a ion during the further clarific euthanized. D Y /as reviewed	s occurrence. nimals will be excluded from the study and/or hum e meeting included: cation of when animals will be excluded from the s and the following points were addressed by the Pr	anely tudy and/or 09-29-2021
nvestigator prior to a. clarificatio b. clarificatio euthanized. Additional discussi a. Request humanely e 2. # The amendment w nvestigator prior to a. None.	o the meeting on of previous on of when a ion during the further clarific euthanized. D Y /as reviewed	r: s occurrence. nimals will be excluded from the study and/or hum e meeting included: cation of when animals will be excluded from the s and the following points were addressed by the Pr	anely tudy and/or 09-29-2021
2. # The amendment w Investigator prior to a. None.	D Y /as reviewed		1
Investigator prior to a. None.			incipal
a. None.	ion during the	meeting included:	•
3. #	DY		09-30-2021
Investigator prior to a. None.	o the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
4. #	D		09-29-2021
Investigator prior to a. Chemical	o the meeting I safety office	and the following points were addressed by the Pr : r confirmed no VHSS was required. e meeting included:	incipal
5. #	DY		-
Investigator prior to a. Pending	o the meeting PI response. ion during the	and the following points were addressed by the Pr : meeting included:	incipal
6. #	D		09-16-2021

		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	:	
	ssion during the	meeting included:	
7.#	С		09-23-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	:	
Additional discus a. None.	ssion during the	meeting included:	
8. #	С		09-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
9.#	D		09-17-2021
The amendment Investigator prior a. None.	t was reviewed a r to the meeting	and the following points were addressed by the Pr : meeting included:	
10. #	С		09-28-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
11. #	DY		09-16-2021
The amendment Investigator prior a. Clarific	r to the meeting ation on using g	and the following points were addressed by the Pr : genetically modified organisms. meeting included:	incipal
12. #	С		-
Investigator prior a. Clarific	r to the meeting ation of frequer ssion during the	and the following points were addressed by the Pr c ncy of monitoring. meeting included:	incipal
13. #	E		09-16-2021
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarify how this relates to the current objectives in the parent protocol. Additional discussion during the meeting included: a. None.			
14. #	D		-
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.			
Additional discussion during the meeting included: a. Clarification of when animals should be excluded from the study and/or humanely euthanized.			
15. #	D		09-16-2021

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:					
a. None.					
Additional discussion during the meeting included: a. None.					
16. #	D		-		
Investigator prior		and the following points were addressed by the Pr	incipal		
a. None.					
Additional discus a. None.	ssion during the	meeting included:			
17. #	DY		09-30-2021		
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : • meeting included:	incipal		
a. None.	0	5			
18. #	D		09-28-2021		
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal		
19. #	DY		09-27-2021		
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal		
20. #	DY		09-30-2021		
Investigator prior a. None.	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:				
21. #	DY		-		
Investigator prior a. Pendin	r to the meeting g PI response.	and the following points were addressed by the Pr : meeting included:	incipal		
a. Remair	ns in DMR.	-			
22. #	С		-		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:					
a. Clarification of when animals should be excluded from the study and/or humanely euthanized.					
23. #	DY		09-24-2021		
Investigator prior a. None.	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
a. None.	_				
24. #	DY		09-20-2021		

The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:	
Additional discussion during the meeting moldaed.	
a. None.	
25. # D 09-2	3-2021
The amendment was reviewed and the following points were addressed by the Principal	
Investigator prior to the meeting: a. None.	
Additional discussion during the meeting included: a. None.	
26. # DY	-
The amendment was reviewed and the following points were addressed by the Principal	
nvestigator prior to the meeting:	
a. Pending BUA amendment approval.	
Additional discussion during the meeting included:	
<ul> <li>Pending BUA amendment approval confirmation</li> </ul>	
27. # C	-
The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Clarification of when animals should be excluded from the study and/or humane	lv.
euthanized.	·· <b>J</b>
28. # D	-
Investigator prior to the meeting:	
Additional discussion during the meeting included: a. Pending PI responses.	
Additional discussion during the meeting included:	-
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal	-
Additional discussion during the meeting included:         a. Pending PI responses.         29. #         D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.	- tact/AV
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending revision following PI/Alternate Contact/AV phone consultation.	
Additional discussion during the meeting included:       a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:       a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:       a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending revision following PI/Alternate Contact/AV phone consultation.         Additional discussion during the meeting included:         a. Pending revision following PI/Alternate Contact/AV phone consultation.	
Additional discussion during the meeting included:         a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending revision following PI/Alternate Contact/AV phone consultation.         Additional discussion during the meeting included:         a. Pending revision following PI/Alternate Contact/AV phone consultation.         Additional discussion following PI/Alternate Contact/AV phone consultation.         31. #       D         09-3         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:	-
Additional discussion during the meeting included:       a. Pending PI responses.         29. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:       a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         Additional discussion during the meeting included:       a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending approval following revision of second amendment per PI/Alternate Comphone consultation.         30. #       D Y         The amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:         a. Pending revision following PI/Alternate Contact/AV phone consultation.         Additional discussion during the meeting included:         a. Pending revision following PI/Alternate Contact/AV phone consultation.	tact/AV -

The amendment Investigator prior a. None.		and the following points were addressed by the Pr <sup>:</sup>	incipal
		une ettern in elevele de	
a. None.	sion during the	e meeting included:	
33. #	D		09-30-2021
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus a. None.	sion during the	e meeting included:	
34. #	С		09-17-2021
Investigator prior a. None. Additional discus a. None.	-	: e meeting included:	
35. #	DY		09-30-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
36. #			-
Investigator prior a. Pending	to the meeting g Reviewer rev sion during the	and the following points were addressed by the Pr : iew of responses . e meeting included:	incipal


### VIII. Administrative and Veterinary Verification Amendments:


Total of **238** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


### IX. New Protocols:


The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1.#	DY		12-02-2021
orior to the mee a. Proce procedu Additional discu	eting: dure clarificatio res and referen ission during th	d the following points were addressed by the Princi ons including drug name, choice and dosing informatices, procedure frequencies. The meeting included: iew following clarifications.	-
IAC	CUC Vote		
Approva	al O		
Withhol	d Approval 0		
v viu i i oi			









## X. Annual Renewals:

Protocol Categor	/ Title	Original Approval	Last Reviewed	Expires
С		10-03-2019	09-30-2021	10-03-2022
В		09-27-2019	09-30-2021	09-27-2022
D		09-19-2019	09-30-2021	09-19-2022
CY		10-08-2019	09-30-2021	10-08-2022
В		10-07-2019	09-30-2021	10-07-2022
С		10-10-2019	09-30-2021	10-10-2022
D		10-10-2019	09-30-2021	10-10-2022
D		10-10-2019	09-30-2021	10-10-2022
D		10-03-2019	09-30-2021	10-03-2022
D		10-10-2019	09-30-2021	10-10-2022
С		10-10-2019	09-30-2021	10-10-2022
CY		09-19-2019	09-30-2021	09-19-2022
С		10-08-2019	09-30-2021	10-08-2022


	,				
	С	0-09-	2019	09-30-2021	10-09-2022
	С	0-07-2	2019	09-30-2021	10-07-2022
	С	0-08-	2019	09-30-2021	10-08-2022
	С	0-10-	2019	09-30-2021	10-10-2022
-	С	0-08-	2019	09-30-2021	10-08-2022
-	С	0-09-	2019	09-30-2021	10-09-2022
-	С	0-15-	2020	09-30-2021	10-15-2022
	D	9-30-	2020	09-30-2021	09-30-2022
	E	0-06-	2020	09-30-2021	10-06-2022
-	D	0-06-	2020	09-30-2021	10-06-2022
	CY	9-17-	2020	09-30-2021	09-17-2022
	E	0-11-2	2020	09-30-2021	10-11-2022
		0.45		00 00 0004	10 15 2022
	D	0-15-	2020	09-30-2021	10-15-2022
	C			09-30-2021	
		0-15-	2020		10-15-2022
	С	0-15-	2020 2020	09-30-2021	10-15-2022 10-15-2022
	C C	0-15- 0-15- 0-02-	2020 2020 2020	09-30-2021 09-30-2021 09-30-2021	10-15-2022 10-15-2022
	C C D	0-15- 0-15- 0-02- 9-30-	2020 2020 2020 2020	09-30-2021 09-30-2021 09-30-2021	10-15-2022 10-15-2022 10-02-2022 09-30-2022
	C C D D	0-15- 0-15- 0-02- 9-30- 0-12-	2020 2020 2020 2020 2020	09-30-2021 09-30-2021 09-30-2021 09-30-2021	10-15-2022 10-15-2022 10-02-2022 09-30-2022 10-12-2022

Discussion: Section Section		n 9 was missing maximum duration of time animals would
		-at least one person on each protocol is in the process of eir OHSS renewal process. IACUC staff is working with the e these are completed ASAP.
provided by the		nittee approved adding the maximum duration of time ne PI. -Committee approved the annual renewals.
1	ACUC Vote	
Appro	val	19
Withh	old Approval	0
Absta	in	0
		1

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1.#	DY		09-30-2021
nvestigator prior a. None.	to the meeting	-	incipal
dditional discus	sion during the	e meeting included:	
IAC	JC Vote		
Approval			
Withhold	Approval 0		
Abstain	0		
Present	20		
2.#	DY		09-30-2021
	JC Vote		
Approval			
	Approval 0		
Abstain	0		
Present	20		
3. #	DY	and the following points were addressed by the Pr	10-15-2021
b. Potenti c. Mitigati d. Potenti e. Failure dditional discus a. Tabled IACI Approval	numbers. al for immune on measures. al impact on in rate. ssion during the for additional i JC Vote	g: responses; graft evaluation and criteria. nmunosuppression. e meeting included: nformation; PI response.	
Present	20		
4. #	D		09-30-2021
- <b>T</b> . <b>N</b>	5		00-00-2021
nvestigator prior a. None.	to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal



	he amendment was reviewed and the following points were addressed by the Principal nvestigator prior to the meeting:				
	a. clarification of piston adjustment procedures.				
	b. clarification of force used and how it will be determined.				
Additional discus	sion during th	e meeting included:			
a. None.	Ŭ	C C			
IAC	UC Vote				
Approval	0				
Withhold	Approval 0				
Abstain	0				
Present	20				
10. #	С		09-30-2021		
		I and the following points were addressed by the Pr	incipal		
Investigator prior	r to the meetin	g:			
a. None.	scion during th	a maating included:			
		e meeting included: of why animals need to be transported and who wil	be transporting		
them.	Stolamouton		be autoporting		
IAC	UC Vote				
Approval	0				
Withhold	Approval 0				
Abstain	0				
Present	20				

# XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-28-2021		
2.08-26-2021		
3. 08-26-2021		
4. 09-22-2021		
5. 09-23-2021		
6. 09-23-2021		
7.09-23-2021		
8. 09-29-2021		
9. 09-29-2021		
10. 09-29-2021		

Discussion: 10. Study is complete and colony has been disbanded.			
Action: 10. This facility will be taken off the IACUC semi-annual inspection schedule.			
ie l			
17			
val 0			
0			
17			
fa			

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol	
			Obtained by Rise for Animals.
		Uploaded to Animal Research Laborato	'y Overview (ARLO) on 02/06/2023

1.07-15-2021	LAB	
2.07-15-2021	LAB	
3. 09-13-2021	LAB	
4. 09-21-2021	LAB	
5. 09-23-2021	LAB	
6. 09-23-2021	LAB	
7.09-27-2021	LAB	
8. 09-27-2021	LAB	
9. 09-23-2021	PAM	

Discussion: None.

Action:	None.	
	ACUC Vote	
Appr	oval	20
With	nold Approval	0
Absta	ain	0
Pres	ent	20

## XIV. Regulatory Inspections:

The IACUC was informed of the following regulatory inspections:					
Inspection Date	Agency	Location	Summary	Discussion	
1. 09-08-2021	USDA		FYI - Inspection report received. No non- compliant items.		
2. 09-30-2021	USDA		FYI - Inspection report received. No non- compliant items.		

## XV. Other Discussion Items:

Торіс	
2. FYI -	- Animals moved to holding protocol
Discussion:	None.
Action:	None.
1. FYI -	- Animals moved to holding protocol
Discussion:	None.
Action:	None.
3. FYI - (Che Notification	emical Safety) Standard of Care Medications and Potential Exposure
Discussion:	FYI - new notification procedural annual review.
Action:	None.
4. SAPR	
Discussion:	Reviewed subcommittee recommendations and notes.
Action:	Approved.
5. PI M	laintain form
Discussion:	PI and collaborator have been using this facility for several years but had not completed the PI maintain form after the policy had been instituted. PI's renewal protocols will be on the 10/14/21 agenda.
Action:	Committee approved the request to remain PI maintained.

## XVI. Program Updates:

Торіс

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### October 14, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M097, M222, M102, M090, A095, M100, M092, A019, M119, A109, M110, M093, A013, M016, M024, M223, M001

### Excused:

M009, M111, M042, M004, M087, M112, M114

#### Guests:

M224, M116, A017

#### I. Minutes from Previous Meetings:

The IA	CUC reviewed and	app	roved the August 5, 2021, meeting minutes as written.
	IACUC Vote		
	Approval	17	
	Withhold Approval	0	
	Abstain	0	
	Present	17	
The IA	CUC reviewed and	app	roved the August 19, 2021, meeting minutes as written.
	IACUC Vote		
	Approval	17	
	Withhold Approval	0	
	Abstain	0	
	Present	17	
The IA	CUC reviewed and	app	roved the September 2, 2021, meeting minutes as written.
			· · · · ·
	IACUC Vote		
	Approval	17	
	Withhold Approval	0	
	Abstain	0	
	Present	17	
The IA	CUC reviewed and	app	roved the September 16, 2021, meeting minutes as written
	IACUC Vote		
	Approval	17	
	Withhold Approval		
	Abstain	0	
	Present	17	
The IA			roved the Sentember 30, 2021, mosting minutes as written
THE IA	COC reviewed and	app	roved the September 30, 2021, meeting minutes as written

IACUC	Vote
Approval	17
Withhold App	proval 0
Abstain	0
Present	17

## II. Protocols Tabled From Previous Meetings:

1. #			Category: D Y
	col was reviewed	lan	d the following points were addressed by the Principal Investigator prior to the
meeting:			
a.	Procedure clarific	atic	ons including drug name, choice and dosing information, SOP procedures and
ref	erences, procedu	ire f	frequencies.
Additiona	discussion durin	g th	ne meeting included:
a.	Tabled, pending I	PI re	esponse.
	IACUC Vote		
A	oproval	0	
W	ithhold Approval	0	
Ał	ostain	0	
Pr	resent	17	

## III. Amendments Tabled From Previous Meetings:

1.#			Category: D Y
the me	eeting: a. Clarify if subset of b. Clarify historic ra c. Clarify impact on d. Clarifying recent e. Clarify failure def onal discussion durir	tes and anticipated future rates. the immunosuppression protocol. graft losses do not appear to be due to lack of material. inition and timeline. ng the meeting included:	gator prior to
	a. Pending PI, rema	ains in DMR.	
	IACUC Vote		
	Approval	0	
	Withhold Approval	0	
	Abstain	0	
	Present	17	
2. #			Category: D
	mendment was revie eeting: a. None.	ewed and the following points were addressed by the Principal Investi	gator prior to
Additio		ng the meeting included: recommendations. Voted to send to DR for PI edits.	
	IACUC Vote		
	Approval	0	
1	1		

Abstain	0	
Present	17	

## IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:

CARU Break in.

Action: FYI. No animal welfare impact. Request increase patrols.

### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee: None at this time.

### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	DY		-
prior to the mee a. Doxyc b. IACUC clarity. Additional discu a. IACUC	ting: ycline requires a c staff working v ssion during the	vith PI to remove unnecessary text, edit and rear e meeting included: vith PI to remove unnecessary text, edit and rear	range text for
2. #	D		-
prior to the mee a. Pendir Additional discu	ting: ng PI.	the following points were addressed by the Prine e meeting included:	cipal Investigator
3. #	С		10-04-2021
prior to the mee a. PI clar	ting: ified potential a	the following points were addressed by the Prin dverse effects and monitoring during studies. e meeting included:	cipal Investigator
4. #	DY		10-14-2021
prior to the mee a. Anima b. Analge c. Clarific	ting: l numbers clarif esia clarification cation of proced		cipal Investigator
5. #	E		10-14-2021

		the following points were addressed by the Princip	oal Investigator	
prior to the mee		rdous material Cage dimensions. Animal numbers	Pain/stress	
<ul> <li>Clarification on: Hazardous material, Cage dimensions, Animal numbers, Pain/stress hormones, Tail clipping and Adverse effects</li> </ul>				
		e meeting included:		
a. None.	-			
6. #	DY		-	
The protocol wa	c roviowed and	the following points were addressed by the Princip	al Investigator	
prior to the mee		the following points were addressed by the Frincip	ai investigator	
a. None.	ung.			
Additional discu	ssion during the	e meeting included:		
a. Pendir	ng space renova	ation and approval. Remains in DMR.		
7.#	DY		-	
The uneteedly in		the following points were addressed by the Drinsi		
prior to the mee		the following points were addressed by the Princip	bal investigator	
•	•	es. PI was contacted to see if he still wants to purs	ue the project	
		es and will get to responses soon.		
		e meeting included:		
a. Remai	ns in DMR.			
8. #	E		-	
		the following points were addressed by the Princip	oal Investigator	
prior to the meet				
	ng PI Response			
	ns in DMR.	e meeting included:		
9. #	DY		10-11-2021	
5. #			10-11-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princip	pal Investigator	
prior to the mee			g	
	erification.			
	accine clarificat			
	ial vaccine side	errects. e meeting included:		
a None	ssion during the			
10. #	D		_	
10. 1			_	
The protocol wa	s reviewed and	the following points were addressed by the Princip	bal Investigator	
prior to the mee			<b>j</b>	
	ng updated BUA			
	ssion during the	e meeting included:		
a. None.	_		10.05.0001	
11.#	D		10-05-2021	
The protocol wa		the following points were addressed by the Drinei		
prior to the mee		the following points were addressed by the Princip	bal investigator	
		tion. Clarify euthanasia.		
Additional discussion during the meeting included:				
a. None.	-			
12. #	С		10-06-2021	
	·			
		the following points were addressed by the Princip	bal Investigator	
prior to the mee		on (floor/ground).		
	e.egy clarificati			

Additional discu a. None.	ssion during th	e meeting included:	
13. #	CY		10-10-2021
prior to the mee a. Clarify	ting: blood collectio	d the following points were addressed by the Princip n sedation. e meeting included:	oal Investigator
14. #	С		10-01-2021
prior to the mee a. Clarific	ting: ation on CRIS	d the following points were addressed by the Princip PR and gene modification. e meeting included:	oal Investigator
15. #	D		10-13-2021
prior to the mee a. Clarific staffing a	ting: ation on monit nd adverse eff	d the following points were addressed by the Princip oring of the animals, animal number justification, hu ect. e meeting included:	-
16. #	С		10-14-2021
prior to the mee a. None. Additional discu a. None.	•	e meeting included:	
17.#	D		10-13-2021
prior to the mee a. Clarific b. Clarific c. Questi d. Clarific e. Clarific	ting: cation of anima cation of farm s on about releva cation of assess cation of long te	d the following points were addressed by the Princip I sources/farms and breeds. taff and investigator responsibilities. ance to caustic paste disbudding. sment period. erm follow up responsibilities. e meeting included:	oal Investigator
18. #	С		-
prior to the mee a. Reque b. Questi	ting: st for clarificati on about anima ssion during th	d the following points were addressed by the Princip on of drug dosing. al source. e meeting included:	oal Investigator
19. #	C		-
prior to the mee		d the following points were addressed by the Princip dures.	oal Investigator

		e meeting included: ACUC policy. Pending additional Committee memb	er questions.
20. #	С		10-14-2021
prior to the meetin a. Clarificat	g: ion of EH&S I ion during the	the following points were addressed by the Princip review, numbers, and procedures. meeting included:	oal Investigator
21. #	С		10-14-2021
The protocol was prior to the meetin a. None.	reviewed and g:	the following points were addressed by the Princip meeting included:	
22. #	DY		10-06-2021
prior to the meetin a. Viral stat b. Clarify fu c. Clarify lit d. Telazol u e. Numbers f. rAAV con g. Confirma h. Procedu i. Pairing de j. Key word k. Alternativ I. Clarify mo	g: us and housir inding. erature search ise. s clarifications taminant testi ation of pharm ral clarification eferral confirm search. ves and references tost locations to	ng and route of administration. haceutical grade; to follow policy if NPG. hs. hation	-
prior to the meetin a. None. Additional discuss	g: ion during the	the following points were addressed by the Princip	oal Investigator
a. Pending			
24. #	с		-
prior to the meetin a. Pending	g: PI's response ion during the	the following points were addressed by the Princip es regarding breeding lines. e meeting included:	oal Investigator
25. #	С		-
prior to the meetin a. None. Additional discuss	g: ion during the	the following points were addressed by the Princip e meeting included: g and mortality	oal Investigator

26. #	DY		10-05-2021
prior to the mee a. Clarifi	eting: cation provided t ission during the	the following points were addressed by the Princi for group 3 and transferring options. meeting included:	pal Investigator
27.#	С		10-14-2021
prior to the mee a. None.	eting: Ission during the	the following points were addressed by the Principe meeting included:	pal Investigator
28. #	CY		10-08-2021
prior to the mee a. None.	eting: Ission during the	the following points were addressed by the Principe meeting included:	pal Investigator
29. #	С		10-13-2021
prior to the mee a. Clarifi	eting: ed if VHSS was ission during the	the following points were addressed by the Princi needed. meeting included:	pal Investigator
30. #	С		10-14-2021
prior to the mee a. Clarify	eting: / breeding proce /ssion during the	the following points were addressed by the Princi edure. e meeting included:	pal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1. #	D		-
Investigator prior a. Pendin Additional discus	r to the meeting g clarification o	and the following points were addressed by the Pr : f numbers justification. meeting included:	incipal
2. #	С		10-14-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
3. #	D		10-14-2021

The amendment Investigator prio		and the following points were addressed by the Pr	incipal
a. None.	r to the meeting		
Additional discus a. None.	ssion during the	e meeting included:	
4. #	D		10-13-2021
		and the following points were addressed by the Pr	incipal
Investigator prio			
	ation of previou	s occurrences. on/euthanasia criteria.	
		e meeting included:	
a. None.		incoding included.	
5. #	С		10-04-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	Г.	
a. None.		and the standards	
a. None.	ssion during the	e meeting included:	
6. #	с		10-14-2021
0. #	Ŭ		10-14-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			-
	ation on acclim		
Additional discus	ssion during the	e meeting included:	
7. #	DY		
		and the following points were addressed by the Pr	- incipal
Investigator prio			ncipai
	g PI response.	•	
		e meeting included:	
a. Remai	ns in DMR.		
8.#	DY		10-04-2021
		and the following points were addressed by the Pr	incipal
Investigator prio		j: I lidocaine dose.	
		e meeting included:	
a. None.		incoding included.	
9.#	С		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	r.	
		ations and responsibilities of new PI.	
Additional discus		e meeting included:	
10. #	іў гі. С		
10. #			-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.			
		e meeting included:	
	ig reviewer.		10 14 2021
11. #		and the following points were addressed by the Dr	10-14-2021
Investigator prio		and the following points were addressed by the Pr	псра
a. None.		,.	
Additional discus	ssion during the	e meeting included:	
a. None.			
12. #	C		10-14-2021

		and the following points were addressed by the Pr	rincipal
Investigator prior a. None.	r to the meeting	].	
	ssion during the	e meeting included:	
13. #	С		10-13-2021
The amendment	was reviewed	and the following points were addressed by the Pr	rincipal
Investigator prior a. None.			
	ssion during the	e meeting included:	
a. None.	· ·	•	
14. #	С		10-06-2021
The amendment	was reviewed	and the following points were addressed by the Pr	rincipal
Investigator prior			
		ocedure monitoring.	
	ssion during the	e meeting included:	
a. None.			
15. #	DY		10-12-2021
		and the following points were addressed by the Pr	rincipal
Investigator prior	r to the meeting	j:	
a. None.	nion during the	meeting included:	
a. None.	ssion during the	e meeting included:	
16. #	D		10-13-2021
		and the fallowing a sinte ways addressed by the D	1
Investigator prior		and the following points were addressed by the Pr	incipal
		ہ. on/euthanasia criteria.	
		e meeting included:	
a. None.			
17.#	E		-
	_		
	was reviewed	and the following points were addressed by the Pr	incipal
			rincipal
The amendment Investigator prior a. None.	r to the meeting		incipal
The amendment Investigator prior a. None. Additional discus	r to the meeting	y: e meeting included:	incipal
The amendment Investigator prior a. None. Additional discus	r to the meeting ssion during the	y: e meeting included:	incipal 10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin	r to the meeting ssion during the g BUA amendr	y: e meeting included:	
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b>	r to the meeting ssion during the g BUA amendr D : was reviewed	and the following points were addressed by the Pr	10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior	r to the meeting ssion during the g BUA amendr D : was reviewed	and the following points were addressed by the Pr	10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin 18. # The amendment Investigator prior a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting	e meeting included: nent and the following points were addressed by the Pr	10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting	and the following points were addressed by the Pr	10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the	e meeting included: nent and the following points were addressed by the Pr	10-01-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting	e meeting included: nent and the following points were addressed by the Pr	10-01-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the	e meeting included: nent and the following points were addressed by the Pr	10-01-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin 18. # The amendment Investigator prior a. None. Additional discus a. None. 19. #	r to the meeting ssion during the g BUA amendr D : was reviewed r to the meeting ssion during the D	e meeting included: nent and the following points were addressed by the Pr g: e meeting included:	10-01-2021 incipal 10-14-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> #	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D	and the following points were addressed by the Pr e meeting included: and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> # The amendment Investigator prior a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr e meeting included: and the following points were addressed by the Pr g: and the following points were addressed by the Pr g:	10-01-2021 incipal 10-14-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> # The amendment Investigator prior a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr e meeting included: and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> # The amendment Investigator prior a. None. Additional discus	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr e meeting included: and the following points were addressed by the Pr g: and the following points were addressed by the Pr g:	10-01-2021 incipal 10-14-2021
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>19. #</b> The amendment Investigator prior a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the r to the meeting ssion during the ssion during the D	and the following points were addressed by the Pr meeting included: meeting included: and the following points were addressed by the Pr and the following points were addressed by the Pr meeting included:	10-01-2021 incipal 10-14-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>19. #</b> The amendment Investigator prior a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the vas reviewed r to the meeting ssion during the D ssion during the D	and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> # The amendment Investigator prior a. None. Additional discus a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. Additional discus a. None. Additional discus a. None. Additional discus a. None. Additional discus a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021 incipal
The amendment Investigator prior a. None. Additional discus a. Pendin <b>18.</b> # The amendment Investigator prior a. None. Additional discus a. None. <b>19.</b> # The amendment Investigator prior a. None. Additional discus a. None. Additional discus a. None.	r to the meeting ssion during the g BUA amendr D was reviewed r to the meeting ssion during the D was reviewed r to the meeting ssion during the D was reviewed r to the meeting	and the following points were addressed by the Pr and the following points were addressed by the Pr	10-01-2021 incipal 10-14-2021 incipal

		and the following points were addressed by the Pr	incipal
Investigator prior			
	st for more liter		
a. None.	ssion during the	e meeting included:	
22. #	С		10-13-2021
	<u> </u>	and the following points were addressed by the Dr	
Investigator prio		and the following points were addressed by the Pr	incipal
		ہ. on/euthanasia criteria.	
		e meeting included:	
a. None.	J		
23. #	D		-
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
	g PI response.		
		e meeting included:	
	ns in DMR.		
24. #	D		10-14-2021
		and the following points were addressed by the Pr	incipal
Investigator prio			
		r confirmed no VHSS is required.	
Additional discus	ssion during the	e meeting included:	
	<b>.</b>		10.11.0001
25. #	DY		10-11-2021
		and the following points were addressed by the Pr	incipal
Investigator prior			
	mendment cont		
a. None.	ssion during the	e meeting included:	
26. #	DY		10-12-2021
		and the following points were addressed by the Pr	
Investigator prior			incipal
a. None.	r to the meeting	j.	
	ssion durina the	e meeting included:	
a. None.	5	5	
27. #	С		10-13-2021
	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prior			
		on/euthanasia criteria.	
	ssion during the	e meeting included:	
a. None.			
28. #	D		-
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	j:	
a. None.	ssion during the	e meeting included:	
a. Pendin			
29. #			
	1	and the following points were addressed by the D	- incinal
Investigator prior		and the following points were addressed by the Pr	incipal
		<i>w</i> ing PI/Alternate Contact/AV phone consultation.	
		e meeting included:	
		wing PI/Alternate Contact/AV phone consultation.	
30. #22096	DY	Amendment clarification on length of surgery	-
		time on protocol	

		and the following points were addressed by the Pr	incipal
Investigator prio			
	g approval follo nsultation.	wing revision of second amendment per PI/Altern	ate Contact/AV
		meeting included:	
		wing revision of second amendment per PI/Alterna	ate Contact/AV
	nsultation.		
31. #	D		10-14-2021
	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.	· · ·		
	ssion during the	meeting included:	
a. None.			
32. #	CY		10-07-2021
		and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting		
a. None.	sion during the	meeting included:	
a. None.			
33. #	BY		09-30-2021
		and the following points were addressed by the Pr	1
Investigator prio			incipal
a. None.	to the mooting	•	
Additional discus	sion during the	meeting included:	
a. None.			
34. #	D		-
The amendment	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio			
		tions and responsibilities of new PI.	
Additional discus	ssion during the	meeting included:	
			40.04.0004
35. #	D		10-04-2021
The amendment	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio			inoipui
		etermination calculations.	
	ssion during the	meeting included:	
a. None.			
36. #	С		09-30-2021
		and the following points were addressed by the Pr	incipal
Investigator prio		: c reason for transportation.	
		provide the transportation.	
		meeting included:	
a. None.	seen aannig are		
37. #	DY		10-14-2021
The amendment	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio	r to the meeting	:	
a. None.	alar data di	waa afir a in daada	
Additional discus	ssion during the	meeting included:	
			10-14-2021
38. #	D		10-14-2021
The amendment	was reviewed a	and the following points were addressed by the Pr	incipal
Investigator prio			nopa
a. None.			

Additional discussion during the meeting included:

a. None.	ision during the	meeting included:	
39. #			10-07-2021
Investigator prior a. Clarifica	to the meeting ation on proced		incipal
40. #	С		-
Investigator prior a. clarifica b.	to the meeting ation of adverse	effects and how they will be addressed.	incipal
Additional discus a. None.	ision auring the	meeting included:	

### VIII. Administrative and Veterinary Verification Amendments:


Total of **242** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


### IX. New Protocols:


The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Proto	col	Catego	ry	Title	Date Approved
				11-19-2021	
prior to th a. Additiona a.	e meetir None. I discuss Voted fo	ng: sion durin	g the	I the following points were addressed by the Princip e meeting included: ng revision and review	oal Investigator
w	••	Approval	~		
Pr	resent		17		
2. #		D			10-25-2021
prior to th a. Additiona	e meetir None. I discuss Mortality	ng: sion durin	g the	I the following points were addressed by the Princip e meeting included: asures voted for DMR	oal Investigator
	pproval /ithhold /	Approval	0		
Al	bstain resent		0 17		

L







			l an	d the following points were addressed by the Princip	pal Investigator	
	prior to the meeting: a. Clarification on tissue collection requirements including type, number of animals and age					
	of animals.					
	b. Clarifica	ation of pe	erso	nnel and timing for euthanasia procedures.		
	c. Clarifica	ation of pu	irpo	se.		
		sion durin	ig th	e meeting included:		
	a. None.					
	IACU	JC Vote				
	Approval		0			
	Withhold	Approval	0			
	Abstain		0			
	Present		17			
16. #		С			10-14-2021	
The pr	otocol was	reviewer	lan	d the following points were addressed by the Princip	al Investigator	
	the meeti			a the following points were addressed by the rinning	Sul investigator	
	a. None.					
Additio	nal discus	sion durin	ig th	e meeting included:		
	a. remnan	ts from pr	evic	ous protocol removed.		
	IACU	JC Vote				
	Approval		17			
	Withhold	Approval	0			
	Abstain		0			
	Present		17			


## X. Annual Renewals:

Protocol Category	Title	Original Approval	Last Reviewed	Expires
DY		10-16-2019	10-14-2021	10-16-2022
D		10-17-2019	10-14-2021	10-17-2022
С		10-18-2019	10-14-2021	10-18-2022
D		10-21-2019	10-14-2021	10-21-2022
CY		10-17-2019	10-14-2021	10-17-2022
С		10-17-2019	10-14-2021	10-17-2022
С		10-17-2019	10-14-2021	10-17-2022
E		10-17-2019	10-14-2021	10-17-2022
D		10-17-2019	10-14-2021	10-17-2022
С		10-17-2019	10-14-2021	10-17-2022
С		10-03-2019	10-14-2021	10-03-2022
С		10-22-2019	10-14-2021	10-22-2022

	D							10-19-2020	10-14-2021	10-19-2022
	D							10-21-2020	10-14-2021	10-21-2022
	С							10-19-2020	10-14-2021	10-19-2022
	D							10-28-2020	10-14-2021	10-28-2022
	С							10-16-2020	10-14-2021	10-16-2022
	С							10-15-2020	10-14-2021	10-15-2022
	D							10-22-2020	10-14-2021	10-22-2022
	С							10-28-2020	10-14-2021	10-28-2022
	DY							10-22-2020	10-14-2021	10-22-2022
	D							10-29-2020	10-14-2021	10-29-2022
	С							10-28-2020	10-14-2021	10-28-2022
	DY							10-29-2020	10-14-2021	10-29-2022
	С							10-29-2020	10-14-2021	10-29-2022
	E							10-29-2020	10-14-2021	10-29-2022
	CY							10-29-2020	10-14-2021	10-29-2022
	С							10-29-2020	10-14-2021	10-29-2022
	D							02-16-2021	02-03-2022	02-16-2023
Discussion	comple		or exper	enewal; p fience in -cor	pending euthana mmittee	appt. asia me approv	thods. ed moving	in process of forward with s a campus		
	IACUC	Vote								
	IACUC.								1	
Ann										
	oroval	18								
With	oroval									

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.



### XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-29-2021		
2. 08-20-2021		
3. 09-27-2021		
4. 09-27-2021		
5. 09-29-2021		

Discussion:	4. Minor deficiency for yearly eyewash/shower check. Monthly checks have been consistently completed.		
Action:	4. Facility sta	ff to receive training/certification to complete annual checks.	
	ACUC Vote		
Appr	oval	18	
With	nold Approval	0	
Absta	ain	0	
Pres	ent	18	

#### XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 09-23-2021	LAB	
2. 09-24-2021	PAM	

Discus	sion: None.	
Ac	tion: None.	
г		
	IACUC V	/ote
	Approval	17
	Withhold App	roval 0
	Abstain	0
	Present	17

### XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс		
	EU- ALL course GUIDE FOR THE CARE AND USE OF AGRICULTURAL RESEARCH AND TEACHING (4TH EDITION)	
	4th edition of the AG Guide adopted by AAALAC council. Voted to add this training for IACUC members.	
	Committee approved adding this ALL training module for CE of all members to be completed by 12/31/21.	

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

### October 28, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

### Present:

M009, M097, M222, M102, M111, M042, A095, M004, M100, M092, A019, A109, M110, M093, A013, M016, M024, M001, M114

#### Excused:

M090, M119, M087, M223, M112

#### Guests:

M224, M116, A017, A018

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

### II. Protocols Tabled From Previous Meetings:

1. #		Category: D Y
The protocol was reviewed meeting:	d an	d the following points were addressed by the Principal Investigator prior to the
references, proced Additional discussion durin a. Reviewer reques	ure f ng th sted	ne meeting included: additional time to review responses to previous clarification requests. Approved
for designated men	nean	review.
Approval	0	
Withhold Approval	0	
Abstain	0	
Present	19	

### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

#### IV. Reports of Concern, Events and Incidents:

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
CABA Trees
Action: Grounds following up.
Records Request from "US Right to Know"
Action: Request for old records no longer available due to retention policy.
Action: PI maintained form to address housekeeping, room, records.

### V. Veterinary Care Program Updates:

	The Attending Veterinarian provided the following updates to the committee:
I	None at this time.

# VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	D		-
prior to the meet a. Pendin Additional discus	ing: g Pl.	the following points were addressed by the Princip e meeting included:	oal Investigator
2. #	D		-
prior to the meet a. Protoco Additional discus a. Pendin	ing: ol needs revisio ssion during the g re-review and	e meeting included:	oal Investigator
3. #	DY		-
prior to the meet a. Pendin Additional discus	ing: g completion of ssion during the	the following points were addressed by the Princip f space renovation and approval. e meeting included: f space renovation and approval. Remains in DMR	-
4. #	D		10-25-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip e meeting included:	bal Investigator
5. #	DY		-
prior to the meet a. Pendin Additional discus	ing: g Pl's response	the following points were addressed by the Principes. e meeting included:	bal Investigator
6. #	E		-
prior to the meet a. Pendin Additional discus	ing: g Pl	the following points were addressed by the Princip meeting included:	oal Investigator
7.#	С		-
prior to the meet a. Pendin	ing: g final BUA app	the following points were addressed by the Princip proval and facilities approval of room. e meeting included:	bal Investigator

a. Remains in DMR.						
8. #	С		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending final BUA approval and facilities approval of room. Additional discussion during the meeting included: a. Remains in DMR.						
9. #	D		-			
prior to the meet a. None. Additional discus	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Pending updated BUA.					
10. #	DY		-			
prior to the meet a. Pair ho b. Pendin Additional discus	iing: osing criteria cla g EH&S review		bal Investigator			
11. #	С		-			
prior to the meet a. Source b. Drug d	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Source of animals. b. Drug dose clarification Additional discussion during the meeting included:					
12. #	СҮ		10-27-2021			
prior to the meet a. Lab fre	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Lab frequency clarified. Additional discussion during the meeting included: a. None					
13. #	E		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarifications of numbers justification. b. Clarification of euthanasia criteria. c. Clarification of testing frequency. d. Clarification of AAV pharmaceutical grade and injection procedure. Additional discussion during the meeting included: a. Pending more questions from reviewer.						
14. #	С		-			
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of procedures, consent, and roster. Additional discussion during the meeting included: a. Pending reviewer.						
15. #	С		10-14-2021			

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:						
a. None.						
	Additional discussion during the meeting included: a. None.					
16. #	DY		10-20-2021			
		the following points were addressed by the Princip				
prior to the meet		the following points were addressed by the Frincip	ai investigator			
	contraceptive f	ailure rate.				
		e meeting included:				
a. None.	-	-				
17. #	D		10-21-2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	al Investigator			
prior to the meet			-			
		loss in procedures section and adverse effects.				
	ssion during the	meeting included:				
a. None.						
18. #	CY		10-14-2021			
		the following points were addressed by the Princip	oal Investigator			
prior to the meet						
	exam frequenc pairing exempt					
		e meeting included:				
a. None.	ssion during the	Theeding moldaed.				
19. #	С		10-18-2021			
			10 10 2021			
The protocol was	s reviewed and	the following points were addressed by the Princip	oal Investigator			
prior to the meet						
	ation of advers					
a. None.	ssion during the	e meeting included:				
	С		10.29.2021			
20. #			10-28-2021			
The protocol way	s reviewed and	the following points were addressed by the Princip	al Investigator			
prior to the meet		the following points were addressed by the finiting	arinvestigator			
a. None.						
Additional discus	ssion during the	e meeting included:				
a. one DF	R reviewer confi	irmed approval during the meeting.				
21. #	С		10-28-2021			
	The protocol was reviewed and the following points were addressed by the Principal Investigator					
	prior to the meeting:					
		regarding animal numbers and groups. • meeting included:				
a. None.	soon during the					
22. #	DY		10-20-2021			
		the following points were addressed by the Drippin				
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:						
a. Clarification on timepoints.						
Additional discussion during the meeting included:						
a. None.		-				
23. #	С		10-27-2021			

prior to the meet		the following points were addressed by the Princip	oal Investigator
	ssion during the g questions ado	e meeting included: dressed.	
24. #	В		10-18-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
25. #	С		10-28-2021
prior to the meet a. None. Additional discus	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
a. None.	СҮ		-
prior to the meet a. Clarify b. Clarify Additional discus	iing: age range. requested tissu	the following points were addressed by the Princip e collection and purpose. e meeting included:	oal Investigator
27.#	С		10-27-2021
prior to the meet a. Clarifie	ing: d timing.	the following points were addressed by the Princip meeting included:	ai investigator
28. #	D		10-28-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	oal Investigator
29. #	D		10-18-2021
prior to the meet a. Update	ing: ed VHSSs.	the following points were addressed by the Princip meeting included:	oal Investigator
30. #	D		-
prior to the meet a. Pendin Additional discus	ing: g Pl.	the following points were addressed by the Princip meeting included:	oal Investigator
31. #	С		10-14-2021
prior to the meet a. Clarifie	ing: d breeding prod	the following points were addressed by the Princip cedures. meeting included:	oal Investigator

a. None.			
32. #	СҮ		10-28-2021
prior to the meet a. Fixed ir	ing: nconsistency in	the following points were addressed by the Princi numbers. meeting included:	bal Investigator
33. #	С		10-15-2021
prior to the meet a. Clarifie	ing: d numbers add	the following points were addressed by the Principed VHSS. meeting included:	
34. #	С		10-28-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princi	pal Investigator
35. #	ΒY		10-25-2021
prior to the meet a. None.	ing:	the following points were addressed by the Princip meeting included:	pal Investigator

# VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved			
1.#	D		10-28-2021			
Investigator prio a. Clarific	r to the meeting ation of animal		rincipal			
2. #	D		10-20-2021			
Investigator prio a. Clarific	r to the meeting ation regarding	and the following points were addressed by the P breeding procedures, group sizes and publication meeting included:				
3. #	С		10-28-2021			
Investigator prio a. Clarifie	The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified numbers. Additional discussion during the meeting included:					
4. #	DY		10-28-2021			
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.						
5.#	DY		10-15-2021			

Investigator prior a. Clarify	r to the meetin		
a. Clarify			
		anket request.	
		nmune response.	
		termination process.	
		h and decision to graft.	
		arding spillage or contamination. g. Clarify any imp	act on
	uppression pro		
Additional discus a. None.	sion during th	e meeting included:	-
6. #	D		10-12-2021
The amendment	was reviewed	I and the following points were addressed by the Pr	rincipal
Investigator prior	to the meetin	g:	
a. Added	VHSS.		
	sion during th	e meeting included:	
a. None.			
7.#	D		10-14-2021
The amendment	was reviewed	I and the following points were addressed by the Pr	rincipal
Investigator prior			
a. None.		5.	
	sion durina th	e meeting included:	
a. None.	j	- ······	
8.#	С		_
	-	l and the following points were addressed by the Pr	ringingl
			nncipai
Investigator prior			
	ation of proce		
		e meeting included:	
a. Pendin	g PI.		
9. #	DY		10-27-2021
The amendment	was reviewed	I and the following points were addressed by the Pr	rincipal
		I and the following points were addressed by the Pr g:	rincipal
Investigator prior	to the meetin		rincipal
Investigator prior a. Clarific	r to the meetin ation on anest	g:	rincipal
Investigator prior a. Clarific	r to the meetin ation on anest	g: hesia and recovery procedures.	rincipal
Investigator prior a. Clarific Additional discus a. None.	r to the meetin ation on anest	g: hesia and recovery procedures.	
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b>	to the meetin ation on anest sion during th D Y	g: hesia and recovery procedures. e meeting included:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment	to the meetin ation on anest ssion during th D Y was reviewed	g: thesia and recovery procedures. e meeting included:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior	to the meetin ation on anest ssion during th D Y was reviewed	g: thesia and recovery procedures. e meeting included:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None.	to the meetin ation on anest ssion during th D Y was reviewed to the meetin	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus	to the meetin ation on anest ssion during th D Y was reviewed to the meetin	g: thesia and recovery procedures. e meeting included:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None.	to the meetin ation on anest soin during th D Y was reviewed to the meetin soion during th	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g:	10-19-2021 rincipal
nvestigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment nvestigator prior a. None. Additional discus	to the meetin ation on anest ssion during th D Y was reviewed to the meetin	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g:	10-19-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b>	to the meetin ation on anest ssion during th D Y was reviewed to the meetin ssion during th C Y	g: thesia and recovery procedures. e meeting included: I and the following points were addressed by the Pr g: e meeting included:	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed	g: thesia and recovery procedures. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin	g: thesia and recovery procedures. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g:	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings.	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding	g: thesia and recovery procedures. e meeting included: I and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g:	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings.	10-19-2021 rincipal 10-28-2021
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings.	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b>	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding soion during th D Y	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b>	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding soion during th D Y was reviewed	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b>	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding soion during th D Y was reviewed	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b> The amendment Investigator prior a. None.	to the meetin ation on anest soin during th D Y was reviewed to the meetin soin during th C Y was reviewed to the meetin ation regarding soin during th D Y was reviewed to the meetin	g: hesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b> The amendment Investigator prior a. None. Additional discus	to the meetin ation on anest soin during th D Y was reviewed to the meetin soin during th C Y was reviewed to the meetin ation regarding soin during th D Y was reviewed to the meetin	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b> The amendment Investigator prior a. None. Additional discus a. None.	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding soion during th D Y was reviewed to the meetin soion during th	g: hesia and recovery procedures. e meeting included: and the following points were addressed by the Pr g: e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Pr g: g can food and dry food feedings. e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal 10-27-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b> The amendment Investigator prior a. None. <b>13. #</b>	to the meetin ation on anest soion during th D Y was reviewed to the meetin soion during th C Y was reviewed to the meetin ation regarding soion during th D Y was reviewed to the meetin soion during th c to the meetin	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal 10-27-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10.</b> # • • • • • • • • • • • • • • • • • •	to the meetin ation on anest ssion during th D Y was reviewed to the meetin ssion during th C Y was reviewed to the meetin ation regarding ssion during th D Y was reviewed to the meetin ssion during th c C was reviewed	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: and the following points were addressed by the Prig: e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal 10-27-2021 rincipal
Investigator prior a. Clarific Additional discus a. None. <b>10. #</b> The amendment Investigator prior a. None. Additional discus a. None. <b>11. #</b> The amendment Investigator prior a. Clarific Additional discus a. None. <b>12. #</b> The amendment Investigator prior a. None. <b>13. #</b>	to the meetin ation on anest ssion during th D Y was reviewed to the meetin ssion during th C Y was reviewed to the meetin ation regarding ssion during th D Y was reviewed to the meetin ssion during th c C was reviewed	g: thesia and recovery procedures. e meeting included: and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: g can food and dry food feedings. e meeting included: I and the following points were addressed by the Prig: e meeting included: I and the following points were addressed by the Prig: and the following points were addressed by the Prig: e meeting included:	10-19-2021 rincipal 10-28-2021 rincipal 10-27-2021 rincipal

Additional discus	ssion during the	meeting included:	
14. #	С		10-27-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio		• • • •	
a. None.	-		
Additional discus a. None.	ssion during the	meeting included:	
15. #	DY		10-28-2021
		and the following points were addressed by the Pr	incipal
Investigator prior			
		y needed the update.	
	ssion during the	meeting included:	
a. None.			
16. #	D		10-28-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	r to the meeting	i.	
a. None.		we attend to the dealer	
a. None.	ssion during the	meeting included:	
			40.00.0004
17.#	D		10-28-2021
		and the following points were addressed by the Pr	incipal
Investigator prior a. None.	r to the meeting	:	
	ssion during the	meeting included:	
a. None.	ssion during the	meeting metudeu.	
18. #	E		10-25-2021
10. 1	-		10-20-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			
a. None.	-		
	ssion during the	meeting included:	
a. None.			
19. #	D		10-14-2021
		and the following points were addressed by the Pr	incipal
Investigator prio		: s made for clarity of intent.	
		meeting included:	
a. None.	ssion during the	meeting meldded.	
20. #	DY		10-28-2021
	1	and the following points were addressed by the Pr	
Investigator prior			incipal
a. None.	r to the meeting		
	ssion during the	meeting included:	
a. None.		5	
21. #	DY		10-27-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio			litopal
a. None.			
Additional discus	ssion during the	meeting included:	
a. None.			
22. #	D		10-27-2021

The amendment was reviewed and the following points were addressed by the Principal						
Investigator prio						
a. Clarification on the animal model and weight. Additional discussion during the meeting included:						
Additional discus a. None.	ssion during the	e meeting included:				
23. #	DY		10-26-2021			
The amendment	t was reviewed	and the following points were addressed by the Pr	incipal			
Investigator prio	r to the meeting	;				
a. None.						
Additional discus a. None.	ssion during the	e meeting included:				
24. #	D		10-28-2021			
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal			
Investigator prio						
		ectives as it relates to original protocol.				
	ssion during the	e meeting included:				
a. None.						
25. #	D		-			
		and the following points were addressed by the Pri	incipal			
Investigator prio						
	ation of proced					
		e meeting included:				
a. Pendin	-					
26. #	DY		-			
		and the following points were addressed by the Pri	incipal			
Investigator prio						
		Contact following phone consultation with AV.				
		meeting included:				
	-	Contact following phone consultation with AV.				
27.#	DY		-			
		and the following points were addressed by the Pri	incipal			
Investigator prio						
		Contact following phone consultation with AV.				
		meeting included:				
	-	Contact following phone consultation with AV.				
28. #	C		-			
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal			
Investigator prio	r to the meeting	li -				
a. None.						
		e meeting included:				
a. Pendin	-					
29. #	C		10-28-2021			
		and the following points were addressed by the Pri	incipal			
Investigator prio	r to the meeting	r.				
a. None.						
	ssion during the	e meeting included:				
a. None.						
30. #	D		10-27-2021			
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal			
Investigator prio						
		protocol with qualifications requested by reviewer.				
Additional discus	ssion during the	e meeting included:				

a. None.							
31. #	С				10-20-2021		
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. CLarification of possible adverse effects and prevention methods requested. Additional discussion during the meeting included: a. None.							
32. #	D				10-28-2021		
32. # D       D       10-28-2021         The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         a. None.       Additional discussion during the meeting included:         a. None.       Additional discussion during the meeting included:							

# VIII. Administrative and Veterinary Verification Amendments:


Total of **188** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.


## IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

	otocol	Catego	ry	Title	Date Approved
1. #		DY			10-28-2021
orior to Additio	o the meet a. IACUC clarity. onal discus a. Discus	ting: staff work ssion durin <u>sed compl</u> UC Vote	king v ng the	the following points were addressed by the Princip with PI to remove unnecessary text, edit and rearra e meeting included: text modifications and wording semantics.	-
	Withhold Abstain Present	l Approval	0 2 19		
2. #		CY			12-02-2021
orior to	a. Discus a. Discus nal discus a. Approv	ting: s and reco ssion durin ved for DM	omm ng th	I the following points were addressed by the Princip end removal of unnecessary references to euthana e meeting included:	-
		UC Vote			
	Approva		0		
	Approva		- T		
	Approva		- T		
	Approva Withhold		0		

	The protocol was reviewed and the following points were addressed by the Principal Investigator							
prior to the meeting:								
	a. Clarification of numbers rationale and groups.							
	b Further describe exam procedures, sedation, and special positioning.							
	c. Housing post AAV administration.							
	d. Animal ages. Additional discussion during the meeting included:							
				ie meeting metuded.				
	a. Approved for DMR.							
	Approva		0					
	Withhold	d Approval	0					
	Abstain		0					
	Present		19					
4. #		DY			10-28-2021			
	eteeel wa			d the following points were addressed by the Drinsin				
	the mee		an	d the following points were addressed by the Princip	arinvestigator			
			valu	ation wording.				
				ne meeting included:				
	a. None.		ig u					
		UC Vote						
			10					
	Approva		19					
	Withhold	d Approval	0					
	Abstain		0					
	Present		19					
5. #		DY			10-29-2021			
J. 7					10-23-2021			
		<u> </u>						
The pr	otocol wa	e roviowod	l on	d the following points were addressed by the Princip	al Investigator			
			an	d the following points were addressed by the Princip	al Investigator			
prior to	the mee	ting:			al Investigator			
prior to	the mee a. clarity	ting: the housin	g of	the animals after AAV administration.	al Investigator			
prior to Additio	the mee a. clarity nal discu	ting: the housin ssion durin	g of ng th		al Investigator			
prior to Additio	the mee a. clarity nal discu a. Appro	ting: the housin ssion durin ved for DM	g of ng th	the animals after AAV administration.	al Investigator			
prior to Additio	the mee a. clarity nal discu a. Appro IAC	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR.	the animals after AAV administration.	al Investigator			
prior to Additio	a. clarity nal discu a. Appro IAC Approva	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR. 0	the animals after AAV administration.	al Investigator			
prior to Additio	a the mee a. clarity nal discu a. Approv IAC Approva Withhold	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR. 0	the animals after AAV administration.	al Investigator			
prior to Additio	a. clarity nal discu a. Appro IAC Approva	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR. 0	the animals after AAV administration.	al Investigator			
prior to Additio	a the mee a. clarity nal discu a. Approv IAC Approva Withhold	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR. 0 0	the animals after AAV administration.	al Investigator			
prior to	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain	ting: the housin ssion durin ved for DM CUC Vote Il d Approval	g of ng th IR. 0 0 0	the animals after AAV administration.				
prior to Additio	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain	ting: the housin ssion durin ved for DM CUC Vote	g of ng th IR. 0 0 0	the animals after AAV administration.	al Investigator 01-12-2022			
prior to	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain	ting: the housin ssion durin ved for DM CUC Vote Il d Approval	g of ng th IR. 0 0 0	the animals after AAV administration.				
prior to Additio	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain Present	ting: the housin ssion durin ved for DM UC Vote I d Approval	g of ng th IR. 0 0 0 19	the animals after AAV administration. ne meeting included:	01-12-2022			
prior to Additio 6. #	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain Present	ting: the housin ssion durin ved for DM UC Vote d Approval	g of ng th IR. 0 0 0 19	the animals after AAV administration.	01-12-2022			
prior to Additio 6. #	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present	ting: the housin ssion durin ved for DM UC Vote d Approval D as reviewed ting:	g of ng th IR. 0 0 0 19	the animals after AAV administration. The meeting included:	01-12-2022			
prior to Additio 6. # The prior to	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present	ting: the housin ssion durin ved for DM UC Vote d Approval	g of ng th IR. 0 0 0 19	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo.	01-12-2022			
prior to Additio 6. # The prior to	o the mee a. clarity nal discu a. Approva IAC Approva Withhold Abstain Present	ting: the housin ssion durin ved for DM UC Vote d Approval b s reviewed ting: cation of sp cation of te	g of ng th IR. 0 0 0 19 J an becie	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo.	01-12-2022			
6. #	o the mee a. clarity onal discu a. Approv IAC Approva Withhold Abstain Present Otocol wa o the mee a. Clarific c. Refere d. Clarific	ting: the housin ssion durin ved for DM UC Vote d Approval d Approval b s reviewed ting: cation of sp cation of te ence for stu cation of su	g of ng th IR. 0 0 0 19 J an pecie rms idies	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training.	01-12-2022			
prior to Additio 6. # The pri prior to	o the mee a. clarity onal discu a. Approv IAC Approva Withhold Abstain Present Otocol wa o the mee a. Clarific c. Refere d. Clarific e. Clarific	ting: the housin ssion durin ved for DM UC Vote d Approval d Approval b as reviewed ting: cation of sp cation of sp cation of su cation of su cation of su cation of su	g of ng th IR. 0 0 0 19 d an pecie rms udies urge	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method.	01-12-2022			
prior to Additio 6. # The pri prior to Additio	o the mee a. clarity nal discu a. Approv IAC Approva Withhold Abstain Present Otocol wa b. Clarific c. Refere d. Clarific e. Clarific nal discu	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b as reviewed ting: cation of sp cation of sp cation of su cation of su cation of su cation of su	g of ng th IR. 0 0 0 19 d an pecie rms udies urge	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training.	01-12-2022			
6. #	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present otocol wa b. Clarific c. Refere d. Clarific e. Clarific e. Clarific anal discu a. Pendir	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b as reviewed ting: cation of sp cation of te snce for stu cation of su cation of su cation of su cation of su cation of su	g of ng th IR. 0 0 0 19 J an pecie rms udies urge utha ng th	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. he meeting included:	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present otocol wa b. Clarific b. Clarific c. Refere d. Clarific e. Clarific e. Clarific nal discu a. Pendir b. Explar	ting: the housin ssion durin ved for DM UC Vote al d Approval d Ap	g of ng th IR. 0 0 0 19 J an J an J an J an J an J an J an J an	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva Approva Withholo Abstain Present Otocol wa o the mee a. Clarific b. Clarific c. Refere d. Clarific onal discu a. Pendir b. Explar this has I	ting: the housin ssion durin ved for DM UC Vote al d Approval d Ap	g of ng th IR. 0 0 0 19 J an J an J an J an J an J an J an J an	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva IAC Approva Withhold Abstain Present Otocol wa b. Clarific b. Clarific c. Refere d. Clarific e. Clarific e. Clarific nal discu a. Pendir b. Explar this has I	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b as reviewed ting: cation of sp cation of su cation of su	g of ng th IR. 0 0 0 19 J an udies urge utha ng th icrov at U	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva Approva Withholo Abstain Present Otocol wa o the mee a. Clarific b. Clarific c. Refere d. Clarific onal discu a. Pendir b. Explar this has I	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b as reviewed ting: cation of sp cation of su cation of su	g of ng th IR. 0 0 0 19 J an J an J an J an J an J an J an J an	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present Otocol wa b. Clarific b. Clarific c. Refere d. Clarific onal discu a. Pendir b. Explar this has I IAC Approva	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b as reviewed ting: cation of sp cation of su cation of su	g of ng th IR. 0 0 19 d an ung that icrov at L 0	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			
prior to Additio 6. # The prior to Additio	o the mee a. clarity nal discu a. Approva Approva Withhold Abstain Present Otocol wa b. Clarific b. Clarific c. Refere d. Clarific onal discu a. Pendir b. Explar this has I IAC Approva	ting: the housin ssion durin ved for DM UC Vote al d Approval d Approval b s reviewed ting: cation of sp cation of sp cation of tel ssion durin ng PI. hation of m been used CUC Vote al	g of ng th IR. 0 0 19 d an ung that icrov at L 0	the animals after AAV administration. The meeting included: d the following points were addressed by the Princip es typo. s in numbers justification requested. ons and surgical training. nasia method. The meeting included: wave fixation as a euthanasia method given as this i	01-12-2022 al Investigator			





# X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		11-13-2019	10-28-2021	11-13-2022
	СҮ		10-31-2019	10-28-2021	10-31-2022
	СҮ		10-31-2019	10-28-2021	10-31-2022

D	11-15-	2019	10-28-2021	11-15-2022
DY	10-31-	2019	10-28-2021	10-31-2022
D	11-14-	2019	10-28-2021	11-14-2022
С	11-13-	2019	10-28-2021	11-13-2022
D	10-31-	2019	10-28-2021	10-31-2022
D	11-02-	2019	10-28-2021	11-02-2022
DY	10-31-	2019	10-28-2021	10-31-2022
D	11-19-	2019	10-28-2021	11-19-2022
C	11-14-	2019	10-28-2021	11-14-2022
В	10-31-	2019	10-28-2021	10-31-2022
С	11-12-	2019	10-28-2021	11-12-2022
С	10-31-	2019	10-28-2021	10-31-2022
С	11-12-	2019	10-28-2021	11-12-2022
С	10-30-	2019	10-28-2021	10-30-2022
CY	11-14-	2019	10-28-2021	11-14-2022
С	11-14-	2019	10-28-2021	11-14-2022
DY	11-12-	2020	10-28-2021	11-12-2022
D	11-19-	2020	10-28-2021	11-19-2022
D	11-17-	2020	10-28-2021	11-17-2022
С	10-30-	2020	10-28-2021	10-30-2022
D	11-02-	2020	10-28-2021	11-02-2022
D	11-12-	2020	10-28-2021	11-12-2022
С	11-12-	2020	10-28-2021	11-12-2022
D	11-04-	2020	10-28-2021	11-04-2022
D	11-02-	2020	10-28-2021	11-02-2022


-								
С						0-23-2020	10-28-2021	10-23-2022
DY						11-12-2020	10-28-2021	11-12-2022
D						11-12-2020	10-28-2021	11-12-2022
С						11-06-2020	10-28-2021	11-06-2022
D						11 12 2020	10 28 2021	11-12-2022
						11-12-2020	10-20-2021	11-12-2022
DY						1-12-2020	10-28-2021	11-12-2022
E						0-29-2020	10-28-2021	10-29-2022
CY						1-09-2020	10-28-2021	11-09-2022
С						11-19-2020	10-28-2021	11-19-2022
						14 40 0000	10.00.0001	11 10 0000
С						11-12-2020	10-28-2021	11-12-2022
their in comple cleared Sacrar section at CE- under	- one person ete the pro -one perso d. Staff me mento resu -PI confirm n 9 to be p -PI clarified - no permit federal per - committee - committee - committee	opt. on has expir cess when on has comp mber worki ults added to hed fasting i opulated. d animals a es. listed in ser mit. e approved e approved e approved	red OHSS they retur pleted the ing with or o Davis re is only for re not bein ction 3. Pl renewal. renewal. renewal.	but is on n. OHSS procupation ecords. a few ho ng transp I clarified	process of co sabbatical ar rocess but ha al health to ha urs and does orted to VMT working on fe	nd will s not been ave not require H and remai		
section	-committee	e protocol. e approved			dding the PI's g PI's respon	-		
IACUC	Vote							
Approval	16							
Withhold Ap	proval 0							

# XI. Amendments for Full Committee Review:

Abstain Present 0

16

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.



XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1. 09-21-2021	
2. 09-22-2021	
3. 09-23-2021	
4. 09-29-2021	
5. 09-29-2021	
6. 10-15-2021	
7. 10-21-2021	
8. 10-26-2021	

Discussion: 1. Facilities no	oted some bulbs out. nor deficiencies noted: roster included people who had left the lab, QA testing of
	as overdue, lab staff wearing shorts, and CVS not contacted when last trial was in F
building.	
	wash check was not scheduled and some rooms needed touch up painting. rash was overflowing.
	wash check and hood check were overdue. Rooms needed touch up painting.
Action: 1. W/O place	
	d all deficiencies and provided plan to prevent them in the future. itted for both deficiencies.
4. PI correcte	d deficiency and will implement removing trash more frequently.
5. W/O submi	itted to correct deficiencies.
IACUC Vote	
Approval	16
Withhold Approval	0
Abstain	0
Present	16
<u>,                                     </u>	

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1.09-13-2021	LAB	
2.09-23-2021	LAB	
3. 09-29-2021	LAB	
4. 10-11-2021	LAB	
5. 10-13-2021	LAB	
6. 10-18-2021	LAB	
7. 10-20-2021	LAB	
8. 10-27-2021	LAB	
9. 10-27-2021	LAB	
10. 07-29-2021	PAM	
11. 07-29-2021	PAM	
12.07-29-2021	PAM	
13.09-02-2021	PAM	
14. 09-23-2021	PAM	
15. 09-27-2021	PAM	
16. 10-13-2021	PAM	
17. 10-13-2021	PAM	
18. 10-14-2021	PAM	

Discussion	None.	
Action	None.	
	IACUC Vote	
Арр	roval	17
With	hold Approval	0
Abs	ain	0
Pres	ent	17

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

## Topic

1. End of year meeting date reminder: 11/18/21; 12/2/21, 12/16/21. Resume January 6, 2022.

Discussion: FYI reminder.

Action: None.

Action: None.

2. Core and Facility SOP's and IACUC Review

Discussion: FYI for future application.

XVI. Program Updates:

## Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### November 18, 2021 Meeting Minutes

#### [regular view | VA view]

#### Attendance:

### Present:

M009, M097, M102, M111, M042, A095, M100, M092, A019, M119, M087, A109, M110, A013, M016, M024, M223, M001, M114

#### Excused:

M222, M090, M004, M093, M112

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### **II. Protocols Tabled From Previous Meetings:**

There were no tabled protocols for discussion.

### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents:
Action: Discussed non-compliance, PAM, and action plan moving forward.
FYI - VA public records request courtesy review
Action: None; FYI
FYI - Dart capture (CNPRC)
Action: lameness, under veterinary observation.
FYI - Public Records Request (PETA) CNPRC necropsy records
Action: None; FYI
Additional FYI on notification of SAEN's request to USDA re coyote activity

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

None at this time.

#### VI. Designated Review Protocols:


Protocol Category Title	Date Approved
-------------------------	------------------

	_		
1. #	D		-
The protocol wa	s reviewed and	the following points were addressed by the Princip	al Investigator
prior to the meet a. Pendin	ting:	the following points were addressed by the Princip	a investigator
		meeting included:	
a. Remai	ns in DMR.		
2. #	D		-
		the following points were addressed by the Princip	oal Investigator
prior to the meet		D and Cham	
	ig re-review, BIC	meeting included:	
	ig Bio and Cher		
	-		
3. #	DY		-
		the following points were addressed by the Princip	oal Investigator
prior to the meet			
		Dex treatment.	
b. larify A	queous Humor	(AH)Outflow facility measurements.	
		of the Simbadol use.	
		pertension as potential adverse effect.	
		meeting included:	
	n in DMR.		
4. #	DY		11-01-2021
The protocol wa	s reviewed and	the following points were addressed by the Princip	oal Investigator
prior to the meet			
		o remove hold posed by renovation.	
	ssion during the	meeting included:	
a. None.			
5. #	DY		-
		the following points were addressed by the Princip	oal Investigator
prior to the meet	ing. Ig PI's response		
		meeting included:	
	ns in DMR.	meeting moldeed.	
6. #	E		-
The protocol wa	s reviewed and	the following points were addressed by the Princip	oal Investigator
prior to the meet			
a. Pendin			
Additional discus	ssion during the	meeting included:	
	ns in DMR.		
7.#	С		-
The protocol wa	s reviewed and	the following points were addressed by the Princip	oal Investigator
prior to the meet			<b>-</b>
	ation of animal	numbers.	
Additional discus	ssion during the	meeting included:	
		cation of numbers with PI.	
8. #	С		-

prior to the meet	ting:	the following points were addressed by the Princip	oal Investigator
Additional discus	g BUA and VH ssion during the ns in DMR.	SS. e meeting included:	
9. <b>#</b>	C		-
orior to the meet a. Pendin Additional discus	ting: Ig BUA and VHS	the following points were addressed by the Princip SS. meeting included:	oal Investigator
10. #	D		11-18-2021
prior to the meet a. Room	ting: approval and B	the following points were addressed by the Princip UA approval. e meeting included:	bal Investigator
11. #	DY		10-29-2021
prior to the meet a. Added	ting: new VHSS's pr	the following points were addressed by the Princip rovided by Chem Safety. e meeting included:	5
12. #	СҮ		-
a. Euthar		meeting included: s not part of this study to be removed. Remains in	DMR.
13. #	DY		-
prior to the meet a. Clarific b Further c. Housin d. Animal Additional discus	ting: ation of number describe exam g post AAV adn ages ssion during the	the following points were addressed by the Princip rs rationale and groups. procedures, sedation, and special positioning. ninistration. meeting included: ending. Continue in DMR.	oal Investigator
14. #	С		-
prior to the meet a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	bal Investigator
15. #	E		11-17-2021
orior to the meet a. Clarific b. Clarific c. clarific	ting: ation of animal ation of euthan ation of testing f		bal Investigator

a. None.	-	e meeting included:	
16. #	С		10-29-2021
prior to the meet a. Clarific	ting: ation of rabies	t the following points were addressed by the Princi requirement via email. e meeting included:	pal Investigator
17.#	DY		10-29-2021
prior to the meet a. Clarify	ting: housing location	the following points were addressed by the Princi on after AAV administration. e meeting included:	pal Investigator
18. #	D		-
rior to the meet a. None.	ting: ssion during th	t the following points were addressed by the Princi e meeting included:	pal Investigator
19. #	D		11-10-2021
orior to the meet a. Clarific	ting: ation of post-s	the following points were addressed by the Princi urgical monitoring. e meeting included:	pan
20. #	СҮ		-
The protocol wa		the following points were addressed by the Princi	nal Investigator
a. Clarify b. Clarify Additional discus	ting: age range. tissue requirer	nents within stated objective. e meeting included:	
a. Clarify b. Clarify Additional discus	ting: age range. tissue requirer ssion during the		11-16-2021
b. Clarify Additional discus a. Remain 21. # The protocol wa prior to the meet a. Clarifie	ting: age range. tissue requirer ssion during the ns in DNR. D s reviewed and ting: ed Animal dispo		11-16-2021 pal Investigator
a. Clarify b. Clarify dditional discus a. Remai 21. # The protocol wa rior to the meet a. Clarifie	ting: age range. tissue requirer ssion during the ns in DNR. D s reviewed and ting: ed Animal dispo	e meeting included: I the following points were addressed by the Princi osition, dosages, wording, and occupational health	11-16-2021 pal Investigator
a. Clarify b. Clarify dditional discus a. Remain 21. # The protocol was brior to the meet a. Clarifie Additional discus a. None. 22. # The protocol was prior to the meet a. Pendin Additional discus	ting: age range. tissue requirer ssion during the ns in DNR. D s reviewed and ting: ed Animal dispo ssion during the s reviewed and ting: ng PI.	e meeting included: I the following points were addressed by the Princi osition, dosages, wording, and occupational health	11-16-2021 pal Investigator and safety.

The protocol was prior to the meet		the following points were addressed by the Princ	pipal Investigator			
	•	dify study endpoint and disposition.				
b. AAV and disposition review by CNPRC.						
	c. VHSS clarification.					
Additional discus a. None.	ssion during the	e meeting included:				
24. #			11-03-2021			
		the following points were addressed by the Princ	ipal Investigator			
prior to the meet						
		als to be implanted. • meeting included:				
a. None.	ssion during the	meeting medded.				
25. #	В		11-16-2021			
The protocol was	s reviewed and	the following points were addressed by the Princ	ipal Investigator			
prior to the meet						
a. None.						
Additional discus	ssion during the	e meeting included:				
26. #	С					
	-	the following points were addressed by the Princ				
prior to the meet		the following points were addressed by the Frind	ipai investigator			
a. None.						
		e meeting included:				
a. Pendin			1			
27.#	С		11-03-2021			
The protocol was	s reviewed and	the following points were addressed by the Princ	ipal Investigator			
prior to the meet		and following points were addressed by the Frint	ipai investigator			
a. None.	C					
	ssion during the	e meeting included:				
a. None.			44.40.0004			
28. #	D		11-18-2021			
		the following points were addressed by the Princ	ipal Investigator			
prior to the meet		rbital sinus injections.				
Additional discussion during the meeting included: a. None.						
29. #	CY		11-18-2021			
		the following points were addressed by the Princ	ipal Investigator			
prior to the meet		a colony onimal core				
		g colony animal care. e meeting included:				
a. None.		included.				
30. #	CY		11-18-2021			
The protocol was	s reviewed and	the following points were addressed by the Princ	ipal Investigator			
prior to the meeting:						
a. None.	naion during the	meeting included:				
a. None.	ssion during the	e meeting included:				
a						



## VII. Designated Review Amendments:

	Category	Request	Date Approved
1.#	D		-
Investigator pric a. Pendi Additional discu	or to the meeting ng BUA.	and the following points were addressed by the Pr g: e meeting included:	incipal
2. #	D		-
Investigator pric a. Clarifi	or to the meeting ed animal numb		
a. None.			
	D		-
a. None. 3. # The amendmen Investigator pric a. Discus Additional discu	D nt was reviewed or to the meeting ssion on enrichr		- incipal
a. None. 3. # The amendmen Investigator pric a. Discus Additional discu	D nt was reviewed for to the meeting ssion on enrichr ussion during the	g: nent for frogs.	- incipal 11-09-2021
a. None. 3. # The amendmen Investigator prio a. Discus Additional discu a. Rema 4. # The amendmen Investigator prio a. None.	D at was reviewed br to the meeting ssion on enrichr ussion during the ins in DMR. D Y at was reviewed br to the meeting ussion during the	g: nent for frogs. e meeting included: and the following points were addressed by the Pr	11-09-2021

Investigator prior		and the following points were addressed by the Pri :	incipal	
	ssion during the	meeting included:		
a. None.			11-17-2021	
The amendment Investigator prio		and the following points were addressed by the Pri	incipal	
a. None. Additional discus	-	meeting included:		
a. None. 7. #	С		11-18-2021	
		and the following points were addressed by the Pr		
Investigator prior a. Clarific	r to the meeting ation of proced	:	·	
8.#	DY		11-15-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : meeting included:	incipal	
9.#	DY	and the following points were addressed by the Pr	11-18-2021	
b. Addres	length of time, i s potential repa	maximum duration, groups, options.		
10. #	С		11-17-2021	
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pri : meeting included:	incipal	
11. #	D		11-01-2021	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.				
12. #	D		11-03-2021	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.				
Additional discus	ssion during the	meeting included:		
13. #	D		10-29-2021	
Investigator prior a. None.	r to the meeting		incipal	
Additional discus a. None.	ssion during the	meeting included:		

14. #	DY		-
		and the following points were addressed by the Pr	incipal
nvestigator prior			
		al health, subjective behavior evaluations, and ana	algesia specifics.
Additional discus	sion during the	e meeting included:	
a. None.			
15.#	D		11-08-2021
		and the following points were addressed by the Pr	
nvestigator prior			incipal
a. None.	to the meeting	j.	
	sion during the	e meeting included:	
a. None.	Sion during the	e meeting included.	
			44 40 0004
16. #			11-18-2021
		and the following points were addressed by the Pr	incipal
Investigator prior	to the meeting	j:	
a. None.			
	sion during the	e meeting included:	
a. None.			
17.#	С		11-18-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
nvestigator prior			
a. None.			
Additional discus	sion during the	e meeting included:	
a. None.	cion danng are	incoming molaced.	
18. #	D		11-18-2021
			1
		and the following points were addressed by the Pr	incipal
nvestigator prior	to the meeting	<b>j</b> :	
a. None.			
	sion during the	e meeting included:	
a. None.			
19. #	D		10-28-2021
The amendment	was reviewed	and the following points were addressed by the Pr	incipal
have a state of the second	the theory of the second se	<u>]</u> :	
Investigator prior	to the meeting		
a. None.	-		
a. None.	-	e meeting included:	
a. None.	-	e meeting included:	
a. None. Additional discus a. None.	-	e meeting included:	11-03-2021
a. None. Additional discus	ssion during the	e meeting included:	11-03-2021
a. None. Additional discus a. None.	ssion during the	e meeting included:	11-03-2021
a. None. Additional discus a. None. 20. #	ssion during the		
a. None. Additional discus a. None. 20. #	b D was reviewed	and the following points were addressed by the Pr	
a. None. Additional discus a. None. 20. # The amendment Investigator prior	D was reviewed to the meeting	and the following points were addressed by the Pr	
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further	was reviewed to the meeting edits to Conse	and the following points were addressed by the Pr g: ent Form.	
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus	was reviewed to the meeting edits to Conse	and the following points were addressed by the Pr	
a. None. Additional discus a. None. 20. # The amendment nvestigator prior a. Further Additional discus a. None.	D was reviewed to the meeting edits to Conse ssion during the	and the following points were addressed by the Pr g: ent Form.	incipal
a. None. Additional discus a. None. 20. # The amendment nvestigator prior a. Further Additional discus	was reviewed to the meeting edits to Conse	and the following points were addressed by the Pr g: ent Form.	
a. None. Additional discus a. None. 20. # The amendment nvestigator prior a. Further Additional discus a. None. 21. #	was reviewed to the meeting edits to Conse ssion during the D Y	and the following points were addressed by the Pr g: ent Form. e meeting included:	incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment nvestigator prior a. Further Additional discus a. None. 21. # The amendment	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr	incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment nvestigator prior a. Further Additional discus a. None. 21. # The amendment nvestigator prior	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g:	incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV.	incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included:	incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus a. Phone	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu ssion during the consultation of	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV.	incipal 11-08-2021 incipal
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included:	incipal 11-08-2021
a. None. Additional discus a. None. 20. # 20. #	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu ssion during the consultation of D Y	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included:	incipal 11-08-2021 incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus a. Phone 22. #	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu ssion during the consultation of D Y was reviewed	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included: ccurred with AV; amendment revised. and the following points were addressed by the Pr	incipal 11-08-2021 incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus a. Phone 22. #	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu ssion during the consultation of D Y was reviewed to the meeting to the meeting to the meeting to the meeting to the meeting to the meeting to the meeting	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included: courred with AV; amendment revised. and the following points were addressed by the Pr g:	incipal 11-08-2021 incipal 11-08-2021
a. None. Additional discus a. None. 20. # The amendment Investigator prior a. Further Additional discus a. None. 21. # The amendment Investigator prior a. Reques Additional discus a. Phone 22. #	D was reviewed to the meeting edits to Conse ssion during the D Y was reviewed to the meeting st further consu ssion during the consultation of D Y was reviewed to the meeting st further consu st further consu st further consultation of D Y	and the following points were addressed by the Pr g: ent Form. e meeting included: and the following points were addressed by the Pr g: ultation with AV. e meeting included: ccurred with AV; amendment revised. and the following points were addressed by the Pr	incipal 11-08-2021 incipal 11-08-2021

23. #	С		10-29-2021
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	j:	
		numbers and ATS.	
	-	e meeting included:	
a. None.			
24. #	D		11-16-2021
The amendment	t was reviewed	and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	j:	
a. None.			
	ssion during the	e meeting included:	
a. None.			
25. #	D		11-18-2021
		and the following points were addressed by the Pri	incipal
Investigator prio			
		a VHSS was attached.	
a. None.	ssion during the	e meeting included:	
			11 10 0001
26. #			11-18-2021
		and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	j:	
a. None.	a a i a un al unita au Ala a	une etimer in elude du	
a. None.	ssion during the	e meeting included:	
			44.40.0004
27.#	D		11-18-2021
		and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	j:	
a. None.		un estimational calculate	
a. None.	ssion during the	e meeting included:	
	D.Y		44.40.0004
28. #	DY		11-18-2021
		and the following points were addressed by the Pri	incipal
Investigator prio	r to the meeting	j:	
a. None.	coion during the	maating included:	
a. None.	-	e meeting included:	
29. #			11-17-2021
29.#	E		11-17-2021
	 • • • • • • • • • • • • • • • • • • •	and the fellowing points were addressed by the Dri	in almal
Investigator prio		and the following points were addressed by the Pri	incipal
a. None.		j.	
	ssion during the	e meeting included:	
a. None.	ssion during the		
30. #	D		11-18-2021
30. #			11-10-2021
The amendment	t was reviewed	and the following points were addressed by the Pri	incinal
Investigator prio			incipai
a. None.		<b>,</b>	
	ssion during the	e meeting included:	
a. None.	j	, and the second se	
31. #	CY		11-09-2021
	<u> </u>	and the following points were addressed by the Pri	
Investigator prio			nopa
		naximum duration of sedation.	
		meeting included:	
a. None.			


32. #	D				11-18-2021
Investigator prio a. None.	r to the meeting	g:		ddressed by the Pr	incipal
Additional discus a. None.	ssion during the	e meeting inclu	ded:		


## VIII. Administrative and Veterinary Verification Amendments:

Total of **279** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.





# X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	E		11-20-2019	11-18-2021	11-20-2022
	E		11-25-2019	11-18-2021	11-25-2022

DY	11-20-2019	11-18-2021	11-20-2022
DY	11-27-2019	11-18-2021	11-27-2022
E	11-22-2019	11-18-2021	11-22-2022
С	11-13-2019	11-18-2021	11-13-2022
С	11-25-2019	11-18-2021	11-25-2022
	11-26-2019	11-18-2021	11-26-2022
С	12-02-2019	11-18-2021	12-02-2022
С	12-02-2019	11-18-2021	12-02-2022
С	11-27-2019	11-18-2021	11-27-2022
E	12-03-2020	11-18-2021	12-03-2022
D	12-03-2020	11-18-2021	12-03-2022
D	11-12-2020	11-18-2021	11-12-2022
С	11-25-2020	11-18-2021	11-25-2022
DY	12-03-2020	11-18-2021	12-03-2022
DY	12-03-2020	11-18-2021	12-03-2022
С	11-30-2020	11-18-2021	11-30-2022
С	12-01-2020	11-18-2021	12-01-2022
D	12-02-2020	11-18-2021	12-02-2022
С	12-03-2020	11-18-2021	12-03-2022
DY	12-03-2020	11-18-2021	12-03-2022
С	12-02-2020	11-18-2021	12-02-2022
DY	12-03-2020	11-18-2021	12-03-2022
E	12-03-2020	11-18-2021	12-03-2022
DY	12-02-2020	11-18-2021	12-02-2022
D	11-23-2020	11-18-2021	11-23-2022
С	12-03-2020	11-18-2021	12-03-2022
D	12-03-2020	11-18-2021	12-03-2022

C	12-03-2	020	11-18-2021	12-03-2022
0	12-03-2	020	11-10-2021	12-00-2022
D	2-03-2	020	11-18-2021	12-03-2022
СҮ	2-03-2	020	11-18-2021	12-03-2022
DY	12-03-2	020	11-18-2021	12-03-2022


Discu	appointment. - Liter submitted an Revie confirmed an	and <b>and</b> = At least one staff member is r OHSS renewal process. Must complete in person ature search inadvertently missing from original protocol. Pl nendment on other protocol for same search criteria. ewed amendments for jealousy study and boxing. Committee by distress in jealousy study is momentary and animals in box postural movement.
Action	renewals. - Com protocol. Com	and Committee voted to approve amittee approved adding literature search results to original mittee approved adding wording to clarify momentary distress having normal postural movement.
	IACUC Vote	
	Approval	14
	Withhold Approval	0
	Abstain	0
	Present	14


# XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	otocol	Catego	ory	Request	Date Approved
1.#		СҮ		mais 11	
nvestię Additio	gator prior a. Anesthe nal discus a. None.	to the me esia, anal sion durin	etin gesi	and the following points were addressed by the Pri g: c clarification. e meeting included:	incipal
		JC Vote			
	Approval		18		
	Withhold	Approval	0		
	Abstain		0		
	Present		18		
2. #		D			11-18-2021
Investi	gator prior a. Confirm	to the me nation for i	etin revie	and the following points were addressed by the Pr g: wer that changes will be added to the protocol. e meeting included:	incipal

a. None.				
IAC	UC Vote			
Approval		18		
	Approval	0		
Abstain		0		
Present		18		
3. #	DY	10		04-28-2022
5. #				04-20-2022
Investigator prio a. Additio b. Clarify pathology New surg Additional discus a. Approv IAC Approval Withhold Abstain Present	r to the meen nal scientifi relation of leon training ssion during red for DMF UC Vote	eting requ ig. g the R. 0	a and the following points were addressed by the Pr ag: ustification requested for transfer. uest and potential mitigation measures with previou e meeting included:	·
nvestigator prio	r to the me	etin		rincipal
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval	r to the med ved procedu ssion during ittee approv UC Vote	eting ure g the ved		rincipal
The amendment Investigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain	r to the med ved procedu ssion during ittee approv UC Vote	eting g the ved 18 0 0	g: differences and lab inspection report. le meeting included:	
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None.	r to the mee ved procedu ssion during ittee approv UC Vote Approval Approval D Y was review r to the mee ssion during	etin lure g th ved 18 0 0 18 wed	ig: differences and lab inspection report. ie meeting included: I clarification.	11-18-2021
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC	r to the mee ved procedu ssion during ittee approv UC Vote Approval Approval D Y was review r to the mee ssion during UC Vote	etin ure g th ved 18 0 18 0 18 wed the	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	11-18-2021
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval	r to the mee ved procedu ssion during ittee approv UC Vote Approval Approval D Y was review r to the mee ssion during UC Vote	eting ure g the ved 18 0 18 wed eting g the 18	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	11-18-2021
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval Withhold Withhold	r to the mee ved procedu ssion during ittee approv UC Vote Approval Approval D Y was review r to the mee ssion during UC Vote	etin ure g the ved 18 0 0 18 wed etin g the 18 0	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	11-18-2021
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain	r to the med ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the med ssion during UC Vote Approval	etin ure g th ved 18 0 0 18 wed etin 18 0 0	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	11-18-2021
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain Present	r to the med ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the med ssion during UC Vote Approval	etin ure g the ved 18 0 0 18 wed etin g the 18 0	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	11-18-2021 rincipal
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain	r to the med ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the med ssion during UC Vote Approval	etin ure g th ved 18 0 0 18 wed etin 18 0 0	ig: differences and lab inspection report. he meeting included: l clarification. d and the following points were addressed by the Pring:	<b>11-18-2021</b> rincipal
The amendment investigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment investigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain Present 6. # The amendment investigator prior a. None. Additional discus	r to the meet ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the meet Approval UC Vote Approval UC Vote Approval	etin ure g the ved 18 0 0 18 wed etin 18 0 0 18 wed etin	I differences and lab inspection report. The meeting included: I clarification. I and the following points were addressed by the Program the meeting included: The meeting included:	11-18-2021 rincipal
The amendment investigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment investigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain Present 6. # The amendment investigator prior a. None. Additional discus a. None.	r to the med ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the med ssion during UC Vote Approval D Y was review r to the med ssion during	etin ure g the ved 18 0 0 18 wed etin 18 0 0 18 wed etin	differences and lab inspection report. The meeting included: I clarification. A and the following points were addressed by the Prog: The meeting included: The meeting included: A and the following points were addressed by the Prog.	11-18-2021 rincipal
The amendment nvestigator prior a. Review Additional discus a. Comm IAC Approval Withhold Abstain Present 5. # The amendment nvestigator prior a. None. Additional discus a. None. IAC Approval Withhold Abstain Present 6. # The amendment nvestigator prior a. None. Additional discus a. None.	r to the mee ved procedu ssion during ittee approv UC Vote Approval D Y was review r to the mee ssion during UC Vote Approval D Y was review r to the mee ssion during UC Vote	etin ure g the ved 18 0 0 18 wed etin 18 0 0 18 wed etin	differences and lab inspection report. The meeting included: I clarification. A and the following points were addressed by the Prog: The meeting included: The meeting included: A and the following points were addressed by the Prog.	11-18-2021 rincipal





## XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-20-2021		
2. 08-11-2021		
3. 10-21-2021		
5. 10-21-2021		

4. 10-22-202	1	
5. 10-26-202	1	
6. 10-27-202	1	
Discussion:		ill be completely retrofitted so some work orders may remain open until the
	renovation begi	
	6. One staff me	mber on the roster had and expired OHSS. One door is not shutting properly.
Action:		vill re-evaluate timelines for facility repairs at the next semi-annual inspection.
		mber had left months ago and it was missed they had not been taken off the
	roster. Work ord	ler submitted for the door.
	ACUC Vote	
Appro	oval 15	5
Withh	old Approval 0	
Absta	ain 0	
Prese	ent 15	5

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 05-19-2021	LAB	
2. 08-11-2021	LAB	
3. 10-01-2021	LAB	
4. 10-07-2021	LAB	
5. 10-12-2021	LAB	
6. 10-18-2021	LAB	
7. 10-18-2021	LAB	
8. 10-18-2021	LAB	
9. 10-25-2021	LAB	
10. 11-02-2021	LAB	
11. 11-04-2021	LAB	
12. 11-08-2021	LAB	
13. 11-10-2021	LAB	
14. 07-29-2021	PAM	
15. 10-21-2021	PAM	
16. 10-25-2021	PAM	
17. 10-29-2021	PAM	
18. 11-04-2021	PAM	

		procedures or	t discussed under FC section. Clarified analgesia for all n protocol and added room inadvertently left off previous
A	ction:	9. Committee	approved changes.
	-		
	IACUC Vote		
	Appro	oval	16
	Withhold Approval 0		0
	Absta	ain	0
	Prese	ent	16

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс				
1. Polices re	ady for review:			
-04 "IACUC Laboratory/Study Area Inspection Program"				
-19 "Laboratory Housing for Research Animals"				
-45 "IACUC Semi-Annual Program Review (SAPR)"				
	nd Fluid Regulation Policy for Rodents"			
-56 "Non-aff	iliated Member Recruitment and Appointment Process"			
Discussion:	04 returns to sub committee 19 Approved 45 Approved 55 Approved 56 Approved			
Action:	None.			
2. IACUC 10	1 Plus Workshop (Zoom Dec 1-2, 10AM-2PM)			
Register by	Nov 30.			
Discussion:	Online opportunity for IACUC 101 course.			
Action:	Interested Committee members to contact IACUC office by 11/30/21.			
3. Complete	ALL course by 12/31/21.			
Discussion:	Reminder regarding AG Guide course assigned to committee members.			
Action:	All members to complete course by 12/31/21.			

# XVI. Program Updates:

# Topic

There were no program updates provided during the meeting.

# University of California, Davis IACUC Business Administration System

### December 02, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

## Present:

M009, M097, M222, M102, M111, M090, A095, M004, M092, A019, M119, M087, A109, M110, A013, M016, M024, M223, M001, M114

### Excused:

M042, M100, M093, M112

### Guests:

M224, M116, A017, A018

### I. Minutes from Previous Meetings:

There are no previous meeting minutes for discussion.

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

### III. Amendments Tabled From Previous Meetings:

There were no tabled amendments for discussion.

### IV. Reports of Concern, Events and Incidents:

There have been no Concerns, Events, or Incidents reported.

# V. Veterinary Care Program Updates:

Tł	he Attending Veterinarian provided the following updates to the committee:
	None at this time.

### VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved		
1. #	D		-		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Pending PI response. Additional discussion during the meeting included: a. Remains in DMR.					
2. #	D		11-19-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. pending meeting and rewrite and chem Additional discussion during the meeting included: a. pending chem					

3. #	DY		12-02-2021
prior to the meet a. Clarific b. larify A c. Clarify d. Inclusio Additional discus a. None. 4. # The protocol wa prior to the meet a. Pendin Additional discus	ting: ation regarding queous Humor stated purpose on of ocular hyp ssion during the <b>D Y</b> s reviewed and ting: ng PI's response ssion during the	(AH)Outflow facility measurements. of the Simbadol use. pertension as potential adverse effect. meeting included: the following points were addressed by the Princip	-
	ns in DMR.		
5. #	<u> </u>		12-02-2021
prior to the meet a. Clarific	ting: ation on the pro	the following points were addressed by the Princip ocedure. meeting included:	ai Investigator
6. #	С		11-30-2021
	r clarification of ssion during the C	numbers. meeting included:	-
prior to the meet a. Pendir Additional discu	ting: ng BUA and VHS	the following points were addressed by the Princip SS. meeting included:	al Investigator
8. #	С		-
prior to the meet a. Pendir Additional discu	ting: ng BUA and VHS	the following points were addressed by the Princip SS. meeting included:	al Investigator
9. #	СҮ		12-02-2021
orior to the meet a. None. Additional discu	ting: ssion during the	the following points were addressed by the Princip meeting included: s not part of this study removed .	al Investigator
10. #	DY		12-02-2021
The protocol wa prior to the meet a. None.		the following points were addressed by the Princip	al Investigator

designate	C C	cage.	_
11. 7			-
orior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
12.#	D		-
prior to the mee a. None.	ting: ssion during the	the following points were addressed by the Princip meeting included:	oal Investigator
13. #	СҮ		12-02-2021
prior to the mee a. Pendir Additional discu a. None.	ting: ng reviewer appi ssion during the	the following points were addressed by the Princip roval. meeting included:	
14. #	D		-
prior to the mee a. Pendir Additional discu	ting: ng PI.	the following points were addressed by the Princip meeting included:	dai investigator
15. #	D		12-02-2021
prior to the mee a. Clarific	ting: cation on the cor	the following points were addressed by the Princip mpound table. meeting included:	oal Investigator
16. #	С		-
		the following points were addressed by the Princip	al Investigator
The protocol wa prior to the mee a. None. Additional discu	ting: ssion during the	meeting included:	
The protocol wa prior to the mee a. None.	ting: ssion during the		11-19-2021
The protocol wa prior to the mee a. None. Additional discu a. Pendir <b>17. #</b> The protocol wa prior to the mee a. Clarific Additional discu	ting: ssion during the ng Chem D s reviewed and ting: cation on prolong		
The protocol wa prior to the mee a. None. Additional discu a. Pendir <b>17. #</b> The protocol wa prior to the mee a. Clarific	ting: ssion during the ng Chem D s reviewed and ting: cation on prolong	the following points were addressed by the Princip ged restraint and pharmaceutical grade VetBond.	

	ation of adverse ssion during the	e effects. e meeting included:	
19. #	DY		11-24-2021
prior to the meet a. Title ve b. Animal c. BUA ve d. Addres	ting: Prification. I numbers clarifi Prification. Previous subj	the following points were addressed by the Princip ication. ject matter publication. meeting included:	oal Investigator
20. #	D		11-22-2021
prior to the meet a. Clarifie	ting: d techniques.	the following points were addressed by the Princip meeting included:	oal Investigator
21. #	С		11-30-2021
prior to the meet a. Discus Additional discus a. None.	ting: sed diet and lac ssion during the	the following points were addressed by the Princip ctation states of animals. e meeting included:	oal Investigator
22. #	D		-
prior to the meet a. Discus	ting: sed water cons	the following points were addressed by the Princip umption monitoring. meeting included:	oal Investigator
23. #	С		12-02-2021
prior to the meet a. None. Additional discus	ting:	the following points were addressed by the Princip meeting included:	oal Investigator
24. #	СҮ		11-29-2021
prior to the meet a. PI clari	ting: fied monitoring	the following points were addressed by the Princip of animals. e meeting included:	bal Investigator
25. #	В		11-29-2021
The protocol was prior to the meet a. None.	ting:	the following points were addressed by the Princip meeting included:	

VII. Designated Review Amendments:

Protocol	Category	Request	Date Approved
1.#	D		-
Investigator prio a. Pendir Additional discu	r to the meeting og additional info	and the following points were addressed by the Pr : ormation regarding housing. e meeting included:	incipal
2.#	D		-
Investigator prio a. Pendir Additional discu	r to the meeting ig BUA and VH		incipal
3. #	D DWR.		12-02-2021
Investigator prio a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
4. #	DY		11-23-2021
Investigator prio a. Clarific	r to the meeting ation regarding	and the following points were addressed by the Pr availability of reader. meeting included:	incipal
5. #	DY		-
Investigator prio a. None. Additional discu	r to the meeting ssion during the	and the following points were addressed by the Pr : e meeting included: vill review further with PI. Remains in DMR.	incipal
6. #	D		11-19-2021
Investigator prio a. Clarifie	r to the meeting d breeding nun		incipal
7.#	D		11-19-2021
Investigator prio a. Clarific	r to the meeting ation on wordin		incipal
8.#	DY		12-01-2021
The amendment Investigator prio a. None.		and the following points were addressed by the Pr j:	incipal

Additional discus a. None.	ssion during the	e meeting included:	
9. #	DY		-
Investigator prior a. Clarify Additional discus	r to the meeting cautery/suture		Principal
10. #	D		12-02-2021
Investigator prio a. Pendin Additional discus	r to the meeting g PI's acknowle	and the following points were addressed by the g: edgement of chemical safety officers review. e meeting included:	Principal
11. #	С		12-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the g: e meeting included:	Principal
12. #	С		12-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the g: e meeting included:	Principal
13. #	С		12-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the g: e meeting included:	Principal
14. #	DY		11-19-2021
Investigator prior a. Discus	r to the meeting sed subjective	and the following points were addressed by the g: evaluations and adjunct sedation. e meeting included:	Principal
15. #	D		11-18-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the g: e meeting included:	Principal
16. #	D		11-22-2021
Investigator prio a. PI prov Additional discus a. None.	r to the meeting vided clarificatio ssion during the	and the following points were addressed by the g: on regarding anesthesia, routes of administration e meeting included:	and incision care.
17.#	D		11-22-2021

Investigator prior		and the following points were addressed by the Pr :	incipal
a. None. Additional discus a. None.	ssion during the	e meeting included:	
18. #	E		11-30-2021
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus a. None.	ssion during the	e meeting included:	
19. #	D		12-01-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
20. #	DY		11-23-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
21. #	D		12-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
22. #	C		-
Investigator prior a. Pendin Additional discus	r to the meeting g Pl.	and the following points were addressed by the Pr : e meeting included:	incipal
23. #	DY		11-24-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
24. #	D		11-18-2021
The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus a. None.	ssion during the	e meeting included:	
25. #	CY		11-30-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal

26. #	D		12-02-2021
Investigator prior a. Housin	r to the meeting g location after	and the following points were addressed by the Pr ; imaging updated. e meeting included:	incipal
27. #	D		11-18-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal
28. #	D		-
Investigator prior a. Pendin Additional discus	r to the meeting g Reviewer.	and the following points were addressed by the Pr : e meeting included:	incipal
29. #	CY		11-23-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr : e meeting included:	incipal


### VIII. Administrative and Veterinary Verification Amendments:


Total of **154** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Title	Date Approved
1.#	DY		01-06-2022
prior to the me a. Clarif b. Inclus c. Samp d. Shav d. Clarif e. Remo Additional disc	eting: ication of typ- sion of chute oling clarificat e biopsy proc y procedure l ove unnecess	system. ons. edures. ocation and any related animal mov ary lab specific details. the meeting included:	
u. , , , , , , , , , , , , , , , , , , ,			
	CUC Vote		





### X. Annual Renewals:

Protocol	Category	Title	Original Approval	Last Reviewed	Expires
	D		12-05-2019	12-02-2021	12-05-2022
	С		12-05-2019	12-02-2021	12-05-2022
	DY		12-05-2019	12-02-2021	12-05-2022
	D		12-05-2019	12-02-2021	12-05-2022

CY	1:	2-05-2019	12-02-2021	12-05-2022
D	1:	2-05-2019	12-02-2021	12-05-2022
	1:	2-04-2019	12-02-2021	12-04-2022
С	1:	2-09-2019	12-02-2021	12-09-2022
D	1:	2-05-2019	12-02-2021	12-05-2022
DY	12	2-04-2019	12-02-2021	12-04-2022
С	1:	2-06-2019	12-02-2021	12-06-2022
С	12	2-05-2019	12-02-2021	12-05-2022
CY	1:	2-05-2019	12-02-2021	12-05-2022
D	1:	2-11-2019	12-02-2021	12-11-2022
С	1:	2-05-2019	12-02-2021	12-05-2022
D	12	2-05-2019	12-02-2021	12-05-2022
DY	12	2-05-2019	12-02-2021	12-05-2022
D	12	2-05-2019	12-02-2021	12-05-2022
С	12	2-09-2019	12-02-2021	12-09-2022
DY	1:	2-05-2019	12-02-2021	12-05-2022
С	12	2-05-2019	12-02-2021	12-05-2022
Y	12	2-05-2019	12-02-2021	12-05-2022
	1:	2-10-2019	12-02-2021	12-10-2022
	11	2-13-2019	12-02-2021	12-13-2022
С	12	2-05-2019	12-02-2021	12-05-2022
D	12	2-10-2019	12-02-2021	12-10-2022
С	12	2-16-2020	12-02-2021	12-16-2022
С	12	2-15-2020	12-02-2021	12-15-2022
DY	12	2-17-2020	12-02-2021	12-17-2022
С	12	2-15-2020	12-02-2021	12-15-2022
			Ohtoina	l hu Dine fer Ar

					 	_			
	С						12-14-2020	12-02-2021	12-14-2022
	E						12-08-2020	12-02-2021	12-08-2022
	D						12-04-2020	12-02-2021	12-04-2022
	D						12-11-2020	12-02-2021	12-11-2022
	E						12-03-2020	12-02-2021	12-03-2022
	С						12-17-2020	12-02-2021	12-17-2022
	D						12-17-2020	12-02-2021	12-17-2022
	CY						12-17-2020	12-02-2021	12-17-2022
	С						12-17-2020	12-02-2021	12-17-2022
	D						12-07-2020	12-02-2021	12-07-2022
	CY						12-17-2020	12-02-2021	12-17-2022
	С						12-17-2020	12-02-2021	12-17-2022
	С						12-16-2020	12-02-2021	12-16-2022
	D						12-17-2020	12-02-2021	12-17-2022
	CY						12-17-2020	12-02-2021	12-17-2022
	D						12-17-2020	12-02-2021	12-17-2022
	1								
Discu	ssion:		nd				ss of updatir		
	their OHSS are awaiting						on exam and m	1	
Action			nd	_			enewals.		
	IACUC Vote	18							
	Approval Withhold Approva								
	Abstain	0							
		0							


### XI. Amendments for Full Committee Review:

18

Present

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1.#	D		12-14-2021



	IAC	JC Vote	
	Approval		0
	Withhold	Approval	0
	Abstain		0
	Present		19
6. #		DY	
		was revie	
ditio	a. Update nal discus a. Commi	to the me d commit sion durir ttee voted	tee ng 1
	IACI	JC Vote	
	Approval		2
	Withhold	Approval	0
	Abstain		0
	Present		20

XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium
1.07-08-2021	
2. 10-21-2021	
3. 11-19-2021	

Di	scussion: None.	
	Action: None.	
	Approval	19
	Withhold Appro	oval 0
	Abstain	0
	Present	19

# XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1. 06-24-2021	LAB	
2. 11-09-2021	LAB	
3. 11-15-2021	LAB	
4. 11-16-2021	LAB	
5. 11-23-2021	LAB	
6. 11-09-2021	PAM	

 Discussion:
 2. Location approved for client and research animals. Oversight of room was ambiguous to users.

 Action:
 2. PI's and clinicians will ensure room is maintained per IACUC policies and guidelines.

IACUC Vote	
Approval <sup>2</sup>	19
Withhold Approval	0
Abstain	0
Present	19

## XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

### XV. Other Discussion Items:

Торіс	
1. record/doo	cument humidity
Discussion:	1. Reviewed policies regarding recording/documentation of environmental controls.
Action:	1. Committee to revise polices when subcommittee meets to clarify expectations.
2. IACUC Po	blicy-04 "IACUC Laboratory/Study Area Inspection Program"
Discussion:	None.
Action:	Approved
3. IACUC Po	blicy-06 "IACUC Meeting Minutes"
Discussion:	None.
Action:	Approved
	blicy-21 "Provision of Veterinary Care by Veterinarians that are not part of ed support Veterinary Teams"
Discussion:	None.
Action:	Approved
5. IACUC Po	licy-20 "Rationale for Species and Numbers"
Discussion:	None.
Action:	Approved
6. IACUC Po	licy-22 "Guidelines for Rodent Survival Surgery"
Discussion:	Discussed PPE.
Action:	Approved

## XVI. Program Updates:

### Topic

There were no program updates provided during the meeting.

## University of California, Davis IACUC Business Administration System

#### December 16, 2021 Meeting Minutes

[regular view | VA view]

#### Attendance:

#### Present:

M009, M097, M102, M111, M042, A095, M004, M100, M092, A019, M119, M087, M110, A013, M016, M024, M223, M001, M114

#### Excused:

M222, M090, A109, M093, M112

#### Guests:

M224, M116, A017, A018

#### I. Minutes from Previous Meetings:

Abstain

Present

The IACUC reviewed and appr	roved the October 28, 2021, meeting minutes as written.
IACUC Vote	
Approval 14	
Withhold Approval 0	

#### II. Protocols Tabled From Previous Meetings:

There were no tabled protocols for discussion.

#### **III. Amendments Tabled From Previous Meetings:**

There were no tabled amendments for discussion.

0

14

#### **IV. Reports of Concern, Events and Incidents:**

The IACUC reviewed and discussed the following report(s) of concern, events, and incidents: Action: IACUC Staff will review procedures for congruency with protocol; complaintant has also been referred to HR for additional support as reported concern involves personnel issues. Action: Procedures outside of protocol, use of glue; Subcommittee will meet with PI to review UCD IACUC policies, procedures and expectations. rodent cage changes Action: Routine schedule per SOP affected by staffing shortages due to COVID. No animal welfare issue.

#### V. Veterinary Care Program Updates:

The Attending Veterinarian provided the following updates to the committee:

# VI. Designated Review Protocols:

Protocol	Category	Title	Date Approved
1. #	D		-
prior to the mee a. Pendir Additional discu	ting: ng PI response	the following points were addressed by the Princi on BSL levels. e meeting included:	pal Investigator
2. #	DY		-
prior to the mee a. IACUC meeting and requ Additional discu	ting: C staff contacted if the PI does no iires an updated	the following points were addressed by the Princip d PI informing them the protocol would be withdraw of respond to committee questions. Protocol was s l literature search. e meeting included:	vn at the 1/6/22
3. #	С		-
prior to the mee a. Pendir Additional discu	eting: ng BUA and VH	the following points were addressed by the Princi SS. e meeting included:	pal Investigator
4. #	С		-
prior to the mee a. Pendir Additional discu	eting: ng BUA and VH	the following points were addressed by the Princi SS. e meeting included:	pal Investigator
5. #	DY		12-02-2021
prior to the mee a. Furthe	eting: er clarification or ission during the	the following points were addressed by the Princi n number rationale. e meeting included:	pal Investigator
6. #	С		-
prior to the mee a. None.	ting: Ission during the	the following points were addressed by the Princi e meeting included:	pal Investigator
7. #	D		-
prior to the mee a. None.	ting:	the following points were addressed by the Princi	pal Investigator

a. Pendi	ng PI.				
8. #	D		-		
	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
Additional discu	a. None. Additional discussion during the meeting included: a. Pending PI responses				
9. #	D		12-16-2021		
prior to the mee a. Clarifi Additional discu a. None.	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on and removal of ITT. Additional discussion during the meeting included: a. None.				
10. #	DY		-		
prior to the mee a. Clarifi b. Addition c. Further Additional discu	eting: cation of typo. onal information er clarification re	the following points were addressed by the Princi requested regarding sampling procedure. garding group disposition. e meeting included:	pal Investigator		
11.#	С		12-06-2021		
prior to the mee a. None. Additional discu	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. Chem provided a VHSS				
12. #	D		12-16-2021		
prior to the mee a. Clarifi	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification on procedures. Additional discussion during the meeting included:				
13. #	С		12-16-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.					
14. #	D		12-15-2021		
prior to the mee a. None.	eting: Ission during the	I the following points were addressed by the Princi e meeting included:	pal Investigator		
15. #	D		12-03-2021		
The protocol wa prior to the mee a. None.	eting:	I the following points were addressed by the Princi	pal Investigator		
Additional discu a. None.		e meeting included:			

16. #	С		-		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.					
	ission during the	e meeting included:			
17. #	С		12-14-2021		
	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
	ission during the	e meeting included:			
18. #	СҮ		12-13-2021		
prior to the mee a. Modifi	eting: cation of study e ission during the	the following points were addressed by the Princi endpoints. e meeting included:	pal Investigator		
19. #	D		12-16-2021		
prior to the mee a. None.	The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included:				
20. #	С		12-14-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Change to needle size description. Additional discussion during the meeting included: a. None.					
21. #	DY		12-06-2021		
<ul> <li>The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:         <ul> <li>a. PI provided clarification regarding animal numbers justification and monitoring procedure details.</li> </ul> </li> <li>Additional discussion during the meeting included:         <ul> <li>a. None.</li> </ul> </li> </ul>					
22. #	С		12-08-2021		
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarification of animal numbers. Additional discussion during the meeting included: a. None.					
23. #	D		12-16-2021		

The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting:				
a. Clarification of experimental procedures (vs. SOC), animal numbers, and drug dose. Additional discussion during the meeting included:				
a. None.		needing moldaed.		
24. #	D		12-03-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princi	pal Investigator	
prior to the mee		unation and the single		
		mption monitoring. e meeting included:		
a. None.		incoming molacea.		
25. #	С		12-02-2021	
		the following points were addressed by the Princi	pal Investigator	
prior to the mee				
		nental design and statical calculations. dditive composition.		
		e meeting included:		
a. None.				
26. #	BY		12-14-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princi	nal Investigator	
prior to the mee			parinvestigator	
a. None		and the first state of the		
a. None.	ssion during the	e meeting included:		
27.#	D		12-14-2021	
The protocol wa		the following points were addressed by the Princi	nal Investigator	
prior to the mee		the following points were addressed by the Princip	par investigator	
a. None.	•			
		e meeting included: ical analysis and parameters tested for after smap	ling blood	
28. #	D, statist	ical analysis and parameters tested for after smap	12-15-2021	
20. #			12-13-2021	
The protocol wa prior to the mee		the following points were addressed by the Princip	pal Investigator	
		etermination procedures.		
b. Clarific	cation of therma	I threshold determination procedures.		
	ation of advers			
a. None.	ssion during the	e meeting included:		
<b>29.</b> #	С		12-01-2021	
The protocol wa	s reviewed and	the following points were addressed by the Princip		
prior to the mee a. None.				
	ssion during the	e meeting included:		
30. #	D		12-16-2021	
prior to the mee	ting:	the following points were addressed by the Princi	pal Investigator	
a. None. Additional discu a. None.	ssion during the	e meeting included:		
,				

31. #	В		12-02-2021	
The protocol was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None. Additional discussion during the meeting included: a. None.				
32. #	D		12-16-2021	
prior to the mee a. None.	ting:	the following points were addressed by the Princi meeting included:	pal Investigator	

## VII. Designated Review Amendments:

nvestigator prio a. PI clari Additional discus a. None. <b>2. #</b> The amendment nvestigator prio	r to the meeting fied housing ar ssion during the D	and the following points were addressed by the Pr g: nd procedures in place per BUA for AAV. e meeting included:	12-13-2021 incipal
a. PI clari a. PI clari a. dditional discus a. None. 2. # The amendment nvestigator prio	r to the meeting fied housing ar ssion during the D	g: nd procedures in place per BUA for AAV.	incipal
The amendment nvestigator prio			
nvestigator prio	was reviewed		12-14-2021
	ation regarding	g: notification to CVS and IACUC. e meeting included:	
3. #	D		12-09-2021
Additional discus a. None.	ssion during the	dverse effects and training of personnel. e meeting included:	40.44.0001
4. #	D	and the following a sinterway of data and by the D	12-14-2021
nvestigator prio a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipai
5. #	DY		-
nvestigator prio a. Pendin Additional discus	r to the meeting og additional co ssion during the	and the following points were addressed by the Pr g: nsult with CNPRC veterinarian. e meeting included: nsult with CNPRC veterinarian.	incipal
a. r chuir	DY		12-02-2021
6. #		and the following points were addressed by the Pr	incipal
6. #			

a. None.				
7.#	E		12-08-2021	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. Clarified procedures.				
	ssion during the	e meeting included:		
			10.10.0001	
8. #	E		12-16-2021	
		and the following points were addressed by the Pr	incipal	
Investigator prio				
		fects and mitigation.		
Additional discu a. None.	ssion during the	e meeting included:		
9. #			12-13-2021	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio a. None.				
	ssion during the	e meeting included:		
a. None.				
10. #	D		12-02-2021	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio				
		r completed their review and provided updated VH	ISS. PI	
		d will communicate with vivarium staff.		
	ssion during the	e meeting included:		
a. None.				
11. #	DY		-	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio a. None.				
		e meeting included:		
12. #	D		12-16-2021	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prior to the meeting: a. None.				
Additional discu	ssion during the	e meeting included:		
a. None.				
13. #	С		-	
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal	
Investigator prio a. None.				
		e meeting included:		
14. #	DY		12-02-2021	
The amondmen		and the following points were addressed by the Dr	incinal	
The amendment was reviewed and the following points were addressed by the Principal Investigator prior to the meeting: a. None.				
	ssion during the	e meeting included:		
15. #	С		12-09-2021	

Investigator prior		and the following points were addressed by the Pr g:	rincipal
		e meeting included: erformance measure, concentrations thus far, and	upper toxic limits
16. #	D		12-16-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
a. None.	-		1
17. #	D		-
Investigator prior a. Clarific	r to the meeting ation on advers	and the following points were addressed by the Pr g: se effects, BUA, and terminology. e meeting included:	rincipal
a. None. 18. #	С		-
Investigator prior a. None.	r to the meeting ssion during the	and the following points were addressed by the Pr g: e meeting included:	rincipal
19. #	CY		12-02-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
20. #	DY		12-16-2021
Investigator prior a. Clarific	r to the meeting ation of dosing	and the following points were addressed by the Pr g: , timing, and proposed next steps. e meeting included:	incipal
21. #	DY		12-08-2021
Investigator prior a. None.	r to the meeting	and the following points were addressed by the Pr g: e meeting included:	incipal
22. #	С		12-16-2021
Investigator prior a. None.	r to the meeting		incipal
Additional discus a. None.	ssion during the	e meeting included:	
23. #	C		12-14-2021
Investigator prior			rincipal

Additional discu a. None.	ssion during the	e meeting included:	
24. #	С		-
	-	and the following points were addressed by the Pr	incipal
Investigator prio	or to the meeting		
a. Pendir		and the standard state	
	ssion during the ins in DMR.	e meeting included:	
25. #	DY		12-02-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio		g:	
a. None.		monting included:	
a. None.	ssion during the	e meeting included:	
26. #	D		12-16-2021
The even due on		and the fellowing points were addressed by the D	in ein el
Investigator prio		and the following points were addressed by the Pr	incipal
a. None.		<b>9</b> .	
	-	e meeting included:	
a. None.			1
27.#	D		-
I he amendmen Investigator prio		and the following points were addressed by the Pr	incipal
a. None.	i to the meeting	j.	
	ssion during the	e meeting included:	
a. Pendir		_	
28. #	D		12-10-2021
The amendmen	t was reviewed	and the following points were addressed by the Pr	incipal
Investigator prio a. None.			
	ssion during the	e meeting included:	
a. None.	j		
29. #	С		12-13-2021
I he amendmen Investigator prio		and the following points were addressed by the Pr	incipal
a. None.		j.	
		e meeting included:	
a. None.			
30. #	C		12-16-2021
		and the following points were addressed by the Pr	incipal
Investigator prio a. None.	or to the meeting	j:	
	ssion during the	e meeting included:	
a. None.	-	0	
31. #	D		12-15-2021
The energy due of	 • • • • • • • • • • • • • • • • • • •	and the following points were addressed by the D	
I he amendmen Investigator prio		and the following points were addressed by the Pr	incipal
a. None.		J.	
	ssion during the	e meeting included:	
a. None.			
32. #	D		12-13-2021

The amendment Investigator prior a. None.		and the following points were addressed by the Pr :	incipal
Additional discus a. None.	sion during the	meeting included:	
33. #	D		_
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : • meeting included:	incipal
34. #	DY		12-16-2021
a. None. Additional discus a. None.	sion during the	meeting included:	
35. #	D		-
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal
36. #	В		12-02-2021
Investigator prior a. None.	to the meeting	and the following points were addressed by the Pr : meeting included:	incipal


### VIII. Administrative and Veterinary Verification Amendments:

Total of **119** Administrative and Veterinary Verification Amendments were processed since the last IACUC meeting.

### IX. New Protocols:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all protocols for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Pro	tocol	Catego	у	Title	Date Approved
1.#		DY			01-18-2022
prior to Additio	the mee a. None. nal discu	eting: Ission durir	ig th	d the following points were addressed by the Princi e meeting included: g response to questions and Biosafety review	pal Investigator
	IAC	CUC Vote			
	Approva	al	0		
	Withhol	d Approval	0		
	Abstain		0		
	Present		18		
2. #		CY			12-16-2021



### X. Annual Renewals:

Protocol Category Title

Last


		Approval	Reviewed	
Γ	C	12-30-2019	12-16-2021	12-30-2022
C	C	01-06-2020	12-16-2021	01-06-2023
	D	01-07-2020	12-16-2021	01-07-2023
D	Y	12-19-2019	12-16-2021	12-19-2022
(	C	12-18-2019	12-16-2021	12-18-2022
E	E	01-06-2020	12-16-2021	01-06-2023
Ē	E	01-07-2020	12-16-2021	01-07-2023
(	C	12-19-2019	12-16-2021	12-19-2022
(	C	12-19-2019	12-16-2021	12-19-2022
E	E	12-05-2019	12-16-2021	12-05-2022
(	C	12-19-2019	12-16-2021	12-19-2022
Ĭ	D	12-05-2019	12-16-2021	12-05-2022
C	C	12-19-2019	12-16-2021	12-19-2022
	C	12-18-2019	12-16-2021	12-18-2022
D	Y	01-07-2020	12-16-2021	01-07-2023
(	C	12-20-2019	12-16-2021	12-20-2022
(	C	01-03-2020	12-16-2021	01-03-2023
(	C	01-06-2020	12-16-2021	01-06-2023
E	3	01-07-2020	12-16-2021	01-07-2023
С	Y	12-19-2019	12-16-2021	12-19-2022
Ĩ	D	12-18-2020	12-16-2021	12-18-2022
	D	01-07-2021	12-16-2021	01-07-2023
[ [	D	12-17-2020	12-16-2021	12-17-2022
D	Y	12-07-2020	12-16-2021	12-07-2022
(	С	01-04-2021	12-16-2021	01-04-2023
			Obtaine	d by Rise for Ar


	D				01-04-2021	12-16-2021	01-04-2023
	С				01-06-2021	12-16-2021	01-06-2023
	С				12-18-2020	12-16-2021	12-18-2022
	D				01-07-2021	12-16-2021	01-07-2023
	С				01-04-2021	12-16-2021	01-04-2023
	В				01-06-2021	12-16-2021	01-06-2023
Action I	tems: 8 - from 9. notified	Literature Other ver Committe to compliant IACUC s AV worki	e search inadvert erinarian listed in Committee appro ee approved mo ee approved rene ete review to ens	n section 11. oved the annual i ving wording to s ewal and Chemic sure no VHSS is i PI to submit an a	d to original protocol. renewals. ection 7 and remove al safety has been needed.		
	Approval Withhold App	18 roval 0					
	withinoid App						
	Abstain	0					

### XI. Amendments for Full Committee Review:

The IACUC staff and Office of Attending Veterinarian, veterinary staff, prior to the submission to the IACUC, reviewed all significant protocol amendments for completeness and consistency with the applicable regulations, UC Davis policies, and IACUC policies and guidelines.

Protocol	Category	Request	Date Approved
1. #	D		12-16-2021
The amendment was reviewed and the following points were addressed by the Princip Investigator prior to the meeting: a. Chemical safety officer completed their review and provided an updated VHS confirmed acknowledgement and will communicate with vivarium staff. Additional discussion during the meeting included: a. Committee voted to approve.			
Approv			
Withhol	d Approval 0		
Abstain	0		
Presen	t 19		





XII. Animal Housing/Facility Inspections:

Inspection Date	Vivarium	
1.07-27-2021		
2. 08-25-2021		
3. 08-25-2021		
4. 09-29-2021		
5. 10-14-2021		
6. 10-19-2021		
7. 10-27-2021		
8. 10-28-2021		
9. 11-03-2021		
10. 11-08-2021		
11. 11-10-2021		
12. 11-12-2021		
13. 11-12-2021		
14. 11-16-2021		
15. 11-17-2021		
16. 11-24-2021		
		hta

Obtained by Rise for Animals. Uploaded to Animal Research Laboratory Overview (ARLO) on 02/06/2023

Discussion:		<ol> <li>Deficiencies noted were impacted by staffing shortage.</li> <li>Discussed facilities computer monitoring of humidity and documentation.</li> </ol>				
Action:	<ul> <li>Action: 15. All deficiencies have been corrected. IACUC discussed campus wide issue of hiring a maintaining staff in many departments.</li> <li>16. Committee agreed documentation can be maintained on the computer since it is check daily and can be reviewed easily for past dates.</li> </ul>					
	ACUC Vote					
Appr	oval	15				
With	nold Approval	0				
Absta	ain	0				
Pres	ent	15				

## XIII. Laboratory/Study Area Inspections:

Inspection Date	Туре	Location or Protocol
1.09-30-2021	LAB	
2. 10-29-2021	LAB	
3. 10-29-2021	LAB	
4. 11-12-2021	LAB	
5. 11-29-2021	LAB	
6. 11-29-2021	LAB	
7. 11-29-2021	LAB	
8. 11-30-2021	LAB	
9. 07-28-2021	PAM	
10. 11-17-2021	PAM	
11. 12-03-2021	PAM	
12. 12-06-2021	PAM	

Discuss	ion: None.	
Act	ion: None.	
		ote
A	Approval	18
V	Vithhold Appr	roval 0
A	Abstain	0
F	Present	18

# XIV. Regulatory Inspections:

There are no regulatory inspections for this agenda.

## XV. Other Discussion Items:

Торіс						
1. ALL cours	1. ALL courses must be completed by 12/31/21.					
Discussion:	Discussion: Reminder to complete training courses.					
Action: All members required to complete all courses by 12/31/21.						
2. 3rd quarter fluid reports.						
Discussion:	Compliant.					
Action:	None.					

3.	
Discussion	IACUC voted to approve AV clinical decision regarding recovering a lamb that was not manipulated for rescheduled procedure.
Action	None.
IACUC Polic	cy-13 "Transporting Research and Teaching Animals"
Discussion	None.
Action	Tabled
	cy-26 "Monoclonal Antibody Production in Mice via Ascites" - dation to retire
Discussion	Recommended to retire
Action	Retired
IACUC Polic	cy-29 "Expired Drugs and Medical Materials"
Discussion	None.
Action	Tabled
IACUC Polic Guidelines"	cy-30 "Anesthesia Machine/Vaporizer Calibration, Use, and Maintenance
Discussion	None.
Action	Tabled
	cy-41 "Guidelines for Changes in the Use of Therapeutic Drugs on CUC Protocols"
Discussion	None.
Action	Tabled
IACUC Polic and Teachin	cy-43 "The Use of Prolonged Physical Restraint in Non-sedated Research g Animals"
Discussion	None.

## XVI. Program Updates:

## Торіс

There were no program updates provided during the meeting.